e424b5
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Maximum Aggregate
|
|
|
Amount of Registration
|
Title of Each Class of Securities Offered
|
|
|
Offering Price(1)
|
|
|
Fee(2)(3)
|
Common Stock, par value $0.01
|
|
|
$3,622,500,000
|
|
|
$258,285
|
|
|
|
|
|
|
|
(1) Assuming exercise in full of the underwriters
over-allotment option.
|
|
|
|
(2)
|
Calculated in accordance with Rule 457(r) under the
Securities Act of 1933 as amended (the Securities
Act).
|
|
|
(3)
|
Pursuant to Rule 457(p) under the Securities Act, the
registration fee of $258,285 due with respect to this offering
is offset against $437,996 that has already been paid with
respect to unsold securities that were previously registered
pursuant to Registration Statement Nos.
333-124358,
333-124358-01
and
333-124358-02
and were not sold thereunder. No additional registration fee has
been paid with respect to this offering. $179,711 remains
available for future registration fees after giving effect to
this offering. This Calculation of Registration Fee
table shall be deemed to update the Calculation of
Registration Fee table in Registration Statement
No. 333-147180
on
Form S-3.
|
Filed
pursuant to Rule 424(b)(5)
Registration No. 333-147180
(To Prospectus Dated November 6, 2007)
75,000,000 Shares
Common Stock
MetLife, Inc. is offering 75,000,000 shares of its common
stock, par value $0.01 per share (the common
stock).
The common stock is listed on the New York Stock Exchange under
the symbol MET. On July 30, 2010, the last
reported sales price of the common stock on the New York Stock
Exchange was $42.06 per share.
Following this offering, it is anticipated that MetLife, Inc.
will offer, by means of one or more separate prospectus
supplements, senior notes in an aggregate principal amount of
$3.1 billion (the additional offerings).
This offering of common stock is not conditioned on the
completion of the additional offerings. There can be no
assurance that the additional offerings will be completed.
See Risk Factors beginning on
page S-21
of this prospectus supplement to read about important factors
you should consider before buying shares of the common stock.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
Total
|
|
Public offering price
|
|
$
|
42.00
|
|
|
$
|
3,150,000,000
|
|
Underwriting discounts and commissions
|
|
$
|
1.08
|
|
|
$
|
81,000,000
|
|
Proceeds, before expenses, to MetLife, Inc.
|
|
$
|
40.92
|
|
|
$
|
3,069,000,000
|
|
To the extent that the underwriters sell more than
75,000,000 shares of common stock, the underwriters have
the option to purchase up to an additional
11,250,000 shares from MetLife, Inc., solely to cover
over-allotments, if any, at the public offering price, less the
underwriting discounts and commissions.
The underwriters expect to deliver the shares of common stock
against payment therefor in New York, New York on August 6,
2010.
Joint Book-Running
Managers
|
|
|
|
|
|
|
|
|
|
|
BofA Merrill Lynch
|
|
Credit Suisse
|
|
Deutsche Bank Securities
|
|
HSBC
|
|
UBS Investment Bank
|
|
Wells Fargo Securities
|
|
|
|
|
|
Sanford C. Bernstein |
|
Macquarie Capital |
|
Sterne Agee |
|
|
|
|
|
|
|
BNP
PARIBAS
|
RBS
|
Societe Generale
|
Cowen and
Company
|
Daiwa Capital
Markets
|
Dowling & Partners Securities,
LLC
|
PNC Capital Markets LLC
|
|
|
|
|
|
Scotia
Capital UCI
Capital Markets
|
The Williams Capital Group,
L.P.
|
BNY Mellon Capital Markets,
LLC
|
COMMERZBANK
|
Mitsubishi UFJ Securities
|
|
|
|
|
|
|
Raymond
James
|
Santander Securities
|
Loop Capital
Markets
|
Blaylock Robert Van,
LLC
|
Cabrera Capital Markets, LLC
|
Guzman & Company
|
|
|
|
|
|
Siebert
Capital Markets
|
Ramirez & Co., Inc.
|
CastleOak Securities, LP
|
MFR Securities, Inc.
|
Toussaint Capital Partners, LLC
|
Prospectus Supplement dated August 3, 2010.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
Prospectus Supplement
|
|
|
|
S-3
|
|
|
|
|
S-3
|
|
|
|
|
S-5
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-21
|
|
|
|
|
S-61
|
|
|
|
|
S-64
|
|
|
|
|
S-65
|
|
|
|
|
S-66
|
|
|
|
|
S-67
|
|
|
|
|
S-77
|
|
|
|
|
S-81
|
|
|
|
|
S-87
|
|
|
|
|
S-87
|
|
Prospectus
|
|
|
|
|
About This Prospectus
|
|
|
1
|
|
Risk Factors
|
|
|
1
|
|
Special Note Regarding Forward-Looking Statements
|
|
|
1
|
|
Where You Can Find More Information
|
|
|
2
|
|
MetLife, Inc.
|
|
|
3
|
|
The Trusts
|
|
|
4
|
|
Use of Proceeds
|
|
|
5
|
|
Ratio of Earnings to Fixed Charges
|
|
|
5
|
|
Description of Securities
|
|
|
5
|
|
Description of Debt Securities
|
|
|
6
|
|
Description of Capital Stock
|
|
|
15
|
|
Description of Depositary Shares
|
|
|
21
|
|
Description of Warrants
|
|
|
23
|
|
Description of Purchase Contracts
|
|
|
24
|
|
Description of Units
|
|
|
25
|
|
Description of Trust Preferred Securities
|
|
|
26
|
|
Description of Guarantees
|
|
|
28
|
|
Plan of Distribution
|
|
|
31
|
|
Legal Opinions
|
|
|
32
|
|
Experts
|
|
|
32
|
|
You should rely only on the information contained or
incorporated by reference in this prospectus supplement and the
accompanying prospectus. Neither we nor the underwriters have
authorized anyone to provide you with additional or different
information. If anyone provided you with additional or different
information, you should not rely on it. Neither we nor the
underwriters are making an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You
should assume that the information contained in this prospectus
supplement, the accompanying prospectus and the documents
incorporated by reference, is accurate only as of their
respective dates. MetLifes business, financial condition,
results of operations and prospects may have changed since those
dates.
S-2
The common stock is offered for sale in those jurisdictions in
the United States, Europe, Asia and elsewhere where it is lawful
to make such offers. The distribution of this prospectus
supplement and the accompanying prospectus and the offering or
sale of the common stock in some jurisdictions may be restricted
by law. Persons into whose possession this prospectus supplement
and the accompanying prospectus come are required by us and the
underwriters to inform themselves about and to observe any
applicable restrictions. This prospectus supplement and the
accompanying prospectus may not be used for or in connection
with an offer or solicitation by any person in any jurisdiction
in which that offer or solicitation is not authorized or to any
person to whom it is unlawful to make that offer or
solicitation. See Underwriting in this prospectus
supplement.
ABOUT
THIS PROSPECTUS SUPPLEMENT
You should read this prospectus supplement along with the
accompanying prospectus carefully before investing in the common
stock. This prospectus supplement and the accompanying
prospectus contain the terms of this offering of common stock.
This prospectus supplement may add, update or change information
in the accompanying prospectus. In addition, the information
incorporated by reference in the accompanying prospectus may
have added, updated or changed information in the accompanying
prospectus. If information in this prospectus supplement is
inconsistent with any information in the accompanying prospectus
(or any information incorporated therein by reference), this
prospectus supplement will apply and will supersede such
information.
It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying
prospectus in making your investment decision. You should also
read and consider the additional information under the caption
Where You Can Find More Information in this
prospectus supplement and the accompanying prospectus.
Unless otherwise stated or the context otherwise requires,
references in this prospectus supplement and the accompanying
prospectus to MetLife, we,
our, or us refer to
MetLife, Inc., together with its direct and indirect
subsidiaries, while references to MetLife,
Inc. refer only to the holding company on an
unconsolidated basis.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the Securities and Exchange Commission (the
SEC). These reports, proxy statements and
other information can be read and copied at the SECs
public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and trading on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York 10005.
The SEC allows incorporation by reference into this
prospectus supplement and the accompanying prospectus of
information that MetLife, Inc. files with the SEC. This permits
MetLife, Inc. to disclose important information to you by
referencing these filed documents. Any information referenced
this way is considered part of this prospectus supplement and
accompanying prospectus, and any information filed with the SEC
subsequent to the date of this prospectus will automatically be
deemed to update and supersede this information. Information
furnished under Item 2.02 and Item 7.01 of MetLife,
Inc.s Current Reports on
Form 8-K
is not incorporated by reference in this prospectus supplement
and accompanying prospectus. MetLife, Inc. incorporates by
reference the following documents which have been filed with the
SEC:
|
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2009 (the 2009
Form
10-K);
|
|
|
|
Quarterly Reports on
Form 10-Q
for the quarters ended March 31, 2010 and June 30,
2010 (the Second Quarter
Form 10-Q);
|
|
|
|
Definitive Proxy Statement filed on March 23, 2010;
|
S-3
|
|
|
|
|
Registration Statement on
Form 8-A,
relating to MetLife, Inc.s common stock and Series A
Junior Participating Preferred Stock purchase rights, filed on
March 31, 2000, as amended and restated by the Registration
Statement on
Form 8-A/A,
Amendment No. 1 filed on March 11, 2010; and
|
|
|
|
Current Reports on
Form 8-K
filed on January 29, 2010, February 22, 2010,
March 5, 2010, March 11, 2010, April 13, 2010,
May 3, 2010, May 7, 2010, May 17, 2010 and
August 2, 2010.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the Exchange
Act), until MetLife, Inc. files a post-effective
amendment which indicates the termination of the offering of
common stock made by this prospectus supplement and accompanying
prospectus. Any reports filed by MetLife, Inc. with the SEC
after the date of this prospectus supplement and before the date
that the offering of common stock by means of this prospectus
supplement and accompanying prospectus is terminated will
automatically update and, where applicable, supersede any
information contained or incorporated by reference in this
prospectus supplement and accompanying prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents that are
incorporated by reference into this prospectus supplement and
accompanying prospectus, other than exhibits to those documents,
unless those exhibits are specifically incorporated by reference
into those documents. Requests should be directed to Investor
Relations, MetLife, Inc., 1095 Avenue of the Americas, New York,
New York 10036, by electronic mail (metir@metlife.com), or
by telephone
(212-578-2211).
You may also obtain the documents incorporated by reference into
this document as of the date hereof at MetLifes website,
www.metlife.com. All other information contained on
MetLifes website is not a part of this document.
S-4
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and the accompanying prospectus may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. You can identify these statements by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance. Actual results could
differ materially from those expressed or implied in the
forward-looking statements. Risks, uncertainties, and other
factors that might cause such differences include the risks,
uncertainties and other factors identified in MetLife,
Inc.s filings with the SEC. These factors include:
(1) any delay or failure to complete the Acquisition (as
defined herein) of the Alico Business (as defined herein);
(2) uncertainty surrounding the consummation of this
offering or the additional offerings in the absence of the
completion of the Acquisition; (3) the imposition of
onerous conditions following the Acquisition;
(4) difficulties in integrating the Alico Business; (5)
uncertainty with respect to the outcome of the closing agreement
entered into between ALICO (as defined herein) and the United
States Internal Revenue Service (IRS) in
connection with the Acquisition; (6) uncertainty with
respect to the making of 338 Elections (as defined herein) and
any benefits therefrom; (7) an inability to manage the
growth of the Alico Business; (8) a write down of the
goodwill established in connection with the Acquisition;
(9) exchange rate fluctuations; (10) an inability to
predict the financial impact of the Acquisition on
MetLifes business and financial results; (11) events
relating to AIG (as defined herein) that could adversely affect
the Alico Business or MetLife; (12) the dilutive impact on
MetLife, Inc.s stockholders resulting from the issuance of
equity securities to ALICO Holdings (as defined herein) in
connection with the Acquisition; (13) a decrease in
MetLife, Inc.s stock price as a result of ALICO
Holdings ability to sell its equity securities;
(14) the conditional payment obligation of approximately
$300 million to ALICO Holdings if the conversion of the
Series B Preferred Stock (as defined herein) into MetLife,
Inc.s common stock is not approved; (15) change of
control provisions in the Alico Business agreements;
(16) effects of guarantees within certain of the Alico
Business variable life and annuity products;
(17) regulatory action in the financial services industry
affecting the combined business; (18) financial instability
in Europe and possible write downs of sovereign debt of European
nations; (19) difficult conditions in the global capital
markets; (20) increased volatility and disruption of the
capital and credit markets, which may affect MetLifes
ability to seek financing or access its credit facilities;
(21) uncertainty about the effectiveness of the
U.S. governments programs to stabilize the financial
system, the imposition of fees relating thereto, or the
promulgation of additional regulations; (22) impact of
comprehensive financial services regulation reform on MetLife;
(23) exposure to financial and capital market risk;
(24) changes in general economic conditions, including the
performance of financial markets and interest rates, which may
affect MetLifes ability to raise capital, generate fee
income and market-related revenue and finance statutory reserve
requirements and may require MetLife to pledge collateral or
make payments related to declines in value of specified assets;
(25) potential liquidity and other risks resulting from
MetLifes participation in a securities lending program and
other transactions; (26) investment losses and defaults,
and changes to investment valuations; (27) impairments of
goodwill and realized losses or market value impairments to
illiquid assets; (28) defaults on MetLifes mortgage
loans; (29) the impairment of other financial institutions;
(30) MetLifes ability to address unforeseen
liabilities, asset impairments or rating actions arising from
any future acquisitions, including the Acquisition, and to
successfully integrate acquired businesses with minimal
disruption; (31) economic, political, currency and other
risks relating to MetLifes international operations;
(32) MetLife, Inc.s primary reliance, as a holding
company, on dividends from its subsidiaries to meet debt payment
obligations and the applicable regulatory restrictions on the
ability of the subsidiaries to pay such dividends;
(33) downgrades in MetLife, Inc.s and its
affiliates claims paying ability, financial strength or
credit ratings; (34) ineffectiveness of risk management
policies and procedures; (35) availability and
effectiveness of reinsurance or indemnification arrangements, as
well as default or failure of
S-5
counterparties to perform; (36) discrepancies between
actual claims experience and assumptions used in setting prices
for MetLifes products and establishing the liabilities for
MetLifes obligations for future policy benefits and
claims; (37) catastrophe losses; (38) heightened
competition, including with respect to pricing, entry of new
competitors, consolidation of distributors, the development of
new products by new and existing competitors, distribution of
amounts available under U.S. government programs, and for
personnel; (39) unanticipated changes in industry trends;
(40) changes in accounting standards, practices
and/or
policies; (41) changes in assumptions related to deferred
policy acquisition costs (DAC), deferred
sales inducements (DSI), value of business
acquired (VOBA) or goodwill;
(42) increased expenses relating to pension and
postretirement benefit plans, as well as health care and other
employee benefits; (43) exposure to losses related to
variable annuity guarantee benefits, including from significant
and sustained downturns or extreme volatility in equity markets,
reduced interest rates, unanticipated policyholder behavior,
mortality or longevity, and the adjustment for nonperformance
risk; (44) deterioration in the experience of the
closed block established in connection with the
reorganization of Metropolitan Life Insurance Company
(MLIC); (45) adverse results or other
consequences from litigation, arbitration or regulatory
investigations; (46) discrepancies between actual
experience and assumptions used in establishing liabilities
related to other contingencies or obligations;
(47) regulatory, legislative or tax changes relating to
MetLifes insurance, banking, international, or other
operations that may affect the cost of, or demand for,
MetLifes products or services, impair its ability to
attract and retain talented and experienced management and other
employees, or increase the cost or administrative burdens of
providing benefits to employees; (48) the effects of
business disruption or economic contraction due to terrorism,
other hostilities, or natural catastrophes; (49) the
effectiveness of MetLifes programs and practices in
avoiding giving its associates incentives to take excessive
risks; (50) other risks and uncertainties described from
time to time in MetLife, Inc.s filings with the SEC; and
(51) any of the foregoing factors as they relate to the
Alico Business and its operations.
MetLife, Inc. does not undertake any obligation to publicly
correct or update any forward-looking statement if MetLife, Inc.
later becomes aware that such statement is not likely to be
achieved. Please consult any further disclosures MetLife, Inc.
makes on related subjects in reports to the SEC.
S-6
NOTE REGARDING
RELIANCE ON STATEMENTS IN OUR CONTRACTS
In reviewing the agreements included as exhibits to any of the
documents incorporated by reference into this prospectus
supplement and the accompanying prospectus, please remember that
they are incorporated to provide you with information regarding
their terms and are not intended to provide any other factual or
disclosure information about MetLife, Inc., its subsidiaries or
the other parties to the agreements. The agreements contain
representations and warranties by each of the parties to the
applicable agreement. These representations and warranties have
been made solely for the benefit of the other parties to the
applicable agreement and:
|
|
|
|
|
should not in all instances be treated as categorical statements
of fact, but rather as a way of allocating the risk to one of
the parties to the agreement if those statements prove to be
inaccurate;
|
|
|
|
have been qualified by disclosures that were made to the other
party in connection with the negotiation of the applicable
agreement, which disclosures are not necessarily reflected in
the agreement;
|
|
|
|
may apply standards of materiality in a way that is different
from what may be viewed as material to investors; and
|
|
|
|
were made only as of the date of the applicable agreement or
such other date or dates as may be specified in the agreement
and are subject to more recent developments.
|
Accordingly, these representations and warranties may not
describe the actual state of affairs as of the date they were
made or at any other time.
S-7
SUMMARY
This summary contains basic information about us and this
offering. Because it is a summary, it does not contain all of
the information that you should consider before investing in the
common stock. You should read this entire prospectus supplement
carefully, including the sections entitled Risk
Factors, our financial statements and the notes thereto
incorporated by reference into this prospectus supplement, and
the accompanying prospectus, before making an investment
decision. Except as otherwise noted, all information in this
prospectus supplement and the accompanying prospectus assumes no
exercise of the underwriters option to purchase additional
shares of common stock.
MetLife
MetLife, Inc. is a leading provider of insurance, employee
benefits and financial services with operations throughout the
United States and the regions of Latin America, Asia Pacific and
Europe, the Middle East and India (EMEI).
Through subsidiaries and affiliates, MetLife, Inc. reaches more
than 70 million customers around the world and MetLife is
the largest life insurer in the United States (based on life
insurance in-force). The MetLife companies offer life insurance,
annuities, auto and home insurance, retail banking and other
financial services to individuals, as well as group insurance
and retirement & savings products and services to
corporations and other institutions.
MetLife is one of the largest insurance and financial services
companies in the United States. MetLife believes that its
franchises and brand names uniquely position it to be the
preeminent provider of protection and savings and investment
products in the United States. In addition, its international
operations are focused on markets where the demand for insurance
and savings and investment products is expected to grow rapidly
in the future.
MetLife divides its business into five operating segments:
Insurance Products, Retirement Products, Corporate Benefit
Funding, Auto & Home and International. The results of
Insurance Products, Retirement Products, Corporate Benefit
Funding and Auto & Home are reported under
MetLifes U.S. Business organization.
|
|
|
|
|
Insurance Products. The Insurance
Products segment offers a broad range of protection products and
services aimed at serving the financial needs of MetLifes
customers throughout their lives. These products are sold to
individuals and corporations, as well as other institutions and
their respective employees. MetLife has built a leading position
in the U.S. group insurance market through long-standing
relationships with many of the largest corporate employers in
the United States, and is one of the largest issuers of
individual life insurance products in the United States.
|
|
|
|
Retirement Products. The Retirement
products segment includes a variety of variable and fixed
annuities that are primarily sold to individuals and employees
of corporations and other institutions.
|
|
|
|
Corporate Benefit Funding. The
Corporate Benefit Funding segment includes an array of annuity
and investment products, including guaranteed interest products
and other stable value products, income annuities, and separate
account contracts for the investment management of defined
benefit and defined contribution plan assets. This segment also
includes certain products to fund postretirement benefits and
company, bank or trust owned life insurance used to finance
non-qualified benefit programs for executives.
|
|
|
|
Auto & Home. The
Auto & Home segment includes personal lines property
and casualty insurance offered directly to employees at their
employers worksite, as well as to individuals through a
variety of retail distribution channels, including independent
agents, property and casualty specialists, direct response
marketing and the agency distribution group.
|
|
|
|
International. International provides
life insurance, accident and health insurance, credit insurance,
annuities, endowment and retirement & savings products
to both individuals and groups. MetLife focuses on emerging
markets primarily within the Latin America, Asia Pacific and
EMEI regions.
|
MetLife operates in international markets through subsidiaries
and joint ventures. MetLifes International segment
operates in 16 countries within the Latin America, Asia Pacific
and EMEI regions. MetLife is the largest life insurer in Mexico
and also holds leading market positions in Chile and Japan.
MetLife is also investing in
S-8
organic growth efforts in a number of countries, including
India, China and South Korea. For the six months ended
June 30, 2010, premiums, fees and other revenues for the
Latin America, Asia Pacific and EMEI regions were
$620 million, $488 million and $106 million,
respectively. For the six months ended June 30, 2009,
premiums, fees and other revenues for the Latin America, Asia
Pacific and EMEI regions were $503 million,
$408 million and $94 million, respectively.
Banking, Corporate & Other contains the excess capital
not allocated to the business segments, which is invested to
optimize investment spread and to fund company initiatives,
various
start-up
entities and run-off entities. Banking, Corporate &
Other also includes interest expense related to the majority of
MetLifes outstanding debt and expenses associated with
certain legal proceedings and the elimination of all
intersegment amounts. Banking, Corporate & Other also
includes the financial results of MetLife Bank, National
Association (MetLife Bank), which offers a
variety of residential mortgage and deposit products, including
forward and reverse residential mortgage loans and consumer
deposits.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York
10166-0188
and its telephone number is
(212) 578-2211.
S-9
Acquisition
of the Alico Business
Overview
of the Acquisition
MetLife, Inc. entered into a Stock Purchase Agreement dated as
of March 7, 2010 (the Stock Purchase
Agreement) with American International Group, Inc.
(AIG) and ALICO Holdings LLC (ALICO
Holdings), pursuant to which MetLife, Inc. agreed to
acquire all of the outstanding shares of capital stock of
American Life Insurance Company (ALICO) and
Delaware American Life Insurance Company
(DelAm) for cash and MetLife, Inc. securities
presently valued at approximately $16.1 billion as of
July 30, 2010, subject to certain pre-closing and closing
adjustments (the Acquisition). In this
prospectus supplement, we refer to the acquired business as the
Alico Business.
The closing of the Acquisition is subject to certain conditions.
Although no assurances can be given that these conditions will
be timely satisfied or waived, we expect the Acquisition to
close in the fourth quarter of 2010. After giving effect to the
Acquisition, MetLife will be one of the leading global insurance
companies conducting business in more than 60 countries and
serving over 90 million customers worldwide. On a pro forma
basis, after giving effect to the Acquisition and the financing
transactions related thereto, as of June 30, 2010,
MetLifes total assets and total stockholders equity
(excluding noncontrolling interests of $495 million) would
have been $685.0 billion and $48.4 billion,
respectively. For the six months ended June 30, 2010 and
the year ended December 31, 2009, on a pro forma basis,
MetLife would have had total revenues of $34.1 billion and
$54.3 billion, and diluted income (loss) per share from
continuing operations, net of income tax of $2.77 and $(1.36),
respectively. See Unaudited Pro Forma Capsule
Financial Information.
Overview
of the Alico Business
Founded in 1921, ALICO is one of the largest and most
diversified international life insurance companies in the world,
providing consumers and businesses with products and services
for life insurance, accident and health insurance, retirement
and wealth management solutions. The Acquisition will include
all of the Alico Business, including the business
distribution system, composed of agents, brokers and financial
institutions; 12,500 employees across more than 50 countries;
and 20 million customers worldwide. The Acquisition also
will include the Alico Business Global Benefits Network
serving U.S. and foreign multinationals.
For the six months ended May 31, 2010 and the year ended
November 30, 2009, the Alico Business had total revenues of
$7.0 billion and $14.1 billion, respectively, and net
income of $694 million and $807 million, respectively.
As of May 31, 2010 and November 30, 2009, the Alico
Business had total assets of $109.6 billion and
$113.0 billion, respectively, and stockholders equity
of $13.2 billion and $12.7 billion, respectively.
International diversification is a key strength of the Alico
Business. The Alico Business is a leader in many of the
countries and markets in which it operates. The Alico
Business principal products, based on revenues for the
year ended November 30, 2009 are: (i) traditional life
insurance (35%); (ii) accident and health insurance (29%);
(iii) fixed and variable annuities (23%); and
(iv) group life insurance (13%). The Alico Business uses a
multi-channel
distribution strategy driven by a captive agency force, brokers,
bancassurance (a bank sales channel used to sell insurance
products) and direct marketing. The Alico Business generated
premium income and other consideration of $9.9 billion for
the year ended November 30, 2009.
The Alico Business principal international markets,
products and distribution methods are as follows:
|
|
|
|
|
Japan. The Alico Business is among the
largest foreign life insurers in Japan, which accounted for
$7.8 billion, or approximately 55%, of its total revenues
for the year ended November 30, 2009. Its principal
products in the Japanese market are accident and health
insurance, traditional life insurance, individual annuity and
group life insurance. Its products are distributed through its
captive agency force, independent agents, brokers, bancassurance
and direct marketing.
|
|
|
|
Western Europe. Western Europe
accounted for $2.7 billion, or approximately 19% of the
Alico Business total revenues for the year ended
November 30, 2009. In the Western European region, the
Alico Business offers niche products combined with a
multi-channel distribution approach in the United Kingdom,
Ireland, France, Spain, Portugal and Italy. Its products are
principally traditional life insurance, accident and health
|
S-10
|
|
|
|
|
insurance and group life insurance, and its products are
distributed through bancassurance, brokers, captive agencies,
direct marketing, family offices, private banks, independent
financial advisers and agencies. In addition, the Alico Business
also provides wealth management services, particularly to the
high net worth market, and other potentially high growth
businesses and also offers cash onshore (unit-linked) bonds,
life savings and retirement products and bulk purchase annuities.
|
|
|
|
|
|
Central and Eastern Europe. The Alico
Business has the largest insurance platform in the Central and
Eastern European region with 13 markets, which include Poland,
Greece, Bulgaria, Slovakia, the Czech Republic, Ukraine, Russia,
Romania, Hungary, Latvia, Serbia, Lithuania and Cyprus. This
region accounted for $1.7 billion, or approximately 12% of
the Alico Business total revenues for the year ended
November 30, 2009. The Alico Business principal
products offered in the region include life insurance
(traditional and unit-linked), accident and health insurance,
individual annuities, group life insurance, pension funds and
mutual funds. Its products are distributed through captive
agency, bancassurance, brokers, group sales force and direct
marketing distribution channels.
|
|
|
|
Middle East, Africa and South
Asia. This region accounted for
$0.8 billion, or approximately 6% of the Alico
Business total revenues for the year ended
November 30, 2009. The Alico Business has the largest
geographical coverage of any insurance company in the Middle
East, Africa and South Asia regions with 16 markets, which
include the United Arab Emirates, Bangladesh, Lebanon, Egypt,
Turkey, Saudi Arabia, Jordan, the area governed by the
Palestinian National Authority, Bahrain, Qatar, Oman, Kuwait,
Pakistan, Nepal, Yemen and Liberia. The Alico Business
principal products offered in these regions include traditional
life insurance, accident and health insurance, group life
insurance and pensions. Its products are distributed through
captive agency, group, bancassurance and broker distribution
channels.
|
|
|
|
Latin America. The Alico Business
conducts operations in the Latin American region in
24 markets, which include Chile, Colombia, Argentina,
Uruguay, Panama, the Caribbean, Mexico and joint ventures in
Peru and Venezuela. This region accounted for $0.8 billion,
or approximately 6% of the Alico Business total revenues
for the year ended November 30, 2009. The Alico
Business principal products in this region include
traditional life insurance, accident and health insurance,
individual annuities, group life insurance and pensions, and its
products are distributed by captive agencies, bancassurance,
brokers, direct marketing and through worksites.
|
The remaining 2% of revenues for the year ended
November 30, 2009 related to ALICOs corporate
segment, which includes home office operations in Delaware and
operations of DelAm.
The Alico Business has a comprehensive investment portfolio,
which includes government bonds issued by Asian and European
nations. In particular, as of November 30, 2009, the Alico
Business held $11.5 billion in carrying value of debt
issued by Japan, $1.3 billion in carrying value of debt
issued by Greece and an aggregate carrying value of
$1.3 billion of debt issued by Portugal, Spain, Italy and
Ireland.
Rationale
for the Acquisition
MetLife expects that the Acquisition will increase stockholder
value by increasing MetLifes return on equity and by being
accretive to operating earnings per share. In addition, MetLife
believes that the Acquisition will provide significant long-term
strategic and financial benefits to its stockholders, including
a significant long-term growth in revenues, earnings and returns
on equity. In particular, MetLife believes that the Acquisition
will:
|
|
|
|
|
Significantly Broaden MetLifes Diversification by
Product, Distribution and Geography. The
Acquisition will greatly diversify MetLifes revenue and
earnings sources by product, distribution and geography.
|
|
|
|
|
|
In terms of geographic diversification, as a result of the
Acquisition, MetLife will have a market presence in 64 different
countries, up from 17 at present, which, MetLife believes, will
create significant advantages over its international competitors
by providing scale and access to many higher growth markets.
|
|
|
|
The Acquisition will also diversify MetLifes product mix
by increasing the proportion of premium, fees and other revenues
in accident and health insurance products and certain types of
traditional life insurance
|
S-11
|
|
|
|
|
products, where the primary risks are morbidity and mortality,
and reducing MetLifes relative exposure to
market-sensitive products such as annuities. For the year ended
November 30, 2009, accident and health insurance and
traditional life insurance products accounted for 64% in the
aggregate of the Alico Business total revenues.
|
|
|
|
|
|
As a result of the Acquisition, MetLifes distribution
sources will be further diversified. In addition to
MetLifes existing professional agency, employers and
third-party distribution channels, MetLife will, in the future,
have the benefit of adding the Alico Business captive and
independent agency and direct marketing distribution channels,
as well as enhancing its own third-party distribution channel by
combining it with that of the Alico Business.
|
|
|
|
|
|
Meaningfully Accelerate MetLifes Global Growth
Strategy. The Acquisition will materially
advance MetLifes presence in mature markets such as Japan
and Western Europe and establish leading positions for MetLife
in many emerging and developing markets. For the year ended
November 30, 2009, approximately $7.8 billion, or
approximately 55%, of the Alico Business revenues were
generated in the Japanese market. Another $2.7 billion, or
approximately 19%, of its 2009 revenues were generated in
Western Europe. The Acquisition will result in the formation of
a premier global life insurance franchise, and, according to
premium income information derived from the AXCO Insurance
Information Services Ltd. 2008 reports, the combined business
will be ranked (i) the number one life insurer in the United
States, Mexico and Chile, (ii) the number one insurer for
individual life insurance in Russia and (iii) the number
one foreign life insurer in Japan, with a growing presence in
India and China and a significant presence in Europe.
|
In addition, the Alico Business has leading positions in many
emerging and developing markets in Central and Eastern Europe,
the Middle East and Latin America. Leveraging the combined
business, the broad portfolio of product solutions and
experience in managing diversified distribution channels,
MetLife believes that it will not only be strongly positioned in
the international markets in which MetLife and the Alico
Business currently operate, but it will also be well positioned
to enter new markets with high growth potential. MetLife
believes that its collective historical expertise in building
and growing operations in developing markets, coupled with
scalability of the combined companys business model around
the globe, will be a cornerstone of MetLifes future
geographic expansion.
|
|
|
|
|
Create the Opportunity to Build an Unparalleled
International Franchise Leveraging the Alico Business Key
Strengths. The Alico Business has an
established track record of organic growth. At the core of the
Alico Business strength are its broad geographic
diversification, its leading position in many of the markets in
which it operates, as well as its diversified distribution
methods and balanced product mix favoring protection products.
MetLife believes that this strong positioning, coupled with the
Alico Business longstanding presence in markets that are
now effectively closed to new entrants as a result of their
restrictive regulatory regimes, makes its platform extremely
difficult to replicate today. Accordingly, the Acquisition will
create a unique opportunity to continue to build MetLife as an
unparalleled international franchise leveraging the Alico
Business key strengths.
|
Unaudited
Pro Forma Capsule Financial Information
The following unaudited pro forma capsule financial information
shows the effect of the Acquisition on certain specified balance
sheet and income statement items. This selected data is referred
to as unaudited pro forma capsule financial information in this
prospectus supplement. The information under Selected Pro
Forma Combined Balance Sheet Items assumes the Acquisition
was completed on June 30, 2010. The information under
Selected Pro Forma Combined Income Statement Items
gives effect to the Acquisition as if it had been completed on
January 1, 2009. This unaudited pro forma capsule financial
information assumes that the Acquisition is accounted for using
the acquisition method of accounting and represents a current
estimate based on available financial information and has been
adjusted to reflect the anticipated financing of the Acquisition
and changes to assets and liabilities to record their
preliminary estimated fair values.
The unaudited pro forma capsule financial information is based
on the combination of the specified line items included in
(i) the unaudited historical interim condensed consolidated
balance sheet of MetLife, Inc. at June 30, 2010,
(ii) the unaudited historical interim condensed
consolidated statement of operations of MetLife, Inc. for the
S-12
six months ended June 30, 2010 and (iii) the
historical consolidated statement of operations of MetLife, Inc.
for the year ended December 31, 2009, with the
corresponding line items included in (x) the unaudited
historical interim condensed combined balance sheet of the Alico
Business at May 31, 2010, (y) the unaudited historical
interim condensed combined statement of income of the Alico
Business for the six months ended May 31, 2010 and
(z) the historical combined statement of income of the
Alico Business for the year ended November 30, 2009. The
unaudited historical interim condensed financial statements and
historical financial statements of both MetLife, Inc. and the
Alico Business have been prepared in conformity with accounting
principles generally accepted in the United States of America
(GAAP).
The unaudited pro forma capsule financial information should be
read in conjunction with the unaudited historical interim
condensed consolidated financial statements at and for the three
and six months ended June 30, 2010 of MetLife, Inc.
included in its Second Quarter
Form 10-Q,
the historical consolidated financial statements at and for the
year ended December 31, 2009 of MetLife, Inc. included in
its 2009
Form 10-K,
as well as the
Form 8-K
filed by MetLife, Inc. on August 2, 2010, which includes as
exhibits: (i) the unaudited historical interim condensed
combined financial statements of the Alico Business as of and
for the six months ended May 31, 2010, and (ii) the
historical combined financial statements of the Alico Business
as of and for the year ended November 30, 2009.
The unaudited pro forma capsule information is based upon pro
forma adjustments reflecting the Acquisition which are based on
certain estimates and assumptions. Such pro forma adjustments
may be revised as additional information becomes available. The
actual adjustments upon consummation of the Acquisition and the
allocation of the purchase price of the Alico Business will
depend on a number of factors, including any purchase price
adjustments pursuant to the Stock Purchase Agreement, additional
financial information available at such time, and changes in
values of the purchase consideration and the net assets
acquired. Therefore, the actual adjustments will differ from the
pro forma adjustments assumed in connection with the unaudited
pro forma capsule financial information and it is possible the
differences may be material. MetLife, Inc.s management
believes that its assumptions provide a reasonable basis for
presenting the significant effects of both the Acquisition and
financing transactions contemplated, and that the pro forma
adjustments give appropriate effect to those assumptions and are
properly applied in the unaudited pro forma capsule financial
information. The unaudited pro forma capsule information has not
been presented in accordance with Regulation S-X published by
the SEC because MetLife, Inc. is not yet required to file the
complete unaudited pro forma financial statements required by
such regulations. MetLife, Inc. will file with the SEC unaudited
pro forma financial information presented in accordance with the
requirements of Regulation S-X no later than 71 calendar
days after the date that the initial report on
Form 8-K
disclosing the completion of the Acquisition must be filed.
The unaudited pro forma capsule financial information does not
reflect future events that may occur after the Acquisition,
including but not limited to expense efficiencies or revenue
enhancements arising from the Acquisition. It also does not give
effect to certain one-time charges MetLife, Inc. expects to
incur such as restructuring and integration costs. The unaudited
pro forma capsule financial information is presented for
informational purposes only and is not intended to reflect the
results of operations or the financial position that would have
resulted had the Acquisition been effected on the dates
indicated, or the results that may be obtained by the
consolidated company in the future. Future results may vary
significantly from the results reflected in the unaudited pro
forma capsule financial information because of various factors,
including those discussed in Risk Factors.
S-13
|
|
|
|
|
|
|
June 30, 2010
|
|
|
|
(In millions)
|
|
|
Selected Pro Forma Combined Balance Sheet Items:
|
|
|
|
|
Investments and cash and cash equivalents
|
|
$
|
462,691
|
|
Total assets
|
|
|
685,023
|
|
Long-term debt
|
|
|
26,773
|
|
Total liabilities (including redeemable noncontrolling interest
of $129 million)
|
|
|
636,089
|
|
Total stockholders equity (excluding noncontrolling
interests of $495 million)
|
|
|
48,439
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Six
|
|
|
|
|
|
|
Months Ended
|
|
|
For the Year Ended
|
|
|
|
June 30, 2010
|
|
|
December 31, 2009
|
|
|
|
(In millions, except per share data)
|
|
|
Selected Pro Forma Combined Income Statement Items:
|
|
|
|
|
|
|
|
|
Premiums, fees and other revenues
|
|
$
|
22,436
|
|
|
$
|
43,661
|
|
Total revenues
|
|
|
34,053
|
|
|
|
54,256
|
|
Total expenses
|
|
|
29,551
|
|
|
|
56,980
|
|
Income (loss) from continuing operations, net of income tax
|
|
|
2,979
|
|
|
|
(1,279
|
)
|
Income (loss) per common share from continuing operations, net
of income tax, available to common shareholders
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
2.78
|
|
|
$
|
(1.36
|
)
|
Diluted
|
|
$
|
2.77
|
|
|
$
|
(1.36
|
)
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
|
|
Basic
|
|
|
1,044
|
|
|
|
1,040
|
|
Diluted
|
|
|
1,051
|
|
|
|
1,040
|
|
Purchase
Price and Financing Considerations
The purchase price for the Acquisition is approximately
$16.1 billion (based on the closing price of MetLife, Inc.
common stock of $42.06 per share on July 30, 2010 and
the estimated fair value of the total securities to be issued to
ALICO Holdings). The closing of the Acquisition is expected to
occur during the fourth quarter of 2010. This purchase price is
subject to certain adjustments, including adjustments based on
the after-tax operating earnings of the Alico Business for the
twelve-month period ending May 31, 2010, ALICOs
risk-based capital at closing, and settlement of intercompany
balances and other items. The potential purchase price
adjustments are more fully described in the Stock Purchase
Agreement. The Stock Purchase Agreement also has indemnification
provisions under which MetLife, Inc. has the ability to recover
a portion of certain losses related to certain specified events.
See Proposed Acquisition of the Alico Business
Purchase Price Adjustments.
Under the terms of the Stock Purchase Agreement, and subject to
the adjustments referred to above, MetLife, Inc. will, upon
closing of the Acquisition, (i) pay $6.8 billion to
ALICO Holdings in cash and (ii) issue to ALICO Holdings
(a) 78,239,712 shares of its common stock,
(b) 6,857,000 shares of Series B Contingent
Convertible Junior Participating Non-Cumulative Perpetual
Preferred Stock (the Series B Preferred
Stock) of MetLife, Inc., which will automatically
convert into approximately 68,570,000 shares of MetLife,
Inc.s common stock (subject to anti-dilution adjustments)
upon a favorable vote of MetLife, Inc.s common
stockholders, and (c) 40,000,000 equity units (the
Equity Units) with an aggregate stated amount
at issuance of $3.0 billion, initially consisting of
(x) Stock Purchase Contracts and (y) an interest in
shares of MetLife, Inc.s preferred stock (the
Unit Preferred Stock), which has been treated
as long-term debt for accounting purposes. Distributions on the
Equity Units will be made quarterly at an annual rate of 5% of
the stated amount (2% on the Stock Purchase Contracts and 3% on
the Unit Preferred Stock). As permitted by the terms of the
Stock Purchase Agreement, MetLife, Inc. may seek to modify the
terms of the Equity Units, including by replacing the Unit
Preferred Stock with a different host security, in order to
achieve the desired equity treatment from the rating agencies.
See Risk Factors Risks Relating to the
Acquisition of the Alico Business A Downgrade or a
Potential Downgrade in Our Financial Strength or Credit Ratings
Could Result in a Loss of Business and Materially Adversely
Affect Our Financial Condition and Results of Operations.
S-14
The $6.8 billion cash portion of the purchase price will be
funded by MetLife, Inc. through the issuance of senior debt with
varying maturities and interest rates, the issuance of common
stock and cash on hand. The unaudited pro forma capsule
financial information reflects (i) the assumed issuance of
$3.1 billion in senior debt and related increase in
interest expense using MetLife, Inc.s current anticipated
borrowing rates for such types of securities and (ii) the
assumed issuance of 75,000,000 shares of MetLife, Inc.
common stock, at an assumed price of $42.06 per share, net of
issuance costs. The underwriters have been given an
overallotment option in the amount of 15% of the shares of
common stock offered. It has been assumed for the unaudited pro
forma capsule financial information that the underwriters will
not exercise this option.
The $3.1 billion in senior debt will be issued in
several series with varying maturities and interest rates which
may be fixed or floating, with an estimated range of interest
rates between 2.9% and 6.6%, depending on maturity. MetLife,
Inc.s borrowing rates are sensitive to changes in
risk-free rates and credit spreads. An increase or decrease in
interest rates of 0.125 percent on debt issuances would
result in a change in estimated annual interest expense of
$4 million ($2 million semi-annually).
Common stock dividends are determined annually by MetLife,
Inc.s Board of Directors after taking into consideration
factors such as MetLife, Inc.s current earnings, financial
condition, regulatory capital position, and applicable
governmental regulations and policies.
This unaudited pro forma capsule financial information reflects
managements best estimate of the forms and amounts of
financing as of July 30, 2010. The actual terms and
conditions of financing of the Acquisition may involve different
forms of financing
and/or
different amounts of the same types of instruments. These
differences in form and amount of financing could result in
materially different amounts than those presented herein.
Series B
Preferred Stock, Common Stock and Equity Units Issued to ALICO
Holdings
The Series B Preferred Stock will automatically convert
into 68,570,000 shares of MetLife, Inc.s common stock
(subject to anti-dilution adjustments) upon a favorable vote of
MetLife, Inc.s common stockholders. If MetLife, Inc. fails
to obtain this favorable vote of its common stockholders before
the first anniversary of the closing of the Acquisition, then
MetLife, Inc. must pay ALICO Holdings approximately
$300 million. The Series B Preferred Stock will
participate in dividends pari passu with MetLife,
Inc.s common stock on an as-converted basis.
Pursuant to the Stock Purchase Agreement, MetLife, Inc. will
issue 78,239,712 shares of its common stock to ALICO
Holdings. The anticipated amount of $3,291 million is based
on the closing price of MetLife, Inc.s common stock of
$42.06 on the New York Stock Exchange on July 30, 2010.
Pursuant to the Stock Purchase Agreement, MetLife, Inc. will
also issue Equity Units in aggregate stated amount of
$3.0 billion and an estimated fair value of
$3,165 million, which will include the Unit Preferred Stock
and the Stock Purchase Contracts that will settle on three
specified future settlement dates (an aggregate of
$1.0 billion on each settlement date). Distributions on the
Equity Units will be made quarterly at an annual rate of 5% of
the stated amount (initially $75) of each Equity Unit.
Purchase
Price Allocation
Of the $16.1 billion of cash and MetLife, Inc. securities
issued to ALICO Holdings relating to the Acquisition,
$456 million is allocated to the effective settlement of
debt securities and guaranteed investment contracts
(GICs) issued by MetLife that are owned by
the Alico Business, and the remainder is allocated to the
purchase of the Alico Business.
The purchase price for the Alico Business will be allocated to
assets acquired (including identifiable intangible assets
arising from the Acquisition) and liabilities assumed based on
their estimated fair values. The fair value adjustments in
connection with the Acquisition are described below. The excess
of the total purchase consideration of the Acquisition over the
estimated fair value of the identifiable net assets acquired
will be recorded as goodwill, which is included in total assets
in the unaudited pro forma capsule financial information.
S-15
For purposes of presentation in the unaudited pro forma capsule
financial information, the financing of the Acquisition and
allocation of purchase price is assumed to be as follows:
|
|
|
|
|
|
|
Anticipated
|
|
|
|
Financing Amount
|
|
|
|
(In millions)
|
|
|
Sources:
|
|
|
|
|
Cash
|
|
$
|
657
|
|
Fixed/floating rate senior debt
|
|
|
3,100
|
|
MetLife, Inc. common stock
|
|
|
3,155
|
|
|
|
|
|
|
Total cash financing
|
|
|
6,912
|
|
Series B Preferred Stock issued to ALICO Holdings
|
|
|
2,884
|
|
MetLife, Inc. common stock issued to ALICO Holdings
|
|
|
3,291
|
|
MetLife, Inc. Equity Units issued to ALICO Holdings
|
|
|
3,165
|
|
|
|
|
|
|
Total securities issued to ALICO Holdings
|
|
|
9,340
|
|
|
|
|
|
|
Total source of funds
|
|
$
|
16,252
|
|
|
|
|
|
|
Uses:
|
|
|
|
|
Debt and equity issuance costs
|
|
$
|
112
|
|
Purchase price
|
|
|
16,140
|
|
|
|
|
|
|
Total uses of funds
|
|
$
|
16,252
|
|
|
|
|
|
|
Purchase Price Allocation:
|
|
|
|
|
Total purchase price
|
|
$
|
16,140
|
|
|
|
|
|
|
Effective settlement of pre-existing relationships
|
|
|
(456
|
)
|
Contractual purchase price adjustments
|
|
|
364
|
|
Fair value of noncontrolling interests
|
|
|
146
|
|
|
|
|
|
|
Total purchase consideration for the Alico Business
|
|
$
|
16,194
|
|
|
|
|
|
|
Carrying value of net balance sheet assets acquired
|
|
|
13,329
|
|
Pre-closing adjustments
|
|
|
300
|
|
|
|
|
|
|
Carrying value of net assets to be acquired
|
|
|
13,629
|
|
Estimated acquisition accounting adjustments
|
|
|
(2,012
|
)
|
|
|
|
|
|
Estimated fair value of net assets acquired
|
|
|
11,617
|
|
|
|
|
|
|
Goodwill
|
|
$
|
4,577
|
|
|
|
|
|
|
Pro
Forma Adjustments
As discussed above, these pro forma adjustments are based on
certain estimates and assumptions. The actual adjustments will
depend on a number of factors, including any purchase price
adjustments pursuant to the Stock Purchase Agreement, additional
financial information available at such time, and changes in
values of the purchase consideration and the net assets
acquired. MetLife, Inc. will record actual adjustments at the
effective date of the Acquisition. Those adjustments will differ
from the pro forma adjustments assumed in connection with the
unaudited pro forma capsule financial information included
herein and the differences may be material.
Pre-Closing
Transactions
Prior to closing, AIG is required to complete certain
transactions that affect the Alico Business. These pre-closing
transactions have an estimated net increase on total
stockholders equity of $300 million at June 30,
2010. These transactions primarily include intercompany
settlements related to a foreign currency derivative, swaps, AIG
common stock and certain other investments and long-term debt
held by the Alico Business. As calculated, in accordance with
the provisions of the Stock Purchase Agreement, certain of these
transactions would result in an increase in the purchase price
of approximately $300 million.
S-16
Related
Income Statement Impact
The following gains and losses related to intercompany
transactions that have settled or will settle prior to the
closing of the Acquisition were adjusted: (i) a loss of
$51 million and a gain of $99 million for the six
months ended June 30, 2010 and for the year ended
December 31, 2009, respectively, associated with an
intercompany settlement of a foreign currency derivative between
the Alico Business and AIG, (ii) a gain of $84 million
for the six months ended June 30, 2010 associated with the
intercompany settlement of swap positions between the Alico
Business and AIG Financial Products, and (iii) a gain of
$108 million for the six months ended June 30, 2010
associated with the sale of AIG common stock to AIG.
Investments
and Cash and Cash Equivalents
Investments and cash and cash equivalents include an adjustment
to decrease to fair value fixed maturity securities (relating to
commercial mortgage-backed securities) and mortgage loans by
$193 million and $572 million, respectively, at
June 30, 2010. These adjustments are partially offset by
indemnification assets discussed in Total Assets
below. In addition, investments and cash and cash equivalents
include a fair value adjustment to increase policy loans by
$101 million at June 30, 2010.
Related
Income Statement Impact
In connection with the adjustments to investments and cash and
cash equivalents, the fair values become the new cost basis upon
which the related amortization of premium and accretion of
discount are calculated and applied. The estimated reduction in
total revenues associated with fixed maturity securities of
$190 million and $536 million for the six months ended
June 30, 2010 and the year ended December 31, 2009,
respectively, relate primarily to the net change in
premium/discount
of those securities. The estimated reduction in total revenues
associated with investments other than fixed maturities of
$9 million and $28 million for the six months ended
June 30, 2010 and the year ended December 31, 2009,
respectively, relates primarily to the amortization associated
with the fair value of policy loans.
Total
Assets
In addition to the investment adjustments described above, total
assets includes the elimination of the Alico Business
historical deferred policy acquisition costs
(DAC) of $10,438 million and deferred
sales inducements of $118 million (as of May 31,
2010). In addition, adjustments related to the establishment of
value of business acquired (VOBA) and the
value of distribution agreements (VODA)
arising from the Acquisition, which are estimated at
$8,290 million and $951 million, respectively, are
included. VOBA effectively adjusts the assumed in-force
insurance policy liabilities to the estimated fair value of the
in-force contracts based on actuarially determined projections
for each block of business. VOBA is amortized in a manner
similar to DAC in relation to estimated gross profits or
premiums, depending on product type. If estimated gross profits
or premiums differ from expectations, the amortization of VOBA
is adjusted to reflect actual experience. The VODA is amortized
in relation to the expected economic benefits of the insurance
policies sold by the acquired distributors.
Total assets includes the establishment of $328 million of
indemnification assets for potential recoveries related to the
deterioration of fixed maturity securities, mortgage loans and
certain investment funds, in accordance with the indemnification
provisions of the Stock Purchase Agreement and related
agreements.
Total assets also include the elimination of the Alico
Business historical goodwill of $21 million as of
May 31, 2010 and inclusion of estimated goodwill arising
from the Acquisition of $4,577 million.
An increase or decrease of $1 in the price per share of MetLife,
Inc.s common stock at the time of completion of the
Acquisition would result in a corresponding increase or decrease
to goodwill of approximately $210 million.
Related
Income Statement Impact
The historical amortization of DAC and other amortizable
intangible assets of the Alico Business for the six months ended
May 31, 2010 of $914 million and for the year ended
November 30, 2009 of $2,319 million were eliminated in
total expenses for the six months ended June 30, 2010 and
for the year ended December 31, 2009,
S-17
respectively. Also reflected in total expenses is the estimated
amortization of the VOBA, VODA and DAC on new business for the
six months ended June 30, 2010 and for the year ended
December 31, 2009 of $648 million and
$1,225 million, respectively.
Long-term
Debt
Long-term debt includes the issuance of $3.1 billion in
aggregate principal amount of senior debt and the issuance of
$3.0 billion in aggregate liquidation amount of three
series of Unit Preferred Stock of MetLife, Inc. included as a
component of the Equity Units to be issued to ALICO Holdings in
connection with the Acquisition.
Long-term debt adjustments also include the settlement of
$1.0 billion as of May 31, 2010 of intercompany debt
of the Alico Business due to AIG and affiliates prior to
closing, which will be partially offset by an intercompany tax
receivable and other intercompany notes receivable totaling
$450 million as of May 31, 2010.
Related
Income Statement Impact
Total expenses include interest expense (including premium
amortization) of $93 million and $185 million for the
six months ended June 30, 2010 and the year ended
December 31, 2009, respectively, on the $3.1 billion
in aggregate principal amount of senior debt and the Unit
Preferred Stock included as a component of the Equity Units.
Interest expense on the senior debt was calculated based on
MetLife, Inc.s borrowing rates for the $3.1 billion
in aggregate principal amount of senior debt to the date of this
prospectus supplement. MetLife, Inc.s borrowing rates are
sensitive to changes in risk-free rates and credit spreads.
Actual interest rates may differ from those estimated. Interest
expense on the Unit Preferred Stock component of the Equity
Units was based on a contractual rate of 3%.
Total
Liabilities
In addition to the long-term debt adjustments described above,
total liabilities includes the elimination of the Alico
Business historical unearned revenue of
$1,412 million as of May 31, 2010, an increase in
insurance liabilities of $2,760 million for certain blocks
of business where the estimated fair value of the in-force
contract obligations exceeds the assumed in-force insurance
policy liabilities as of May 31, 2010 and a
$52 million contingent consideration liability for the
estimated fair value of potential payments under provisions of
the Stock Purchase Agreement relating to the adequacy of
reserves for guarantees on certain U.K. unit-linked business.
Related
Income Statement Impact
The elimination of the Alico Business historical unearned
revenues reduced estimated pro forma premiums, fees and other
revenues by $75 million and $232 million for the six
months ended June 30, 2010 and the year ended
December 31, 2009, respectively. The release of insurance
liabilities resulted in a reduction of total expenses of
$99 million and $391 million for the six months ended
June 30, 2010 and the year ended December 31, 2009,
respectively.
Total
Stockholders Equity
Total stockholders equity includes the elimination of the
Alico Business historical equity balances of
$13,183 million, including $972 million in accumulated
other comprehensive income as of May 31, 2010. In addition,
total stockholders equity includes the issuance of
6,857,000 shares of Series B Preferred Stock to ALICO
Holdings, the issuance of 78,239,712 shares of common stock
to ALICO Holdings, the issuance of 75,000,000 shares in a
public offering in connection with the financing of the
Acquisition and the Stock Purchase Contracts that form part of
the Equity Units to be issued to ALICO Holdings and the
associated contract payments. Total stockholders equity
excludes noncontrolling interests of $495 million (of which
$146 million relates to the Alico Business) relating to
certain legal entities that are controlled but not 100% owned.
Income
Taxes
Deferred income taxes of the Alico Business have been adjusted
to reflect the income tax effects of the pro forma purchase
adjustments and the adjustment of the tax basis of the assets
and liabilities acquired reflecting
S-18
elections pursuant to Section 338 of the U.S. Internal
Revenue Code of 1986, as amended (the Code).
The net effect of the tax adjustments was $1.4 billion
($217 million reflected as an increase in foreign deferred
tax liabilities) resulting in a net deferred tax liability
balance of $425 million for the Alico Business.
Related
Income Statement Impact
The pro forma pre-tax adjustments were tax effected at the U.S.
tax rate of 35% except for those adjustments related to certain
foreign subsidiaries whose earnings are permanently reinvested,
which were tax effected at the applicable local statutory tax
rate and certain permanent items. The pro forma pre-tax
adjustments to the income statement resulted in an increase to
income tax expense of $191 million for the year ended
December 31, 2009 and a decrease to income tax expense of
$46 million for the six months ended June 30, 2010 for
the Alico Business.
Net
Income (Loss) from Continuing Operations per Common
Share
The pro forma weighted average number of shares of common stock
on both a basic and diluted basis reflects the (i) public
offering of 75,000,000 shares of MetLife, Inc. common stock
in this offering, (ii) issuance of 78,239,712 shares
of MetLife, Inc. common stock to ALICO Holdings and
(iii) conversion of the Series B Preferred Stock into
68,570,000 shares of MetLife, Inc. common stock. The difference
between basic shares and diluted shares for the six months ended
June 30, 2010 relates to the existing potential dilutive
securities issued by MetLife, Inc. and is not impacted by
securities to be issued as part of the Acquisition. For the year
ended December 31, 2009 there is no difference between
basic shares and diluted shares since the existing potential
dilutive securities issued by MetLife, Inc. have been excluded
from the calculation as these securities are anti-dilutive.
The Equity Units issued to ALICO Holdings had no dilutive impact
on pro forma diluted earnings per share under the application of
the treasury stock method.
S-19
The
Offering
|
|
|
Issuer |
|
MetLife, Inc. |
|
Securities offered |
|
75,000,000 shares of common stock, $0.01 par value per
share, of MetLife, Inc. |
|
|
|
To the extent that the underwriters sell more than
75,000,000 shares of common stock, the underwriters have
the option to purchase up to an additional
11,250,000 shares of common stock, solely to cover
over-allotments, if any. |
|
Common stock outstanding at June 30, 2010, as adjusted for
this offering |
|
895,397,071 shares of common stock (906,647,071 shares
of common stock assuming the exercise of the over-allotment
option in full), not including shares of common stock to be
issued as consideration in the Acquisition. |
|
Use of proceeds |
|
We estimate that the net proceeds of this offering will be
$3,069,000,000 (or $3,529,350,000 assuming the exercise of the
over-allotment option in full). We intend to use the net
proceeds from this offering to fund a portion of the purchase
price for the Acquisition. In the event that the net proceeds
from this offering and the additional offerings exceed the
amount required for the Acquisition, we will use the excess net
proceeds for general corporate purposes. In the event that the
Acquisition is not consummated, we will use the net proceeds
from the sale of the common stock for general corporate purposes. |
|
New York Stock Exchange symbol |
|
MET |
|
Additional Offerings |
|
Following this offering, it is anticipated that MetLife, Inc.
will offer, by means of one or more separate prospectus
supplements, senior notes in an aggregate principal amount of
$3.1 billion. This offering of common stock is not
conditioned on the completion of the additional offerings. There
can be no assurance that the additional offerings will be
completed. |
S-20
RISK
FACTORS
In considering whether to purchase common stock, you should
carefully consider all the information included or incorporated
by reference in this prospectus supplement and in the
accompanying prospectus. In particular, you should carefully
consider the following risk factors.
Risks
Relating to the Acquisition of the Alico Business
The
Acquisition of the Alico Business May Not Be Completed Within
the Expected Timeframe, or At All
Completion of the Acquisition is subject to the satisfaction (or
waiver) of a number of conditions precedent, including relevant
antitrust and regulatory clearances. Any relevant regulatory
agency may refuse its approval or seek to make its approval
subject to compliance with unanticipated or onerous conditions.
The Acquisition is also subject to a number of other conditions
beyond our control that may prevent, delay or otherwise
negatively affect its completion. We cannot predict whether and
when these other conditions will be satisfied. Failure to
complete the Acquisition would, and any delay in completing the
Acquisition could, prevent us from realizing the benefits that
we expect from the Acquisition.
This
Offering of Common Stock is Not Conditioned on the Completion of
the Acquisition
This offering of common stock is not conditioned on the
completion of the Acquisition. Although certain information
contained in this prospectus supplement generally assumes the
completion of the Acquisition, we cannot assure you that the
Acquisition, this common stock offering or the additional
offerings will be consummated on the terms described in this
prospectus supplement or at all. The completion of the
Acquisition, this common stock offering and the additional
offerings are all subject to a number of conditions precedent,
which may or may not be satisfied. If we do not complete the
Acquisition, we will retain broad discretion to use the net
proceeds from this offering of common stock for general
corporate purposes.
Regulatory
Agencies in Certain Jurisdictions May Impose Onerous Conditions
Following the Acquisition
In certain jurisdictions, although consent may not be required
from the relevant regulator, there is a risk that the regulator
may impose onerous requirements on the Alico Business or MetLife
following the Acquisition. These conditions could have the
effect, among other things, of imposing significant additional
costs, limiting our revenues, requiring divestitures of certain
assets, reducing the anticipated benefits of the Acquisition or
imposing other operating restrictions.
We May
Experience Difficulties in Integrating the Alico Business,
Including Its Joint Ventures and Other Arrangements with Third
Parties
Our ability to achieve the benefits we anticipate from the
Acquisition will depend in large part upon whether we are able
to integrate the Alico Business into our business in an
efficient and effective manner. We may not be able to integrate
the Alico Business smoothly or successfully and the process may
take longer than expected. The integration of certain operations
and the differences in operational culture following the
Acquisition will require the dedication of significant
management resources, which may distract managements
attention from
day-to-day
business operations. Integration planning has already required
significant management resources. If we are unable to
successfully integrate the operations of the Alico Business into
MetLife, we may be unable to realize the cross-selling and other
distribution benefits, revenue growth and other anticipated
benefits we expect to achieve as a result of the Acquisition and
our business and results of operations could be adversely
affected.
The success with which we are able to integrate the Alico
Business will depend on our ability to manage a variety of
issues, including the following:
|
|
|
|
|
Loss of key personnel or higher than expected employee attrition
rates could adversely affect the performance of the Alico
Business and our ability to integrate it successfully.
|
|
|
|
Customers of the Alico Business may reduce, delay or defer
decisions concerning their use of the products and services of
the Alico Business as a result of the Acquisition or
uncertainties related to the consummation
|
S-21
|
|
|
|
|
of the Acquisition, including any potential unfamiliarity with
the MetLife brand in regions where MetLife has not had a market
presence prior to the time of the Acquisition.
|
|
|
|
|
|
The Alico Business relies in part upon independent distributors
to distribute its products. Unaffiliated distributors typically
distribute products for many different financial institutions
and may not continue to generate the same volume of business for
MetLife after the Acquisition. Independent distributors may
reexamine the scope of their relationship with the Alico
Business as a result of the Acquisition and decide to curtail or
eliminate distribution of its products.
|
|
|
|
Integrating the Alico Business with our existing operations will
require us to coordinate geographically separated organizations,
address possible differences in corporate culture and management
philosophies, merge financial processes and risk and compliance
procedures, combine separate information technology platforms
and integrate the Alico Business operations that were
previously closely tied to other AIG service providers.
|
There is the risk that MetLife, Inc. will be exposed to
obligations and liabilities of the Alico Business that are not
adequately covered, in amount, scope or duration, by the
indemnification provisions in the Stock Purchase Agreement or
reflected or reserved for in the Alico Business historical
financial statements, and there is the risk that such historical
financial statements may contain errors. The Stock Purchase
Agreement provides that ALICO Holdings will indemnify MetLife,
Inc. for losses arising out of inaccuracies or breaches of
representations or warranties, or the breach or failure to
perform covenants or agreements set forth in the Stock Purchase
Agreement, in addition to losses arising out of certain matters
identified during MetLifes due diligence review of the
Alico Business. However, the survival periods for bringing, and
the monetary limitations imposed on, certain indemnification
claims may result in insufficient protection from all potential
losses that MetLife, Inc. may suffer in connection with the
Acquisition. For example, pursuant to the terms of the Stock
Purchase Agreement, ALICO Holdings has agreed to indemnify
MetLife, Inc. against losses arising out of a breach of a
representation and warranty relating to the absence of
undisclosed liabilities. However, in the event that MetLife,
Inc. suffers a loss because of the existence of a liability of
the Alico Business that was required to be disclosed and was not
disclosed by ALICO Holdings to MetLife, Inc., we cannot be
certain that indemnification by ALICO Holdings will be, among
other things, collectible or sufficient in amount, scope or
duration to fully offset any such loss since losses arising from
any such breach will be subject to a
21-month
survival period and an indemnification deductible and cap.
MetLife, Inc. is indemnified under the Stock Purchase Agreement
for various tax matters, including U.S. federal income
taxes attributable to periods during which the Alico Business
was included in AIGs consolidated federal income tax
return. We cannot be certain that any such indemnification will
ultimately be fully collectible. We may also become exposed to
obligations and liabilities that were undiscovered in the course
of performing due diligence of the Alico Business in connection
with the Acquisition and, therefore, may not be adequately
addressed in the Stock Purchase Agreement. See Proposed
Acquisition of the Alico Business
Indemnification. Any of these liabilities, individually or
in the aggregate, could have a material adverse effect on our
business, financial condition or results of operations.
We expect to incur significant one-time costs in connection with
the Acquisition and the related integration of the Alico
Business. The costs and liabilities actually incurred in
connection with the Acquisition and subsequent integration
process may exceed those anticipated.
In addition, we and the Alico Business operate in certain
markets through joint ventures. Our ability to exercise
management control or influence over these joint venture
operations and our investment in them will depend on the
continued cooperation between the joint venture participants and
on the terms of the joint venture agreements, which allocate
control among the joint venture participants. We may face
financial or other exposure in the event that any of these joint
venture partners fail to meet their obligations under the joint
venture, encounter financial difficulty or elect to alter,
modify or terminate the relationship. In addition, a significant
proportion of the Alico Business product distribution is
and will be carried out through arrangements with third parties
not controlled by the Alico Business and is dependent upon
continuation of these relationships. A temporary or permanent
disruption to these distribution arrangements could adversely
affect the combined business results of operations
following the Acquisition.
S-22
There
Can Be No Assurance That the Closing Agreement ALICO Entered
Into With the IRS Will Achieve Its Intended Effect, or That
ALICO Will Be Able to Comply with the Related Agreed Upon
Plan
On March 4, 2010, ALICO entered into a closing agreement
with the Commissioner of the IRS with respect to a
U.S. withholding tax issue arising from payments by foreign
branches of a life insurance company incorporated under
U.S. law. IRS Revenue Ruling
2004-75,
effective January 1, 2005, requires foreign branches of
U.S. life insurance companies in certain circumstances to
withhold U.S. income taxes on payments of taxable income
made with respect to certain insurance and annuity products paid
to customers resident in a foreign country. The closing
agreement provides transitional relief under
Section 7805(b) of the Code to ALICO, such that
ALICOs foreign branches will not be required to withhold
U.S. income tax on the income portion of payments made
pursuant to ALICOs life insurance and annuity contracts
(Covered Payments) under IRS Revenue Ruling
2004-75 for
any tax periods beginning on January 1, 2005 and ending on
December 31, 2013 (the Deferral Period).
The closing agreement provides that ALICO will submit a plan to
the IRS within 90 days after the close of the Acquisition,
indicating the steps ALICO will take (on a country by country
basis) to ensure that no substantial amount of
U.S. withholding tax will arise from Covered Payments made
by ALICOs foreign branches to foreign customers after the
Deferral Period. In addition, the closing agreement requires
that such plan be updated in quarterly filings with the IRS. The
closing agreement is final and binding upon ALICO and the IRS;
provided, however, that the agreement can be
reopened in the event of malfeasance, fraud or a
misrepresentation of a material fact, and is subject to change
of law risk that occurs after the effective date of the closing
agreement (with certain exceptions). In addition, the closing
agreement provides that no legislative amendment to
Section 861(a)(1)(A) of the Code shall shorten the Deferral
Period, regardless of when such amendment is enacted. We expect
that the plan ALICO is required to deliver to the IRS may
involve the transfer of businesses from certain of the foreign
branches of ALICO to one or more existing or newly-formed
foreign affiliates of ALICO; however, ALICO has not completed
this plan. Although it is not known at this time, there could be
potentially significant costs associated with the implementation
of the plan and, in addition, there can be no assurance that
ALICO will achieve the plan presented to the IRS within the
required time frame of December 31, 2013 because of
regulatory approvals and other requirements. Failure to achieve
the plan in a timely manner could cause ALICO to be required to
withhold U.S. income taxes on the taxable portion of
payments made by ALICOs foreign branches after
December 31, 2013 to customers resident in a foreign
country, which could put ALICO at a competitive disadvantage
with its competitors that sell similar products through foreign
entities and could have a material adverse effect on
ALICOs future revenues or expenses or both.
There
Can Be No Assurance That Any Elections Under Section 338 of
the Code Will Be Made or That Any Incremental Benefit Will
Result From Such Elections, If Made
ALICO Holdings is making elections under Section 338(g) of
the Code (and, as appropriate, Section 338(h)(10) of the
Code) (collectively, 338 Elections) with
respect to ALICO Holdings acquisition of ALICO and certain
of its subsidiaries in 2009. As a result of these elections,
ALICO is expected to realize certain tax benefits in the future.
In addition, MetLife, Inc. has the right under the Stock
Purchase Agreement to have 338 Elections made, at its
option, with respect to its acquisition of ALICO and its
subsidiaries. The incremental benefit of these additional
338 Elections, if made, will depend on the value of
MetLife, Inc.s stock at the time of the closing of the
Acquisition that is issued to ALICO Holdings as part of the
purchase price for ALICO and the effectiveness of such
elections, among other things. It has been assumed for purposes
of the unaudited capsule pro forma financial information
included herein, that additional 338 Elections will be made
and that ALICO and its subsidiaries will have additional
amortizable basis in their assets for U.S. tax purposes as
a result of such additional elections. MetLife, Inc. has entered
into certain arrangements with the underwriters with respect to
the offering so as to facilitate the preservation of MetLife,
Inc.s eligibility to make 338 Elections with respect
to ALICO and its eligible subsidiaries. No assurance can be
given, however, that such additional elections will be made or
as to the incremental benefit, if any, that will result from
such elections, if made.
Following
the Acquisition, the Prospects of the Combined Business May Be
Materially and Adversely Affected if We Are Not Able to Manage
the Growth of the Alico Business Operations
Successfully
The life insurance markets in many of the international markets
in which the Alico Business operates have experienced
significant growth in recent years. Management of the Alico
Business growth to date has required significant
management and operational resources and is likely to continue
to do so. Future growth of our combined
S-23
business will require, among other things, the continued
development of adequate underwriting and claim handling
capabilities and skills, sufficient capital base, increased
marketing and sales activities, and the hiring and training of
new personnel.
There can be no assurance that we will be successful in managing
future growth. In particular, there may be difficulties in
hiring and training sufficient numbers of customer service
personnel and agents to keep pace with any future growth in the
number of customers in our developing or developed markets. In
addition, we may experience difficulties in upgrading,
developing and expanding information technology systems quickly
enough to accommodate any future growth. If we are unable to
manage future growth following the Acquisition, our prospects
may be materially and adversely affected.
If the
Alico Business Does Not Perform Well or We Do Not Integrate It
Successfully, We May Incur Significant Charges to Write Down the
Goodwill Established in the Acquisition
As a result of the Acquisition, we expect goodwill will increase
substantially. See Summary Unaudited Pro Forma
Capsule Financial Information. Under applicable accounting
guidance, we must test our goodwill annually for impairment and,
if we determine that the goodwill has been impaired, we must
write down the goodwill by the amount of the impairment, with a
corresponding charge to net income. If the Alico Business does
not perform well or we do not integrate it successfully, the
reporting units containing parts of the Alico Business may have
fair values lower than their respecting carrying values, which
would result in a write down of goodwill. As such, this could
have a material adverse effect on our results of operations.
We Are
and, Following the Acquisition, Will Be Subject to the Risk of
Exchange Rate Fluctuations Owing to the Geographical Diversity
of Our Combined Business
Due to our geographical diversity and the Alico Business
significant international operations, following the Acquisition
we will be subject to increased risk of exchange rate
fluctuations. In particular, in periods when any foreign
currency in which we derive our revenues (such as the Japanese
yen) weakens, translating amounts expressed in that currency
into U.S. dollars causes fewer U.S. dollars to be
reported. When the relevant foreign currency strengthens,
translating such currency into U.S. dollars causes more
U.S. dollars to be reported. Between March 31, 2010
and June 30, 2010, the Japanese yen has strengthened
against the U.S. dollar, which fluctuated from a low point
of ¥88.45 to the U.S. dollar on June 29, 2010 to
a high point of ¥94.67 to the U.S. dollar on
April 2, 2010, which has been somewhat offset by the
weakening of the euro, which fluctuated from a high point of
0.8382 euro to the U.S. dollar on June 7, 2010, to
0.7339 euro to the U.S. dollar on April 14, 2010. Any
unrealized foreign currency translation adjustments are reported
in accumulated other comprehensive income (loss). The weakening
of a foreign currency relative to the U.S. dollar will
generally adversely affect the value of investments in
U.S. dollar terms and reduce the level of reserves
denominated in that currency. See Risks
Related to Our Business Fluctuations in Foreign
Currency Exchange Rates Could Negatively Affect Our
Profitability below.
The
Unaudited Pro Forma Capsule Financial Information in This
Prospectus Supplement May Not Be Indicative of What Our Actual
Financial Position or Results of Operations Would Have
Been
The unaudited pro forma capsule financial information contained
in this prospectus supplement is not necessarily indicative of
what our actual financial position or results of operations
would have been had the Acquisition been completed on the dates
indicated. It is presented for illustrative purposes only and
has not been presented in accordance with the SECs
Regulation S-X
rules on pro forma financial information because we are not
required to do so yet. The unaudited pro forma capsule financial
information reflects adjustments, which are based upon
preliminary estimates, to allocate the purchase price to the net
assets of the Alico Business. The purchase price allocation as
well as other assumptions reflected in this prospectus
supplement are preliminary, and the final allocation of the
purchase price will be based upon the actual purchase price and
the fair value of the assets and liabilities of the Alico
Business as of the date of the completion of the Acquisition. In
addition, subsequent to the completion of the Acquisition, there
may be further refinements of the purchase price allocation as
additional information becomes available. Accordingly, the final
purchase accounting adjustments may differ materially from the
pro forma adjustments reflected in this prospectus supplement.
In addition, the unaudited pro forma capsule financial
information is based in substantial part on an estimate relating
to the financing of the Acquisition, as well
S-24
as adjustments reflecting the fair value of ALICOs
noncontrolling interest and a reduction for MetLife, Inc. debt
securities and guaranteed investment contracts owned by the
Alico Business that are effectively extinguished as a result of
the Acquisition. These estimates, although made in good faith,
may not be correct, in which case the unaudited pro forma
capsule financial information could be materially incorrect. See
Summary Unaudited Pro Forma Capsule Financial
Information for more information.
The
Carve Out Financial Statements of the Alico Business
Incorporated by Reference Herein Are Not Representative of the
Future Financial Position, Future Results of Operations or
Future Cash Flows of the Alico Business as Part of MetLife Nor
Do They Reflect What the Financial Position, Results of
Operations or Cash Flows of the Alico Business Would Have Been
as a Part of MetLife During the Periods Presented
The financial position, results of operations and cash flows of
the Alico Business presented in the carve-out financial
statements of the Alico Business, which are incorporated by
reference in this prospectus supplement, may be different from
those that would have resulted had the Alico Business been
operated as part of MetLife or different from those that may
result in the future from the Alico Business being operated as a
part of MetLife. This is primarily because, among other things:
|
|
|
|
|
The carve out financial information reflects allocation of
expenses from AIG. Such allocations may be different from the
comparable expenses the Alico Business would have incurred as
part of MetLife.
|
|
|
|
Certain factors resulting from the Acquisition will impact the
financial position, results of operations and cash flows of the
Alico Business as a result of the Alico Business being operated
as a part of MetLife, including, but not limited to, fair value
adjustments, policy differences, the price of MetLife,
Inc.s common stock and tax impacts.
|
Events
Relating to AIG Could Continue to Harm the Alico Business and
Its Reputation and Could Also Harm Our Business and
Reputation
Following the financial difficulties involving AIG, the Alico
Business customers, agents and employees, regulators and
business counterparties expressed concerns about the business
and financial condition of AIG and, consequently, the Alico
Business. As a result, the Alico Business experienced certain
adverse consequences to its business and reputation, including a
temporary increase in policy surrenders and withdrawals and a
reduction in new business, primarily attributable to a perceived
reduction in its financial strength. In addition, any perception
of additional instability surrounding AIG or other events
related or relating to AIG may adversely impact the reputation
of the Alico Business. Furthermore, following the completion of
the Acquisition, the Alico Business will continue to have
relationships with AIG, including the receipt and provision of
services. See Proposed Acquisition of the Alico
Business Other Ancillary Agreements. There is
also a risk that following the Acquisition, our association with
the Alico Business (and therefore AIG) may cause our business to
suffer. For example, we may face higher withdrawals, lower new
business sales, a negative impact on relations with creditors, a
negative impact on our credit ratings or restrictions on the
ability of the Alico Business to pay dividends or transfer
assets in certain jurisdictions.
The
Issuance of Certain Equity Securities to ALICO Holdings in
Connection with the Acquisition Will Have a Dilutive Impact on
MetLife, Inc.s Stockholders
As part of the consideration to be paid to Alico Holdings
pursuant to the terms of the Stock Purchase Agreement, and
subject to certain purchase price adjustments, MetLife, Inc.
will issue to ALICO Holdings (A) 78,239,712 shares of
its common stock, (B) 6,857,000 shares of the
Series B Preferred Stock, which will be convertible into
approximately 68,570,000 shares of MetLife, Inc.s
common stock (subject to anti-dilution adjustments) upon a
favorable vote of MetLife, Inc.s common stockholders, and
(C) $3.0 billion aggregate stated amount of the Equity
Units, which, as currently structured, will initially consist of
(x) forward purchase contracts obligating the holder to
purchase a variable number of shares of MetLife, Inc.s
common stock on each of three specified future settlement dates
(expected to be approximately two, three and four years after
the closing of the Acquisition) for a fixed amount per purchase
contract (an aggregate of $1.0 billion on each settlement
date) (the Stock Purchase Contracts) and
(y) an interest in shares of the Unit Preferred Stock. The
aggregate amount of
S-25
MetLife, Inc.s common stock expected to be issued to ALICO
Holdings in connection with the Acquisition (including shares of
common stock issuable upon conversion of the Series B
Preferred Stock and shares of common stock issuable upon
settlement of the Stock Purchase Contracts) is expected to be
approximately 214,600,000 to 231,500,000 shares.
As a result of the issuance of these securities, more shares of
common stock will be outstanding and each existing stockholder
will own a smaller percentage of our common stock then
outstanding.
Subject
to Certain Limitations, ALICO Holdings Will Be Able to Sell
MetLife, Inc.s Equity Securities at Any Time From and
After the Date 270 Days After the Closing of the
Acquisition, Which Could Cause MetLife, Inc.s Stock Price
to Decrease
ALICO Holdings will agree in accordance with the terms of the
Investor Rights Agreement to be entered into at the closing of
the Acquisition (the Investor Rights
Agreement), not to transfer any of MetLife,
Inc.s securities received pursuant to the terms of the
Stock Purchase Agreement, at any time up to the date
270 days after the closing of the Acquisition. However,
from and after such date, ALICO Holdings will be able to
transfer up to half of such equity securities, and from and
after the first anniversary of the closing of the Acquisition,
ALICO Holdings will be able to transfer all of such securities,
subject in each case to certain limited volume and timing
restrictions set forth in the Investor Rights Agreement.
Moreover, ALICO Holdings will agree to use commercially
reasonable efforts to transfer, and it will cause its affiliates
to so transfer, all of MetLife, Inc.s securities received
in connection with the Acquisition prior to the later of
(i) the fifth anniversary of the closing of the
Acquisition, and (ii) the first anniversary of the third
stock purchase date under the Stock Purchase Contracts. Subject
to certain conditions, we have agreed to register the resale of
MetLife, Inc.s equity and other securities to be issued to
ALICO Holdings under the Securities Act of 1933, as amended (the
Securities Act). The sale or transfer of a
substantial number of these securities within a short period of
time could cause MetLife, Inc.s stock price to decrease,
make it more difficult for us to raise funds through future
offerings of MetLife, Inc.s common stock or acquire other
businesses using MetLife, Inc.s common stock as
consideration.
If
MetLife, Inc.s Stockholders Do Not Vote to Approve the
Conversion of the Series B Preferred Stock Into Common
Stock, MetLife, Inc. Will Be Required to Pay Approximately $300
Million to ALICO Holdings
ALICO Holdings will receive shares of the Series B
Preferred Stock at the date of completion of the Acquisition.
Each share of Series B Preferred Stock will convert into
10 shares of MetLife, Inc.s common stock if
conversion is approved by MetLife, Inc.s common
stockholders. If we fail to obtain such approval prior to the
first anniversary of the closing of the Acquisition, MetLife,
Inc. will be required to pay approximately $300 million to
ALICO Holdings, assuming no purchase price adjustments, and list
the Series B Preferred Stock on the New York Stock Exchange.
Change
of Control Provisions in the Alico Business Agreements May
Be Triggered Upon the Completion of the Acquisition and May Lead
to Adverse Consequences
We and the Alico Business are party to contracts, agreements and
instruments, including reinsurance contracts, that contain
change of control provisions that may be triggered upon the
completion of the Acquisition. Agreements with change of control
provisions typically provide for, or permit the termination of,
the agreement upon the occurrence of a change of control of one
of the parties or, in the case of debt instruments, require
repayment of the outstanding indebtedness. Usually these
provisions, if any, may be waived with the consent of the other
party, and we will consider whether to seek these waivers. In
the absence of these waivers, the operation of the change of
control provisions, if any, could result in the loss of
significant contractual rights and benefits, the termination of
significant agreements, the payment of a termination fee or the
need to renegotiate financing agreements. In addition,
employment agreements or other employee benefit arrangements may
contain change of control provisions providing for additional
payments following a change of control.
S-26
Guarantees
Within Certain of Alico Business Variable Life and Annuity
Products That Protect Policyholders Against Significant
Downturns in Equity Markets May Increase the Volatility of
Results, Increase ALICOs Exposure to Foreign Exchange
Risk, and Decrease Alico Business Earnings
The Alico Business has certain variable life and annuity
products with little or no cash value that contain guaranteed
death benefits. If policyholder lapses are less than expected or
if investment performance is worse than expected, these
guarantees will become more valuable, increasing liabilities,
resulting in a reduction in net income. Also, the Alico Business
has funding agreement liabilities that guarantee payment of the
highest fund value over the life of the funding agreement,
protecting the policyholder even if the fund value declines at
the maturity date. If fund values decline, the value of these
guarantees will increase, increasing the liabilities associated
with these contracts, resulting in a reduction of net income. In
addition, certain products are exposed to foreign exchange risk.
Payments under these contracts may be required to be made in
different currencies, depending on the circumstances. Therefore,
payments may be required in a different currency than the
currency upon which the liability valuation is based. If the
currency upon which expected future payments are made
strengthens relative to the currency upon which the liability
valuation is based, the liability valuation may increase,
resulting in a reduction of net income.
The
Resolution of Several Issues Affecting the Financial Services
Industry Could Have a Negative Impact on Our Reported Results
and, Following the Acquisition, the Combined Business
Reported Results or on Its Relations with Current and Potential
Customers
Both we and the Alico Business are and, following the
Acquisition, will continue to be subject to legal and regulatory
actions in the ordinary course of our business, both in the
United States and internationally. This could result in a review
of business sold in the past under previously acceptable market
practices at the time. Regulators are increasingly interested in
the approach that product providers use to select third-party
distributors and to monitor the appropriateness of sales made by
them. In some cases, product providers can be held responsible
for the deficiencies of third-party distributors.
In the United States, federal and state regulators have focused
on, and continue to devote substantial attention to, the mutual
fund, fixed, index and variable annuity and insurance product
industries. This includes new regulations in respect of the
suitability of broker-dealers sales of certain products.
As a result of publicity relating to widespread perceptions of
industry abuses, there have been numerous regulatory inquiries
and proposals for legislative and regulatory reforms.
In Asia, where the Alico Business derives and will continue to
derive a significant portion of its income, regulatory regimes
are developing at different speeds, driven by a combination of
global factors and local considerations. New requirements may be
introduced that are retrospectively applied to sales made prior
to their introduction. See Risks Related to
Our Business Actions of the U.S. Government,
Federal Reserve Bank of New York and Other Governmental and
Regulatory Bodies for the Purpose of Stabilizing and
Revitalizing the Financial Markets and Protecting Investors and
Consumers May Not Achieve the Intended Effect or Could Adversely
Affect MetLifes Competitive Position.
The
Alico Business Investment Portfolio Contains a Substantial
Amount of Sovereign Debt of European Nations, Which May Be
Written Down as a Result of Financial Instability in
Europe
The Alico Business investment portfolio contains
investments in government bonds issued by European nations.
Recently, the European Union member states have experienced
above average public debt, inflation and unemployment as the
global economic downturn has developed. A number of member
states are significantly impacted by the economies of their more
influential neighbors, such as Germany. In addition, financial
troubles of one nation can trigger a domino effect on others. In
particular, a number of large European banks hold significant
amounts of sovereign financial institution debt of other
European nations and could experience difficulties as a result
of defaults or declines in the value of such debt.
In response to the financial crises affecting certain member
states, including Greece, Spain, Ireland and Portugal, on
May 10, 2010, the European Union, the European Central Bank
and the International Monetary Fund announced a rescue package
of up to 750 billion, or approximately $1 trillion,
for European nations in the euro area. Although the rescue
package is intended to stabilize these economies, there can be
no assurance that such
S-27
package ultimately will be successful. Recent sovereign debt
issuances have been well received by investors, but, to the
extent that the rescue package does not achieve its intended
effect, European nations such as Greece could continue to incur
widening credit spreads and depressed asset valuations. In such
case, the Alico Business may be forced to write down the value
of the Greek bonds contained in its investment portfolio, and it
could experience similar results with respect to its investments
in securities issued by other countries in the region.
Risks
Related to Our Business
The Alico Business is similar to our own business in many
respects, and the Acquisition will increase our exposure to many
of the risks described below.
Difficult
Conditions in the Global Capital Markets and the Economy
Generally May Materially Adversely Affect Our Business and
Results of Operations and These Conditions May Not Improve in
the Near Future
Our business and results of operations are materially affected
by conditions in the global capital markets and the economy
generally, both in the United States and elsewhere around the
world. Stressed conditions, volatility and disruptions in global
capital markets or in particular markets or financial asset
classes can have an adverse effect on us, in part because we
have a large investment portfolio. Disruptions in one market or
asset class can also spread to other markets or asset classes.
Although the disruption in the global financial markets that
began in late 2007 has moderated, not all global financial
markets are functioning normally, and some remain reliant upon
government intervention and liquidity. Upheavals in the
financial markets can also affect our business through their
effects on general levels of economic activity, employment and
customer behavior. Although many economists believe the recent
recession ended in the third quarter of 2009, after a brief
rebound, the recovery has slowed, and the unemployment rate is
expected to remain high for some time. In addition, inflation
has fallen over the last several years and remains at very low
levels. Some economists believe that disinflation and deflation
risk remains in the economy. Our revenues are likely to remain
under pressure in such circumstances and our profit margins
could erode. Also, in the event of extreme prolonged market
events, such as the recent global credit crisis, we could incur
significant capital or operating losses. Even in the absence of
a market downturn, we are exposed to substantial risk of loss
due to market volatility.
We are a significant writer of variable annuity products. The
account values of these products decrease as a result of
downturns in capital markets. Decreases in account values reduce
the fees generated by our variable annuity products, cause the
amortization of deferred acquisition costs to accelerate and
could increase the level of liabilities we must carry to support
those variable annuities issued with any associated guarantees.
Factors such as consumer spending, business investment,
government spending, the volatility and strength of the capital
markets, and inflation all affect the business and economic
environment and, ultimately, the amount and profitability of our
business. In an economic downturn characterized by higher
unemployment, lower family income, lower corporate earnings,
lower business investment and lower consumer spending, the
demand for our financial and insurance products could be
adversely affected. Group insurance, in particular, is affected
by the higher unemployment rate. In addition, we may experience
an elevated incidence of claims and lapses or surrenders of
policies. Our policyholders may choose to defer paying insurance
premiums or stop paying insurance premiums altogether. Adverse
changes in the economy could affect earnings negatively and
could have a material adverse effect on our business, results of
operations and financial condition. The recent market turmoil
has precipitated, and may continue to raise the possibility of,
legislative, regulatory and governmental actions. We cannot
predict whether or when such actions may occur, or what impact,
if any, such actions could have on our business, results of
operations and financial condition. See
Actions of the U.S. Government, Federal
Reserve Bank of New York and Other Governmental and Regulatory
Bodies for the Purpose of Stabilizing and Revitalizing the
Financial Markets and Protecting Investors and Consumers May Not
Achieve the Intended Effect or Could Adversely Affect
MetLifes Competitive Position,
President Obama Recently Signed a Bill
Providing for Comprehensive Reform of Financial Services
Regulation in the United States, Various Aspects of Which Could
Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth, Our
Insurance and Banking Businesses Are Heavily Regulated, and
Changes in Regulation May Reduce Our Profitability and
Limit Our Growth and Competitive Factors
May Adversely Affect Our Market Share and Profitability.
S-28
Adverse
Capital and Credit Market Conditions May Significantly Affect
Our Ability to Meet Liquidity Needs, Access to Capital and Cost
of Capital
The capital and credit markets are sometimes subject to periods
of extreme volatility and disruption. Such volatility and
disruption could cause liquidity and credit capacity for certain
issuers to be limited.
We need liquidity to pay our operating expenses, interest on our
debt and dividends on our capital stock, maintain our securities
lending activities and replace certain maturing liabilities.
Without sufficient liquidity, we will be forced to curtail our
operations, and our business will suffer. The principal sources
of our liquidity are insurance premiums, annuity considerations,
deposit funds, and cash flow from our investment portfolio and
assets, consisting mainly of cash or assets that are readily
convertible into cash. Sources of liquidity in normal markets
also include short-term instruments such as funding agreements
and commercial paper. Sources of capital in normal markets
include long-term instruments, medium- and long-term debt,
junior subordinated debt securities, capital securities and
equity securities.
In the event market or other conditions have an adverse impact
on our capital and liquidity beyond expectations and our current
resources do not satisfy our needs, we may have to seek
additional financing. The availability of additional financing
will depend on a variety of factors such as market conditions,
regulatory considerations, the general availability of credit,
the volume of trading activities, the overall availability of
credit to the financial services industry, our credit ratings
and credit capacity, as well as the possibility that customers
or lenders could develop a negative perception of our long- or
short-term financial prospects if we incur large investment
losses or if the level of our business activity decreases due to
a market downturn. Similarly, our access to funds may be
impaired if regulatory authorities or rating agencies take
negative actions against us. Our internal sources of liquidity
may prove to be insufficient and, in such case, we may not be
able to successfully obtain additional financing on favorable
terms, or at all.
Our liquidity requirements may change if, among other things, we
are required to return significant amounts of cash collateral on
short notice under securities lending agreements.
Disruptions, uncertainty or volatility in the capital and credit
markets may also limit our access to capital required to operate
our business, most significantly our insurance operations. Such
market conditions may limit our ability to replace, in a timely
manner, maturing liabilities; satisfy statutory capital
requirements; and access the capital necessary to grow our
business. As such, we may be forced to delay raising capital,
issue different types of securities than we would otherwise,
less effectively deploy such capital, issue shorter tenor
securities than we prefer, or bear an unattractive cost of
capital which could decrease our profitability and significantly
reduce our financial flexibility. Our results of operations,
financial condition, cash flows and statutory capital position
could be materially adversely affected by disruptions in the
financial markets.
Actions
of the U.S. Government, Federal Reserve Bank of New York
and Other Governmental and Regulatory Bodies for the Purpose of
Stabilizing and Revitalizing the Financial Markets and
Protecting Investors and Consumers May Not Achieve the Intended
Effect or Could Adversely Affect MetLifes Competitive
Position
The Emergency Economic Stabilization Act of 2008
(EESA) gave the U.S. Treasury the
authority to, among other things, purchase up to
$700.0 billion of securities (including newly issued
preferred shares and subordinated debt) from financial
institutions for the purpose of stabilizing the financial
markets. The U.S. federal government, the Federal Reserve
Bank of New York, the Federal Deposit Insurance Corporation
(FDIC) and other governmental and regulatory
bodies also took other actions to address the financial crisis.
For example, the Federal Reserve Bank of New York made funds
available to commercial and financial companies under a number
of programs, including the Commercial Paper Funding Facility,
which expired in early 2010. The U.S. Treasury established
programs based in part on EESA and in part on the separate
authority of the Federal Reserve Board and the FDIC, to foster
purchases from and by banks, insurance companies and other
financial institutions of certain kinds of assets for which
valuations have been low and markets weak. Although such actions
appear to have provided some stability to the financial markets,
our business, financial condition and results of operations and
the trading price of MetLife, Inc.s common stock could be
materially and adversely affected to the extent that credit
availability and prices for financial assets revert to their low
levels of late 2008 and early 2009 or do not improve
S-29
further. These programs have largely run their course or been
discontinued. More likely to be relevant to MetLife, Inc. are
the monetary policy by the Federal Reserve Board and the
Dodd-Frank Wall Street Reform and Consumer Protection Act
(Dodd-Frank), which was recently signed by
President Obama and will significantly change financial
regulation in the U.S. in a number of areas that could
affect MetLife. We cannot predict what impact, if any, this
could have on our business, results of operations and financial
condition.
It is not certain what effect the enactment of Dodd-Frank will
have on the financial markets, the availability of credit, asset
prices and MetLifes operations. See
President Obama Recently Signed a Bill
Providing for Comprehensive Reform of Financial Services
Regulation in the United States, Various Aspects of Which Could
Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth. Furthermore, Congress
has considered, and may consider in the future, legislative
proposals that could impact the estimated fair value of mortgage
loans, such as legislation that would permit bankruptcy courts
to rewrite the terms of a mortgage contract, including reducing
the principal balance of mortgage loans owed by bankrupt
borrowers, or legislation that requires loan modifications. If
such legislation is enacted, it could cause loss of principal on
certain of our non-agency prime residential mortgage-backed
security (RMBS) holdings and could cause a
ratings downgrade in such holdings which, in turn, would cause
an increase in unrealized losses on such securities and increase
the risk-based capital that we must hold to support such
securities. See We Are Exposed to Significant
Financial and Capital Markets Risk Which May Adversely Affect
Our Results of Operations, Financial Condition and Liquidity,
and Our Net Investment Income Can Vary from Period to
Period. In addition, the U.S. federal government
(including the FDIC) and private lenders have instituted
programs to reduce the monthly payment obligations of mortgagors
and/or
reduce the principal payable on residential mortgage loans. As a
result of such programs or of any legislation requiring loan
modifications, we may need to maintain or increase our
engagement in similar activities in order to comply with program
or statutory requirements and to remain competitive. We cannot
predict whether the funds made available by the
U.S. federal government and its agencies will be enough to
continue stabilizing or to further revive the financial markets
or, if additional amounts are necessary, whether Congress will
be willing to make the necessary appropriations, what the
publics sentiment would be towards any such
appropriations, or what additional requirements or conditions
might be imposed on the use of any such additional funds.
The choices made by the U.S. Treasury, the Federal Reserve
Board and the FDIC in their distribution of funds under EESA and
any future asset purchase programs, as well as any decisions
made regarding the imposition of additional regulation on large
financial institutions may have, over time, the effect of
supporting some aspects of the financial services industry more
than others. Some of our competitors have received, or may in
the future receive, benefits under one or more of the federal
governments programs. This could adversely affect our
competitive position. See Competitive Factors
May Adversely Affect Our Market Share and Profitability.
See also New and Impending Compensation and
Corporate Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively and Our Insurance and
Banking Businesses Are Heavily Regulated, and Changes in
Regulation May Reduce Our Profitability and Limit Our
Growth.
Our
Insurance and Banking Businesses Are Heavily Regulated, and
Changes in Regulation May Reduce Our Profitability and Limit Our
Growth
Our insurance operations are subject to a wide variety of
insurance and other laws and regulations. State insurance laws
regulate most aspects of our U.S. insurance businesses, and
our insurance subsidiaries are regulated by the insurance
departments of the states in which they are domiciled and the
states in which they are licensed. Our
non-U.S. insurance
operations are principally regulated by insurance regulatory
authorities in the jurisdictions in which they are domiciled and
operate.
State laws in the United States grant insurance regulatory
authorities broad administrative powers with respect to, among
other things:
|
|
|
|
|
licensing companies and agents to transact business;
|
|
|
|
calculating the value of assets to determine compliance with
statutory requirements;
|
S-30
|
|
|
|
|
mandating certain insurance benefits;
|
|
|
|
regulating certain premium rates;
|
|
|
|
reviewing and approving policy forms;
|
|
|
|
regulating unfair trade and claims practices, including through
the imposition of restrictions on marketing and sales practices,
distribution arrangements and payment of inducements;
|
|
|
|
regulating advertising;
|
|
|
|
protecting privacy;
|
|
|
|
establishing statutory capital and reserve requirements and
solvency standards;
|
|
|
|
fixing maximum interest rates on insurance policy loans and
minimum rates for guaranteed crediting rates on life insurance
policies and annuity contracts;
|
|
|
|
approving changes in control of insurance companies;
|
|
|
|
restricting the payment of dividends and other transactions
between affiliates; and
|
|
|
|
regulating the types, amounts and valuation of investments.
|
State insurance guaranty associations have the right to assess
insurance companies doing business in their state for funds to
help pay the obligations of insolvent insurance companies to
policyholders and claimants. Because the amount and timing of an
assessment is beyond our control, the liabilities that we have
currently established for these potential liabilities may not be
adequate.
State insurance regulators and the National Association of
Insurance Commissioners (NAIC) regularly
reexamine existing laws and regulations applicable to insurance
companies and their products. Changes in these laws and
regulations, or in interpretations thereof, are often made for
the benefit of the consumer at the expense of the insurer and,
thus, could have a material adverse effect on our financial
condition and results of operations.
The NAIC and several states legislatures have considered
the need for regulations
and/or laws
to address agent or broker practices that have been the focus of
investigations of broker compensation in the State of New York
and in other jurisdictions. The NAIC adopted a Compensation
Disclosure Amendment to its Producers Licensing Model Act which,
if adopted by the states, would require disclosure by agents or
brokers to customers that insurers will compensate such agents
or brokers for the placement of insurance and documented
acknowledgement of this arrangement in cases where the customer
also compensates the agent or broker. Several states have
enacted laws similar to the NAIC amendment. Others have enacted
laws or proposed disclosure regulations which, under differing
circumstances, require disclosure of specific compensation
earned by a producer on the sale of an insurance or annuity
product. We cannot predict how many states may promulgate the
NAIC amendment or alternative regulations or the extent to which
these regulations may have a material adverse impact on our
business.
Currently, the U.S. federal government does not directly
regulate the business of insurance. However, federal legislation
and administrative policies in several areas can significantly
and adversely affect insurance companies. These areas include
financial services regulation, securities regulation, pension
regulation, health care regulation, privacy, tort reform
legislation and taxation. In addition, various forms of direct
and indirect federal regulation of insurance have been proposed
from time to time, including proposals for the establishment of
an optional federal charter for insurance companies. As part of
a comprehensive reform of financial services regulation,
Dodd-Frank creates an office within the federal government to
collect information about the insurance industry, recommend
prudential standards, and represent the United States in
dealings with foreign insurance regulators. Other aspects of our
insurance operations could also be affected by Dodd-Frank. For
example, Dodd-Frank imposes new restrictions on the ability of
affiliates of insured depository institutions (such as MetLife
Bank) to engage in proprietary trading or sponsor or invest in
hedge funds or private equity funds. See
President Obama Recently Signed a Bill
Providing for Comprehensive Reform of Financial Services
Regulation in the United States, Various Aspects of Which Could
Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth.
S-31
As a federally chartered national association, MetLife Bank is
subject to a wide variety of banking laws, regulations and
guidelines. Federal banking laws regulate most aspects of the
business of MetLife Bank, but certain state laws may apply as
well. MetLife Bank is principally regulated by the OCC, the
Federal Reserve and the FDIC.
Federal banking laws and regulations address various aspects of
MetLife Banks business and operations with respect to,
among other things:
|
|
|
|
|
chartering to carry on business as a bank;
|
|
|
|
maintaining minimum capital ratios;
|
|
|
|
capital management in relation to the banks assets;
|
|
|
|
safety and soundness standards;
|
|
|
|
loan loss and other related liabilities;
|
|
|
|
liquidity;
|
|
|
|
financial reporting and disclosure standards;
|
|
|
|
counterparty credit concentration;
|
|
|
|
restrictions on related party and affiliate transactions;
|
|
|
|
lending limits (and, in addition, Dodd-Frank includes the credit
exposures arising from securities lending by MetLife Bank within
lending limits otherwise applicable to loans);
|
|
|
|
payment of interest;
|
|
|
|
unfair or deceptive acts or practices;
|
|
|
|
privacy; and
|
|
|
|
bank holding company and bank change of control.
|
In addition, the ability of MetLife Bank to pay dividends could
be reduced by any additional capital requirements that might be
imposed as a result of the enactment of Dodd-Frank.
Furthermore, Dodd-Frank establishes a new Consumer Financial
Protection Bureau that would supervise and regulate institutions
providing certain financial products and services to consumers.
Although the consumer financial services to which this
legislation would apply would exclude certain insurance
business, the new Bureau would have authority to regulate
consumer services provided by MetLife Bank. Federal pre-emption
of state consumer protection laws applicable to banking services
would be significantly restricted under the bills, which would
increase the regulatory and compliance burden on MetLife Bank
and could adversely affect its business and results of
operations. Dodd-Frank also includes provisions on mortgage
lending, anti-predatory lending and other regulatory and
supervisory provisions that could impact the business and
operations of MetLife Bank.
In addition, bank regulatory agencies have issued proposed
interagency guidance for funding and liquidity risk management
that would apply to MetLife, Inc. as a bank holding company. The
FDIC has the right to assess FDIC-insured banks for funds to
help pay the obligations of insolvent banks to depositors.
Because the amount and timing of an assessment is beyond our
control, the liabilities that we have currently established for
these potential liabilities may not be adequate.
In addition, Dodd-Frank will result in increased assessment for
banks with assets of $10 billion or more, which includes
MetLife Bank. Federal and state banking regulators regularly
re-examine existing laws and regulations applicable to banks and
their products. Changes in these laws and regulations, or in
interpretations thereof, are often made for the benefit of the
consumer at the expense of the bank and, thus, could have a
material adverse effect on the financial condition and results
of operations of MetLife Bank.
Our international operations are subject to regulation in the
jurisdictions in which they operate, which in many ways is
similar to that of the state regulation outlined above. This
regulation may impact many of our customers and independent
sales intermediaries. Changes in the regulations that affect
their operations also may affect our business
S-32
relationships with them and their ability to purchase or
distribute our products. Accordingly, these changes could have a
material adverse effect on our financial condition and results
of operations. See Our International
Operations Face Political, Legal, Operational and Other Risks,
Including Exposure to Local and Regional Economic Conditions,
that Could Negatively Affect Those Operations or Our
Profitability.
Compliance with applicable laws and regulations is time
consuming and personnel-intensive, and changes in these laws and
regulations may materially increase our direct and indirect
compliance and other expenses of doing business, thus having a
material adverse effect on our financial condition and results
of operations.
From time to time, regulators raise issues during examinations
or audits of MetLife, Inc.s subsidiaries that could, if
determined adversely, have a material impact on us. We cannot
predict whether or when regulatory actions may be taken that
could adversely affect our operations. In addition, the
interpretations of regulations by regulators may change and
statutes may be enacted with retroactive impact, particularly in
areas such as accounting or statutory reserve requirements.
We are also subject to other regulations and may in the future
become subject to additional regulations.
President
Obama Recently Signed a Bill Providing for Comprehensive Reform
of Financial Services Regulation in the United States, Various
Aspects of Which Could Impact Our Business Operations, Capital
Requirements and Profitability and Limit Our
Growth
On July 21, 2010, President Obama signed Dodd-Frank.
Various provisions of Dodd-Frank could affect our business
operations and our profitability and limit our growth. For
example:
|
|
|
|
|
As a large, interconnected bank holding company with assets of
$50 billion or more, or possibly as an otherwise
systemically important financial company, MetLife, Inc. will be
subject to enhanced prudential standards imposed on systemically
significant financial companies. Enhanced standards will be
applied to risk-based capital, liquidity, leverage (unless
another, similar, standard is appropriate for the company),
resolution plan and credit exposure reporting, concentration
limits, and risk management. Off-balance sheet activities are
required to be accounted for in meeting capital requirements. In
addition, if it was determined that MetLife posed a grave threat
to U.S. financial stability, the applicable federal
regulators would have the right to require it to take one or
more other mitigating actions to reduce that risk, including
limiting its ability to merge with or acquire another company,
terminating activities, restricting its ability to offer
financial products or requiring it to sell assets or off-balance
sheet items to unaffiliated entities. Enhanced standards would
also permit, but not require, regulators to establish
requirements with respect to contingent capital, enhanced public
disclosures and short term debt limits. These standards are
described as being more stringent than those otherwise imposed
on bank holding companies; however, the Federal Reserve Board is
permitted to apply them on an
institution-by-institution
basis, depending on its determination of the institutions
riskiness. In addition, under Dodd-Frank, all bank holding
companies that have elected to be treated as financial holding
companies, such as MetLife, Inc., will be required to be
well capitalized and well managed as
defined by the Federal Reserve Board, on a consolidated basis
and not just at their depository institution(s), a higher
standard than is applicable to financial holding companies under
current law.
|
|
|
|
MetLife, Inc., as a bank holding company, will have to meet
minimum leverage ratio and risk-based capital requirements on a
consolidated basis to be established by the Federal Reserve
Board that are not less than those applicable to insured
depository institutions under so-called prompt corrective action
regulations as in effect on the date of the enactment of the
legislation. One consequence of these new rules will ultimately
be the inability of bank holding companies to include
trust-preferred securities as part of their Tier 1 capital.
Because of the phase-in period for these new rules, they should
have little practical effect on MetLifes ability to treat
its currently outstanding trust-preferred securities as part of
its Tier 1 capital, but they could have an effect on
securities to be used as part of the consideration for the
Acquisition, since the new rules apply immediately to
instruments issued after May 19, 2010.
|
|
|
|
Under the provisions of Dodd-Frank relating to the resolution or
liquidation of certain types of financial institutions,
including bank holding companies, if MetLife, Inc. were to
become insolvent or were in danger
|
S-33
|
|
|
|
|
of defaulting on its obligations, it could be compelled to
undergo liquidation with the FDIC as receiver. For this new
regime to be applicable, a number of determinations would have
to be made, including that a default by the affected company
would have serious adverse effects on financial stability in the
United States. If the FDIC were to be appointed as the receiver
for such a company, the liquidation of that company would occur
under the provisions of the new liquidation authority, and not
under the Bankruptcy Code. In such a liquidation, the holders of
such companys debt could in certain respects be treated
differently than under the Bankruptcy Code. In particular,
unsecured creditors and shareholders are intended to bear the
losses of the company being liquidated. The FDIC is authorized
to establish rules for the priority of creditors claims
and, under certain circumstances, to treat similarly situated
creditors differently. Dodd-Frank also provides for the
assessment of bank holding companies with assets of
$50.0 billion or more, non-bank financial companies
supervised by the Federal Reserve Bank, and other financial
companies with assets of $50.0 billion or more to cover the
costs of liquidating any financial company subject to the new
liquidation authority. Although it is not possible to assess the
full impact of the liquidation authority at this time, it could
affect the funding costs of large bank holding companies or
financial companies that might be viewed as systemically
significant. It could also lead to an increase in secured
financings.
|
|
|
|
|
|
Dodd-Frank also includes a new framework of regulation of the
OTC derivatives markets which could require clearing of certain
types of transactions currently traded
over-the-counter
and potentially impose additional costs, including new capital
and margin requirements and additional regulation on MetLife.
Increased margin requirements on MetLife, Inc.s part could
reduce its liquidity and narrow the range of securities in which
it invests. However, increased margin requirements on MetLife,
Inc.s counterparties could reduce MetLife, Inc.s
exposure to its counterparties default. MetLife, Inc. uses
derivatives to mitigate the impact of increased benefit
exposures from our annuity products that offer guaranteed
benefits. The derivative clearing requirements of Dodd-Frank
could increase the cost of such mitigation. In addition, we are
subject to the risk that hedging and other management procedures
prove ineffective in reducing the risks to which insurance
policies expose us or that unanticipated policyholder behavior
or mortality, combined with adverse market events, produces
economic losses beyond the scope of the risk management
techniques employed. Any such losses could be increased by any
higher costs of writing derivatives or the potentially greater
difficulty in customizing derivatives that might result from the
enactment of Dodd-Frank.
|
|
|
|
Dodd-Frank restricts the ability of insured depository
institutions and of companies, such as MetLife, Inc., that
control an insured depository institution and their affiliates,
to engage in proprietary trading and to sponsor or invest in
funds (referred to in the bill as hedge funds and private equity
funds) that rely on certain exemptions from the Investment
Company Act of 1940, as amended (the Investment Company
Act). Dodd-Frank provides an exemption for investment
activity by a regulated insurance company or its affiliate
solely for the general account of such insurance company if such
activity is in compliance with the insurance company investments
laws of the state or jurisdiction in which such company is
domiciled and the appropriate Federal regulators after
consultation with relevant insurance commissioners have not
jointly determined such laws to be insufficient to protect the
safety and soundness of the institution or the financial
stability of the United States. Notwithstanding the foregoing,
the appropriate Federal regulatory authorities are permitted
under the legislation to impose, as part of rulemaking,
additional capital requirements and other restrictions on any
exempted activity. Dodd-Frank provides for a period of study and
rule making during which the effects of the statutory language
may be clarified. Among other considerations, the study is to
assess and include recommendations so as to appropriately
accommodate the business of insurance within an insurance
company subject to regulation in accordance with relevant
insurance company investments laws. While these provisions of
Dodd-Frank are supposed to accommodate the business of
insurance, until the related study and rulemaking are complete,
it is unclear whether MetLife, Inc. may have to alter any of its
future investment activities to comply.
|
|
|
|
Until various studies are completed and final regulations are
promulgated pursuant to Dodd-Frank, the full impact of
Dodd-Frank on the investments and investment activities of
MetLife, Inc. and its subsidiaries remain unclear. Besides
directly limiting our future investment activities, Dodd-Frank
could potentially negatively impact the market for, the returns
from, or liquidity in, primary and secondary investments in
private equity funds and hedge funds that are affiliated with an
insured depository institution. The number of
|
S-34
|
|
|
|
|
sponsors of such funds going forward may diminish, which may
impact our available fund investment opportunities. Although
Dodd-Frank provides for various transition periods for coming
into compliance, fund sponsors that are subject to Dodd-Frank,
and whose funds we have invested in, may have to spin off their
funds business or reduce their ownership stakes in their funds,
thereby potentially impacting our related investments in such
funds. In addition, should such funds be required or choose to
liquidate or sell their underlying assets, the market value and
liquidity of such assets or the broader related asset classes
could negatively be affected, including securities and real
estate assets that MetLife, Inc. and its subsidiaries hold or
may plan to sell. Our existing derivatives counterparties and
the financial institutions subject to Dodd-Frank in which we
have invested also could be negatively impacted by Dodd-Frank.
|
|
|
|
|
|
In addition, Dodd-Frank statutorily imposes the requirement that
MetLife, Inc. serve as a source of strength for MetLife Bank.
|
The addition of a new regulatory regime over MetLife, Inc. and
its subsidiaries, the likelihood of additional regulations, and
the other changes discussed above could require changes to
MetLife, Inc.s operations. Whether such changes would
affect our competitiveness in comparison to other institutions
is uncertain, since it is possible that at least some of our
competitors, for example insurance holding companies that
control thrifts, rather than banks, will be similarly affected.
Competitive effects are possible, however, if MetLife, Inc. were
required to pay any new or increased assessments and capital
requirements are imposed, and to the extent any new prudential
supervisory standards are imposed on MetLife, Inc. but not on
its competitors. We cannot predict whether other proposals will
be adopted, or what impact, if any, the adoption of Dodd-Frank
or other proposals and the resulting studies and regulations
could have on our business, financial condition or results of
operations or on our dealings with other financial companies.
See also New and Impending Compensation and
Corporate Governance Regulations Could Hinder or Prevent Us From
Attracting and Retaining Management and Other Employees with the
Talent and Experience to Manage and Conduct Our Business
Effectively.
Moreover, Dodd-Frank potentially affects such a wide range of
the activities and markets in which MetLife, Inc. and its
subsidiaries engage and participate that it may not be possible
to anticipate all of the ways in which it could affect us. For
example, many of our methods for managing risk and exposures are
based upon the use of observed historical market behavior or
statistics based on historical models. Historical market
behavior may be altered by the enactment of Dodd-Frank. As a
result of this enactment and otherwise, these methods may not
fully predict future exposures, which can be significantly
greater than our historical measures indicate.
We Are
Exposed to Significant Financial and Capital Markets Risk Which
May Adversely Affect Our Results of Operations, Financial
Condition and Liquidity, and Our Net Investment Income Can Vary
from Period to Period
We are exposed to significant financial and capital markets
risk, including changes in interest rates, credit spreads,
equity prices, real estate markets, foreign currency exchange
rates, market volatility, the performance of the economy in
general, the performance of the specific obligors included in
our portfolio and other factors outside our control.
Our exposure to interest rate risk relates primarily to the
market price and cash flow variability associated with changes
in interest rates. A rise in interest rates will increase the
net unrealized loss position of our fixed income investment
portfolio and, if long-term interest rates rise dramatically
within a six to twelve month time period, certain of our life
insurance businesses may be exposed to disintermediation risk.
Disintermediation risk refers to the risk that our policyholders
may surrender their contracts in a rising interest rate
environment, requiring us to liquidate fixed income investments
in an unrealized loss position. Due to the long-term nature of
the liabilities associated with certain of our life insurance
businesses, guaranteed benefits on variable annuities, and
structured settlements, sustained declines in long-term interest
rates may subject us to reinvestment risks and increased hedging
costs. In other situations, declines in interest rates may
result in increasing the duration of certain life insurance
liabilities, creating asset-liability duration mismatches.
Our investment portfolio also contains interest rate sensitive
instruments, such as fixed income securities, which may be
adversely affected by changes in interest rates from
governmental monetary policies, domestic and international
economic and political conditions and other factors beyond our
control. A rise in interest rates would
S-35
increase the net unrealized loss position of our fixed income
investment portfolio, offset by our ability to earn higher rates
of return on funds reinvested. Conversely, a decline in interest
rates would decrease the net unrealized loss position of our
fixed income investment portfolio, offset by lower rates of
return on funds reinvested. Our mitigation efforts with respect
to interest rate risk are primarily focused towards maintaining
an investment portfolio with diversified maturities that has a
weighted average duration that is approximately equal to the
duration of our estimated liability cash flow profile. However,
our estimate of the liability cash flow profile may be
inaccurate and we may be forced to liquidate fixed income
investments prior to maturity at a loss in order to cover the
liability. Although we take measures to manage the economic
risks of investing in a changing interest rate environment, we
may not be able to mitigate the interest rate risk of our fixed
income investments relative to our liabilities. See also
Changes in Market Interest Rates May
Significantly Affect Our Profitability.
Our exposure to credit spreads primarily relates to market price
and cash flow variability associated with changes in credit
spreads. A widening of credit spreads will increase the net
unrealized loss position of the fixed-income investment
portfolio, will increase losses associated with credit-based
non-qualifying derivatives where we assume credit exposure, and,
if issuer credit spreads increase significantly or for an
extended period of time, will likely result in higher
other-than-temporary
impairments. Credit spread tightening will reduce net investment
income associated with new purchases of fixed maturity
securities. In addition, market volatility can make it difficult
to value certain of our securities if trading becomes less
frequent. As such, valuations may include assumptions or
estimates that may have significant period to period changes
which could have a material adverse effect on our consolidated
results of operations or financial condition. Credit spreads on
both corporate and structured securities widened significantly
during 2008, resulting in continuing depressed pricing. As a
result of improved conditions, credit spreads narrowed in 2009
and have changed minimally in 2010. If there is a resumption of
significant volatility in the markets, it could cause changes in
credit spreads and defaults and a lack of pricing transparency
which, individually or in tandem, could have a material adverse
effect on our consolidated results of operations, financial
condition, liquidity or cash flows through realized investment
losses, impairments, and changes in unrealized loss positions.
Our primary exposure to equity risk relates to the potential for
lower earnings associated with certain of our insurance
businesses where fee income is earned based upon the estimated
fair value of the assets under management. Equity market
downturns and volatility may discourage purchases of separate
account products, such as variable annuities and variable life
insurance that have underlying mutual funds with returns linked
to the performance of the equity markets, and may cause some of
our existing customers to withdraw or reduce investments in
those products. In addition, downturns and volatility in equity
markets can have a material adverse effect on the revenues and
returns from our savings and investment products and services.
Because these products and services generate fees related
primarily to the value of assets under management, a decline in
the equity markets could reduce our revenues from the reduction
in the value of the investments we manage. The retail annuity
business in particular is highly sensitive to equity markets,
and a sustained weakness in the equity markets could decrease
revenues and earnings in variable annuity products. Furthermore,
certain of our annuity products offer guaranteed benefits which
increase our potential benefit exposure should equity markets
decline. MetLife, Inc. uses derivatives to mitigate the impact
of such increased potential benefit exposures. We are also
exposed to interest rate and equity risk based upon the discount
rate and expected long-term rate of return assumptions
associated with our pension and other postretirement benefit
obligations. Sustained declines in long-term interest rates or
equity returns likely would have a negative effect on the funded
status of these plans. Lastly, we invest a portion of our
investments in equity securities, leveraged buy-out funds, hedge
funds and other private equity funds and the estimated fair
value of such investments may be impacted by downturns or
volatility in equity markets.
Our primary exposure to real estate risk relates to commercial
and agricultural real estate. Our exposure to commercial and
agricultural real estate risk stems from various factors. These
factors include, but are not limited to, market conditions
including the demand and supply of space, creditworthiness of
tenants and partners, capital markets volatility and the
inherent interest rate movement. In addition, our real estate
joint venture development program is subject to risks,
including, but not limited to, reduced property sales and
decreased availability of financing which could adversely impact
the joint venture developments
and/or
operations. The state of the economy and speed of recovery in
fundamental and capital market conditions in the commercial and
agricultural real estate sectors will continue to influence the
performance of our investments in these sectors. These factors
and others
S-36
beyond our control could have a material adverse effect on our
consolidated results of operations, financial condition,
liquidity or cash flows through net investment income, realized
investment losses and impairments.
Our primary foreign currency exchange risks are described under
Fluctuations in Foreign Currency Exchange
Rates Could Negatively Affect Our Profitability.
Significant declines in equity prices, changes in
U.S. interest rates, changes in credit spreads, and changes
in foreign currency exchange rates could have a material adverse
effect on our consolidated results of operations, financial
condition or liquidity. Changes in these factors, which are
significant risks to us, can affect our net investment income in
any period, and such changes can be substantial. A portion of
our investments are made in leveraged buy-out funds, hedge funds
and other private equity funds reported within other limited
partnership interests, many of which make private equity
investments. The amount and timing of net investment income from
such investment funds tends to be uneven as a result of the
performance of the underlying investments, including private
equity investments. The timing of distributions from the funds,
which depends on particular events relating to the underlying
investments, as well as the funds schedules for making
distributions and their needs for cash, can be difficult to
predict. As a result, the amount of net investment income that
we record from these investments can vary substantially from
quarter to quarter. Recent equity, real estate and credit market
volatility have further reduced net investment income and
related yields for these types of investments and we may
continue to experience reduced net investment income due to
continued volatility in the equity, real estate and credit
markets in 2010. Although the disruption in the global financial
markets has moderated, not all global financial markets are
functioning normally and some remain reliant upon government
intervention and liquidity. Continuing challenges include
continued weakness in the U.S. real estate market and
increased mortgage loan delinquencies, investor anxiety over the
U.S. and European economies, rating agency downgrades of
various structured products and financial issuers, unresolved
issues with structured investment vehicles and monoline
financial guarantee insurers, deleveraging of financial
institutions and hedge funds and a serious dislocation in the
inter-bank market. If there is a resumption of significant
volatility in the markets, it could cause changes in interest
rates, declines in equity prices, and the strengthening or
weakening of foreign currencies against the U.S. dollar
which, individually or in tandem, could have a material adverse
effect on our consolidated results of operations, financial
condition, liquidity or cash flows through realized investment
losses, impairments, and changes in unrealized loss positions.
Changes
in Market Interest Rates May Significantly Affect Our
Profitability
Some of our products, principally traditional whole life
insurance, fixed annuities and guaranteed interest contracts,
expose us to the risk that changes in interest rates will reduce
our investment margin or spread, or the difference
between the amounts that we are required to pay under the
contracts in our general account and the rate of return we are
able to earn on general account investments intended to support
obligations under the contracts. Our spread is a key component
of our net income.
As interest rates decrease or remain at low levels, we may be
forced to reinvest proceeds from investments that have matured
or have been prepaid or sold at lower yields, reducing our
investment margin. Moreover, borrowers may prepay or redeem the
fixed income securities, commercial or agricultural mortgage
loans and mortgage-backed securities in our investment portfolio
with greater frequency in order to borrow at lower market rates,
which exacerbates this risk. Lowering interest crediting rates
can help offset decreases in investment margins on some
products. However, our ability to lower these rates could be
limited by competition or contractually guaranteed minimum rates
and may not match the timing or magnitude of changes in asset
yields. As a result, our spread could decrease or potentially
become negative. Our expectation for future spreads is an
important component in the amortization of DAC and VOBA, and
significantly lower spreads may cause us to accelerate
amortization, thereby reducing net income in the affected
reporting period. In addition, during periods of declining
interest rates, life insurance and annuity products may be
relatively more attractive investments to consumers, resulting
in increased premium payments on products with flexible premium
features, repayment of policy loans and increased persistency,
or a higher percentage of insurance policies remaining in force
from year to year, during a period when our new investments
carry lower returns. A decline in market interest rates could
also reduce our return on investments that do not support
particular policy obligations. Accordingly, declining interest
rates may materially adversely affect our results of operations,
financial position and cash flows and significantly reduce our
profitability.
S-37
The sufficiency of our life insurance statutory reserves in
Taiwan is highly sensitive to interest rates and other related
assumptions. This is due to the sustained low interest rate
environment in Taiwan coupled with long-term interest rate
guarantees of approximately 6% embedded in the life and health
contracts sold prior to 2003 and the lack of availability of
long-duration investments in the Taiwanese capital markets to
match such long-duration liabilities. The key assumptions
include current Taiwan government bond yield rates increasing
from current levels of 1.8% to 3.0% over the next ten years, a
modest increase in lapse rates, mortality and morbidity levels
remaining consistent with recent experience, and
U.S. dollar-denominated investments making up 35% of total
assets backing life insurance statutory reserves. Current
statutory reserve adequacy analysis shows that provisions are
adequate; however, adverse changes in key assumptions for
interest rates, lapse experience and mortality and morbidity
levels could lead to a need to strengthen reserves.
Increases in market interest rates could also negatively affect
our profitability. In periods of rapidly increasing interest
rates, we may not be able to replace, in a timely manner, the
investments in MetLifes general account with higher
yielding investments needed to fund the higher crediting rates
necessary to keep interest sensitive products competitive. We,
therefore, may have to accept a lower spread and, thus, lower
profitability or face a decline in sales and greater loss of
existing contracts and related assets. In addition, policy
loans, surrenders and withdrawals may tend to increase as
policyholders seek investments with higher perceived returns as
interest rates rise. This process may result in cash outflows
requiring that we sell investments at a time when the prices of
those investments are adversely affected by the increase in
market interest rates, which may result in realized investment
losses. Unanticipated withdrawals and terminations may cause us
to accelerate the amortization of DAC and VOBA, which reduces
net income. An increase in market interest rates could also have
a material adverse effect on the value of our investment
portfolio, for example, by decreasing the estimated fair values
of the fixed income securities that comprise a substantial
portion of our investment portfolio. Lastly, an increase in
interest rates could result in decreased fee income associated
with a decline in the value of variable annuity account balances
invested in fixed income funds.
Some
of Our Investments Are Relatively Illiquid and Are in Asset
Classes That Have Been Experiencing Significant Market Valuation
Fluctuations
We hold certain investments that may lack liquidity, such as
privately-placed fixed maturity securities; mortgage loans;
policy loans and leveraged leases; equity real estate, including
real estate joint ventures and funds; and other limited
partnership interests. These asset classes represented 31.5% of
the carrying value of our total cash and investments at
June 30, 2010. Even some of our very high quality
investments have been more illiquid as a result of the current
market conditions. If we require significant amounts of cash on
short notice in excess of normal cash requirements or are
required to post or return cash collateral in connection with
our investment portfolio, derivatives transactions or securities
lending program, we may have difficulty selling these
investments in a timely manner, be forced to sell them for less
than we otherwise would have been able to realize, or both. The
reported value of our relatively illiquid types of investments,
our investments in the asset classes described above and, at
times, our high quality, generally liquid asset classes, do not
necessarily reflect the lowest current market price for the
asset. If we were forced to sell certain of our investments in
the current market, there can be no assurance that we will be
able to sell them for the prices at which we have recorded them
and we could be forced to sell them at significantly lower
prices.
Our
Participation in a Securities Lending Program Subjects Us to
Potential Liquidity and Other Risks
We participate in a securities lending program whereby blocks of
securities, which are included in fixed maturity securities and
short-term investments, are loaned to third parties, primarily
brokerage firms and commercial banks. We generally obtain
collateral in an amount equal to 102% of the estimated fair
value of the loaned securities, which is obtained at the
inception of a loan and maintained at a level greater than or
equal to 100% for the duration of the loan. Returns of loaned
securities by the third parties would require us to return the
cash collateral associated with such loaned securities. In
addition, in some cases, the maturity of the securities held as
invested collateral (i.e., securities that we have purchased
with cash collateral received from the third parties) may exceed
the term of the related securities on loan and the estimated
fair value may fall below the amount of cash received as
collateral and invested. If we are required to return
significant amounts of cash collateral on short notice and we
are forced to sell securities to meet the return obligation, we
may have difficulty selling such collateral that is invested in
securities in a timely manner, be forced to sell securities in a
volatile or illiquid market for less than we otherwise
S-38
would have been able to realize under normal market conditions,
or both. In addition, under stressful capital market and
economic conditions, liquidity broadly deteriorates, which may
further restrict our ability to sell securities. If we decrease
the amount of our securities lending activities over time, the
amount of net investment income generated by these activities
will also likely decline.
Our
Requirements to Pledge Collateral or Make Payments Related to
Declines in Estimated Fair Value of Specified Assets May
Adversely Affect Our Liquidity and Expose Us to Counterparty
Credit Risk
Some of our transactions with financial and other institutions
specify the circumstances under which the parties are required
to pledge collateral related to any decline in the estimated
fair value of the specified assets. In addition, under the terms
of some of our transactions, we may be required to make payments
to our counterparties related to any decline in the estimated
fair value of the specified assets. The amount of collateral we
may be required to pledge and the payments we may be required to
make under these agreements may increase under certain
circumstances, which could adversely affect our liquidity.
Gross
Unrealized Losses on Fixed Maturity and Equity Securities May Be
Realized or Result in Future Impairments, Resulting in a
Reduction in Our Net Income
Fixed maturity and equity securities classified as
available-for-sale,
except trading securities, are reported at their estimated fair
value. Unrealized gains or losses on
available-for-sale
securities are recognized as a component of other comprehensive
income (loss) and are, therefore, excluded from net income. Our
gross unrealized losses on fixed maturity and equity securities
at June 30, 2010 were $7.0 billion. The portion of the
$7.0 billion of gross unrealized losses for fixed maturity
and equity securities where the estimated fair value has
declined and remained below amortized cost or cost by 20% or
more for six months or greater was $3.1 billion at
June 30, 2010. The accumulated change in estimated fair
value of these
available-for-sale
securities is recognized in net income when the gain or loss is
realized upon the sale of the security or in the event that the
decline in estimated fair value is determined to be
other-than-temporary
and an impairment charge to earnings is taken. Realized losses
or impairments may have a material adverse effect on our net
income in a particular quarterly or annual period.
The
Determination of the Amount of Allowances and Impairments Taken
on Our Investments is Highly Subjective and Could Materially
Impact Our Results of Operations or Financial
Position
The determination of the amount of allowances and impairments
varies by investment type and is based upon our periodic
evaluation and assessment of known and inherent risks associated
with the respective asset class. Such evaluations and
assessments are revised as conditions change and new information
becomes available. We update our evaluations regularly and
reflect changes in allowances and impairments in net investment
losses as such evaluations are revised. There can be no
assurance that we have accurately assessed the level of
impairments taken and allowances provided as reflected in our
consolidated financial statements. Furthermore, additional
impairments may need to be taken or allowances provided for in
the future. Historical trends may not be indicative of future
impairments or allowances.
For example, the cost of our fixed maturity and equity
securities is adjusted for impairments deemed to be
other-than-temporary
that are charged to earnings in the period in which the
determination is made. The assessment of whether impairments
have occurred is based on our
case-by-case
evaluation of the underlying reasons for the decline in
estimated fair value. The review of our fixed maturity and
equity securities for impairments includes an analysis of the
total gross unrealized losses by three categories of securities:
(i) securities where the estimated fair value has declined
and remained below cost or amortized cost by less than 20%;
(ii) securities where the estimated fair value has declined
and remained below cost or amortized cost by 20% or more for
less than six months; and (iii) securities where the
estimated fair value has declined and remained below cost or
amortized cost by 20% or more for six months or greater.
Additionally, we consider a wide range of factors about the
security issuer and use our best judgment in evaluating the
cause of the decline in the estimated fair value of the security
and in assessing the prospects for near term recovery. Inherent
in our evaluation of the security are assumptions and estimates
about the operations of the issuer and its future earnings
potential. Considerations in the impairment evaluation process
include, but are not
S-39
limited to: (i) the length of time and the extent to which
the estimated fair value has been below cost or amortized cost;
(ii) the potential for impairments of securities when the
issuer is experiencing significant financial difficulties;
(iii) the potential for impairments in an entire industry
sector or
sub-sector;
(iv) the potential for impairments in certain economically
depressed geographic locations; (v) the potential for
impairments of securities where the issuer, series of issuers or
industry has suffered a catastrophic type of loss or has
exhausted natural resources; (vi) with respect to fixed
maturity securities, whether we have the intent to sell or will
more likely than not be required to sell a particular security
before recovery of the decline in estimated fair value below
amortized cost; (vii) with respect to equity securities,
whether we have the ability and intent to hold a particular
security for a period of time sufficient to allow for the
recovery of its estimated fair value to an amount at least equal
to its cost; (viii) unfavorable changes in forecasted cash
flows on mortgage-backed and asset-backed securities; and
(ix) other subjective factors, including concentrations and
information obtained from regulators and rating agencies.
Defaults
on Our Mortgage Loans and Volatility in Performance May
Adversely Affect Our Profitability
Our mortgage loans face default risk and are principally
collateralized by commercial, agricultural and residential
properties, as well as automobiles. The carrying value of
mortgage loans is stated at original cost net of repayments,
amortization of premiums, accretion of discounts and valuation
allowances, except for residential mortgage loans
held-for-sale
accounted for under the fair value option which are carried at
estimated fair value, as determined on a recurring basis, and
certain commercial and residential mortgage loans carried at the
lower of cost or estimated fair value, as determined on a
nonrecurring basis. We establish valuation allowances for
estimated impairments at the balance sheet date. Such valuation
allowances are based on the excess carrying value of the loan
over the present value of expected future cash flows discounted
at the loans original effective interest rate, the
estimated fair value of the loans collateral if the loan
is in the process of foreclosure or otherwise collateral
dependent, or the loans observable market price. We also
establish valuation allowances for loan losses for pools of
loans with similar risk characteristics, such as property types,
or loans having similar
loan-to-value
ratios and debt service coverage ratios, when based on past
experience, it is probable that a credit event has occurred and
the amount of the loss can be reasonably estimated. These
valuation allowances are based on loan risk characteristics,
historical default rates and loss severities, real estate market
fundamentals and outlook as well as other relevant factors. At
June 30, 2010, loans that were either delinquent or in the
process of foreclosure totaled less than 0.7% of our mortgage
loan investments. The performance of our mortgage loan
investments, however, may fluctuate in the future. In addition,
substantially all of our mortgage loans
held-for-investment
have balloon payment maturities. An increase in the default rate
of our mortgage loan investments could have a material adverse
effect on our business, results of operations and financial
condition through realized investment losses or increases in our
valuation allowances.
Further, any geographic or sector concentration of our mortgage
loans may have adverse effects on our investment portfolios and
consequently on our consolidated results of operations or
financial condition. While we seek to mitigate this risk by
having a broadly diversified portfolio, events or developments
that have a negative effect on any particular geographic region
or sector may have a greater adverse effect on the investment
portfolios to the extent that the portfolios are concentrated.
Moreover, our ability to sell assets relating to such particular
groups of related assets may be limited if other market
participants are seeking to sell at the same time. In addition,
legislative proposals that would allow or require modifications
to the terms of mortgage loans could be enacted. We cannot
predict whether these proposals will be adopted, or what impact,
if any, such proposals or, if enacted, such laws, could have on
our business or investments.
The
Impairment of Other Financial Institutions Could Adversely
Affect Us
We have exposure to many different industries and
counterparties, and routinely execute transactions with
counterparties in the financial services industry, including
brokers and dealers, commercial banks, investment banks, hedge
funds and other investment funds and other institutions. Many of
these transactions expose us to credit risk in the event of
default of our counterparty. In addition, with respect to
secured transactions, our credit risk may be exacerbated when
the collateral held by us cannot be realized or is liquidated at
prices not sufficient to recover the full amount of the loan or
derivative exposure due to us. We also have exposure to these
financial institutions in the form of unsecured debt
instruments, non-redeemable and redeemable preferred securities,
derivative transactions, joint venture, hedge fund and equity
investments. Further, potential action by governments and
regulatory bodies in response to the financial crisis affecting
the global banking system and financial markets, such as
S-40
investment, nationalization, conservatorship, receivership and
other intervention, whether under existing legal authority or
any new authority that may be created, could negatively impact
these instruments, securities, transactions and investments.
There can be no assurance that any such losses or impairments to
the carrying value of these investments would not materially and
adversely affect our business and results of operations.
We
Face Unforeseen Liabilities, Asset Impairments or Rating Actions
Arising from Possible Acquisitions and Dispositions of
Businesses or Difficulties Integrating Such
Businesses
We have engaged in dispositions and acquisitions of businesses
in the past, and expect to continue to do so in the future. We
entered into the Stock Purchase Agreement dated as of
March 7, 2010 to acquire the Alico Business. There could be
unforeseen liabilities or asset impairments, including goodwill
impairments, that arise in connection with the businesses that
we may sell or the businesses that we may acquire in the future.
In addition, there may be liabilities or asset impairments that
we fail, or are unable, to discover in the course of performing
due diligence investigations on each business that we have
acquired or may acquire. Furthermore, the use of our own funds
as consideration in any acquisition would consume capital
resources that would no longer be available for other corporate
purposes. We also may not be able to raise sufficient funds to
consummate an acquisition if, for example, we are unable to sell
our securities or close related bridge credit facilities.
Moreover, as a result of uncertainty and risks associated with
potential acquisitions and dispositions of businesses, rating
agencies may take certain actions with respect to the ratings
assigned to MetLife, Inc.
and/or its
subsidiaries.
Our ability to achieve certain benefits we anticipate from any
acquisitions of businesses will depend in large part upon our
ability to successfully integrate such businesses in an
efficient and effective manner. We may not be able to integrate
such businesses smoothly or successfully, and the process may
take longer than expected. The integration of operations may
require the dedication of significant management resources,
which may distract managements attention from
day-to-day
business. If we are unable to successfully integrate the
operations of such acquired businesses, we may be unable to
realize the benefits we expect to achieve as a result of such
acquisitions and our business and results of operations may be
less than expected. See Risks Relating to the
Acquisition of the Alico Business and
We May Experience Difficulties in Integrating the Alico
Business, Including Its Joint Venture and Other Arrangements
with Third Parties.
Fluctuations
in Foreign Currency Exchange Rates Could Negatively Affect Our
Profitability
We are exposed to risks associated with fluctuations in foreign
currency exchange rates against the U.S. dollar resulting
from our holdings of
non-U.S. dollar
denominated investments, investments in foreign subsidiaries and
net income from foreign operations and issuance of
non-U.S. dollar
denominated instruments, including guaranteed interest contracts
and funding agreements. These risks relate to potential
decreases in estimated fair value and income resulting from a
strengthening or weakening in foreign exchange rates versus the
U.S. dollar. In general, the weakening of foreign
currencies versus the U.S. dollar will adversely affect the
estimated fair value of our
non-U.S. dollar
denominated investments, our investments in foreign
subsidiaries, and our net income from foreign operations.
Although we use foreign currency swaps and forward contracts to
mitigate foreign currency exchange rate risk, we cannot provide
assurance that these methods will be effective or that our
counterparties will perform their obligations.
From time to time, various emerging market countries have
experienced severe economic and financial disruptions, including
significant devaluations of their currencies. Our exposure to
foreign exchange rate risk is exacerbated by our investments in
certain emerging markets.
Historically, we have matched substantially all of our foreign
currency liabilities in our foreign subsidiaries with
investments denominated in their respective foreign currency,
which limits the effect of currency exchange rate fluctuation on
local operating results; however, fluctuations in such rates
affect the translation of these results into our
U.S. dollar basis consolidated financial statements.
Although we take certain actions to address this risk, foreign
currency exchange rate fluctuation could materially adversely
affect our reported results due to unhedged positions or the
failure of hedges to effectively offset the impact of the
foreign currency exchange rate fluctuation.
The Acquisition will increase our exposure to risks associated
with fluctuations in foreign currency exchange rates against the
U.S. dollar and increase our exposure to emerging markets.
Fluctuations in the yen/ U.S. dollar
S-41
exchange rate can have a significant effect on our reported
financial position and results of operations following the
Acquisition because the Alico Business has substantial
operations in Japan and a significant portion of its premiums
and investment income are received in yen. Claims and expenses
are also paid in yen and the Alico Business primarily purchases
yen-denominated assets to support yen-denominated policy
liabilities. These and other yen-denominated financial statement
items are, however, translated into U.S. dollars for
financial reporting purposes. Accordingly, fluctuations in the
yen/U.S. dollar exchange rate can have a significant effect
on our reported financial position and results of operations
following the Acquisition. See Risks Relating
to the Acquisition of the Alico Business We Are and,
Following the Acquisition, Will Be Subject to the Risk of
Exchange Rate Fluctuations Owing to the Geographical Diversity
of Our Combined Business.
Our
International Operations Face Political, Legal, Operational and
Other Risks, Including Exposure to Local and Regional Economic
Conditions, That Could Negatively Affect Those Operations or Our
Profitability
Our international operations face political, legal, operational
and other risks that we do not face in our domestic operations.
We face the risk of discriminatory regulation, nationalization
or expropriation of assets, price controls and exchange controls
or other restrictions that prevent us from transferring funds
from these operations out of the countries in which they operate
or converting local currencies we hold into U.S. dollars or
other currencies. Some of our foreign insurance operations are,
and are likely to continue to be, in emerging markets where
these risks are heightened. In addition, we rely on local sales
forces in these countries and may encounter labor problems
resulting from workers associations and trade unions in
some countries. In Japan, China and India we operate with local
business partners with the resulting risk of managing partner
relationships to the business objectives. If our business model
is not successful in a particular country, we may lose all or
most of our investment in building and training the sales force
in that country. The Acquisition will increase our exposure to
these risks.
We are expanding our international operations in certain markets
where we operate and in selected new markets. This may require
considerable management time, as well as
start-up
expenses for market development before any significant revenues
and earnings are generated. Operations in new foreign markets
may achieve low margins or may be unprofitable, and expansion in
existing markets may be affected by local economic and market
conditions. Therefore, as we expand internationally, we may not
achieve expected operating margins and our results of operations
may be negatively impacted.
In addition, in recent years, the operating environment in
Argentina has been very challenging. In Argentina, we were
formerly principally engaged in the pension business. In
December 2008, the Argentine government nationalized private
pensions and seized the pension funds investments,
eliminating the private pensions business in Argentina. As a
result, we have experienced and will continue to experience
reductions in the operations revenues and cash flows. The
Argentine government now controls all assets which previously
were managed by our Argentine pension operations. Further
governmental or legal actions related to our operations in
Argentina could negatively impact our operations in Argentina
and result in future losses.
Following the Acquisition, we will have market presence in
64 different countries, up from 17, at present, and
increased exposure to risks posed by local and regional economic
conditions. Europe has recently experienced a deep recession and
countries such as Italy, Spain, Portugal, Ireland and, in
particular, Greece, have been particularly affected by the
recession, resulting in increased national debts and depressed
economic activity. The Alico Business has significant operations
and investments in these countries which could be adversely
affected by economic developments such as higher taxes, growing
inflation, decreasing government spending, rising unemployment
and currency instability.
In addition to fluctuations in the yen/U.S. dollar exchange
rate discussed above, we will face increased exposure to the
Japanese markets after completion of the Acquisition as a result
of the Alico Business considerable presence there.
Deterioration in Japans economic recovery could have an
adverse effect on our results of operations and financial
condition following the Acquisition.
The Alico Business also has significant operations in the Middle
East where the legal systems and regulatory frameworks are still
evolving. Following the completion of the Acquisition, lack of
legal certainty in the region will expose our operations to
increased risk of adverse or unpredictable actions by regulators
and may make it more
S-42
difficult for us to enforce our contracts, which may negatively
impact our business in this region. See also
Changes in Market Interest Rates May
Significantly Affect Our Profitability regarding the
impact of low interest rates on our Taiwanese operations.
As a
Holding Company, MetLife, Inc. Depends on the Ability of Its
Subsidiaries to Transfer Funds to It to Meet Its Obligations and
Pay Dividends
MetLife, Inc. is a holding company for its insurance and
financial subsidiaries and does not have any significant
operations of its own. Dividends from its subsidiaries and
permitted payments to it under its tax sharing arrangements with
its subsidiaries are its principal sources of cash to meet its
obligations and to pay preferred and common stock dividends. If
the cash MetLife, Inc. receives from its subsidiaries is
insufficient for it to fund its debt service and other holding
company obligations, MetLife, Inc. may be required to raise cash
through the incurrence of debt, the issuance of additional
equity or the sale of assets.
The payment of dividends and other distributions to MetLife,
Inc. by its insurance subsidiaries is regulated by insurance
laws and regulations. In general, dividends in excess of
prescribed limits require insurance regulatory approval. In
addition, insurance regulators may prohibit the payment of
dividends or other payments by its insurance subsidiaries to
MetLife, Inc. if they determine that the payment could be
adverse to our policyholders or contractholders. The payment of
dividends and other distributions by insurance companies is also
influenced by business conditions and rating agency
considerations.
Any payment of interest, dividends, distributions, loans or
advances by our foreign subsidiaries to MetLife, Inc. could be
subject to taxation or other restrictions on dividends or
repatriation of earnings under applicable law, monetary transfer
restrictions and foreign currency exchange regulations in the
jurisdiction in which such foreign subsidiaries operate. See
Our International Operations Face Political,
Legal, Operational and Other Risks, Including Exposure to Local
and Regional Economic Conditions That Could Negatively Affect
Those Operations or Our Profitability.
A
Downgrade or a Potential Downgrade in Our Financial Strength or
Credit Ratings Could Result in a Loss of Business and Materially
Adversely Affect Our Financial Condition and Results of
Operations
Financial strength ratings, which various Nationally Recognized
Statistical Rating Organizations (each, an
NRSRO) publish as indicators of an insurance
companys ability to meet contractholder and policyholder
obligations, are important to maintaining public confidence in
our products, our ability to market our products and our
competitive position.
Downgrades in our financial strength ratings could have a
material adverse effect on our financial condition and results
of operations in many ways, including:
|
|
|
|
|
reducing new sales of insurance products, annuities and other
investment products;
|
|
|
|
adversely affecting our relationships with our sales force and
independent sales intermediaries;
|
|
|
|
materially increasing the number or amount of policy surrenders
and withdrawals by contractholders and policyholders;
|
|
|
|
requiring us to reduce prices for many of our products and
services to remain competitive; and
|
|
|
|
adversely affecting our ability to obtain reinsurance at
reasonable prices or at all.
|
In addition to the financial strength ratings of our insurance
subsidiaries, various NRSROs also publish credit ratings for
MetLife, Inc. and several of its subsidiaries. Credit ratings
are indicators of a debt issuers ability to meet the terms
of debt obligations in a timely manner and are important factors
in our overall funding profile and ability to access certain
types of liquidity. Downgrades in our credit ratings could have
a material adverse effect on our financial condition and results
of operations in many ways, including adversely limiting our
access to capital markets, potentially increasing the cost of
debt, and requiring us to post collateral. For example, with
respect to derivative transactions with credit ratings downgrade
triggers, a one-notch downgrade would have increased our
derivative collateral requirements by $67 million at
June 30, 2010. Also, $438 million of liabilities
associated with
S-43
funding agreements and other capital market products were
subject to credit ratings downgrade triggers that permit early
termination subject to a notice period of 90 days.
In view of the difficulties experienced during 2008 and 2009 by
many financial institutions, including our competitors in the
insurance industry, we believe it is possible that the NRSROs
will continue to heighten the level of scrutiny that they apply
to such institutions, will continue to increase the frequency
and scope of their credit reviews, will continue to request
additional information from the companies that they rate, and
may adjust upward the capital and other requirements employed in
the NRSRO models for maintenance of certain ratings levels.
Rating agencies use an outlook statement of
positive, stable, negative
or developing to indicate a medium- or long-term
trend in credit fundamentals which, if continued, may lead to a
ratings change. A rating may have a stable outlook
to indicate that the rating is not expected to change; however,
a stable rating does not preclude a rating agency
from changing a rating at any time, without notice. Certain
rating agencies assign rating modifiers such as
CreditWatch or Under Review to indicate
their opinion regarding the potential direction of a rating.
These ratings modifiers are generally assigned in connection
with certain events such as potential mergers and acquisitions,
or material changes in a companys results, in order for
the rating agencies to perform their analyses to fully determine
the rating implications of the event. Certain rating agencies
have recently implemented rating actions, including downgrades,
outlook changes and modifiers, for MetLife, Inc.s and
certain of its subsidiaries insurer financial strength and
credit ratings.
In February 2010, Fitch Ratings downgraded by one-notch the
ratings of MetLife, Inc. and its subsidiaries. In February 2010,
Standard & Poors Ratings Services, a
Standard & Poors Financial Services LLC
business, and A.M. Best each placed the ratings of MetLife,
Inc. and its subsidiaries on CreditWatch with negative
implications and Under Review with negative
implications, respectively, based on the announcement of
the Acquisition. In March, 2010, Moodys changed the
ratings outlook of MetLife, Inc. and its subsidiaries from
stable to negative outlook. We believe that all the NRSROs will
continue to review our ratings in light of the Acquisition and
may take further action at, or in anticipation of, the
consummation of the Acquisition.
On July 1, 2010, Moodys published revised guidance
called Revisions to Moodys Hybrid Tool Kit
(the Guidance) for assigning equity credit to
so-called hybrid securities, i.e., securities with both
debt and equity characteristics (Hybrids).
Moodys evaluates Hybrids using certain specified criteria
and then places each such security into a basket,
with a specific percentage of debt and equity being associated
with each basket, which is then used to adjust full sets of
financial statements for purposes of, among other things,
calculating the issuing companys financial leverage. Under
the Guidance, Hybrids are one element that Moodys
considers within the context of an issuers overall credit
profile. We currently have approximately $5.3 billion of
Hybrids outstanding, which includes approximately
$3.2 billion of junior subordinated debt securities and
$2.1 billion of preferred stock. Application of the
Guidance will likely result in Moodys significantly
reducing the amount of equity credit it assigns to these
securities and to the Equity Units to be issued to ALICO
Holdings in connection with the Acquisition. We do not expect at
this time, as a result of the Guidance, a reduction in
Moodys equity treatment of our existing Hybrids or, once
issued, the Equity Units, would result in any material negative
impact on MetLife, Inc.s credit rating or the financial
strength ratings of its insurance company subsidiaries. However,
if we decided to increase our adjusted capital as a result of
the application of the Guidance, we may seek to (i) issue
additional common equity or higher equity content Hybrids
satisfying the Guidances revised rating criteria,
(ii) redeem, repurchase or restructure existing Hybrids,
and/or
(iii) modify the terms of the Equity Units in order to
achieve the desired equity treatment or otherwise take into
account the application of the Guidance. Any sale of additional
common equity would have a dilutive effect on our common
stockholders and any modification of the terms of the Equity
Units could involve negotiations with ALICO Holdings, AIG and
the lenders in our bridge loan facility.
We cannot predict what actions rating agencies may take, or what
actions we may take in response to the actions of rating
agencies, which could adversely affect our business. As with
other companies in the financial services industry, our ratings
could be downgraded at any time and without any notice by any
NRSRO.
S-44
An
Inability to Access Our Credit Facilities Could Result in a
Reduction in Our Liquidity and Lead to Downgrades in Our Credit
and Financial Strength Ratings
We have a $2.85 billion five-year revolving credit facility
that matures in June 2012, as well as other facilities which we
enter into in the ordinary course of business. In addition,
concurrently with our entry into the agreement to acquire the
Alico Business, we signed a commitment letter (amended and
restated on March 16, 2010) with various financial
institutions for a senior credit facility in an aggregate
principal amount of up to $5.0 billion (the Senior
Credit Facility). The Senior Credit Facility will be
used to finance any portion of the cash component of the
purchase price of the Acquisition that is not financed with
sales of MetLife, Inc.s securities or cash on hand. An
amount equal to 100% of the proceeds of sales of MetLife,
Inc.s securities, less certain ordinary-course
transactions, will be applied to prepay any loans under the
Senior Credit Facility and, if such proceeds or commitments are
received on or prior to the date of the closing of the
Acquisition, will permanently reduce
dollar-for-dollar
the commitments, if any, of the lenders under the Senior Credit
Facility.
We rely on our credit facilities as a potential source of
liquidity. The availability of these facilities could be
critical to our credit and financial strength ratings and our
ability to meet our obligations as they come due in a market
when alternative sources of credit are tight. The credit
facilities contain certain administrative, reporting, legal and
financial covenants. We must comply with covenants under our
credit facilities (including the $2.85 billion five-year
revolving credit facility), including a requirement to maintain
a specified minimum consolidated net worth.
Our right to make borrowings under these facilities is subject
to the fulfillment of certain important conditions, including
our compliance with all covenants, and our ability to borrow
under these facilities is also subject to the continued
willingness and ability of the lenders that are parties to the
facilities to provide funds. Our failure to comply with the
covenants in the credit facilities or fulfill the conditions to
borrowings, or the failure of lenders to fund their lending
commitments (whether due to insolvency, illiquidity or other
reasons) in the amounts provided for under the terms of the
facilities, would restrict our ability to access these credit
facilities when needed and, consequently, could have a material
adverse effect on our financial condition and results of
operations.
Defaults,
Downgrades or Other Events Impairing the Carrying Value of Our
Fixed Maturity or Equity Securities Portfolio May Reduce Our
Earnings
We are subject to the risk that the issuers, or guarantors, of
fixed maturity securities we own may default on principal and
interest payments they owe us. We are also subject to the risk
that the underlying collateral within loan-backed securities,
including mortgage-backed securities, may default on principal
and interest payments causing an adverse change in cash flows
paid to our investment. Fixed maturity securities represent a
significant portion of our investment portfolio. The occurrence
of a major economic downturn, acts of corporate malfeasance,
widening risk spreads, or other events that adversely affect the
issuers, guarantors or underlying collateral of these securities
could cause the estimated fair value of our fixed maturity
securities portfolio and our earnings to decline and the default
rate of the fixed maturity securities in our investment
portfolio to increase. A ratings downgrade affecting issuers or
guarantors of particular securities, or similar trends that
could worsen the credit quality of issuers, such as the
corporate issuers of securities in our investment portfolio,
could also have a similar effect. With economic uncertainty,
credit quality of issuers or guarantors could be adversely
affected. Similarly, a ratings downgrade affecting asset-backed
securities (ABS) we hold could indicate the
credit quality of that security has deteriorated and could
increase the capital we must hold to support that security to
maintain our risk-based capital levels. Any event reducing the
estimated fair value of these securities other than on a
temporary basis could have a material adverse effect on our
business, results of operations and financial condition. Levels
of writedowns or impairments are impacted by our assessment of
intent to sell, or whether it is more likely than not that we
will be required to sell, fixed maturity securities and the
intent and ability to hold equity securities which have declined
in value until recovery. If we determine to reposition or
realign portions of the portfolio so as not to hold certain
equity securities, or intend to sell or determine that it is
more likely than not that we will be required to sell, certain
fixed maturity securities in an unrealized loss position prior
to recovery, then we will incur an
other-than-temporary
impairment charge in the period that the decision was made not
to hold the equity security to recovery, or to sell, or the
determination was made it is more likely than not that we will
be required to sell the fixed maturity security.
S-45
Our
Risk Management Policies and Procedures May Leave Us Exposed to
Unidentified or Unanticipated Risk, Which Could Negatively
Affect Our Business
Management of risk requires, among other things, policies and
procedures to record properly and verify a large number of
transactions and events. We have devoted significant resources
to develop our risk management policies and procedures and
expect to continue to do so in the future. Nonetheless, our
policies and procedures may not be comprehensive. Many of our
methods for managing risk and exposures are based upon the use
of observed historical market behavior or statistics based on
historical models. As a result, these methods may not fully
predict future exposures, which can be significantly greater
than our historical measures indicate. Other risk management
methods depend upon the evaluation of information regarding
markets, clients, catastrophe occurrence or other matters that
is publicly available or otherwise accessible to us. This
information may not always be accurate, complete,
up-to-date
or properly evaluated.
Reinsurance
May Not Be Available, Affordable or Adequate to Protect Us
Against Losses
As part of our overall risk management strategy, we purchase
reinsurance for certain risks underwritten by our various
business segments. While reinsurance agreements generally bind
the reinsurer for the life of the business reinsured at
generally fixed pricing, market conditions beyond our control
determine the availability and cost of the reinsurance
protection for new business. In certain circumstances, the price
of reinsurance for business already reinsured may also increase.
Any decrease in the amount of reinsurance will increase our risk
of loss and any increase in the cost of reinsurance will, absent
a decrease in the amount of reinsurance, reduce our earnings.
Accordingly, we may be forced to incur additional expenses for
reinsurance or may not be able to obtain sufficient reinsurance
on acceptable terms, which could adversely affect our ability to
write future business or result in the assumption of more risk
with respect to those policies we issue.
If the
Counterparties to Our Reinsurance or Indemnification
Arrangements or to the Derivative Instruments We Use to Hedge
Our Business Risks Default or Fail to Perform, We May Be Exposed
to Risks We Had Sought to Mitigate, Which Could Materially
Adversely Affect Our Financial Condition and Results of
Operations
We use reinsurance, indemnification and derivative instruments
to mitigate our risks in various circumstances. In general,
reinsurance does not relieve us of our direct liability to our
policyholders, even when the reinsurer is liable to us.
Accordingly, we bear credit risk with respect to our reinsurers
and indemnitors. We cannot provide assurance that our reinsurers
will pay the reinsurance recoverables owed to us or that
indemnitors will honor their obligations now or in the future or
that they will pay these recoverables on a timely basis. A
reinsurers or indemnitors insolvency, inability or
unwillingness to make payments under the terms of reinsurance
agreements or indemnity agreements with us could have a material
adverse effect on our financial condition and results of
operations.
In addition, we use derivative instruments to hedge various
business risks. We enter into a variety of derivative
instruments, including options, forwards, interest rate, credit
default and currency swaps with a number of counterparties. If
our counterparties fail or refuse to honor their obligations
under these derivative instruments, our hedges of the related
risk will be ineffective. This is a more pronounced risk to us
in view of the stresses suffered by financial institutions over
the past two years. Such failure could have a material adverse
effect on our financial condition and results of operations.
Differences
Between Actual Claims Experience and Underwriting and Reserving
Assumptions May Adversely Affect Our Financial
Results
Our earnings significantly depend upon the extent to which our
actual claims experience is consistent with the assumptions we
use in setting prices for our products and establishing
liabilities for future policy benefits and claims. Our
liabilities for future policy benefits and claims are
established based on estimates by actuaries of how much we will
need to pay for future benefits and claims. For life insurance
and annuity products, we calculate these liabilities based on
many assumptions and estimates, including estimated premiums to
be received over the assumed life of the policy, the timing of
the event covered by the insurance policy, the amount of
benefits or claims to be paid
S-46
and the investment returns on the investments we make with the
premiums we receive. We establish liabilities for property and
casualty claims and benefits based on assumptions and estimates
of damages and liabilities incurred. To the extent that actual
claims experience is less favorable than the underlying
assumptions we used in establishing such liabilities, we could
be required to increase our liabilities.
Due to the nature of the underlying risks and the high degree of
uncertainty associated with the determination of liabilities for
future policy benefits and claims, we cannot determine precisely
the amounts which we will ultimately pay to settle our
liabilities. Such amounts may vary from the estimated amounts,
particularly when those payments may not occur until well into
the future. We evaluate our liabilities periodically based on
accounting requirements, which change from time to time, the
assumptions used to establish the liabilities, as well as our
actual experience. We charge or credit changes in our
liabilities to expenses in the period the liabilities are
established or re-estimated. If the liabilities originally
established for future benefit payments prove inadequate, we
must increase them. Such increases could affect earnings
negatively and have a material adverse effect on our business,
results of operations and financial condition.
Catastrophes
May Adversely Impact Liabilities for Policyholder Claims and
Reinsurance Availability
Our life insurance operations are exposed to the risk of
catastrophic mortality, such as a pandemic or other event that
causes a large number of deaths. Significant influenza pandemics
have occurred three times in the last century, but neither the
likelihood, timing, nor the severity of a future pandemic can be
predicted. A significant pandemic could have a major impact on
the global economy or the economies of particular countries or
regions, including travel, trade, tourism, the health system,
food supply, consumption, overall economic output and,
eventually, on the financial markets. In addition, a pandemic
that affected our employees or the employees of our distributors
or of other companies with which we do business could disrupt
our business operations. The effectiveness of external parties,
including governmental and non-governmental organizations, in
combating the spread and severity of such a pandemic could have
a material impact on the losses experienced by us. In our group
insurance operations, a localized event that affects the
workplace of one or more of our group insurance customers could
cause a significant loss due to mortality or morbidity claims.
These events could cause a material adverse effect on our
results of operations in any period and, depending on their
severity, could also materially and adversely affect our
financial condition.
Our Auto & Home business has experienced, and will
likely in the future experience, catastrophe losses that may
have a material adverse impact on the business, results of
operations and financial condition of the Auto & Home
segment. Although Auto & Home makes every effort to
manage our exposure to catastrophic risks through volatility
management and reinsurance programs, these efforts do not
eliminate all risk. Catastrophes can be caused by various
events, including pandemics, hurricanes, windstorms,
earthquakes, hail, tornadoes, explosions, severe winter weather
(including snow, freezing water, ice storms and blizzards),
fires and man-made events such as terrorist attacks.
Historically, substantially all of our catastrophe-related
claims have related to homeowners coverages. However,
catastrophes may also affect other Auto & Home
coverages. Due to their nature, we cannot predict the incidence,
timing and severity of catastrophes. In addition, changing
climate conditions, primarily rising global temperatures, may be
increasing, or may in the future increase, the frequency and
severity of natural catastrophes such as hurricanes.
Hurricanes and earthquakes are of particular note for our
homeowners coverages. Areas of major hurricane exposure include
coastal sections of the northeastern United States (including
lower New York, Connecticut, Rhode Island and Massachusetts),
the Gulf Coast (including Alabama, Mississippi, Louisiana and
Texas) and Florida. We also have some earthquake exposure,
primarily along the New Madrid fault line in the central United
States and in the Pacific Northwest.
The extent of losses from a catastrophe is a function of both
the total amount of insured exposure in the area affected by the
event and the severity of the event. Most catastrophes are
restricted to small geographic areas; however, pandemics,
hurricanes, earthquakes and man-made catastrophes may produce
significant damage or loss of life in larger areas, especially
those that are heavily populated. Claims resulting from natural
or man-made catastrophic events could cause substantial
volatility in our financial results for any fiscal quarter or
year and could materially reduce our profitability or harm our
financial condition. Also, catastrophic events could harm the
financial condition of our reinsurers and thereby increase the
probability of default on reinsurance recoveries. Our
S-47
ability to write new business could also be affected. It is
possible that increases in the value, caused by the effects of
inflation or other factors, and geographic concentration of
insured property, could increase the severity of claims from
catastrophic events in the future.
Most of the jurisdictions in which our insurance subsidiaries
are admitted to transact business require life and property and
casualty insurers doing business within the jurisdiction to
participate in guaranty associations, which are organized to pay
contractual benefits owed pursuant to insurance policies issued
by impaired, insolvent or failed insurers. These associations
levy assessments, up to prescribed limits, on all member
insurers in a particular state on the basis of the proportionate
share of the premiums written by member insurers in the lines of
business in which the impaired, insolvent or failed insurer is
engaged. In addition, certain states have government owned or
controlled organizations providing life and property and
casualty insurance to their citizens. The activities of such
organizations could also place additional stress on the adequacy
of guaranty fund assessments. Many of these organizations also
have the power to levy assessments similar to those of the
guaranty associations described above. Some states permit member
insurers to recover assessments paid through full or partial
premium tax offsets.
While in the past five years, the aggregate assessments levied
against MetLife, Inc.s insurance subsidiaries have not
been material, it is possible that a large catastrophic event
could render such guaranty funds inadequate and we may be called
upon to contribute additional amounts, which may have a material
impact on our financial condition or results of operations in a
particular period. We have established liabilities for guaranty
fund assessments that we consider adequate for assessments with
respect to insurers that are currently subject to insolvency
proceedings, but additional liabilities may be necessary.
Consistent with industry practice and accounting standards, we
establish liabilities for claims arising from a catastrophe only
after assessing the probable losses arising from the event. We
cannot be certain that the liabilities we have established will
be adequate to cover actual claim liabilities. From time to
time, states have passed legislation that has the effect of
limiting the ability of insurers to manage risk, such as
legislation restricting an insurers ability to withdraw
from catastrophe-prone areas. While we attempt to limit our
exposure to acceptable levels, subject to restrictions imposed
by insurance regulatory authorities, a catastrophic event or
multiple catastrophic events could have a material adverse
effect on our business, results of operations and financial
condition.
Our ability to manage this risk and the profitability of our
property and casualty and life insurance businesses depends in
part on our ability to obtain catastrophe reinsurance, which may
not be available at commercially acceptable rates in the future.
See Reinsurance May Not Be Available,
Affordable or Adequate to Protect Us Against Losses.
Our
Statutory Reserve Financings May Be Subject to Cost Increases
and New Financings May Be Subject to Limited Market
Capacity
To support statutory reserves for several products, including,
but not limited to, our level premium term life and universal
life with secondary guarantees and MLICs closed block, we
currently utilize capital markets solutions for financing a
portion of our statutory reserve requirements. While we have
financing facilities in place for our previously written
business and have remaining capacity in existing facilities to
support writings through the end of 2010 or later, certain of
these facilities are subject to cost increases upon the
occurrence of specified ratings downgrades of MetLife or are
subject to periodic repricing. Any resulting cost increases
could negatively impact our financial results.
Future capacity for these statutory reserve funding structures
in the marketplace is not guaranteed. If capacity becomes
unavailable for a prolonged period of time, hindering our
ability to obtain funding for these new structures, our ability
to write additional business in a cost effective manner may be
impacted.
Competitive
Factors May Adversely Affect Our Market Share and
Profitability
Our business segments are subject to intense competition. We
believe that this competition is based on a number of factors,
including service, product features, scale, price, financial
strength, claims-paying ratings, credit ratings,
e-business
capabilities and name recognition. We compete with a large
number of other insurers, as well as
S-48
non-insurance financial services companies, such as banks,
broker-dealers and asset managers, for individual consumers,
employers and other group customers and agents and other
distributors of insurance and investment products. Some of these
companies offer a broader array of products, have more
competitive pricing or more attractive features in their
products or, with respect to other insurers, have higher claims
paying ability ratings. Some may also have greater financial
resources with which to compete. National banks, which may sell
annuity products of life insurers in some circumstances, also
have pre-existing customer bases for financial services
products. Many of our group insurance products are underwritten
annually, and, accordingly, there is a risk that group
purchasers may be able to obtain more favorable terms from
competitors rather than renewing coverage with us. The effect of
competition may, as a result, adversely affect the persistency
of these and other products, as well as our ability to sell
products in the future.
In addition, the investment management and securities brokerage
businesses have relatively few barriers to entry and continually
attract new entrants.
Finally, the choices made by the U.S. Treasury in the
administration of EESA and in its distribution of amounts
available thereunder may have had the effect of supporting some
parts of the financial system more than others, and the new
requirements imposed on the financial industry by Dodd-Frank
could similarly have differential effects. See
Actions of the U.S. Government, Federal
Reserve Bank of New York and Other Governmental and Regulatory
Bodies for the Purpose of Stabilizing and Revitalizing the
Financial Markets and Protecting Investors and Consumers May Not
Achieve the Intended Effect or Could Adversely Affect
MetLifes Competitive Position and
President Obama Recently Signed a Bill
Providing for Comprehensive Reform of Financial Services
Regulation in the United States, Various Aspects of Which Could
Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth.
Industry
Trends Could Adversely Affect the Profitability of Our
Businesses
Our business segments continue to be influenced by a variety of
trends that affect the insurance industry, including competition
with respect to product features, price, distribution
capability, customer service and information technology. The
impact on our business and on the life insurance industry
generally of the volatility and instability of the financial
markets is difficult to predict, and our business plans,
financial condition and results of operations may be negatively
impacted or affected in other unexpected ways. In addition, the
life insurance industry is subject to state regulation, and, as
complex products are introduced, regulators may refine capital
requirements and introduce new reserving standards. Furthermore,
regulators have undertaken market and sales practices reviews of
several markets or products, including variable annuities and
group products. The market environment may also lead to changes
in regulation that may benefit or disadvantage us relative to
some of our competitors.
Consolidation
of Distributors of Insurance Products May Adversely Affect the
Insurance Industry and the Profitability of Our
Business
The insurance industry distributes many of its individual
products through other financial institutions such as banks and
broker-dealers. An increase in bank and broker-dealer
consolidation activity may negatively impact the industrys
sales, and such consolidation could increase competition for
access to distributors, result in greater distribution expenses
and impair our ability to market insurance products to our
current customer base or to expand our customer base.
Consolidation of distributors
and/or other
industry changes may also increase the likelihood that
distributors will try to renegotiate the terms of any existing
selling agreements to terms less favorable to us.
Our
Valuation of Fixed Maturity, Equity and Trading Securities and
Short-Term Investments May Include Methodologies, Estimations
and Assumptions Which Are Subject to Differing Interpretations
and Could Result in Changes to Investment Valuations That May
Materially Adversely Affect Our Results of Operations or
Financial Condition
Fixed maturity, equity, and trading securities and short-term
investments which are reported at estimated fair value on the
consolidated balance sheets represent the majority of our total
cash and investments. We have
S-49
categorized these securities into a three-level hierarchy, based
on the priority of the inputs to the respective valuation
technique.
The fair value hierarchy gives the highest priority to quoted
prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable
inputs (Level 3). An asset or liabilitys
classification within the fair value hierarchy is based on the
lowest level of significant input to its valuation. The input
levels are as follows:
Level 1 Unadjusted quoted prices in active
markets for identical assets or liabilities. We define active
markets based on average trading volume for equity securities.
The size of the bid/ask spread is used as an indicator of market
activity for fixed maturity securities.
Level 2 Quoted prices in markets that are not
active or inputs that are observable either directly or
indirectly. Level 2 inputs include quoted prices for
similar assets or liabilities other than quoted prices in
Level 1; quoted prices in markets that are not active; or
other inputs that are observable or can be derived principally
from or corroborated by observable market data for substantially
the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported
by little or no market activity and are significant to the fair
value of the assets or liabilities. Unobservable inputs reflect
the reporting entitys own assumptions about the
assumptions that market participants would use in pricing the
asset or liability. Level 3 assets and liabilities include
financial instruments whose values are determined using pricing
models, discounted cash flow methodologies, or similar
techniques, as well as instruments for which the determination
of fair value requires significant management judgment or
estimation.
At June 30, 2010, 8.6%, 84.2% and 7.2% of these securities
represented Level 1, Level 2 and Level 3,
respectively. The Level 1 securities primarily consist of
certain U.S. Treasury, agency and government guaranteed
fixed maturity securities; certain foreign government fixed
maturity securities; exchange-traded common stock; certain
trading securities; and certain short-term investments. The
Level 2 assets include fixed maturity and equity securities
priced principally through independent pricing services using
observable inputs. These fixed maturity securities include most
U.S. Treasury, agency and government guaranteed securities,
as well as the majority of U.S. and foreign corporate
securities, RMBS, CMBS, state and political subdivision
securities, foreign government securities, and ABS. Equity
securities classified as Level 2 primarily consist of
non-redeemable preferred securities and certain equity
securities where market quotes are available but are not
considered actively traded and are priced by independent pricing
services. We review the valuation methodologies used by the
independent pricing services on an ongoing basis and ensure that
any changes to valuation methodologies are justified.
Level 3 assets include fixed maturity securities priced
principally through independent non-binding broker quotations or
market standard valuation methodologies using inputs that are
not market observable or cannot be derived principally from or
corroborated by observable market data. Level 3 consists of
less liquid fixed maturity securities with very limited trading
activity or where less price transparency exists around the
inputs to the valuation methodologies including: U.S. and
foreign corporate securities including below
investment grade private placements; RMBS; CMBS; and
ABS including all of those supported by
sub-prime
mortgage loans. Equity securities classified as Level 3
securities consist principally of nonredeemable preferred stock
and common stock of companies that are privately held or
companies for which there has been very limited trading activity
or where less price transparency exists around the inputs to the
valuation.
Prices provided by independent pricing services and independent
non-binding broker quotations can vary widely even for the same
security.
The determination of estimated fair values by management in the
absence of quoted market prices is based on: (i) valuation
methodologies; (ii) securities we deem to be comparable;
and (iii) assumptions deemed appropriate given the
circumstances. The fair value estimates are made at a specific
point in time, based on available market information and
judgments about financial instruments, including estimates of
the timing and amounts of expected future cash flows and the
credit standing of the issuer or counterparty. Factors
considered in estimating fair value include: coupon rate,
maturity, estimated duration, call provisions, sinking fund
requirements, credit rating, industry sector of the issuer, and
quoted market prices of comparable securities. The use of
different methodologies and assumptions may have a material
effect on the estimated fair value amounts.
S-50
During periods of market disruption including periods of
significantly rising or high interest rates, rapidly widening
credit spreads or illiquidity, it may be difficult to value
certain of our securities, for example
sub-prime
mortgage-backed securities, mortgage-backed securities where the
underlying loans are Alt-A and CMBS, if trading becomes less
frequent
and/or
market data becomes less observable. In times of financial
market disruption, certain asset classes that were in active
markets with significant observable data may become illiquid. In
such cases, more securities may fall to Level 3 and thus
require more subjectivity and management judgment. As such,
valuations may include inputs and assumptions that are less
observable or require greater estimation, as well as valuation
methods which are more sophisticated or require greater
estimation thereby resulting in estimated fair values which may
be greater or less than the amount at which the investments may
be ultimately sold. Further, rapidly changing and unprecedented
credit and equity market conditions could materially impact the
valuation of securities as reported within our consolidated
financial statements and the
period-to-period
changes in estimated fair value could vary significantly.
Decreases in value may have a material adverse effect on our
results of operations or financial condition.
If Our
Business Does Not Perform Well, We May Be Required to Recognize
an Impairment of Our Goodwill or Other Long-Lived Assets or to
Establish a Valuation Allowance Against the Deferred Income Tax
Asset, Which Could Adversely Affect Our Results of Operations or
Financial Condition
Goodwill represents the excess of the amounts we paid to acquire
subsidiaries and other businesses over the estimated fair value
of their net assets at the date of acquisition. See
If the Alico Business Does Not Perform Well or
We Do Not Integrate It Successfully, We May Incur Significant
Charges to Write Down the Goodwill Established in the
Acquisition. We test goodwill at least annually for
impairment. Impairment testing is performed based upon estimates
of the estimated fair value of the reporting unit to
which the goodwill relates. The reporting unit is the operating
segment or a business one level below that operating segment if
discrete financial information is prepared and regularly
reviewed by management at that level. The estimated fair value
of the reporting unit is impacted by the performance of the
business. The performance of our businesses may be adversely
impacted by prolonged market declines. If it is determined that
the goodwill has been impaired, we must write down the goodwill
by the amount of the impairment, with a corresponding charge to
net income. Such writedowns could have an adverse effect on our
results of operations or financial position.
Long-lived assets, including assets such as real estate, also
require impairment testing to determine whether changes in
circumstances indicate that MetLife will be unable to recover
the carrying amount of the asset group through future operations
of that asset group or market conditions that will impact the
estimated fair value of those assets. Such writedowns could have
a material adverse effect on our results of operations or
financial position. Deferred income tax represents the tax
effect of the differences between the book and tax basis of
assets and liabilities.
Deferred tax assets are assessed periodically by management to
determine if they are realizable. Factors in managements
determination include the performance of the business including
the ability to generate future taxable income. If based on
available information, it is more likely than not that the
deferred income tax asset will not be realized then a valuation
allowance must be established with a corresponding charge to net
income. Such charges could have a material adverse effect on our
results of operations or financial position.
If Our
Business Does Not Perform Well or if Actual Experience Versus
Estimates Used in Valuing and Amortizing DAC, DSI and VOBA Vary
Significantly, We May Be Required to Accelerate the Amortization
and/or
Impair the DAC, DSI and VOBA Which Could Adversely Affect Our
Results of Operations or Financial Condition
We incur significant costs in connection with acquiring new and
renewal business. Those costs that vary with and are primarily
related to the production of new and renewal business are
deferred and referred to as DAC. Bonus amounts credited to
certain policyholders, either immediately upon receiving a
deposit or as excess interest credits for a period of time, are
referred to as DSI. The recovery of DAC and DSI is dependent
upon the future profitability of the related business. The
amount of future profit or margin is dependent principally on
investment returns in excess of the amounts credited to
policyholders, mortality, morbidity, persistency, interest
crediting rates, dividends paid to policyholders, expenses to
administer the business, creditworthiness of reinsurance
counterparties and
S-51
certain economic variables, such as inflation. Of these factors,
we anticipate that investment returns are most likely to impact
the rate of amortization of such costs. The aforementioned
factors enter into managements estimates of gross profits
or margins, which generally are used to amortize such costs.
If the estimates of gross profits or margins were overstated,
then the amortization of such costs would be accelerated in the
period the actual experience is known and would result in a
charge to income. Significant or sustained equity market
declines could result in an acceleration of amortization of the
DAC and DSI related to variable annuity and variable universal
life contracts, resulting in a charge to income. Such
adjustments could have a material adverse effect on our results
of operations or financial condition.
VOBA reflects the estimated fair value of in-force contracts in
a life insurance company acquisition and represents the portion
of the purchase price that is allocated to the value of the
right to receive future cash flows from the insurance and
annuity contracts in-force at the acquisition date. VOBA is
based on actuarially determined projections. Actual experience
may vary from the projections. Revisions to estimates result in
changes to the amounts expensed in the reporting period in which
the revisions are made and could result in a charge to income.
Also, as VOBA is amortized similarly to DAC and DSI, an
acceleration of the amortization of VOBA would occur if the
estimates of gross profits or margins were overstated.
Accordingly, the amortization of such costs would be accelerated
in the period in which the actual experience is known and would
result in a charge to net income. Significant or sustained
equity market declines could result in an acceleration of
amortization of the VOBA related to variable annuity and
variable universal life contracts, resulting in a charge to
income. Such adjustments could have a material adverse effect on
our results of operations or financial condition.
Changes
in Accounting Standards Issued by the Financial Accounting
Standards Board or Other Standard- Setting Bodies May Adversely
Affect Our Financial Statements
Our financial statements are subject to the application of GAAP,
which is periodically revised
and/or
expanded. Accordingly, from time to time we are required to
adopt new or revised accounting standards issued by recognized
authoritative bodies, including the Financial Accounting
Standards Board. Market conditions have prompted accounting
standard setters to expose new guidance which further interprets
or seeks to revise accounting pronouncements related to
financial instruments, structures or transactions, as well as to
issue new standards expanding disclosures. The impact of
accounting pronouncements that have been issued but not yet
implemented is disclosed in our annual and quarterly reports on
Form 10-K
and
Form 10-Q.
An assessment of proposed standards is not provided as such
proposals are subject to change through the exposure process
and, therefore, the effects on our financial statements cannot
be meaningfully assessed. It is possible that future accounting
standards we are required to adopt could change the current
accounting treatment that we apply to our consolidated financial
statements and that such changes could have a material adverse
effect on our financial condition and results of operations.
Changes in Our Discount Rate, Expected Rate of Return and
Expected Compensation Increase Assumptions for Our Pension and
Other Postretirement Benefit Plans May Result in Increased
Expenses and Reduce Our Profitability
We determine our pension and other postretirement benefit plan
costs based on our best estimates of future plan experience.
These assumptions are reviewed regularly and include discount
rates, expected rates of return on plan assets and expected
increases in compensation levels and expected medical inflation.
Changes in these assumptions may result in increased expenses
and reduce our profitability.
Guarantees Within Certain of Our Products that Protect
Policyholders Against Significant Downturns in Equity Markets
May Decrease Our Earnings, Increase the Volatility of Our
Results if Hedging or Risk Management Strategies Prove
Ineffective, Result in Higher Hedging Costs and Expose Us to
Increased Counterparty Risk
Certain of our variable annuity products include guaranteed
benefits. These include guaranteed death benefits, guaranteed
withdrawal benefits, lifetime withdrawal guarantees, guaranteed
minimum accumulation benefits, and guaranteed minimum income
benefits. Periods of significant and sustained downturns in
equity markets, increased equity volatility, or reduced interest
rates could result in an increase in the valuation of the future
policy benefit or policyholder account balance liabilities
associated with such products, resulting in a reduction to net
income. We use reinsurance in combination with derivative
instruments to mitigate the liability exposure and the
volatility of net
S-52
income associated with these liabilities, and while we believe
that these and other actions have mitigated the risks related to
these benefits, we remain liable for the guaranteed benefits in
the event that reinsurers or derivative counterparties are
unable or unwilling to pay. In addition, we are subject to the
risk that hedging and other management procedures prove
ineffective or that unanticipated policyholder behavior or
mortality, combined with adverse market events, produces
economic losses beyond the scope of the risk management
techniques employed. These, individually or collectively, may
have a material adverse effect on net income, financial
condition or liquidity. We are also subject to the risk that the
cost of hedging these guaranteed minimum benefits increases,
resulting in a reduction to net income.
The valuation of certain of the foregoing liabilities (carried
at fair value) includes an adjustment for nonperformance risk
that reflects the credit standing of the issuing entity. This
adjustment, which is not hedged, is based in part on publicly
available information regarding credit spreads related to
MetLife, Inc.s debt, including credit default swaps. In
periods of extreme market volatility, movements in these credit
spreads can have a significant impact on net income.
We May Need to Fund Deficiencies in Our Closed Block;
Assets Allocated to the Closed Block Benefit Only the Holders of
Closed Block Policies
MLICs plan of reorganization, as amended (the
Plan), required that we establish and operate
an accounting mechanism, known as a closed block, to ensure that
the reasonable dividend expectations of policyholders who own
certain individual insurance policies of MLIC are met. We
allocated assets to the closed block in an amount that will
produce cash flows which, together with anticipated revenue from
the policies included in the closed block, are reasonably
expected to be sufficient to support obligations and liabilities
relating to these policies, including, but not limited to,
provisions for the payment of claims and certain expenses and
tax, and to provide for the continuation of the policyholder
dividend scales in effect for 1999, if the experience underlying
such scales continues, and for appropriate adjustments in such
scales if the experience changes. We cannot provide assurance
that the closed block assets, the cash flows generated by the
closed block assets and the anticipated revenue from the
policies included in the closed block will be sufficient to
provide for the benefits guaranteed under these policies. If
they are not sufficient, we must fund the shortfall. Even if
they are sufficient, we may choose, for competitive reasons, to
support policyholder dividend payments with our general account
funds.
The closed block assets, the cash flows generated by the closed
block assets and the anticipated revenue from the policies in
the closed block will benefit only the holders of those
policies. In addition, to the extent that these amounts are
greater than the amounts estimated at the time the closed block
was funded, dividends payable in respect of the policies
included in the closed block may be greater than they would be
in the absence of a closed block. Any excess earnings will be
available for distribution over time only to closed block
policyholders.
Litigation and Regulatory Investigations Are Increasingly
Common in Our Businesses and May Result in Significant Financial
Losses and Harm to Our Reputation
We face a significant risk of litigation and regulatory
investigations and actions in the ordinary course of operating
our businesses, including the risk of class action lawsuits. Our
pending legal and regulatory actions include proceedings
specific to us and others generally applicable to business
practices in the industries in which we operate. In connection
with our insurance operations, plaintiffs lawyers may
bring or are bringing class actions and individual suits
alleging, among other things, issues relating to sales or
underwriting practices, claims payments and procedures, product
design, disclosure, administration, denial or delay of benefits
and breaches of fiduciary or other duties to customers.
Plaintiffs in class action and other lawsuits against us may
seek very large or indeterminate amounts, including punitive and
treble damages, and the damages claimed and the amount of any
probable and estimable liability, if any, may remain unknown for
substantial periods of time.
Due to the vagaries of litigation, the outcome of a litigation
matter and the amount or range of potential loss at particular
points in time may be inherently impossible to ascertain with
any degree of certainty. Inherent uncertainties can include how
fact finders will view individually and in their totality
documentary evidence, the credibility and effectiveness of
witnesses testimony, and how trial and appellate courts
will apply the law in the context of the pleadings or evidence
presented, whether by motion practice, or at trial or on appeal.
Disposition
S-53
valuations are also subject to the uncertainty of how opposing
parties and their counsel will themselves view the relevant
evidence and applicable law.
On a quarterly and annual basis, we review relevant information
with respect to litigation and contingencies to be reflected in
our consolidated financial statements. The review includes
senior legal and financial personnel. Unless stated elsewhere
herein, estimates of possible losses or ranges of loss for
particular matters cannot in the ordinary course be made with a
reasonable degree of certainty. Liabilities are established when
it is probable that a loss has been incurred and the amount of
the loss can be reasonably estimated.
Liabilities have been established for a number of matters noted
in Note 8 of the Notes to the Interim Condensed
Consolidated Financial Statements included in the Second Quarter
Form 10-Q.
It is possible that some of the matters could require us to pay
damages or make other expenditures or establish accruals in
amounts that could not be estimated at June 30, 2010.
MLIC and its affiliates are currently defendants in numerous
lawsuits including class actions and individual suits, alleging
improper marketing or sales of individual life insurance
policies, annuities, mutual funds or other products.
In addition, MLIC is a defendant in a large number of lawsuits
seeking compensatory and punitive damages for personal injuries
allegedly caused by exposure to asbestos or asbestos-containing
products. These lawsuits principally have focused on allegations
with respect to certain research, publication and other
activities of one or more of MLICs employees during the
period from the 1920s through approximately the
1950s and have alleged that MLIC learned or should have
learned of certain health risks posed by asbestos and, among
other things, improperly publicized or failed to disclose those
health risks. Additional litigation relating to these matters
may be commenced in the future. The ability of MLIC to estimate
its ultimate asbestos exposure is subject to considerable
uncertainty, and the conditions impacting its liability can be
dynamic and subject to change. The availability of reliable data
is limited and it is difficult to predict with any certainty the
numerous variables that can affect liability estimates,
including the number of future claims, the cost to resolve
claims, the disease mix and severity of disease in pending and
future claims, the impact of the number of new claims filed in a
particular jurisdiction and variations in the law in the
jurisdictions in which claims are filed, the possible impact of
tort reform efforts, the willingness of courts to allow
plaintiffs to pursue claims against MLIC when exposure took
place after the dangers of asbestos exposure were well known,
and the impact of any possible future adverse verdicts and their
amounts. The number of asbestos cases that may be brought or the
aggregate amount of any liability that MLIC may incur, and the
total amount paid in settlements in any given year are uncertain
and may vary significantly from year to year. Accordingly, it is
reasonably possible that our total exposure to asbestos claims
may be materially greater than the liability recorded by us in
our consolidated financial statements and that future charges to
income may be necessary. The potential future charges could be
material in the particular quarterly or annual periods in which
they are recorded.
We are also subject to various regulatory inquiries, such as
information requests, subpoenas and books and record
examinations, from state and federal regulators and other
authorities. A substantial legal liability or a significant
regulatory action against us could have a material adverse
effect on our business, financial condition and results of
operations. Moreover, even if we ultimately prevail in the
litigation, regulatory action or investigation, we could suffer
significant reputational harm, which could have a material
adverse effect on our business, financial condition and results
of operations, including our ability to attract new customers,
retain our current customers and recruit and retain employees.
Regulatory inquiries and litigation may cause volatility in the
price of stocks of companies in our industry.
The New York Attorney General recently announced that his office
had launched a major fraud investigation into the life insurance
industry for practices related to the use of retained asset
accounts and that subpoenas requesting comprehensive data
related to retained asset accounts have been served on MetLife
and other insurance carriers. We received the subpoena on
July 30, 2010. We offer a retained asset account for death
benefit payments called a Total Control Account
(TCA) as a settlement option under our
individual and group life insurance policies. When a TCA is
established for a beneficiary, we retain the death benefit
proceeds in the general account and pay interest on those
proceeds at a rate set by reference to objective indices.
Additionally, the accounts enjoy a guaranteed minimum interest
rate. Beneficiaries can withdraw all of the funds or a portion
of the funds held in the
S-54
account at any time. It is possible that other state and federal
regulators or legislative bodies may pursue similar
investigations or make related inquiries. We cannot predict what
effect any such investigations might have on our earnings or the
availability of the TCA, but we believe that our financial
statements taken as a whole would not be materially affected. We
believe that any allegations that information about the TCA is
not adequately disclosed or that the accounts are fraudulent or
violate state or federal laws are without merit.
We cannot give assurance that current claims, litigation,
unasserted claims probable of assertion, investigations and
other proceedings against us will not have a material adverse
effect on our business, financial condition or results of
operations. It is also possible that related or unrelated
claims, litigation, unasserted claims probable of assertion,
investigations and proceedings may be commenced in the future,
and we could become subject to further investigations and have
lawsuits filed or enforcement actions initiated against us. In
addition, increased regulatory scrutiny and any resulting
investigations or proceedings could result in new legal actions
and precedents and industry-wide regulations that could
adversely affect our business, financial condition and results
of operations.
New and Impending Compensation and Corporate Governance
Regulations Could Hinder or Prevent Us From Attracting and
Retaining Management and Other Employees with the Talent and
Experience to Manage and Conduct Our Business Effectively
The compensation and corporate governance practices of financial
institutions will become subject to increasing regulation and
scrutiny. Dodd-Frank includes new requirements that will affect
our corporate governance and compensation practices, including
some that are likely to lead to shareholders having the limited
right to use MetLife, Inc.s proxy statement to solicit
proxies to vote for their own candidates for director, impose
additional requirements for membership on Board committees,
require additional shareholder votes on compensation matters,
require policies to recover compensation previously paid to
certain executives under certain circumstances, eliminate broker
discretionary voting on compensation matters, require additional
performance and compensation disclosure, and other requirements.
See President Obama Recently Signed a Bill
Providing for Comprehensive Reform of Financial Services
Regulation in the United States, Various Aspects of Which Could
Impact Our Business Operations, Capital Requirements and
Profitability and Limit Our Growth. In addition, the
Federal Reserve Board, the FDIC and other U.S. bank
regulators have released guidelines on incentive compensation
that may apply to or impact MetLife, Inc. as a bank holding
company.
These requirements and restrictions, and others Congress or
regulators may propose or implement, could hinder or prevent us
from attracting and retaining management and other employees
with the talent and experience to manage and conduct our
business effectively. Other new rules, such as the Health Care
Act (as defined below), could also limit our tax deductions for
certain compensation paid to executive officers and other
employees in excess of specified amounts. We may also be subject
to requirements and restrictions on our business if we
participate in some of the programs established in whole or in
part under EESA.
Although AIG, the ultimate parent company of the Alico Business,
has received assurances from the TARP Special Master for
Executive Compensation that neither we nor the Alico Business
will be subject to compensation related requirements and
restrictions under programs established in whole or in part
under EESA, there can be no assurance that the Acquisition will
not lead to greater public or governmental scrutiny, regulation,
or restrictions on our compensation practices as a result of the
Acquisition and expansion into new markets outside the United
States, whether in connection with AIGs having received
U.S. government funding or as a result of other factors.
Legislative and Regulatory Activity in Health Care and
Other Employee Benefits Could Increase the Costs or
Administrative Burdens of Providing Benefits to Our Employees or
Hinder or Prevent Us From Attracting and Retaining Employees, or
Affect our Profitability As a Provider of Life Insurance,
Annuities, and Non-Medical Health Insurance Benefit
Products.
The Patient Protection and Affordable Care Act, signed into law
on March 23, 2010, and The Health Care and Education
Reconciliation Act of 2010, signed into law on March 30,
2010 (together, the Health Care Act), may
lead to fundamental changes in the way that employers, including
us, provide health care benefits, other benefits, and other
forms of compensation to their employees and former employees.
Among other changes, and subject to various effective dates, the
Health Care Act generally restricts certain limits on benefits,
mandates coverage for certain kinds of care, extends the
required coverage of dependent children through age 26,
eliminates pre-existing
S-55
condition exclusions or limitations, requires cost reporting
and, in some cases, requires premium rebates to participants
under certain circumstances, limits coverage waiting periods,
establishes several penalties on employers who fail to offer
sufficient coverage to their full-time employees, and requires
employers under certain circumstances to provide employees with
vouchers to purchase their own health care coverage. The Health
Care Act also provides for increased taxation of high
cost coverage, restricts the tax deductibility of certain
compensation paid by health care and some other insurers,
reduces the tax deductibility of retiree health care costs to
the extent of any retiree prescription drug benefit subsidy
provided to the employer by the federal government, increases
Medicare taxes on certain high earners, and establishes health
insurance exchanges for individual purchases of
health insurance.
The impact of the Health Care Act on us as an employer and on
the benefit plans we sponsor for employees or retirees and their
dependents, whether those benefits remain competitive or
effective in meeting their business objectives, and our costs to
provide such benefits and our tax liabilities in connection with
benefits or compensation, cannot be predicted. Furthermore, we
cannot predict the impact of choices that will be made by
various regulators, including the United States Treasury, the
IRS, the United States Department of Health and Human Services,
and state regulators, to promulgate regulations or guidance, or
to make determinations under or related to the Health Care Act.
Either the Health Care Act or any of these regulatory actions
could adversely affect our ability to attract, retain, and
motivate talented associates. They could also result in
increased or unpredictable costs to provide employee benefits,
and could harm our competitive position if we are subject to
fees, penalties, tax provisions or other limitations in the
Health Care Act and our competitors are not.
The Health Care Act also imposes requirements on us as a
provider of life insurance, annuities, and non-medical health
insurance benefit products, subject to various effective dates.
It also imposes requirements on the purchasers of certain of
these products. We cannot predict the impact of the Act or of
regulations, guidance or determinations made by various
regulators, on the various products that we offer. Either the
Health Care Act or any of these regulatory actions could
adversely affect our ability to offer certain of these products
in the same manner as we do today. They could also result in
increased or unpredictable costs to provide certain products,
and could harm our competitive position if the Health Care Act
has a disparate impact on our products compared to products
offered by our competitors.
The Preservation of Access to Care for Medicare Beneficiaries
and Pension Relief Act of 2010 also includes certain provisions
for defined benefit pension plan funding relief. These
provisions may impact the likelihood
and/or
timing of corporate plan sponsors terminating their plans
and/or
engaging in transactions to partially or fully transfer pension
obligations to an insurance company. As part of our Corporate
Benefit Funding segment, we offer general account and separate
account group annuity products that enable a plan sponsor to
transfer these risks, often in connection with the termination
of defined benefit pension plans. Consequently, this legislation
could indirectly affect the mix of our business, with fewer
closeouts and more non-guaranteed funding products, and
adversely impact our results of operations.
Changes in U.S. Federal and State Securities Laws and
Regulations May Affect Our Operations and Our
Profitability
Federal and state securities laws and regulations apply to
insurance products that are also securities,
including variable annuity contracts and variable life insurance
policies. As a result, some of MetLife, Inc.s subsidiaries
and their activities in offering and selling variable insurance
contracts and policies are subject to extensive regulation under
these securities laws. These subsidiaries issue variable annuity
contracts and variable life insurance policies through separate
accounts that are registered with the SEC as investment
companies under the Investment Company Act. Each registered
separate account is generally divided into
sub-accounts,
each of which invests in an underlying mutual fund which is
itself a registered investment company under the Investment
Company Act. In addition, the variable annuity contracts and
variable life insurance policies issued by the separate accounts
are registered with the SEC under the Securities Act. Other
subsidiaries are registered with the SEC as broker-dealers under
the Exchange Act, and are members of, and subject to, regulation
by Financial Industry Regulatory Authority, Inc.
(FINRA). Further, some of our subsidiaries
are registered as investment advisers with the SEC under the
Investment Advisers Act of 1940, and are also registered as
investment advisers in various states, as applicable.
S-56
Federal and state securities laws and regulations are primarily
intended to ensure the integrity of the financial markets and to
protect investors in the securities markets, as well as protect
investment advisory or brokerage clients. These laws and
regulations generally grant regulatory agencies broad rulemaking
and enforcement powers, including the power to limit or restrict
the conduct of business for failure to comply with the
securities laws and regulations. A number of changes have
recently been suggested to the laws and regulations that govern
the conduct of our variable insurance products business that
could have a material adverse effect on our financial condition
and results of operations. For example, Dodd-Frank authorizes
the SEC to establish a standard of conduct applicable to brokers
and dealers when providing personalized investment advice to
retail and other customers. This standard of conduct would be to
act in the best interest of the customer without regard to the
financial or other interest of the broker or dealer providing
the advice. In addition, the NAIC has adopted a revised
Suitability in Annuity Transactions Model Regulation, that will,
if enacted by the states, place new responsibilities upon
issuing insurance companies with respect to the suitability of
annuity sales, including responsibilities for training agents.
Changes in Tax Laws, Tax Regulations, or Interpretations
of Such Laws or Regulations Could Increase Our Corporate Taxes;
Changes in Tax Laws Could Make Some of Our Products Less
Attractive to Consumers
Changes in tax laws, Treasury and other regulations promulgated
thereunder, or interpretations of such laws or regulations could
increase our corporate taxes. The Obama Administration has
proposed corporate tax changes. Changes in corporate tax rates
could affect the value of deferred tax assets and deferred tax
liabilities. Furthermore, the value of deferred tax assets could
be impacted by future earnings levels.
Changes in tax laws could make some of our products less
attractive to consumers. A shift away from life insurance and
annuity contracts and other tax-deferred products would reduce
our income from sales of these products, as well as the assets
upon which we earn investment income. The Obama Administration
has proposed certain changes to individual income tax rates and
rules applicable to certain policies.
We cannot predict whether any tax legislation impacting
corporate taxes or insurance products will be enacted, what the
specific terms of any such legislation will be or whether, if at
all, any legislation would have a material adverse effect on our
financial condition and results of operations.
We May
Be Unable to Attract and Retain Sales Representatives for Our
Products
We must attract and retain productive sales representatives to
sell our insurance, annuities and investment products. Strong
competition exists among insurers for sales representatives with
demonstrated ability. In addition, there is competition for
representatives with other types of financial services firms,
such as independent broker-dealers.
We compete with other insurers for sales representatives
primarily on the basis of our financial position, support
services and compensation and product features. We continue to
undertake several initiatives to grow our career agency force
while continuing to enhance the efficiency and production of our
existing sales force. We cannot provide assurance that these
initiatives will succeed in attracting and retaining new agents.
Sales of individual insurance, annuities and investment products
and our results of operations and financial condition could be
materially adversely affected if we are unsuccessful in
attracting and retaining agents.
MetLife, Inc.s Board of Directors May Control the
Outcome of Stockholder Votes on Many Matters Due to the Voting
Provisions of the MetLife Policyholder Trust
Under the Plan, we established the MetLife Policyholder Trust
(the Trust) to hold the shares of MetLife,
Inc. common stock allocated to eligible policyholders not
receiving cash or policy credits under the plan. At
July 28, 2010, the Trust held 226,995,571 shares, or
27.7%, of the outstanding shares of MetLife, Inc. common stock.
Because of the number of shares held in the Trust and the voting
provisions of the Trust, the Trust may affect the outcome of
matters brought to a stockholder vote.
Except on votes regarding certain fundamental corporate actions
described below, the trustee will vote all of the shares of
common stock held in the Trust in accordance with the
recommendations given by MetLife, Inc.s Board of Directors
to its stockholders or, if the board gives no such
recommendations, as directed by the board. As a result of the
voting provisions of the Trust, the Board of Directors may be
able to control votes on matters submitted
S-57
to a vote of stockholders, excluding those fundamental corporate
actions, so long as the Trust holds a substantial number of
shares of common stock.
If the vote relates to fundamental corporate actions specified
in the Trust, the trustee will solicit instructions from the
Trust beneficiaries and vote all shares held in the Trust in
proportion to the instructions it receives. These actions
include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s Board of Directors
or a vote on a stockholders proposal to oppose a board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution, of MetLife, Inc., in each case requiring a vote of
stockholders under applicable Delaware law;
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the Trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s Board of Directors
to amend or redeem the rights under MetLife, Inc.s
stockholder rights plan, other than a proposal with respect to
which we have received advice of nationally- recognized legal
counsel to the effect that the proposal is not a proper subject
for stockholder action under Delaware law. MetLife, Inc. does
not currently have a stockholder rights plan.
|
If a vote concerns any of these fundamental corporate actions,
the trustee will vote all of the shares of common stock held by
the Trust in proportion to the instructions it received, which
will give disproportionate weight to the instructions actually
given by Trust beneficiaries.
State Laws, Federal Laws, Our Certificate of Incorporation
and Our By-Laws May Delay, Deter or Prevent Takeovers and
Business Combinations that Stockholders Might Consider in Their
Best Interests
State laws and our certificate of incorporation and by-laws may
delay, deter or prevent a takeover attempt that stockholders
might consider in their best interests. For instance, they may
prevent stockholders from receiving the benefit from any premium
over the market price of MetLife, Inc.s common stock
offered by a bidder in a takeover context. Even in the absence
of a takeover attempt, the existence of these provisions may
adversely affect the prevailing market price of MetLife,
Inc.s common stock if they are viewed as discouraging
takeover attempts in the future.
Any person seeking to acquire a controlling interest in us would
face various regulatory obstacles which may delay, deter or
prevent a takeover attempt that stockholders of MetLife, Inc.
might consider in their best interests. First, the insurance
laws and regulations of the various states in which MetLife,
Inc.s insurance subsidiaries are organized may delay or
impede a business combination involving us. State insurance laws
prohibit an entity from acquiring control of an insurance
company without the prior approval of the domestic insurance
regulator. Under most states statutes, an entity is
presumed to have control of an insurance company if it owns,
directly or indirectly, 10% or more of the voting stock of that
insurance company or its parent company. We are also subject to
banking regulations, and may in the future become subject to
additional regulations. Dodd-Frank contains provisions that
could restrict or impede consolidation, mergers and acquisitions
by systemically significant firms
and/or large
bank holding companies. In addition, the Investment Company Act
would require approval by the contract owners of our variable
contracts in order to effectuate a change of control of any
affiliated investment adviser to a mutual fund underlying our
variable contracts. Finally, FINRA approval would be necessary
for a change of control of any FINRA registered broker-dealer
that is a direct or indirect subsidiary of MetLife, Inc.
In addition, Section 203 of the Delaware General
Corporation Law may affect the ability of an interested
stockholder to engage in certain business combinations,
including mergers, consolidations or acquisitions of additional
shares, for a period of three years following the time that the
stockholder becomes an interested stockholder. An
interested stockholder is defined to include persons
owning, directly or indirectly, 15% or more of the outstanding
voting stock of a corporation.
S-58
MetLife, Inc.s certificate of incorporation and by-laws
also contain provisions that may delay, deter or prevent a
takeover attempt that stockholders might consider in their best
interests. These provisions may adversely affect prevailing
market prices for MetLife, Inc.s common stock and include:
classification of MetLife, Inc.s Board of Directors into
three classes; a prohibition on the calling of special meetings
by stockholders; advance notice procedures for the nomination of
candidates to the Board of Directors and stockholder proposals
to be considered at stockholder meetings; and supermajority
voting requirements for the amendment of certain provisions of
the certificate of incorporation and by-laws.
The
Continued Threat of Terrorism and Ongoing Military Actions May
Adversely Affect the Level of Claim Losses We Incur and the
Value of Our Investment Portfolio
The continued threat of terrorism, both within the United States
and abroad, ongoing military and other actions and heightened
security measures in response to these types of threats may
cause significant volatility in global financial markets and
result in loss of life, property damage, additional disruptions
to commerce and reduced economic activity. Some of the assets in
our investment portfolio may be adversely affected by declines
in the credit and equity markets and reduced economic activity
caused by the continued threat of terrorism. We cannot predict
whether, and the extent to which, companies in which we maintain
investments may suffer losses as a result of financial,
commercial or economic disruptions, or how any such disruptions
might affect the ability of those companies to pay interest or
principal on their securities or mortgage loans. The continued
threat of terrorism also could result in increased reinsurance
prices and reduced insurance coverage and potentially cause us
to retain more risk than we otherwise would retain if we were
able to obtain reinsurance at lower prices. Terrorist actions
also could disrupt our operations centers in the United States
or abroad. In addition, the occurrence of terrorist actions
could result in higher claims under our insurance policies than
anticipated. See Difficult Conditions in the
Global Capital Markets and the Economy Generally May Materially
Adversely Affect Our Business and Results of Operations and
These Conditions May Not Improve in the Near Future.
The
Occurrence of Events Unanticipated in Our Disaster Recovery
Systems and Management Continuity Planning Could Impair Our
Ability to Conduct Business Effectively
In the event of a disaster such as a natural catastrophe, an
epidemic, an industrial accident, a blackout, a computer virus,
a terrorist attack or war, unanticipated problems with our
disaster recovery systems could have a material adverse impact
on our ability to conduct business and on our results of
operations and financial position, particularly if those
problems affect our computer-based data processing,
transmission, storage and retrieval systems and destroy valuable
data. We depend heavily upon computer systems to provide
reliable service. Despite our implementation of a variety of
security measures, our computer systems could be subject to
physical and electronic break-ins, and similar disruptions from
unauthorized tampering. In addition, in the event that a
significant number of our managers were unavailable in the event
of a disaster, our ability to effectively conduct business could
be severely compromised. These interruptions also may interfere
with our suppliers ability to provide goods and services
and our employees ability to perform their job
responsibilities.
Our
Associates May Take Excessive Risks Which Could Negatively
Affect Our Financial Condition and Business
As an insurance enterprise, we are in the business of being paid
to accept certain risks. The associates who conduct our
business, including executive officers and other members of
management, sales managers, investment professionals, product
managers, sales agents, and other associates, do so in part by
making decisions and choices that involve exposing us to risk.
These include decisions such as setting underwriting guidelines
and standards, product design and pricing, determining what
assets to purchase for investment and when to sell them, which
business opportunities to pursue, and other decisions. Although
we endeavor, in the design and implementation of our
compensation programs and practices, to avoid giving our
associates incentives to take excessive risks, associates may
take such risks regardless of the structure of our compensation
programs and practices. Similarly, although we employ controls
and procedures designed to monitor associates business
decisions and prevent us from taking excessive risks, there can
be no assurance that these controls and procedures are or may be
effective. If our associates take excessive risks, the impact of
those risks could have a material adverse effect on our
financial condition or business operations.
S-59
Risks
Relating to the Offering of the Common Stock
MetLife,
Inc.s Share Price Will Fluctuate
Although there has been some recent stabilization, stock markets
in general, and stock prices of financial services companies in
particular, including MetLife, Inc., have experienced
significant price and volume volatility since 2008. The market
price and volume of MetLife, Inc.s common stock may
continue to be subject to significant fluctuations due not only
to general stock market conditions but also to a change in
sentiment in the market regarding our operations, business
prospects, future funding, including in relation to the
Acquisition, or this offering. In addition to the risk factors
discussed above, the price and volume volatility of MetLife,
Inc.s common stock may be affected by:
|
|
|
|
|
the success or failure of our operating strategies and our
perceived prospects;
|
|
|
|
actual or anticipated fluctuations in our financial condition or
operating results;
|
|
|
|
variances in our operating results, for the third quarter of
2010 or for other periods, from the expectations of securities
analysts and investors;
|
|
|
|
the operating performance and securities price performance of
companies that investors consider to be comparable to
us; and
|
|
|
|
announcement of strategic developments, acquisitions and other
material events by us or our competitors.
|
There
May Be Future Sales or Other Dilution of MetLife, Inc.s
Equity, Which May Adversely Affect the Market Price of Its
Common Stock
In addition to the equity securities being issued as part of the
consideration for the Acquisition as discussed above, except as
may be required by the underwriters for this offering of common
stock, MetLife, Inc. is not restricted from issuing additional
common stock or preferred stock, including any securities that
are convertible into or exchangeable for, or that represent the
right to receive, common stock (including the Series B
Preferred Stock and the Stock Purchase Contracts forming part of
the Equity Units). The market price of MetLife, Inc.s
common stock could decline as a result of sales of a large
number of shares of its common stock or preferred stock or
similar securities in the market after this offering, or the
perception that such sales could occur. The issuance of
additional common stock will dilute the ownership interest of
existing common stockholders. See Risks
Relating to the Acquisition of the Alico Business
The Issuance of Certain Equity Securities to Alico Holdings
Pursuant to the Terms of the Stock Purchase Agreement Will Have
a Dilutive Impact on MetLife, Inc.s Stockholders,
Including Those Investors who Purchase Shares of the Common
Stock in the Offering.
The
Common Stock, Which is Subordinate to MetLife, Inc.s
Existing and Future Indebtedness and Preferred Stock, Will Pay
Dividends Only if and When Declared by MetLife, Inc.s
Board of Directors
Shares of the common stock are equity interests in MetLife, Inc.
and do not constitute indebtedness. As such, shares of the
common stock will rank junior to all indebtedness and other
non-equity claims on MetLife, Inc. with respect to assets
available to satisfy claims on MetLife, Inc., including in a
liquidation of MetLife, Inc. Additionally, holders of MetLife,
Inc.s common stock are subject to the prior dividend and
liquidation rights of any holders of MetLife, Inc.s
preferred stock then outstanding.
Dividends on the common stock are payable only if declared by
MetLife, Inc.s board of directors and are subject to
restrictions on payment of dividends out of lawfully available
funds. Also, as a holding company for its insurance and
financial subsidiaries, the payment of dividends and other
distributions to MetLife, Inc. by its insurance subsidiaries is
regulated by insurance laws and regulations. See
Risks Related to Our Business As a
Holding Company, MetLife, Inc. Depends on the Ability of Its
Subsidiaries to Transfer Funds to It to Meet Its Obligations and
Pay Dividends. MetLife, Inc. has issued and outstanding
indebtedness and preferred stock under which it may defer
interest or dividend payments from time to time (although
MetLife, Inc. has no present intention to, and believes the
likelihood is remote that it will elect or be required to defer
interest payments on these instruments), but in that case,
MetLife, Inc. would not be permitted to declare or pay dividends
on, make any distribution with respect to, or redeem, purchase,
acquire or make a liquidation payment with respect to, any
shares of its common stock, during the deferral period.
S-60
SELECTED
HISTORICAL CONSOLIDATED FINANCIAL INFORMATION FOR
METLIFE
The following tables set forth selected historical consolidated
financial information for MetLife. The selected historical
consolidated financial information at December 31, 2009 and
2008 and for the years ended December 31, 2009, 2008 and
2007 has been derived from our audited consolidated financial
statements included in the 2009 Form 10-K, the selected
historical consolidated financial information at
December 31, 2007 and 2006 and for the years ended
December 31, 2006 and 2005 has been derived from our
audited consolidated financial statements included in our Annual
Report on
Form 10-K
for the year ended December 31, 2007, and the selected
historical consolidated financial information at
December 31, 2005 has been derived from our audited
consolidated financial statements included in our Annual Report
on
Form 10-K
for the year ended December 31, 2005. This selected
consolidated financial information should be read in conjunction
with and is qualified by reference to these financial statements
and the related notes. The selected historical consolidated
financial information at June 30, 2010 and for the six
months ended June 30, 2010 and 2009 has been derived from
the unaudited interim condensed consolidated financial
statements included in the Second Quarter Form 10-Q. The
following consolidated statements of operations and consolidated
balance sheet data have been prepared in conformity with GAAP.
Some previously reported amounts have been reclassified to
conform with the presentation for the six months ended
June 30, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Six
|
|
|
|
|
|
|
Months Ended
|
|
|
|
|
|
|
June 30,
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
(In millions)
|
|
|
|
|
|
|
|
|
|
|
|
Statement of Operations Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums
|
|
$
|
13,516
|
|
|
$
|
12,698
|
|
|
$
|
26,460
|
|
|
$
|
25,914
|
|
|
$
|
22,970
|
|
|
$
|
22,052
|
|
|
$
|
20,979
|
|
Universal life and investment-type product policy fees
|
|
|
2,892
|
|
|
|
2,399
|
|
|
|
5,203
|
|
|
|
5,381
|
|
|
|
5,238
|
|
|
|
4,711
|
|
|
|
3,775
|
|
Net investment income
|
|
|
8,431
|
|
|
|
6,991
|
|
|
|
14,838
|
|
|
|
16,291
|
|
|
|
18,057
|
|
|
|
16,241
|
|
|
|
14,058
|
|
Other revenues
|
|
|
1,057
|
|
|
|
1,126
|
|
|
|
2,329
|
|
|
|
1,586
|
|
|
|
1,465
|
|
|
|
1,301
|
|
|
|
1,221
|
|
Net investment gains (losses)
|
|
|
1,540
|
|
|
|
(4,735
|
)
|
|
|
(7,772
|
)
|
|
|
1,812
|
|
|
|
(578
|
)
|
|
|
(1,382
|
)
|
|
|
(112
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
27,436
|
|
|
|
18,479
|
|
|
|
41,058
|
|
|
|
50,984
|
|
|
|
47,152
|
|
|
|
42,923
|
|
|
|
39,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder benefits and claims
|
|
|
14,555
|
|
|
|
13,528
|
|
|
|
28,336
|
|
|
|
27,437
|
|
|
|
23,783
|
|
|
|
22,869
|
|
|
|
22,236
|
|
Interest credited to policyholder account balances
|
|
|
2,192
|
|
|
|
2,397
|
|
|
|
4,849
|
|
|
|
4,788
|
|
|
|
5,461
|
|
|
|
4,899
|
|
|
|
3,650
|
|
Policyholder dividends
|
|
|
765
|
|
|
|
858
|
|
|
|
1,650
|
|
|
|
1,751
|
|
|
|
1,723
|
|
|
|
1,698
|
|
|
|
1,678
|
|
Other expenses
|
|
|
6,362
|
|
|
|
5,033
|
|
|
|
10,556
|
|
|
|
11,947
|
|
|
|
10,405
|
|
|
|
9,514
|
|
|
|
8,269
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
23,874
|
|
|
|
21,816
|
|
|
|
45,391
|
|
|
|
45,923
|
|
|
|
41,372
|
|
|
|
38,980
|
|
|
|
35,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before provision for
income tax
|
|
|
3,562
|
|
|
|
(3,337
|
)
|
|
|
(4,333
|
)
|
|
|
5,061
|
|
|
|
5,780
|
|
|
|
3,943
|
|
|
|
4,088
|
|
Provision for income tax expense (benefit)
|
|
|
1,188
|
|
|
|
(1,333
|
)
|
|
|
(2,015
|
)
|
|
|
1,580
|
|
|
|
1,675
|
|
|
|
1,027
|
|
|
|
1,156
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations, net of income tax
|
|
|
2,374
|
|
|
|
(2,004
|
)
|
|
|
(2,318
|
)
|
|
|
3,481
|
|
|
|
4,105
|
|
|
|
2,916
|
|
|
|
2,932
|
|
Income (loss) from discontinued operations, net of income tax
|
|
|
7
|
|
|
|
38
|
|
|
|
40
|
|
|
|
(203
|
)
|
|
|
360
|
|
|
|
3,524
|
|
|
|
1,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
2,381
|
|
|
|
(1,966
|
)
|
|
|
(2,278
|
)
|
|
|
3,278
|
|
|
|
4,465
|
|
|
|
6,440
|
|
|
|
4,811
|
|
Less: Net income (loss) attributable to noncontrolling interests
|
|
|
(11
|
)
|
|
|
(20
|
)
|
|
|
(32
|
)
|
|
|
69
|
|
|
|
148
|
|
|
|
147
|
|
|
|
97
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to MetLife, Inc.
|
|
|
2,392
|
|
|
|
(1,946
|
)
|
|
|
(2,246
|
)
|
|
|
3,209
|
|
|
|
4,317
|
|
|
|
6,293
|
|
|
|
4,714
|
|
Less: Preferred stock dividends
|
|
|
61
|
|
|
|
61
|
|
|
|
122
|
|
|
|
125
|
|
|
|
137
|
|
|
|
134
|
|
|
|
63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,331
|
|
|
$
|
(2,007
|
)
|
|
$
|
(2,368
|
)
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
$
|
4,651
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In millions)
|
|
|
Balance Sheet Data (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General account assets (2)
|
|
$
|
420,545
|
|
|
$
|
390,273
|
|
|
$
|
380,839
|
|
|
$
|
399,007
|
|
|
$
|
383,758
|
|
|
$
|
354,857
|
|
Separate account assets
|
|
|
153,362
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
127,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
573,907
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
$
|
482,712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Policyholder liabilities (3)
|
|
$
|
293,576
|
|
|
$
|
283,759
|
|
|
$
|
282,261
|
|
|
$
|
261,442
|
|
|
$
|
252,099
|
|
|
$
|
243,834
|
|
Payables for collateral under securities loaned and other
transactions
|
|
|
29,772
|
|
|
|
24,196
|
|
|
|
31,059
|
|
|
|
44,136
|
|
|
|
45,846
|
|
|
|
34,515
|
|
Bank deposits
|
|
|
9,790
|
|
|
|
10,211
|
|
|
|
6,884
|
|
|
|
4,534
|
|
|
|
4,638
|
|
|
|
4,339
|
|
Short-term debt
|
|
|
879
|
|
|
|
912
|
|
|
|
2,659
|
|
|
|
667
|
|
|
|
1,449
|
|
|
|
1,414
|
|
Long-term debt (2)
|
|
|
20,647
|
|
|
|
13,220
|
|
|
|
9,667
|
|
|
|
9,100
|
|
|
|
8,822
|
|
|
|
9,088
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
|
|
5,192
|
|
|
|
4,882
|
|
|
|
|
|
|
|
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
3,758
|
|
|
|
4,075
|
|
|
|
3,381
|
|
|
|
2,134
|
|
Other (2)
|
|
|
17,669
|
|
|
|
15,989
|
|
|
|
15,374
|
|
|
|
33,186
|
|
|
|
32,277
|
|
|
|
29,141
|
|
Separate account liabilities
|
|
|
153,362
|
|
|
|
149,041
|
|
|
|
120,839
|
|
|
|
160,142
|
|
|
|
144,349
|
|
|
|
127,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
534,183
|
|
|
|
505,816
|
|
|
|
477,693
|
|
|
|
522,164
|
|
|
|
492,861
|
|
|
|
452,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s stockholders equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
Common stock, at par value
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
|
|
8
|
|
Additional paid-in capital
|
|
|
16,896
|
|
|
|
16,859
|
|
|
|
15,811
|
|
|
|
17,098
|
|
|
|
17,454
|
|
|
|
17,274
|
|
Retained earnings
|
|
|
21,820
|
|
|
|
19,501
|
|
|
|
22,403
|
|
|
|
19,884
|
|
|
|
16,574
|
|
|
|
10,865
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(190
|
)
|
|
|
(236
|
)
|
|
|
(2,890
|
)
|
|
|
(1,357
|
)
|
|
|
(959
|
)
|
Accumulated other comprehensive income (loss)
|
|
|
822
|
|
|
|
(3,058
|
)
|
|
|
(14,253
|
)
|
|
|
1,078
|
|
|
|
1,118
|
|
|
|
1,912
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total MetLife, Inc.s stockholders equity
|
|
|
39,375
|
|
|
|
33,121
|
|
|
|
23,734
|
|
|
|
35,179
|
|
|
|
33,798
|
|
|
|
29,101
|
|
Noncontrolling interests
|
|
|
349
|
|
|
|
377
|
|
|
|
251
|
|
|
|
1,806
|
|
|
|
1,448
|
|
|
|
1,291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
39,724
|
|
|
|
33,498
|
|
|
|
23,985
|
|
|
|
36,985
|
|
|
|
35,246
|
|
|
|
30,392
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
573,907
|
|
|
$
|
539,314
|
|
|
$
|
501,678
|
|
|
$
|
559,149
|
|
|
$
|
528,107
|
|
|
$
|
482,712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Six Months
|
|
|
|
|
|
|
Ended June 30,
|
|
|
For the Years Ended December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
(In millions, except per share data)
|
|
|
Other Data (1),(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) available to MetLife, Inc.s common
shareholders
|
|
$
|
2,331
|
|
|
$
|
(2,007
|
)
|
|
$
|
(2,368
|
)
|
|
$
|
3,084
|
|
|
$
|
4,180
|
|
|
$
|
6,159
|
|
|
$
|
4,651
|
|
Return on MetLife, Inc.s common equity
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
(9.0
|
)%
|
|
|
11.2
|
%
|
|
|
12.9
|
%
|
|
|
20.9
|
%
|
|
|
18.6
|
%
|
Return on MetLife, Inc.s common equity, excluding
accumulated other comprehensive income (loss)
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
(6.8
|
)%
|
|
|
9.1
|
%
|
|
|
13.3
|
%
|
|
|
22.1
|
%
|
|
|
20.7
|
%
|
EPS Data (1),(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss) from Continuing Operations, Net of Income Tax
Available to MetLife, Inc.s Common Shareholders Per Common
Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
2.82
|
|
|
$
|
(2.51
|
)
|
|
$
|
(2.94
|
)
|
|
$
|
4.60
|
|
|
$
|
5.32
|
|
|
$
|
3.64
|
|
|
$
|
3.85
|
|
Diluted
|
|
$
|
2.80
|
|
|
$
|
(2.51
|
)
|
|
$
|
(2.94
|
)
|
|
$
|
4.54
|
|
|
$
|
5.20
|
|
|
$
|
3.60
|
|
|
$
|
3.81
|
|
Income (Loss) from Discontinued Operations, Net of Income Tax
Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
0.05
|
|
|
$
|
(0.41
|
)
|
|
$
|
0.30
|
|
|
$
|
4.45
|
|
|
$
|
2.36
|
|
Diluted
|
|
$
|
0.01
|
|
|
$
|
0.05
|
|
|
$
|
0.05
|
|
|
$
|
(0.40
|
)
|
|
$
|
0.28
|
|
|
$
|
4.39
|
|
|
$
|
2.35
|
|
Net Income (Loss) Available to MetLife, Inc.s Common
Shareholders Per Common Share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
2.83
|
|
|
$
|
(2.46
|
)
|
|
$
|
(2.89
|
)
|
|
$
|
4.19
|
|
|
$
|
5.62
|
|
|
$
|
8.09
|
|
|
$
|
6.21
|
|
Diluted
|
|
$
|
2.81
|
|
|
$
|
(2.46
|
)
|
|
$
|
(2.89
|
)
|
|
$
|
4.14
|
|
|
$
|
5.48
|
|
|
$
|
7.99
|
|
|
$
|
6.16
|
|
Dividends Declared Per Common Share
|
|
$
|
|
|
|
$
|
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.74
|
|
|
$
|
0.59
|
|
|
$
|
0.52
|
|
|
|
|
(1) |
|
On July 1, 2005, MetLife, Inc. completed the acquisition of
the Travelers Insurance Company, excluding certain assets, most
significantly, Primerica, from Citigroup Inc.
(Citigroup), and substantially all of
Citigroups international insurance businesses. The 2005
selected financial data includes total revenues and total
expenses of $966 million and $577 million,
respectively, from the date of the acquisition. |
|
(2) |
|
In 2010, general account assets, long-term debt and other
liabilities include amounts relating to variable interest
entities of $11,089 million, $7,187 million and
$79 million, respectively. |
|
(3) |
|
Policyholder liabilities include future policy benefits,
policyholder account balances, other policyholder funds,
policyholder dividends payable and the policyholder dividend
obligation. |
|
(4) |
|
Return on common equity is defined as net income (loss)
available to MetLife, Inc.s common shareholders divided by
average common stockholders equity. |
|
(5) |
|
For the six months ended June 30, 2009 and the year ended
December 31, 2009, shares related to the exercise or
issuance of stock-based awards have been excluded from the
calculation of diluted earnings per common share as these shares
are anti-dilutive. |
S-63
USE OF
PROCEEDS
We estimate that the net proceeds from the sale of MetLife,
Inc.s common stock will be $3,068,220,000 (or
$3,528,570,000 assuming the exercise of the over-allotment
option in full), after deducting the underwriting discounts and
commissions and the estimated offering expenses payable by us.
We intend to use the net proceeds from this offering to fund a
portion of the purchase price for the Acquisition as described
in this prospectus supplement. In the event that the net
proceeds from this offering and the additional offerings exceed
the amount required for the Acquisition, we will use the excess
net proceeds for general corporate purposes. In the event that
the Acquisition is not consummated, we will use the net proceeds
from the sale of the common stock for general corporate purposes.
S-64
CAPITALIZATION
The following table sets forth our consolidated capitalization
at June 30, 2010, on an actual basis and as adjusted to
give effect to (i) the offering of the common stock and (ii) the
Acquisition and related financings. This information should be
read in conjunction with our consolidated financial statements
at June 30, 2010 and December 31, 2009, including the
notes thereto, and other financial information pertaining to us
incorporated herein by reference as well as the unaudited pro
forma capsule financial information included in
Summary Unaudited Pro Forma Capsule Financial
Information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At June 30, 2010
|
|
|
|
|
|
|
|
|
|
As Adjusted
|
|
|
|
|
|
|
As Adjusted
|
|
|
for the
|
|
|
|
|
|
|
for this
|
|
|
Acquisition
|
|
|
|
|
|
|
Offering of
|
|
|
and Related
|
|
|
|
Actual
|
|
|
Common Stock (1)
|
|
|
Financings (2)
|
|
|
|
(In millions)
|
|
|
Short-term debt
|
|
$
|
879
|
|
|
$
|
879
|
|
|
$
|
879
|
|
Long-term debt (3)
|
|
|
20,647
|
|
|
|
20,647
|
|
|
|
26,773
|
|
Collateral financing arrangements
|
|
|
5,297
|
|
|
|
5,297
|
|
|
|
5,297
|
|
Junior subordinated debt securities
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
3,191
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
30,014
|
|
|
|
30,014
|
|
|
|
36,140
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MetLife, Inc.s Stockholders Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, at par value
|
|
|
1
|
|
|
|
1
|
|
|
|
1
|
|
Convertible preferred stock, at par value
|
|
|
|
|
|
|
|
|
|
|
1
|
|
Common stock, at par value
|
|
|
8
|
|
|
|
9
|
|
|
|
10
|
|
Additional paid-in capital
|
|
|
16,896
|
|
|
|
19,963
|
|
|
|
25,965
|
|
Retained earnings
|
|
|
21,820
|
|
|
|
21,820
|
|
|
|
21,820
|
|
Treasury stock, at cost
|
|
|
(172
|
)
|
|
|
(172
|
)
|
|
|
(172
|
)
|
Accumulated other comprehensive income
|
|
|
822
|
|
|
|
822
|
|
|
|
822
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
39,375
|
|
|
|
42,443
|
|
|
|
48,447
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
69,389
|
|
|
$
|
72,457
|
|
|
$
|
84,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects the issuance of 75,000,000 shares at a price per
share of $42.00 for total consideration of $3,150 million
less transaction costs of approximately $82 million for net
proceeds from the offering of $3,068 million. |
|
(2) |
|
Adjusted for the elimination of $216 million of MetLife,
Inc. debt securities resulting from the Acquisition, additional
debt (net of pre-closing settlements) of $80 million
assumed from the Alico Business and the anticipated related
financing transactions. The financing transactions include
(i) this offering of $3,150 million of common stock,
(ii) the offering of $3,100 million of senior notes,
(iii) the issuance of $3,165 million of Equity Units
to ALICO Holdings consisting of an interest in shares of
MetLife, Inc.s preferred stock (included in long term
debt) and the $174 million reduction in additional paid-in
capital related to the estimated present value of the
contractual payments to be made under the terms of the forward
contract component, (iv) the issuance of
$2,884 million of convertible preferred stock issued to
ALICO Holdings, and (v) the issuance of $3,291 million
of common stock issued to ALICO Holdings. These adjustments
reflect managements best estimate of the forms and amounts
of financing at the time of this offering. The actual form of
financing of the Acquisition may involve different forms of
financing and/or different amounts of the same types of
securities. Please refer to Summary Unaudited
Pro Forma Capsule Financial Information. |
|
(3) |
|
Includes $7,187 million of long-term debt relating to
variable interest entities. |
S-65
COMMON
STOCK PRICE RANGE AND DIVIDENDS
MetLife, Inc.s common stock is listed on the New York
Stock Exchange. Trading, as reported on the New York Stock
Exchange, and dividend information follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Price Range
|
|
|
Cash Dividend
|
|
|
|
High
|
|
|
Low
|
|
|
Per Share
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
Third Quarter (through July 30, 2010)
|
|
$
|
42.06
|
|
|
$
|
36.89
|
|
|
|
|
|
Second Quarter
|
|
$
|
47.10
|
|
|
$
|
37.76
|
|
|
|
|
|
First Quarter
|
|
$
|
43.34
|
|
|
$
|
33.64
|
|
|
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
38.35
|
|
|
$
|
33.22
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
40.83
|
|
|
$
|
26.90
|
|
|
|
|
|
Second Quarter
|
|
$
|
35.50
|
|
|
$
|
23.43
|
|
|
|
|
|
First Quarter
|
|
$
|
35.97
|
|
|
$
|
12.10
|
|
|
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
48.15
|
|
|
$
|
16.48
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
63.00
|
|
|
$
|
43.75
|
|
|
|
|
|
Second Quarter
|
|
$
|
62.88
|
|
|
$
|
52.77
|
|
|
|
|
|
First Quarter
|
|
$
|
61.52
|
|
|
$
|
54.62
|
|
|
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
70.87
|
|
|
$
|
60.46
|
|
|
$
|
0.74
|
|
Third Quarter
|
|
$
|
69.92
|
|
|
$
|
59.62
|
|
|
|
|
|
Second Quarter
|
|
$
|
69.04
|
|
|
$
|
63.29
|
|
|
|
|
|
First Quarter
|
|
$
|
65.92
|
|
|
$
|
59.10
|
|
|
|
|
|
The reported last sale price for our common stock on the New
York Stock Exchange on July 30, 2010 was $42.06 per share.
As of June 30, 2010, there were 820,397,071 shares of
common stock outstanding. As of June 30, 2010, our
outstanding shares of common stock were held by 90,566
stockholders of record.
S-66
PROPOSED
ACQUISITION OF THE ALICO BUSINESS
In this section we discuss the terms and conditions of the
proposed acquisition of the Alico Business and provisions of the
Stock Purchase Agreement. This discussion does not purport to be
complete and is qualified in its entirety by reference to the
Stock Purchase Agreement (including the Investor Rights
Agreement and the other exhibits thereto), which is attached as
an exhibit to MetLife, Inc.s Current Report on
Form 8-K,
filed with the SEC on March 11, 2010, which is incorporated
herein by reference.
General
MetLife, Inc. entered into the Stock Purchase Agreement dated as
of March 7, 2010 with AIG and ALICO Holdings, pursuant to
which MetLife, Inc. agreed to acquire the Alico Business for
cash and MetLife, Inc. securities presently valued at
approximately $16.1 billion as of July 30, 2010,
subject to certain pre-closing and closing adjustments.
ALICOs capital stock is wholly owned by ALICO Holdings (a
special purpose vehicle formed by AIG specifically for that
purpose), and DelAms capital stock is wholly owned by AIG.
All of the common voting equity interests of ALICO Holdings are
owned by AIG and the preferred non-voting equity interests are
owned by the Federal Reserve Bank of New York.
The closing of the Acquisition is subject to certain conditions.
Although no assurances can be given that these conditions will
be timely satisfied or waived, we expect the Acquisition to
close in the fourth quarter of 2010. After giving effect to the
Acquisition, MetLife will be one of the leading global insurance
companies conducting business in more than 60 countries and
serving over 90 million customers worldwide. On a pro forma
basis, after giving effect to the Acquisition and the financing
transactions related thereto, as of June 30, 2010,
MetLifes total assets and total stockholders equity
(excluding noncontrolling interests of $495 million) would have
been $685.0 billion and $48.4 billion, respectively.
For the six months ended June 30, 2010 and the year ended
December 31, 2009, on a pro forma basis, MetLife would
have had total revenues of $34.1 billion and
$54.3 billion, and diluted income (loss) per share from
continuing operations, net of income tax of $2.77 and $(1.36),
respectively. See Summary Unaudited Pro Forma
Capsule Financial Information.
Irrespective of this offering, the aggregate amount of MetLife,
Inc.s common stock expected to be issued in the
Acquisition (including shares issuable upon conversion of the
Series B Preferred Stock and shares issuable upon
settlement of the Stock Purchase Contracts) estimated
immediately after the closing thereof is expected to be less
than 23.5% of MetLife, Inc.s outstanding common stock. The
Stock Purchase Agreement does not contain a financing condition
to closing. In the Stock Purchase Agreement, MetLife, Inc.
represented that it will have all funds necessary at the closing
to pay the purchase price and consummate the proposed
transactions thereunder. In addition, the Stock Purchase
Agreement contains a specific performance covenant that permits
AIG to obtain an injunction requiring MetLife, Inc. to close in
the event the closing conditions are satisfied. We intend to
finance the cash portion of the purchase price through cash on
hand and proceeds from this offering and the additional
offerings. Concurrently with its entry into the Stock Purchase
Agreement to acquire the Alico Business, MetLife, Inc. executed
a commitment letter in connection with the Senior Credit
Facility. Subject to the conditions set forth therein, the
Senior Credit Facility will be used to finance any portion of
the cash component of the purchase price of the Acquisition that
is not financed with sales of MetLife, Inc.s securities or
cash on hand. An amount equal to 100% of the proceeds of sales
of MetLife, Inc.s securities, less certain ordinary-course
transactions, will be applied to prepay any loans under the
Senior Credit Facility and, if such proceeds or commitments are
received on or prior to the date of the closing of the
Acquisition, will permanently reduce
dollar-for-dollar
the commitments, if any, of the lenders under the Senior Credit
Facility. See Capitalization and
Summary Unaudited Pro Forma Capsule
Information.
At the closing, ALICO Holdings, AIG and MetLife, Inc. will enter
into an Investor Rights Agreement, described below, that will
provide, among other things, for neutralized voting by ALICO
Holdings and its affiliates of the shares of MetLife,
Inc.s common stock and will provide for registration
rights in favor of ALICO Holdings with respect to the MetLife,
Inc. securities to be issued to ALICO Holdings.
S-67
Overview
of the Alico Business
Founded in 1921, ALICO is one of the largest and most
diversified international life insurance companies in the world,
providing consumers and businesses with products and services
for life insurance, accident and health insurance, retirement
and wealth management solutions. The Acquisition will include
all of the Alico Business, including the business
distribution system composed of agents, brokers and financial
institutions; 12,500 employees across more than 50
countries; and 20 million customers worldwide. The
Acquisition also will include the Alico Business Global
Benefits Network serving U.S. and foreign multinationals.
For the six months ended May 31, 2010 and the year ended
November 30, 2009, the Alico Business had total revenues of
$7.0 billion and $14.1 billion, respectively, and net
income of $694 million and $807 million, respectively.
As of May 31, 2010 and November 30, 2009, the Alico
Business had total assets of $109.6 billion and
$113.0 billion, respectively, and stockholders equity
of $13.2 billion and $12.7 billion, respectively.
International diversification is a key strength of the Alico
Business. The Alico Business is a leader in many of the
countries and markets in which it operates. The Alico
Business principal products, based on revenues for the
year ended November 30, 2009 are: (i) traditional life
insurance (35%); (ii) accident and health insurance (29%);
(iii) fixed and variable annuities (23%); and
(iv) group life insurance (13%). The Alico Business uses a
multi-channel
distribution strategy driven by a captive agency force, brokers,
bancassurance (a bank sales channel used to sell insurance
products) and direct marketing. The Alico Business generated
premium income and other consideration of $9.9 billion for
the year ended November 30, 2009.
The Alico Business principal international markets,
products and distribution methods are as follows:
|
|
|
|
|
Japan. The Alico Business is among the
largest foreign life insurers in Japan, which accounted for
$7.8 billion, or approximately 55%, of its total revenues
for the year ended November 30, 2009. Its principal
products in the Japanese market are accident and health
insurance, traditional life insurance, individual annuity and
group life insurance. Its products are distributed through its
captive agency force, independent agents, brokers, bancassurance
and direct marketing.
|
|
|
|
Western Europe. Western Europe
accounted for $2.7 billion, or approximately 19% of the
Alico Business total revenues for the year ended
November 30, 2009. In the Western European region, the
Alico Business offers niche products combined with a
multi-channel distribution approach in the United Kingdom,
Ireland, France, Spain, Portugal and Italy. Its products are
principally traditional life insurance accident and health
insurance and group life insurance, and its products are
distributed through bancassurance, brokers, captive agencies,
direct marketing, family offices, private banks, independent
financial advisers and agencies. In addition, the Alico Business
also provides wealth management services, particularly to the
high net worth market, and other potentially high growth
businesses and also offers cash onshore (unit-linked) bonds,
life savings and retirement products and bulk purchase annuities.
|
|
|
|
Central and Eastern Europe. The Alico
Business has the largest insurance platform in the Central and
Eastern European region with 13 markets, which include Poland,
Greece, Bulgaria, Slovakia, the Czech Republic, Ukraine, Russia,
Romania, Hungary, Latvia, Serbia, Lithuania and Cyprus. This
region accounted for $1.7 billion, or approximately 12% of
the Alico Business total revenues for the year ended
November 30, 2009. The Alico Business principal
products offered in the region include life insurance
(traditional and unit-linked), accident and health insurance,
individual annuities, group life insurance, pension funds and
mutual funds. Its products are distributed through captive
agency, bancassurance, brokers, group sales force and direct
marketing distribution channels.
|
|
|
|
Middle East, Africa and South
Asia. This region accounted for
$0.8 billion, or approximately 6% of the Alico
Business total revenues for the year ended
November 30, 2009. The Alico Business has the largest
geographical coverage of any insurance company in the Middle
East, Africa and South Asia regions with 16 markets, which
include the United Arab Emirates, Bangladesh, Lebanon, Egypt,
Turkey, Saudi Arabia, Jordan, the area governed by the
Palestinian National Authority, Bahrain, Qatar, Oman, Kuwait,
Pakistan, Nepal, Yemen and Liberia. The Alico Business
principal products offered in these regions include traditional
life insurance, accident and health insurance, group life
insurance and pensions. Its products are distributed through
captive agency, group, bancassurance and broker distribution
channels.
|
S-68
|
|
|
|
|
Latin America. The Alico Business
conducts operations in the Latin American region in 24 markets,
which include Chile, Colombia, Argentina, Uruguay, Panama, the
Caribbean, Mexico and joint ventures in Peru and Venezuela. This
region accounted for $0.8 billion, or approximately 6% of
the Alico Business total revenues for the year ended
November 30, 2009. The Alico Business principal
products in this region include traditional life insurance,
accident and health insurance, individual annuities, group life
insurance and pensions, and its products are distributed by
captive agencies, bancassurance, brokers, direct marketing and
through worksites.
|
The remaining 2% of revenues for the year ended
November 30, 2009 related to ALICOs corporate
segment, which includes home office operations in Delaware and
operations of DelAm.
The Alico Business has a comprehensive investment portfolio,
which includes government bonds issued by Asian and European
nations. In particular, as of November 30, 2009, the Alico
Business held $11.5 billion in carrying value of debt
issued by Japan, $1.3 billion in carrying value of debt
issued by Greece, and an aggregate carrying value of
$1.3 billion of debt issued by Portugal, Spain, Italy and
Ireland.
Rationale
for the Acquisition
MetLife expects that the Acquisition will increase stockholder
value by increasing MetLifes return on equity and by being
accretive to operating earnings per share. In addition, MetLife
believes that the Acquisition will provide significant long-term
strategic and financial benefits to its stockholders, including
a significant long-term growth in revenues, earnings and returns
on equity. In particular, MetLife believes that the Acquisition
will:
|
|
|
|
|
Significantly Broaden MetLifes Diversification by
Product, Distribution and Geography. The
Acquisition will greatly diversify MetLifes revenue and
earnings sources by product, distribution and geography.
|
|
|
|
|
|
In terms of geographic diversification, as a result of the
Acquisition, MetLife will have a market presence in 64 different
countries, up from 17 at present, which, MetLife believes, will
create significant advantages over its international competitors
by providing scale and access to many higher growth markets.
|
|
|
|
The Acquisition will also diversify MetLifes product mix
by increasing the proportion of premium, fees and other revenues
from accident and health insurance products and certain types of
traditional life insurance products, where the primary risks are
morbidity and mortality, and reducing MetLifes relative
exposure to market-sensitive products such as annuities. For the
year ended November 30, 2009, accident and health insurance
and traditional life insurance products accounted for 64% in the
aggregate of the Alico Business total revenues.
|
|
|
|
As a result of the Acquisition, MetLifes distribution
sources will be further diversified. In addition to
MetLifes existing professional agency, employers and
third-party distribution channels, MetLife will, in the future,
have the benefit of adding the Alico Business captive and
independent agency and direct marketing distribution channels,
as well as enhancing its own third-party distribution channel by
combining it with that of the Alico Business.
|
|
|
|
|
|
Meaningfully Accelerate MetLifes Global Growth
Strategy. The Acquisition will materially
advance MetLifes presence in mature markets such as Japan
and Western Europe and establish leading positions for MetLife
in many emerging and developing markets. For the year ended
November 30, 2009, approximately $7.8 billion, or
approximately 55%, of the Alico Business revenues were
generated in the Japanese market. Another $2.7 billion, or
approximately 19%, of its 2009 revenues were generated in
Western Europe. The Acquisition will result in the formation of
a premier global life insurance franchise, and, according to
premium income information derived from the AXCO Insurance
Information Services Ltd. 2008 reports, the combined business
will be ranked (i) the number one life insurer in the United
States, Mexico and Chile, (ii) the number one insurer for
individual life insurance in Russia and (iii) the number one
foreign life insurer in Japan, with a growing presence in India
and China and a significant presence in Europe.
|
In addition, the Alico Business has leading positions in many
emerging and developing markets in Central and Eastern Europe,
the Middle East and Latin America. Leveraging the combined
business, the broad portfolio of product solutions and
experience in managing diversified distribution channels,
MetLife
S-69
believes that it will not only be strongly positioned in the
international markets in which MetLife and the Alico Business
currently operate, but it will also be well positioned to enter
new markets with high growth potential. MetLife believes that
its collective historical expertise in building and growing
operations in developing markets, coupled with scalability of
the combined companys business model around the globe,
will be a cornerstone of MetLifes future geographic
expansion.
|
|
|
|
|
Create the Opportunity to Build an Unparalleled
International Franchise Leveraging the Alico Business Key
Strengths. The Alico Business has an
established track record of organic growth. At the core of the
Alico Business strength are its broad geographic
diversification, its leading position in many of the markets in
which it operates, as well as its diversified distribution
methods and balanced product mix favoring protection products.
MetLife believes that this strong positioning, coupled with the
Alico Business longstanding presence in markets that are
now effectively closed to new entrants as a result of their
restrictive regulatory regimes, makes its platform extremely
difficult to replicate today. Accordingly, the Acquisition will
create a unique opportunity to continue to build MetLife as an
unparalleled international franchise leveraging the Alico
Business key strengths.
|
Consideration
Under the terms of the Stock Purchase Agreement, assuming no
purchase price adjustments, MetLife, Inc. will:
(i) pay $6.8 billion to ALICO Holdings in
cash; and
(ii) issue to ALICO Holdings:
(a) 78,239,712 shares of common stock,
(b) 6,857,000 shares of Series B Preferred Stock,
which will automatically convert into 68,570,000 shares of
common stock (subject to anti-dilution adjustments) upon a
favorable vote of MetLife, Inc.s common
stockholders, and
(c) $3.0 billion aggregate stated amount of Equity
Units, initially consisting of (x) the Stock Purchase
Contracts obligating the holder to purchase a variable number of
shares of MetLife, Inc.s common stock on each of three
specified future settlement dates (expected to be approximately
two, three and four years after the closing of the Acquisition)
for a fixed amount per contract (an aggregate of
$1.0 billion on each settlement date) and (y) an
interest in shares of the Unit Preferred Stock.
The consideration is currently valued at approximately
$16.1 billion (the Purchase Price)
(based on the fair value of the Equity Units and the closing
price of MetLife, Inc.s common stock on July 30,
2010), and is subject to certain adjustments described below.
Purchase
Price Adjustments
Pursuant to the Stock Purchase Agreement, the Purchase Price
will be subject to, among other adjustments: (a) a positive
or negative adjustment based on the after-tax net operating
earnings of ALICO during the
12-month
period ended May 31, 2010, to the extent that such
earnings, as adjusted, are greater than $1.65 billion or
less than $1.35 billion; (b) a positive or negative
adjustment based on the actual settlement amount of various
accounts payable and receivable relative to the carrying value
of each such account payable and receivable; and (c) in the
event that ALICO Holdings estimates ALICOs risk-based
capital to be less than 400% as of the closing date, a negative
adjustment at the closing in an amount equal to the estimated
amount required for ALICO to have a risk-based capital of 400%
as of the closing date, followed by (i) a post-closing
negative adjustment that requires AIG to pay to MetLife, Inc. an
amount equal to the actual amount of capital required for ALICO
(together with any amounts deducted at closing) to have an
actual risk-based capital of 400% as of the closing date or
(ii) a post-closing positive adjustment that requires
MetLife, Inc. to pay back to AIG, in cash, an amount equal to
the amount of any negative adjustment made at the closing as a
result of ALICOs estimated risk-based capital, to the
extent that the risk-based capital of ALICO equals or exceeds
400% at the closing, in each case, in accordance with the terms
and procedures set forth in the Stock Purchase Agreement. In
addition, AIG will receive a credit against the purchase price
at the closing equal to the amount of costs and expenses that
the Alico Business incurs in connection with the
S-70
completion of certain required separation actions prior to the
closing, followed by a negative purchase price adjustment to the
extent that such costs and expenses incurred between
June 1, 2010 and the closing date exceeded
$21.5 million.
Series B
Preferred Stock
At the closing, MetLife, Inc. will issue to ALICO Holdings the
Series B Preferred Stock, which will rank junior to all
shares of the other series of MetLife, Inc.s outstanding
preferred stock. The Series B Preferred Stock will not have
voting rights on most matters that are submitted to a vote of
MetLife, Inc.s common stockholders, but is intended to
have economic rights substantially equivalent to shares of
MetLife, Inc.s common stock, i.e., if MetLife, Inc.
declares any dividend or distribution, it will simultaneously
declare a dividend or distribution on the Series B
Preferred Stock in the amount of dividends or distributions that
would be made with respect to the shares of common stock into
which the Series B Preferred Stock is convertible, as if
the Series B Preferred Stock had been converted into shares
of common stock on the record date for such dividend or
distribution.
No later than the first anniversary of the closing, MetLife,
Inc. will submit to its common stockholders a proposal to
approve the conversion of the Series B Preferred Stock into
shares of its common stock, and each share of Series B
Preferred Stock will automatically convert on the third business
day following such approval at a conversion rate of ten shares
of common stock for each share of Series B Preferred Stock
(subject to anti-dilution adjustments). If such approval has not
been obtained prior to the first anniversary of the closing, the
Series B Preferred Stock will be deemed to be
Transferable Preferred Stock (the
Transferable Preferred Stock) pursuant to the
Investor Rights Agreement, and MetLife, Inc. will: (a) pay
to ALICO Holdings an amount equal to the product of $43.750911
and the number of shares of Series B Preferred Stock
delivered to ALICO Holdings at the closing (which product,
assuming the issuance of 6,857,000 shares of Series B
Preferred Stock at the closing, would equal $300 million);
(b) pursuant to the Investor Rights Agreement, provide
ALICO Holdings with registration rights to sell the
Series B Preferred Stock in an orderly manner and seek to
list the Series B Preferred Stock on the New York Stock
Exchange in connection with any registration and sale; and
(c) retain the option of converting the Series B
Preferred Stock into common stock at a later date.
Equity
Units
At the closing, MetLife, Inc. will issue the Equity Units to
ALICO Holdings pursuant to the terms of the Stock Purchase
Contract Agreement to be entered into between MetLife, Inc. and
the stock purchase contract agent. Each Equity Unit will
initially pay distributions at a rate of 5% per annum, payable
quarterly, and will initially consist of (i) a
1/40th ownership interest in one share of each of three
series of Unit Preferred Stock that will rank pari passu
in liquidation preference with MetLife, Inc.s
currently outstanding series of preferred stock and senior to
the Series B Preferred Stock, and (ii) three Stock
Purchase Contracts obligating the holder of such Equity Units to
purchase, on three settlement dates, a variable number of shares
of MetLife, Inc.s common stock for a fixed price. The Unit
Preferred Stock will be initially pledged as collateral to
secure the obligations of the holders under the Stock Purchase
Contracts.
Each series of Unit Preferred Stock will be automatically
exchanged for a related interest in debt securities of MetLife,
Inc. (issuable in one or more tranches) (the Unit Debt
Securities) prior to the applicable settlement date.
The Unit Debt Securities will: (i) be issued in an
aggregate principal amount equal to the liquidation preference
of the exchanged Unit Preferred Stock, (ii) have a stated
maturity date or stated maturity dates, (iii) rank pari
passu with all senior unsecured debt of MetLife, Inc., and
(iv) initially bear an interest rate equal to the greater
of (A) the dividend rate of the exchanged Unit Preferred
Stock and (B) the applicable federal rate prescribed by the
IRS on the exchange date. The Unit Debt Securities will be
callable by MetLife, Inc. after they are remarketed subject to a
customary make-whole provision.
Until certain deadlines prior to a settlement date, each holder
can elect to strip the Unit Preferred Stock or Unit Debt
Securities, as applicable, from the Equity Units;
provided that they are replaced with U.S. Treasury
Securities with principal amounts payable on or, in certain
cases, prior to the relevant settlement dates in an amount
sufficient to settle the related Stock Purchase Contracts.
Each of the Stock Purchase Contracts is expected to settle on
the settlement dates approximately two, three and four years
after the closing of the Acquisition, subject to extension in
the event of a failed remarketing of the Unit
S-71
Debt Securities, in shares of common stock. The number of shares
of common stock to be delivered on each such settlement date
will be determined in accordance with the provisions of the
Stock Purchase Contract Agreement and will generally depend on
the average of the volume-weighted average prices of MetLife,
Inc.s common stock during a 20 trading day period ending
on the third trading day prior to the initially applicable
scheduled settlement date.
Each holder may choose to settle the Stock Purchase Contracts
before the applicable settlement dates by delivering cash to
MetLife, Inc. and, in such case, will receive the minimum number
of shares of common stock that would have been deliverable upon
settlement on the originally scheduled settlement date, together
with the related pledged Unit Preferred Stock, Unit Debt
Securities or U.S. Treasury Securities, as applicable.
Prior to each of the settlement dates, the relevant Unit Debt
Securities will be remarketed, and, in connection therewith,
their interest rate may be reset in order to realize aggregate
proceeds sufficient to (i) meet the holders
obligations under the related Stock Purchase Contracts,
(ii) pay the remarketing agents fee,
(iii) cover, in certain circumstances, a payment to the
holders equal to any accrued but unpaid interest on the Unit
Debt Securities being remarketed, and (iv) cover a payment
to the holders equal to 0.05% of the principal amounts of the
Unit Debt Securities being remarketed. Each series of the Unit
Debt Securities may be remarketed up to five times, in
three-month intervals, but if the fifth such remarketing fails,
each holder will have the right to choose to settle the
applicable Stock Purchase Contract either by using cash or by
putting the relevant Unit Debt Securities back to MetLife, Inc.,
in each case in order to receive the related shares of common
stock.
The Equity Units and Unit Preferred Securities will not be
redeemable at the option of MetLife, Inc. The Unit Debt
Securities will be callable by MetLife, Inc. after they are
remarketed.
As permitted by the terms of the Stock Purchase Agreement,
MetLife, Inc. may seek to modify the terms of the Equity Units,
including by replacing the Unit Preferred Stock with a different
host security, in order to achieve the desired equity treatment
from the rating agencies. See Risk Factors A
Downgrade in Our Financial Strength or Credit Ratings Could
Result in a Loss of Business and Materially Adversely Affect Our
Financial Condition and Results of Operations.
Indemnification
The Stock Purchase Agreement provides that MetLife, Inc., on the
one hand, and ALICO Holdings, on the other hand, will indemnify
the other party and certain of the other partys
representatives for certain defined losses arising out of
inaccuracies or breaches of applicable representations or
warranties contained in the Stock Purchase Agreement and
breaches of or failures to perform applicable covenants,
obligations or agreements set forth in the Stock Purchase
Agreement. In addition, the Stock Purchase Agreement provides
for certain specific indemnities relating to (a) the
Premier Access Bond/Premier Bond Enhanced Fund or the Protected
Recovery Fund, each formed by the Alico Business U.K.
branch, (b) certain unit-linked insurance products offered
or sold prior to the closing by ALICO Life International Limited
(Italy branch) (the Italy Matter),
(c) scheduled class action lawsuits relating to premiums
charged in connection with credit life policies sold prior to
the closing by ALICO Compania de Seguros, S.A. and other
third-party claims based on substantially similar facts and
circumstances as those underlying such class action lawsuits
with respect to premiums charged in connection with credit life
policies sold prior to the closing by ALICO Compania de Seguros,
S.A., (the Argentina Matter) (d) the
leak and subsequent unauthorized use of credit card numbers of
policyholders of the Japan branch of the Alico Business (the
Japan Matter) and (e) certain other
specified matters relating to (i) loss of value resulting
from the loss of certain joint venture interests in such cases
where the consummation of the Acquisition triggers a third-party
joint venture partners call right, right of first refusal
or similar rights; (ii) the failure of certain reinsurance
contracts to remain in full force and effect at the closing of
the Acquisition; and (iii) loss of value resulting from the
loss of certain governmental permits or the failure to obtain
certain governmental approvals at or prior to the closing of the
Acquisition.
The indemnification provided by each of ALICO Holdings and
MetLife, Inc. with respect to breaches of representations and
warranties (other than with respect to certain specified
fundamental representations and warranties, indemnification for
which is not subject to any U.S. dollar limitations) is
subject to a materiality threshold of $87,500, a deductible of
$125 million and a $2.25 billion cap (the
Cap). Losses incurred by MetLife,
S-72
Inc. in connection with the Argentina Matter, the Italy Matter
and the Japan Matter are aggregated with losses incurred by
MetLife, Inc. in connection with breaches of representations and
warranties (other than with respect to specified fundamental
representations and warranties) for purposes of the Cap. ALICO
Holdings will also indemnify MetLife, Inc. with respect to
defined losses arising from any actions taken, or fines and
penalties imposed by, a governmental agency in the event that
the Alico Business violated the Foreign Corrupt Practices Act of
1977, as amended, anti-money laundering laws and laws enforced
by the Office of Foreign Assets Control, subject to the Cap and
with respect to tax matters, including certain tax indemnities
applicable to specified matters.
AIG has agreed that ALICO Holdings will initially deposit the
Equity Units into an indemnification collateral account as
security for ALICO Holdings indemnification and other
payment obligations. In addition, AIG has agreed to contribute
additional assets to ALICO Holdings in order to ensure ALICO
Holdings performance of its obligations under the Stock
Purchase Agreement in the event that it lacks the requisite
amount of cash or liquid assets to so perform. This collateral
will be released periodically over a
30-month
period on each of the
12-month,
24-month and
30-month
anniversary of the closing of the Acquisition as follows: Equity
Units with an aggregate stated amount of $1.0 billion (or
such amount of net cash proceeds from the sale of Equity Units
or other eligible collateral equal to such stated amount), less,
on each such release date, specified reserve amounts, including,
but not limited to, amounts necessary to satisfy then
outstanding indemnification claims made by MetLife, Inc.
However, if an AIG bankruptcy event occurs, any then remaining
indemnification collateral will remain in the indemnification
collateral account and will be released in part on each of the
30-month,
36-month and
48-month
anniversary of the closing of the Acquisition, less, on each
such release date, any such reserved amounts.
Non-Competition
and Non-Solicitation Provisions
The Stock Purchase Agreement contains a limited non-competition
provision which, subject to certain exceptions, prohibits AIG
from competing in the marketing and sale of certain specified
lines of business and products in the United States and
overseas. AIG has also agreed, subject to certain exceptions,
not to solicit or hire certain employees and producers of the
Alico Business. The term of the non-competition and
non-solicitation limitations is two years after the closing of
the Acquisition.
Investor
Rights Agreement
At the closing, MetLife, Inc. will enter into an investor rights
agreement (the Investor Rights Agreement)
with AIG and ALICO Holdings (including any permitted
transferees, all of whom will be subject to the terms and
provisions described below). Under the terms of the Investor
Rights Agreement, commencing nine months after the closing,
ALICO Holdings may require MetLife, Inc. to effect up to three
registrations of Subject Securities (as defined below) under the
Securities Act in any year; provided that ALICO Holdings
will be limited to one registration statement in any
120-day
period and may not require MetLife, Inc. to effect a
registration if a shelf registration statement covering all of
the Subject Securities is already in effect at such time. The
Subject Securities include: (i) MetLife,
Inc.s common stock; (ii) the Equity Units, including
their component securities; (iii) the Unit Preferred Stock
and the Unit Debt Securities; and (iv) the Transferrable
Preferred Stock.
Commencing nine months from the closing, pursuant to a
registration statement, ALICO Holdings may make up to three
public offerings of Subject Securities in each consecutive
365-day
period, each offering with anticipated aggregate gross proceeds
of $500 million or more, subject to the requirement that
there are at least 120 days between each such offering.
ALICO Holdings is limited to offering and selling: (a) 15%
or less of MetLife, Inc.s common stock or its equivalent
in any offering; (b) Subject Securities in any offering,
the aggregate gross proceeds of which would not exceed
$4.0 billion; and (c) Subject Securities in any
offering or other transfer, the aggregate gross proceeds of
which would not exceed $6.6 billion in any
180-day
period.
The right of ALICO Holdings to require MetLife, Inc. to register
or offer Subject Securities will be subject to certain
lock-ups and
deferrals described below.
MetLife, Inc. can defer a registration demand or suspend an
offering for up to:
|
|
|
|
|
60 consecutive days (with respect to any of the events described
in (a) through (d) below); and
|
|
|
|
195 days in the aggregate in any
365-day
period (with respect to any of the events described in
(a) through (d) below and after a request by MetLife,
Inc. to stand off before or after an underwritten
offering of its common stock);
|
S-73
in any of the following circumstances (and, as applicable,
during the occurrence of a requested market stand-off):
(a) MetLife, Inc. is subject to a customary suspension or
blackout period; (b) the offering would occur shortly
before or after an investor day presentation; (c) MetLife,
Inc. believes that in connection with an offering disclosures
would be required that would not otherwise be required and are
not in the best interests of MetLife, Inc.; or
(d) MetLife, Inc. is pursuing a primary underwritten
offering (with respect to which ALICO Holdings will have
piggyback registration rights). The stand-off referred to above
would prevent ALICO Holdings from selling or otherwise
transferring Subject Securities, upon the request of MetLife,
Inc., other than (i) to any wholly owned subsidiary or
other permitted transferee (which, in the case of a permitted
pledge of Subject Securities would include the
U.S. Treasury or any U.S. Federal Reserve Bank) of AIG or
(ii) as part of the exercise of piggyback registration,
from the date of the request and during the 60 days
following an offering of common stock by MetLife, Inc. Once in
any 365-day
period, MetLife, Inc. may also defer a registration demand or
suspend an offering for up to 60 days if MetLife, Inc. is
making an equity offering to fund a business combination or
acquisition of assets or to meet capital funding requirements.
ALICO Holdings will generally be permitted, subject to the other
restrictions in the Investor Rights Agreement, to transfer in a
registered public offering or in a forward-sale or hedge
transaction (a) nine months after the closing, up to 50% of
the MetLife, Inc. common stock consideration (or Transferable
Preferred Stock or Equity Units on a common-stock equivalent
basis) and 50% of the Unit Preferred Stock; and (b) one
year after the closing, 100% of the Subject Securities. After
the date which is eighteen months after the closing or, if
earlier, after the date on which the aggregate value of the
remaining Subject Securities is less than $1.0 billion,
ALICO Holdings may transfer the Subject Securities in compliance
with the volume and manner of sale requirements of
Rule 144(e) and (f) (regardless of whether such
requirements are applicable by law).
ALICO Holdings cannot transfer (a) common stock or
(b) Transferable Preferred Stock or Equity Units (in each
case, on a common stock equivalent basis) which would
(i) constitute the equivalent of 3.5% or more of the
outstanding common stock of MetLife, Inc. to any one transferee
or (ii) result, to the actual knowledge of ALICO Holdings,
in any transferee beneficially owning more than 5% of the
outstanding common stock of MetLife, Inc.
ALICO Holdings will be able to assign its registration rights in
connection with the transfer of at least $500 million of
Subject Securities to AIG, any wholly owned subsidiary or other
permitted transferee (which, in the case of a permitted pledge
of Subject Securities would include the U.S. Treasury or
any U.S. Federal Reserve Bank) of AIG that is or agrees to be
bound by the terms of the Investor Rights Agreement. ALICO
Holdings will agree to use commercially reasonable efforts to
transfer all of the Subject Securities held by it or a permitted
transferee before the later of: (i) the fifth anniversary
of the closing; and (ii) the first anniversary of the last
settlement date of the Stock Purchase Contracts under the terms
of the Equity Units. The Investor Rights Agreement will
terminate by consent of the parties or when ALICO Holdings no
longer owns any Subject Securities.
AIG will be required to either remain in control of
ALICO Holdings or guarantee all obligations of ALICO Holdings.
Furthermore, ALICO Holdings and AIG will agree to certain
standstill provisions, to the effect (among other things) that
ALICO Holdings and AIG or their respective affiliates will not
acquire or own more than 23.5% of the common stock or other
voting securities (or securities convertible into common stock
or other voting securities) of MetLife, Inc.
ALICO Holdings and AIG will agree that they will not seek to
control or influence the management, board of
directors, stockholders or policies of MetLife, Inc. or its
affiliates. In addition, ALICO Holdings will agree to vote all
of the common stock or other voting securities in the same
proportion as the shares voted by all other holders of MetLife,
Inc.s common stock or other voting securities. This
agreement with respect to voting will not apply to any common
stock or other voting securities that are not Subject Securities
unless, in the absence of such agreement, ALICO Holdings, AIG or
their respective affiliates would be found to control MetLife,
Inc. for purposes of the Bank Holding Company Act of 1956, as
amended (the BHC), in which case ALICO
Holdings will be subject to the voting agreement to the extent
necessary so that ALICO Holdings, AIG or any of their respective
affiliates will not be found to control MetLife, Inc. for
purposes of the BHC.
The Investor Rights Agreement will contain customary
indemnification provisions. ALICO Holdings will have piggyback
registration rights on any underwritten offerings of common
stock by MetLife, Inc., subject to customary exceptions.
Finally, if ALICO Holdings transfers any Subject Securities that
are subject to any custody
S-74
arrangement securing its indemnification obligations under the
Stock Purchase Agreement, any proceeds in connection therewith
must also be subject to a first priority security interest in
favor of MetLife, Inc.
Other
Ancillary Agreements
In addition to the agreements described above, MetLife, Inc.
will also enter into several other agreements with ALICO
Holdings and its affiliates in connection with the Acquisition.
These agreements include a special asset protection agreement
pursuant to which ALICO Holdings will agree to partly reimburse
MetLife, Inc. for losses relating to certain assets protected
under the agreement and a transition services agreement,
pursuant to which AIG and MetLife, Inc., following the closing
of the Acquisition, will continue to provide each other with
certain scheduled services and access to certain facilities, in
each case for a specified term.
Conditions
to Closing
Except as noted below, the obligations of AIG, ALICO Holdings
and MetLife, Inc. to close the Acquisition are subject to the
receipt of all governmental approvals, including
anti-competition, insurance and pension regulatory approvals
(or expirations of waiting periods), unless the parties waive
such approvals. These governmental approvals must be in full
force and effect without the imposition of certain conditions or
restrictions including any condition or restriction requiring
the taking of any action that would materially adversely affect
the economic benefits reasonably expected to be derived by a
party to the Stock Purchase Agreement in connection with the
consummation of the Acquisition, requiring the divestiture or
other disposition of any assets that are material to such
partys enterprise, or that would otherwise materially
adversely affect such party or interfere with the ability of
such party (taken as a whole with its subsidiaries) to conduct
its business substantially in the manner as such business is
currently being conducted. However, if six months have elapsed
since the date of the Stock Purchase Agreement and not all
governmental approvals have been obtained, then only certain
specified governmental approvals will be required to be
obtained, such as (a) the Federal Reserve Boards
determination that AIG and ALICO Holdings will not be deemed to
control MetLife, Inc. due to the Acquisition,
(b) governmental approvals in the State of Delaware,
France, Japan, Poland, the United Kingdom, Greece, the United
Arab Emirates, Slovakia, Lebanon, Spain and jurisdictions where
MetLife, Inc. operated on the date of the Stock Purchase
Agreement, (c) governmental approvals to permit ALICO
Holdings and AIG to receive MetLife, Inc. securities as part of
the consideration for the Acquisition and (d) governmental
approvals in such other jurisdictions under the laws of which
criminal penalties may be imposed if the Acquisition is closed
without obtaining such approvals.
Furthermore, except as noted above, the obligation of AIG, ALICO
Holdings and MetLife, Inc. to close the Acquisition is subject
to the absence of any governmental order issued or law enacted
that would enjoin, prohibit or make illegal the Acquisition,
unless such governmental order or law is vacated, terminated or
withdrawn.
MetLife, Inc.s obligation to close the Acquisition is
subject to the following additional conditions:
(i) ALICO Holdings and AIGs specified
fundamental representations and warranties are true and correct
in all respects;
(ii) ALICO Holdings and AIGs representations
and warranties (that are not considered fundamental) are true
and correct without regard to any materiality or material
adverse effect qualifiers to such representations and warranties
(except where the failure to be true and correct would not
reasonably be expected to have a material adverse effect on the
Alico Business);
(iii) ALICO Holdings and AIG have performed their
obligations on or before the closing;
(iv) all ancillary agreements to which ALICO Holdings and
its Affiliates are a party have been executed and delivered to
MetLife, Inc.;
(v) since the date of the Stock Purchase Agreement, no
material adverse effect with respect to the Alico Business has
occurred;
(vi) the estimated ratio (expressed as a percentage) that
ALICOs total adjusted capital bears to its authorized
control level risk-based capital is no less than 400% as of the
closing; and
S-75
(vii) receipt of an opinion from outside counsel to ALICO
Holdings in a form reasonably acceptable to MetLife, Inc.,
concerning MetLife, Inc.s security interest in the
indemnification collateral account funds.
The obligation of ALICO Holdings to close the Acquisition is
subject to the following additional conditions:
(i) MetLife, Inc.s specified fundamental
representations and warranties are true and correct in all
respects;
(ii) MetLife, Inc.s representations and warranties
(that are not considered fundamental) are true and correct
without regard to any materiality or material adverse effect
qualifiers to such representations and warranties (except where
the failure to be true and correct would not reasonably be
expected to have a material adverse effect on the business of
MetLife, Inc.);
(iii) MetLife, Inc. has performed its obligations in all
material respects on or before the closing;
(iv) all ancillary agreements to which MetLife, Inc. and
its affiliates are a party have been executed and delivered to
ALICO Holdings;
(v) receipt of an opinion from Dewey & LeBoeuf
LLP, in a form reasonably acceptable to ALICO Holdings,
concerning the valid issuance of the shares MetLife, Inc.s
common stock, the Equity Units and the Series B Preferred
Stock; and
(vi) since the date of the Stock Purchase Agreement, no
material adverse effect with respect to MetLife, Inc. has
occurred.
Termination
The Stock Purchase Agreement may be terminated (i) by
mutual consent, (ii) by either ALICO Holdings or MetLife,
Inc if the closing is not consummated by January 10, 2011
(provided, that either ALICO Holdings or MetLife, Inc.
may extend the outside date until July 10, 2011 if the
closing has not occurred due to the failure to receive one or
more governmental approvals), (iii) by either ALICO
Holdings or MetLife, Inc, if there is a final, non-appealable
governmental order issued or law enacted that would restrain,
enjoin, prohibit or make illegal the Acquisition (other than in
the case where approval under such order or law is not required
to satisfy the regulatory approval closing condition described
under Conditions to Closing) or
(iv) by either party, if there is an incurable breach
precluding fulfillment of any of the conditions obligating such
party to consummate the Acquisition. If such breach can be
cured, the Stock Purchase Agreement may be terminated if the
breach is not cured within 60 calendar days after the alleged
breaching party receives written notice.
The Stock Purchase Agreement will terminate automatically
without the requirement of any action or notice by any party
upon (i) the institution prior to the closing by or against
AIG, ALICO Holdings or ALICO of any insolvency, bankruptcy or
similar proceeding or (ii) prior to the closing, the
appointment of, or petition for appointment of, an
administrator, provisional liquidator, conservator, receiver,
trustee, custodian or other similar official for all or
substantially all of the assets of AIG, ALICO Holdings or ALICO.
S-76
CERTAIN
MATERIAL U.S. FEDERAL INCOME TAX
CONSIDERATIONS FOR
NON-U.S.
HOLDERS
The following is a general discussion of certain material
U.S. federal income tax consequences resulting from the
purchase, ownership and disposition of our common stock by a
non-U.S. holder
(as defined below) that acquires our common stock pursuant to
this offering. The following discussion is based on provisions
of the Code, applicable U.S. Treasury regulations
promulgated thereunder and administrative and judicial
interpretations, all as in effect on the date of this prospectus
supplement, and all of which are subject to change, possibly on
a retroactive basis. This discussion is limited to
non-U.S. holders
who hold our common stock as a capital asset within
the meaning of Section 1221 of the Code. This discussion is
only addressed to
non-U.S. holders
and does not consider and does not address tax considerations
applicable to holders in light of their particular circumstances
or to holders that may be subject to special tax rules,
including, without limitation, financial institutions (including
banks), insurance companies, retirement plans, mutual funds,
hybrid entities, certain former citizens or former long-term
residents of the United States, dealers in securities or
currencies, holders who acquire their common stock pursuant to
the exercise of employee stock options or as compensation,
persons subject to the
mark-to-market
rules of the Code, foreign governments, international
organizations, controlled foreign corporations, passive foreign
investment companies, persons that will hold our stock as a part
of a hedging transaction, synthetic security,
straddle, conversion transaction, or
other integrated transaction for U.S. federal income tax
purposes, entities treated as partnerships for U.S. federal
income tax purposes, and tax-exempt organizations. This
discussion does not consider any U.S. federal gift or
estate tax consequences, or U.S. state or local or
non-U.S. tax
consequences resulting from the purchase, ownership or
disposition of our common stock.
If a partnership (including any entity treated as a partnership
for U.S. federal income tax purposes) is a holder of our
common stock, the tax treatment of a partner in the partnership
generally will depend upon the status of the partner and the
activities of the partnership. Holders that are partnerships,
and partners in such partnerships, should consult their tax
advisors about the tax consequences resulting from the purchase,
ownership and disposition of our common stock.
As used in this discussion, the term
non-U.S. holder
means a holder that is a beneficial owner of our common stock
that is not, for U.S. federal income tax purposes:
|
|
|
|
|
an individual citizen or resident of the United States;
|
|
|
|
a corporation (or other entity treated as a corporation for
U.S. federal income tax purposes) created or organized in
or under the laws of the United States, any state thereof or the
District of Columbia;
|
|
|
|
an estate the income of which is subject to U.S. federal
income tax regardless of its source; or
|
|
|
|
a trust, if (1) a court within the United States is able to
exercise primary supervision over the administration of the
trust and one or more United States persons have authority to
control all substantial decisions of the trust or (2) it
has a valid election in effect under applicable
U.S. Treasury regulations to be treated as a domestic trust.
|
Prospective investors are urged to consult their own tax
advisors regarding the U.S. federal, state, local, and
non-U.S. income
and other tax considerations with respect to purchasing, owning
and disposing of shares of our common stock.
Distributions
on Our Common Stock
Distributions paid on our common stock will constitute dividends
for U.S. federal income tax purposes to the extent paid
from our current or accumulated earnings and profits, as
determined under U.S. federal income tax principles.
With respect to distributions that are treated as dividends for
U.S. federal income tax purposes, we will have to withhold
U.S. federal income tax at a rate of 30% (or such lower
rate under an applicable income tax treaty), from the gross
amount of the dividends paid to a
non-U.S. holder,
unless such dividends are effectively connected with such
holders conduct of a trade or business in the United
States (and, if an income tax treaty applies, are attributable
to a permanent establishment maintained by the
non-U.S. holder
in the United States). Under applicable
S-77
U.S. Treasury regulations,
non-U.S. holders
are required to satisfy certain certification and other
requirements (e.g., as set forth on IRS
Form W-8
BEN (or suitable substitute form)) in order to claim a reduced
rate of withholding on dividend payments pursuant to an
applicable income tax treaty. A
non-U.S. holder
that is eligible for a reduced rate of withholding of
U.S. federal income tax under an income tax treaty may
obtain a refund or credit of any excess amounts withheld by
timely filing an appropriate claim for refund with the IRS.
Non-U.S. holders
should consult their tax advisors regarding their entitlement to
benefits under a relevant income tax treaty.
Dividends that are effectively connected with a
non-U.S. holders
conduct of a trade or business in the United States (and,
if an income tax treaty applies, are attributable to a permanent
establishment maintained by the
non-U.S. holder
in the United States) are taxed on a net income basis at the
regular graduated U.S. federal income tax rates in the same
manner as if the
non-U.S. holder
were a resident of the United States. In such cases, we will not
have to withhold U.S. federal income tax if the
non-U.S. holder
complies with applicable certification and other requirements
(e.g., as set forth on IRS
Form W-8ECI
(or suitable substitute form)). In addition, a branch
profits tax may be imposed at a 30% rate, or a lower rate
under an applicable income tax treaty, if the
non-U.S. holder
is a foreign corporation that has earnings and profits
(attributable to dividends or otherwise) that are effectively
connected with such holders conduct of a trade or business
in the United States.
To the extent distributions exceed our current and accumulated
earnings and profits, such distributions will constitute a
return of capital to
non-U.S. holders
of our common stock, and will first reduce the
non-U.S. holders
adjusted tax basis in such stock, but not below zero. The
amounts of any such distribution in excess of such adjusted tax
basis will be treated as gain from the sale of stock which
generally should not be subject to U.S. federal income tax
(except as described below). See discussion below under
Gain on Disposition of Common Stock for
a more detailed discussion regarding the U.S. federal
income tax consequences to a
non-U.S. holder
with respect to gain on the sale of our common stock.
Gain on
Disposition of Common Stock
Subject to the discussion below under
Information Reporting and Backup Withholding
Tax and Newly Enacted Legislation,
a
non-U.S. holder
generally will not be subject to U.S. federal income tax or
any withholding thereof with respect to any gain realized on a
sale or other disposition of our common stock (including, as a
result of receiving distributions that are not treated as
dividends on such stock in excess of such holders adjusted
tax basis in such stock) unless one of the following applies:
|
|
|
|
|
the gain is effectively connected with the
non-U.S. holders
conduct of a trade or business in the United States (and,
if an income tax treaty applies, is attributable to a permanent
establishment maintained by the
non-U.S. holder
in the United States); in which case, the
non-U.S. holder
will generally be taxed on its net gain derived from the
disposition at the regular graduated rates and in the same
manner as if the
non-U.S. holder
were a resident of the United States and, if the
non-U.S. holder
is a foreign corporation, the branch profits tax
described above may also apply;
|
|
|
|
the
non-U.S. holder
is an individual who is present in the United States for
183 days or more in the taxable year of the disposition and
meets certain other requirements; in which case, the
non-U.S. holder
will be subject to a 30% tax on the gain derived from the
disposition, although such gain may be offset by
U.S. source capital losses recognized during the same
taxable year; or
|
|
|
|
our common stock constitutes a United States real property
interest (USRPI) by reason of our
status as a United States real property holding
corporation (USRPHC) for
U.S. federal income tax purposes at any time during the
shorter of the
5-year
period ending on the date the
non-U.S. holder
disposes of our common stock or the period such holder held our
common stock.
|
We believe that we are not currently and do not anticipate
becoming a USRPHC. Moreover, even if we are, or become, a
USRPHC,
non-U.S. holders
would not be subject to U.S. federal income tax (including
withholding thereof) if our stock is regularly traded on
an established securities market within the meaning of
Section 897(c)(3) of the Code, unless such a holder owned
(directly or indirectly) more than 5% of our common stock during
the applicable period (in which case, such holder would be
subject to U.S. federal income tax with respect to the net
gain recognized on the sale of our common stock at regular
graduated rates and related reporting
S-78
and filing requirements). We believe that our common stock
should be treated as regularly traded on an established
securities market. If our common stock does not meet this
requirement and we are, or become, a USRPHC,
non-U.S. holders
(regardless of the percentage of our common stock owned by such
holders) would be subject to U.S. federal income tax
(including withholding thereof at the rate of 10% on the gross
proceeds paid to such holder) and related reporting and filing
requirements with respect to the sale of our common stock.
Non-U.S. holders
who own or may own (in each case, directly or indirectly) more
than 5% of our common stock should consult their tax advisors
with respect to the tax consequences of a disposition of our
common stock.
Information
Reporting and Backup Withholding Tax
Annual reports to the IRS and to each
non-U.S. holder
will be made reporting the amount of distributions paid to such
holder and the tax withheld from those distributions, if any.
These reporting requirements apply regardless of whether
withholding was reduced or eliminated by an applicable income
tax treaty. Copies of the information returns reporting those
distributions and withholding may also be made available under
the provisions of an applicable income tax treaty or agreement
to the tax authorities in the country in which the
non-U.S. holder
is a resident.
Under some circumstances, U.S. Treasury regulations require
backup withholding and additional information reporting on
reportable payments on common stock. The gross amount of
dividends paid to a
non-U.S. holder
that fails to certify its
non-U.S. holder
status in accordance with applicable U.S. Treasury
regulations generally will be reduced by backup withholding at
the applicable rate (currently 28%), unless the 30% rate of
withholding described above applies.
The payment of the proceeds of the sale or other disposition of
common stock by a
non-U.S. holder
to or through the U.S. office of any broker, U.S. or
foreign, generally will be reported to the IRS and reduced by
backup withholding, unless the
non-U.S. holder
either certifies under penalties of perjury that it is a
non-U.S. holder
and that certain other conditions are met, or otherwise
establishes an exemption. The payment of the proceeds from the
disposition of common stock by a
non-U.S. holder
to or through a
non-U.S. office
of a
non-U.S. broker
generally will not be reduced by backup withholding or reported
to the IRS. However, the payment of proceeds from the
disposition of common stock to or through a
non-U.S. office
of a broker that is a United States person or has certain
enumerated connections with the United States will be reported
to the IRS unless the broker has documentary evidence in its
files that the holder is a
non-U.S. holder
and certain other conditions are met, or the
non-U.S. holder
otherwise establishes an exemption.
Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules from a payment to a
non-U.S. holder
can be refunded or credited against the
non-U.S. holders
U.S. federal income tax liability, if any; provided,
that the required information is furnished to the IRS in a
timely manner. These backup withholding and information
reporting rules are complex and
non-U.S. holders
are urged to consult their own tax advisors regarding the
application of these rules to them.
Newly
Enacted Legislation
Legislation was enacted on March 18, 2010 that generally
imposes a withholding tax of 30% on dividends paid with respect
to stock of U.S. issuers and the gross proceeds of a
disposition of such stock paid to a foreign financial
institution (other than with respect to dividends or gross
proceeds that are effectively connected with the conduct of a
trade or business in the United States), unless such institution
enters into an agreement with the U.S. government to
collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such
institution (which would include certain account holders that
are foreign entities with U.S. owners). For this purpose, a
foreign financial institution includes, among others, a
non-U.S. entity
that (i) is a bank, (ii) holds, as a substantial
portion of its business, financial assets for the account for
others or (iii) is engaged primarily in the business of
investing, reinvesting or trading in securities, partnership
interests, commodities or any interest in securities,
partnership interests or commodities. The legislation also
generally imposes a withholding tax of 30% on dividends from
such stock and the gross proceeds of a disposition of such stock
paid to a non-financial foreign entity (other than with respect
to dividends or gross proceeds that are effectively connected
with the conduct of a trade or business in the United States),
unless such entity provides the withholding agent with a
certification that it does not
S-79
have any substantial U.S. owners or a certification
identifying the direct and indirect substantial U.S. owners
of the entity. These reporting requirements generally will not
apply to any payment beneficially owned by (i) a
non-financial foreign entity that is a corporation the stock of
which is regularly traded on an established securities market,
(ii) certain corporations that are affiliated with an
entity described in clause (i), or (iii) certain other
specified types of entities. Under certain circumstances (for
example, if the recipient is a resident in a country having a
treaty with the United States), a holder of such stock might be
eligible for refunds or credits of such taxes. The newly enacted
withholding and reporting requirements generally will apply to
payments made on or after January 1, 2013 and will not
require any amount to be deducted or withheld from any payment
under any obligation outstanding on March 18, 2012 or from
the gross proceeds from any disposition of such an obligation.
The legislation also imposes new U.S. return disclosure
obligations (and related penalties for failure to disclose) on
individuals required to file U.S. federal income tax
returns that hold certain specified foreign financial assets
(which include financial accounts in foreign financial
institutions). Potential investors are urged to consult with
their own tax advisors regarding the possible implications of
this recently enacted legislation on their investment in our
common stock.
The foregoing discussion of U.S. federal income tax
considerations is for general information purposes only and is
not tax or legal advice. Accordingly, you should consult your
own tax advisor as to the particular tax consequences to you of
purchasing, owning and disposing of our common stock, including
the applicability and effect of any U.S. federal, state,
local or
non-U.S. tax
laws, and of any changes or proposed changes in applicable
law.
S-80
UNDERWRITING
Merrill Lynch, Pierce, Fenner & Smith Incorporated,
Credit Suisse Securities (USA) LLC, Deutsche Bank Securities
Inc., HSBC Securities (USA) Inc., UBS Securities LLC, and Wells
Fargo Securities, LLC are acting as representatives of each of
the underwriters named below. Subject to the terms and
conditions set forth in an underwriting agreement among MetLife,
Inc. and the underwriters, MetLife, Inc. has agreed to sell to
the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from MetLife, Inc., the
number of shares of common stock set forth opposite its name
below.
|
|
|
|
|
|
|
Number of
|
|
Underwriter
|
|
Shares
|
|
|
Merrill Lynch, Pierce, Fenner & Smith Incorporated
|
|
|
12,024,825
|
|
Credit Suisse Securities (USA) LLC
|
|
|
12,024,825
|
|
Deutsche Bank Securities Inc.
|
|
|
12,024,825
|
|
HSBC Securities (USA) Inc.
|
|
|
5,789,700
|
|
UBS Securities LLC
|
|
|
5,789,700
|
|
Wells Fargo Securities, LLC
|
|
|
5,789,700
|
|
Sanford C. Bernstein & Co., LLC
|
|
|
777,475
|
|
Macquarie Capital (USA) Inc.
|
|
|
777,475
|
|
Sterne, Agee & Leach, Inc
|
|
|
777,475
|
|
BNP Paribas Securities Corp
|
|
|
1,425,000
|
|
RBS Securities Inc.
|
|
|
1,425,000
|
|
SG Americas Securities, LLC
|
|
|
1,425,000
|
|
Cowen and Company, LLC
|
|
|
1,087,500
|
|
Daiwa Capital Markets America Inc.
|
|
|
1,087,500
|
|
Dowling & Partners Securities, LLC
|
|
|
1,087,500
|
|
PNC Capital Markets LLC
|
|
|
1,087,500
|
|
Scotia Capital (USA) Inc.
|
|
|
1,087,500
|
|
UniCredit Capital Markets, Inc.
|
|
|
1,087,500
|
|
The Williams Capital Group, L.P.
|
|
|
990,750
|
|
BNY Mellon Capital Markets, LLC
|
|
|
750,000
|
|
Commerzbank Capital Markets Corp.
|
|
|
750,000
|
|
Mitsubishi UFJ Securities (USA), Inc.
|
|
|
750,000
|
|
Raymond James & Associates, Inc.
|
|
|
750,000
|
|
Santander Investment Securities Inc.
|
|
|
750,000
|
|
Loop Capital Markets LLC
|
|
|
495,000
|
|
Blaylock Robert Van, LLC
|
|
|
490,500
|
|
Cabrera Capital Markets, LLC
|
|
|
490,500
|
|
Guzman & Company
|
|
|
490,500
|
|
Muriel Siebert & Co., Inc.
|
|
|
490,500
|
|
Samuel A. Ramirez & Co., Inc.
|
|
|
490,500
|
|
CastleOak Securities, LP
|
|
|
245,250
|
|
MFR Securities, Inc.
|
|
|
245,250
|
|
Toussaint Capital Partners, LLC
|
|
|
245,250
|
|
|
|
|
|
|
Total
|
|
|
75,000,000
|
|
|
|
|
|
|
Subject to the terms and conditions set forth in the
underwriting agreement, the underwriters have agreed, severally
and not jointly, to purchase all of the shares sold under the
underwriting agreement if any of these shares are purchased. If
an underwriter defaults, the underwriting agreement provides
that the purchase commitments of the non-defaulting underwriters
may be increased or the underwriting agreement may be terminated.
S-81
MetLife, Inc. has agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities
Act, or to contribute to payments the underwriters may be
required to make in respect of those liabilities.
The underwriters are offering the shares of common stock,
subject to prior sale, when, as and if issued to and accepted by
them, subject to approval of legal matters by their counsel,
including the validity of the shares, and other conditions
contained in the underwriting agreement, such as the receipt by
the underwriters of officers certificates and legal
opinions. The underwriters reserve the right to withdraw, cancel
or modify offers to the public and to reject orders in whole or
in part.
Commissions
and Discounts
The representatives have advised MetLife, Inc. that the
underwriters propose initially to offer the shares to the public
at the public offering price set forth on the cover page of this
prospectus supplement and to dealers at that price less a
concession not in excess of $0.648 per share. After the initial
offering, the public offering price, concession or any other
term of the offering may be changed.
The following table shows the public offering price,
underwriting discounts and commissions and proceeds before
expenses to us. The information assumes either no exercise or
full exercise by the underwriters of their overallotment option
described below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per
|
|
Without
|
|
With
|
|
|
Share
|
|
Option
|
|
Option
|
|
Public offering price
|
|
$
|
42.00
|
|
|
$
|
3,150,000,000
|
|
|
$
|
3,622,500,000
|
|
Underwriting discount
|
|
$
|
1.08
|
|
|
$
|
81,000,000
|
|
|
$
|
93,150,000
|
|
Proceeds, before expenses, to MetLife, Inc.
|
|
$
|
40.92
|
|
|
$
|
3,069,000,000
|
|
|
$
|
3,529,350,000
|
|
The expenses of the offering, not including the underwriting
discount, are estimated at $780,000 and are payable by MetLife,
Inc.
Overallotment
Option
MetLife, Inc. has granted an option to the underwriters to
purchase up to 11,250,000 additional shares of common stock
at the public offering price, less the underwriting discounts
and commissions. The underwriters may exercise this option for
30 days from the date of this prospectus solely to cover
any overallotments. If the underwriters exercise this option,
each will be obligated, subject to conditions contained in the
purchase agreement, to purchase a number of additional shares
proportionate to that underwriters initial amount
reflected in the above table.
No Sales
of Similar Securities
MetLife, Inc., its executive officers and directors have agreed
not to sell or transfer any common stock or securities
convertible into, exchangeable for or exercisable for common
stock, for 60 days after the date of this prospectus
without first obtaining the written consent of Merrill Lynch,
Pierce, Fenner & Smith Incorporated. Specifically, MetLife,
Inc. and these other persons have agreed, with certain limited
exceptions (including relating to securities issued under our
benefit plans and securities to be issued in the Acquisition),
not to directly or indirectly:
|
|
|
|
|
offer, sell, issue, contract to sell, pledge or otherwise
dispose of any shares of the common stock or securities
convertible into or exchangeable or exercisable for any shares
of the common stock;
|
|
|
|
enter into a transaction that would have the same effect as
described above;
|
|
|
|
enter into any swap, hedge or other arrangement that transfers,
in whole or in part, any of the economic consequences of
ownership of the common stock;
|
|
|
|
in the case of MetLife, Inc., establish or increase a put
equivalent position or liquidate or decrease a call equivalent
position in the common stock;
|
|
|
|
in the case of our executive officers and directors, demand that
we file a registration statement related to the common stock;
|
S-82
|
|
|
|
|
in the case of MetLife, Inc., file a registration statement
related to the common stock; or
|
|
|
|
publicly disclose the intention to take any of the foregoing
actions;
|
in each case, without the prior written consent of Merrill
Lynch, Pierce, Fenner & Smith Incorporated.
New York
Stock Exchange Listing
The shares of common stock are listed on the New York Stock
Exchange under the symbol MET.
Price
Stabilization, Short Positions
Until the distribution of the shares is completed, SEC rules may
limit underwriters and selling group members from bidding for
and purchasing the common stock. However, the representatives
may engage in transactions that stabilize the price of the
common stock, such as bids or purchases to peg, fix or maintain
that price.
In connection with the offering, the underwriters may purchase
and sell the common stock in the open market. These transactions
may include short sales, purchases on the open market to cover
positions created by short sales and stabilizing transactions.
Short sales involve the sale by the underwriters of a greater
number of shares than they are required to purchase in the
offering. Covered short sales are sales made in an
amount not greater than the underwriters overallotment
option described above. The underwriters may close out any
covered short position by either exercising their overallotment
option or purchasing shares in the open market. In determining
the source of shares to close out the covered short position,
the underwriters will consider, among other things, the price of
shares available for purchase in the open market as compared to
the price at which they may purchase shares through the
overallotment option. Naked short sales are sales in
excess of the overallotment option. The underwriters must close
out any naked short position by purchasing shares in the open
market. A naked short position is more likely to be created if
the underwriters are concerned that there may be downward
pressure on the price of the common stock in the open market
after pricing that could adversely affect investors who purchase
in the offering. Stabilizing transactions consist of various
bids for or purchases of shares of common stock made by the
underwriters in the open market prior to the completion of the
offering.
Similar to other purchase transactions, the underwriters
purchases to cover the syndicate short sales may have the effect
of raising or maintaining the market price of the common stock
or preventing or retarding a decline in the market price of the
common stock. As a result, the price of the common stock may be
higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on the
New York Stock Exchange, in the
over-the-counter
market or otherwise.
Neither MetLife, Inc. nor any of the underwriters make any
representation or prediction as to the direction or magnitude of
any effect that the transactions described above may have on the
price of the common stock. In addition, neither MetLife, Inc.
nor any of the underwriters make any representation that the
representatives will engage in these transactions or that these
transactions, once commenced, will not be discontinued without
notice.
Electronic
Offer, Sale and Distribution of Shares
In connection with the offering, certain of the underwriters or
securities dealers may distribute prospectuses by electronic
means, such as
e-mail. In
addition, one or more of the underwriters may facilitate
Internet distribution for this offering to certain of its
Internet subscription customers. One or more of the underwriters
may allocate a limited number of shares for sale to its online
brokerage customers. An electronic prospectus is available on
the Internet web site maintained by one or more of the
underwriters. Other than the prospectus in electronic format,
the information on such underwriters web site is neither part of
this prospectus supplement nor of the accompanying prospectus.
Other
Relationships
In the ordinary course of their respective businesses, the
underwriters and their affiliates have engaged, and may in the
future engage, in commercial banking or investment banking
transactions with us and our affiliates for which they have in
the past received, and may in the future receive, customary
fees. Affiliates of some of the lenders under MetLife,
Inc.s credit agreements are acting as underwriters for
this offering. Affiliates of the joint book-running managers are
the commitment parties to the Senior Credit Facility for which
they have received, and may in the future receive, fees from
S-83
us. An affiliate of Merrill Lynch, Pierce, Fenner &
Smith Incorporated serves as sole administrative agent under the
Senior Credit Facility and affiliates of Merrill Lynch, Pierce,
Fenner & Smith Incorporated, Credit Suisse Securities
(USA) LLC, Deutsche Bank Securities Inc., and HSBC Securities
(USA) Inc. serve as joint lead arrangers and joint book managers
under the Senior Credit Facility and as financial advisors to us
in connection with the Acquisition and have received, and may in
the future receive, fees from us in connection with serving in
one or more of such capacities.
In the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial
instruments (including bank loans) for their own account and for
the accounts of their customers and such investment and
securities activities may involve securities
and/or
instruments of MetLife, Inc. The underwriters and their
respective affiliates may also make investment recommendations
and/or
publish or express independent research views in respect of such
securities or instruments and may at any time hold, or recommend
to clients that they acquire, long
and/or short
positions in such securities and instruments.
Notice to
Prospective Investors in the EEA
In relation to each Member State of the European Economic Area
(the EEA) which has implemented the
Prospectus Directive (each, a Relevant Member
State) an offer to the public of any common stock
which is the subject of the offering contemplated by this
prospectus supplement (and the accompanying prospectus) may not
be made in that Relevant Member State, except that an offer to
the public in that Relevant Member State of any common stock may
be made at any time under the following exemptions under the
Prospectus Directive, if they have been implemented in that
Relevant Member State:
(a) to legal entities which are authorized or regulated to
operate in the financial markets or, if not so authorized or
regulated, whose corporate purpose is solely to invest in
securities;
(b) to any legal entity which has two or more of
(1) an average of at least 250 employees during the
last financial year; (2) a total balance sheet of more than
43,000,000 and (3) an annual net turnover of more
than 50,000,000, as shown in its last annual or
consolidated accounts;
(c) by the underwriters to fewer than 100 natural or legal
persons (other than qualified investors as defined
in the Prospectus Directive) subject to obtaining the prior
consent of the representatives for any such offer; or
(d) in any other circumstances falling within
Article 3(2) of the Prospectus Directive;
provided, that no such offer of common stock shall result
in a requirement for the publication by MetLife, Inc. or any
representative of a prospectus pursuant to Article 3 of the
Prospectus Directive.
Any person making or intending to make any offer of common stock
within the EEA should only do so in circumstances in which no
obligation arises for us or any of the underwriters to produce a
prospectus for such offer. Neither we nor the underwriters have
authorized, nor do they authorize, the making of any offer of
common stock through any financial intermediary, other than
offers made by the underwriters which constitute the final
offering of common stock contemplated in this prospectus
supplement (and the accompanying prospectus).
For the purposes of this provision, and your representation
below, the expression an offer to the public in
relation to any common stock in any Relevant Member State means
the communication in any form and by any means of sufficient
information on the terms of the offer and any common stock to be
offered so as to enable an investor to decide to purchase any
common stock, as the same may be varied in that Relevant Member
State by any measure implementing the Prospectus Directive in
that Relevant Member State and the expression Prospectus
Directive means Directive 2003/71/EC and includes any
relevant implementing measure in each Relevant Member State.
Each person in a Relevant Member State who receives any
communication in respect of, or who acquires any common stock
under, the offer of common stock contemplated by this prospectus
supplement (and the accompanying prospectus) will be deemed to
have represented, warranted and agreed to and with MetLife, Inc.
and each underwriter that:
(A) it is a qualified investor within the
meaning of the law in that Relevant Member State implementing
Article 2(1)(e) of the Prospectus Directive; and
S-84
(B) in the case of any common stock acquired by it as a
financial intermediary, as that term is used in
Article 3(2) of the Prospectus Directive, (i) the
common stock acquired by it in the offering has not been
acquired on behalf of, nor has it been acquired with a view to
their offer or resale to, persons in any Relevant Member State
other than qualified investors (as defined in the
Prospectus Directive), or in circumstances in which the prior
consent of the representatives has been given to the offer or
resale; or (ii) where common stock has been acquired by it
on behalf of persons in any Relevant Member State other than
qualified investors, the offer of that common stock to it is not
treated under the Prospectus Directive as having been made to
such persons.
Notice to
Prospective Investors in the United Kingdom
In the United Kingdom, this prospectus supplement (and the
accompanying prospectus) is being distributed only to, and is
directed only at, and any offer subsequently made may only be
directed at persons who are qualified investors (as
defined in the Prospectus Directive) (i) who have
professional experience in matters relating to investments
falling within Article 19 (5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the Order)
and/or
(ii) who are high net worth companies (or persons to whom
it may otherwise be lawfully communicated) falling within
Article 49(2)(a) to (d) of the Order (all such persons
together being referred to as relevant persons).
This prospectus supplement (and the accompanying prospectus)
must not be acted on or relied on in the United Kingdom by
persons who are not relevant persons. In the United Kingdom, any
investment or investment activity to which this prospectus
supplement (and the accompanying prospectus) relates is only
available to, and will be engaged in with, relevant persons.
Notice to
Prospective Investors in Switzerland
This prospectus supplement (and the accompanying prospectus), as
well as any other material relating to the common stock which is
the subject of the offering contemplated by this prospectus
supplement (and the accompanying prospectus), do not constitute
an issue prospectus pursuant to Article 652a or
Article 1156 of the Swiss Code of Obligations. The common
stock will not be listed on the SIX Swiss Exchange and,
therefore, the documents relating to the common stock,
including, but not limited to, this prospectus supplement (and
the accompanying prospectus) may not comply with the disclosure
standards of the listing rules (including any additional listing
rules or prospectus schemes) of the SIX Swiss Exchange. The
common stock is being offered in Switzerland by way of a private
placement, i.e., to a small number of selected
investors only, without any public offer and only to investors
who do not purchase the common stock with the intention to
distribute it to the public. The investors will be individually
approached by the issuer from time to time. This prospectus
supplement (and the accompanying prospectus) as well as any
other material relating to the common stock, is personal and
confidential and does not constitute an offer to any other
person. This prospectus supplement (and the accompanying
prospectus) may only be used by those investors to whom it has
been handed out in connection with the offering described herein
and may neither directly nor indirectly be distributed or made
available to other persons without express consent of the
issuer. It may not be used in connection with any other offer
and shall in particular not be copied
and/or
distributed to the public in (or from) Switzerland.
Notice to
Prospective Investors in the Dubai International Financial
Centre
This prospectus supplement (and the accompanying prospectus)
relates to an exempt offer in accordance with the Offered
Securities Rules of the Dubai Financial Services Authority. This
prospectus supplement (and the accompanying prospectus) is
intended for distribution only to persons of a type specified in
those rules. It must not be delivered to, or relied on by, any
other person. The Dubai Financial Services Authority has no
responsibility for reviewing or verifying any documents in
connection with exempt offers. The Dubai Financial Services
Authority has not approved this prospectus supplement (and the
accompanying prospectus) nor taken steps to verify the
information set out in it, and has no responsibility for it. The
common stock which is the subject of the offering contemplated
by this prospectus supplement may be illiquid
and/or
subject to restrictions on their resale. Prospective purchasers
of the common stock offered should conduct their own due
diligence on the common stock. If you do not understand the
contents of this prospectus supplement (and the accompanying
prospectus) you should consult an authorized financial adviser.
S-85
Notice to
Prospective Investors in Australia
This prospectus supplement (and the accompanying prospectus) is
not a formal disclosure document and has not been, nor will be,
lodged with the Australian Securities and Investments
Commission. This prospectus supplement (and the accompanying
prospectus) does not purport to contain all information that
investors or their professional advisers would expect to find in
a prospectus or other disclosure document (as defined in the
Corporations Act 2001 (Australia)) for the purposes of
Part 6D.2 of the Corporations Act 2001 (Australia) or in a
product disclosure statement for the purposes of Part 7.9
of the Corporations Act 2001 (Australia), in either case, in
relation to the common stock.
The common stock is not being offered in Australia to
retail clients as defined in sections 761G and
761GA of the Corporations Act 2001 (Australia). This offering is
being made in Australia solely to wholesale clients
for the purposes of section 761G of the Corporations Act
2001 (Australia) and, as such, no prospectus, product disclosure
statement or other disclosure document in relation to the common
stock has been, or will be, prepared.
This prospectus supplement (and the accompanying prospectus)
does not constitute an offer in Australia other than to
wholesale clients. By submitting an application for the common
stock, you represent and warrant to us that you are a wholesale
client for the purposes of section 761G of the Corporations
Act 2001 (Australia). If any recipient of this prospectus
supplement (and the accompanying prospectus) is not a wholesale
client, no offer of, or invitation to apply for, the common
stock shall be deemed to be made to such recipient and no
applications for the common stock will be accepted from such
recipient. Any offer to a recipient in Australia, and any
agreement arising from acceptance of such offer, is personal and
may only be accepted by the recipient. In addition, by applying
the common stock you undertake to us that, for a period of
12 months from the date of issue of the common stock, you
will not transfer any interest in the common stock to any person
in Australia other than to a wholesale client.
Notice to
Prospective Investors in Hong Kong
The common stock may not be offered or sold by means of any
document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the
Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder, or (iii) in other
circumstances which do not result in this prospectus supplement
or the accompanying prospectus being a prospectus
within the meaning of the Companies Ordinance (Cap.32, Laws of
Hong Kong), and no advertisement, invitation or document
relating to the common stock may be issued or may be in the
possession of any person for the purpose of issue (in each case
whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the
public in Hong Kong (except if permitted to do so under the laws
of Hong Kong) other than with respect to the common stock which
is or is intended to be disposed of only to persons outside Hong
Kong or only to professional investors within the
meaning of the Securities and Futures Ordinance (Cap. 571, Laws
of Hong Kong) and any rules made thereunder.
Notice to
Prospective Investors in Japan
The common stock has not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (Law
No. 25 of 1948 of Japan, as amended) (FIEL) and
the underwriters will not offer or sell the common stock
directly or indirectly, in Japan or to, or for the benefit of,
any resident of Japan (which term as used herein means, unless
otherwise provided herein, any person resident in Japan,
including any corporation or other entity organized under the
laws of Japan), or to others for re-offering or resale, directly
or indirectly, in Japan or to a resident of Japan, except
pursuant to an exemption from the registration requirements of,
and otherwise in compliance with, the FIEL and any other
applicable laws, regulations and ministerial guidelines of Japan.
Notice to
Prospective Investors in the Singapore
Neither this prospectus supplement nor the accompanying
prospectus has been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, none of this prospectus
supplement, the accompanying prospectus and any other document
or material in connection with the offer or sale, or invitation
for subscription or purchase, of the common stock may be
circulated or distributed, nor may the common stock be offered
or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to
persons in Singapore other than (i) to an institutional
investor under Section 274 of the Securities and Futures
Act, Chapter 289 of Singapore (the
S-86
SFA), (ii) to a relevant person, or any
person pursuant to Section 275(1A), and in accordance with
the conditions, specified in Section 275 of the SFA or
(iii) otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA, in
each case subject to compliance with conditions set forth in the
SFA.
Where the common stock is subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary is an accredited investor,
shares, debentures and units of shares and debentures of that
corporation or the beneficiaries rights and interest in
that trust shall not be transferable for 6 months after
that corporation or that trust has acquired the common stock
under Section 275 except: (1) to an institutional
investor under Section 274 of the SFA or to a relevant
person, or any person pursuant to Section 275(1A), and in
accordance with the conditions, specified in Section 275 of
the SFA; (2) where no consideration is given for the
transfer; or (3) by operation of law.
LEGAL
OPINIONS
Certain legal matters will be passed upon for MetLife, Inc. by
Matthew Ricciardi, Chief Counsel Public Company and
Corporate Law, of MetLife Group, Inc., an affiliate of MetLife,
Inc. The validity of the common stock offered hereby will be
passed upon for MetLife, Inc. by Dewey & LeBoeuf LLP,
New York, New York, which has also acted as special tax counsel
for MetLife, Inc. Mr. Ricciardi is paid a salary by an
affiliate of MetLife, Inc., is a participant in various employee
benefit plans offered by MetLife, Inc. and its affiliates to
employees generally, is paid equity-based compensation in
accordance with MetLifes compensation programs and owns
MetLife, Inc. common stock. Dewey & LeBoeuf LLP has,
from time to time, represented, currently represents, and may
continue to represent, some or all of the underwriters in
connection with various legal matters. Dewey & LeBoeuf
LLP maintains various group and other insurance policies with
MLIC. Debevoise & Plimpton LLP, New York, New York, is
acting as counsel to the underwriters. Debevoise &
Plimpton LLP has in the past provided, and continues to provide,
legal services to MetLife, Inc. and certain of its affiliates.
Debevoise & Plimpton LLP maintains various group
insurance policies with MLIC.
EXPERTS
The consolidated financial statements and financial statement
schedules, incorporated by reference in this prospectus
supplement from MetLifes 2009
Form 10-K,
and the effectiveness of MetLifes internal control over
financial reporting for the year ended December 31, 2009,
have been audited by Deloitte & Touche LLP, an
independent registered public accounting firm, as stated in
their reports (which (1) express an unqualified opinion on
the consolidated financial statements and financial statement
schedules and includes an explanatory paragraph regarding
changes in MetLifes method of accounting for the
recognition and presentation of
other-than-temporary
impairment losses for certain investments as required by
accounting guidance adopted on April 1, 2009, its method of
accounting for certain assets and liabilities to a fair value
measurement approach as required by accounting guidance adopted
on January 1, 2008, and its method of accounting for
deferred acquisition costs and for income taxes as required by
accounting guidance adopted on January 1, 2007, and,
(2) express an unqualified opinion on MetLifes
effectiveness of internal control over financial reporting),
which are incorporated herein by reference. Such consolidated
financial statements and financial statement schedules have been
so incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
The audited historical combined financial statements of American
Life Insurance Company, ALICO Services, Inc. and Delaware
American Life Insurance Company and subsidiaries (collectively,
the Company) included as Exhibit 99.1 to
MetLife, Inc.s Current Report on
Form 8-K
dated August 2, 2010 and incorporated by reference in this
prospectus supplement have been so incorporated in reliance on
the report (which contains an explanatory paragraph related to
the Companys change in method of accounting for
other-than-temporary
impairments of fixed maturity securities as of March 1,
2009) of PricewaterhouseCoopers LLP, an independent
registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting.
S-87
PROSPECTUS
METLIFE, INC.
DEBT SECURITIES, PREFERRED
STOCK, DEPOSITARY SHARES,
COMMON STOCK, WARRANTS,
PURCHASE CONTRACTS AND UNITS
METLIFE CAPITAL
TRUST V
METLIFE CAPITAL
TRUST VI
METLIFE CAPITAL
TRUST VII
METLIFE CAPITAL
TRUST VIII
METLIFE CAPITAL
TRUST IX
TRUST PREFERRED
SECURITIES
Fully and Unconditionally
Guaranteed by MetLife, Inc.,
As Described in this Prospectus
and the Accompanying Prospectus Supplement
MetLife, Inc., or any of the trusts named above, may offer these
securities, or any combination thereof, from time to time in
amounts, at prices and on other terms to be determined at the
time of the offering. MetLife, Inc., or any of the trusts named
above, will provide the specific terms of these securities in
supplements to this prospectus. You should read this prospectus
and the accompanying prospectus supplement carefully before you
make your investment decision.
THIS PROSPECTUS MAY NOT BE USED TO SELL SECURITIES UNLESS
ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.
MetLife, Inc., or any of the trusts named above, may offer
securities through underwriting syndicates managed or co-managed
by one or more underwriters, through agents, or directly to
purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for
that offering. For general information about the distribution of
securities offered, please see Plan of Distribution
in this prospectus.
MetLife, Inc.s common stock is listed on the New York
Stock Exchange under the trading symbol MET. Unless
otherwise stated in this prospectus or an accompanying
prospectus supplement, none of these securities will be listed
on a securities exchange, other than MetLife, Inc.s common
stock.
MetLife, Inc., or any of the trusts named above, or any of their
respective affiliates may use this prospectus and the applicable
prospectus supplement in a remarketing or other resale
transaction involving the securities after their initial sale.
These transactions may be executed at negotiated prices that are
related to market prices at the time of purchase or sale, or at
other prices, as determined from time to time.
Investing in our securities or the securities of the trusts
involves risk. See Risk Factors on page 1 of this
prospectus.
None of the Securities and Exchange Commission, any state
securities commission, the New York Superintendent of Insurance
or any other regulatory body has approved or disapproved of
these securities or determined if this prospectus or the
accompanying prospectus supplement is truthful or complete. They
have not made, nor will they make, any determination as to
whether anyone should buy these securities. Any representation
to the contrary is a criminal offense.
The date of this prospectus is November 6, 2007
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
6
|
|
|
|
|
15
|
|
|
|
|
21
|
|
|
|
|
23
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
26
|
|
|
|
|
28
|
|
|
|
|
31
|
|
|
|
|
32
|
|
|
|
|
32
|
|
ABOUT
THIS PROSPECTUS
Unless otherwise stated or the context otherwise requires,
references in this prospectus to MetLife,
we, our, or us refer to
MetLife, Inc., and its direct and indirect subsidiaries, while
references to MetLife, Inc. refer only to MetLife,
Inc. on an unconsolidated basis. References in this prospectus
to the trusts refer to MetLife Capital Trust V,
MetLife Capital Trust VI, MetLife Capital Trust VII,
MetLife Capital Trust VIII and MetLife Capital
Trust IX.
This prospectus is part of a registration statement that
MetLife, Inc. and the trusts filed with the U.S. Securities
and Exchange Commission (the SEC) using a
shelf registration process. Under this shelf
process, MetLife, Inc. may, from time to time, sell any
combination of debt securities, preferred stock, depositary
shares, common stock, warrants, purchase contracts and units and
the trusts may, from time to time, sell trust preferred
securities guaranteed by MetLife, Inc., as described in this
prospectus, in one or more offerings in one or more foreign
currencies, foreign currency units or composite currencies. This
prospectus provides you with a general description of the
securities MetLife, Inc. and the trusts may offer. Each time
that securities are sold, a prospectus supplement that will
contain specific information about the terms of that offering
will be provided. The prospectus supplement may also add, update
or change information contained in this prospectus. You should
read both this prospectus and any prospectus supplement together
with additional information described under the heading
Where You Can Find More Information.
You should rely on the information contained or incorporated by
reference in this prospectus. Neither MetLife, Inc. nor the
trusts have authorized anyone to provide you with different
information. If anyone provides you with different or
inconsistent information, you should not rely on it. Neither
MetLife, Inc. nor the trusts are making an offer to sell these
securities in any jurisdiction where the offer or sale is not
permitted.
You should assume that the information in this prospectus is
accurate as of the date of the prospectus. Our business,
financial condition, results of operations and prospects may
have changed since that date.
RISK
FACTORS
Investing in MetLife, Inc. securities or the securities of the
trusts involve risks. You should carefully consider the risks
described in our filings with the SEC referred to under the
heading Where You Can Find More Information,
referenced in Special Note Regarding Forward-Looking
Statements below, as well as those included in any
prospectus supplement hereto. For example, MetLife, Inc.s
Annual Report on
Form 10-K
for the year ended December 31, 2006 contains a discussion
of significant risks under the heading Risk Factors
which could be relevant to your investment in the securities.
Subsequent filings with the SEC may contain amended and updated
discussions of significant risks.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the accompanying prospectus supplement may
contain or incorporate by reference information that includes or
is based upon forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements give expectations or forecasts of
future events. You can identify these statements by the fact
that they do not relate strictly to historical or current facts.
They use words such as anticipate,
estimate, expect, project,
intend, plan, believe, and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance. In
particular, these include statements relating to future actions,
prospective services or products, future performance or results
of current and anticipated services or products, sales efforts,
expenses, the outcome of contingencies such as legal
proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong.
They can be affected by inaccurate assumptions or by known or
unknown risks and uncertainties. Many such factors will be
important in determining MetLifes actual future results.
These statements are based on current expectations and the
current economic environment. They involve a number of risks and
uncertainties that are difficult to predict. These statements
are not guarantees of future performance, and there are no
guarantees about the performance of any securities offered by
1
this prospectus. Actual results could differ materially from
those expressed or implied in the forward-looking statements.
Risks, uncertainties and other factors that might cause such
differences include the risks, uncertainties and other factors
identified in our filings with the SEC referred to under the
heading Where You Can Find More Information,
including those identified under Risk Factors above.
These factors include:
|
|
|
|
|
changes in general economic conditions, including the
performance of financial markets and interest rates;
|
|
|
|
heightened competition, including with respect to pricing, entry
of new competitors, the development of new products by new and
existing competitors and for personnel;
|
|
|
|
investment losses and defaults;
|
|
|
|
unanticipated changes in industry trends;
|
|
|
|
catastrophe losses;
|
|
|
|
ineffectiveness of risk management policies and procedures;
|
|
|
|
changes in accounting standards, practices and/or policies;
|
|
|
|
changes in assumptions related to deferred policy acquisition
costs (DAC), value of business acquired or goodwill;
|
|
|
|
discrepancies between actual claims experience and assumptions
used in setting prices for our products and establishing the
liabilities for our obligations for future policy benefits and
claims;
|
|
|
|
discrepancies between actual experience and assumptions used in
establishing liabilities related to other contingencies or
obligations;
|
|
|
|
adverse results or other consequences from litigation,
arbitration or regulatory investigations;
|
|
|
|
downgrades in our and our affiliates claims paying
ability, financial strength or credit ratings;
|
|
|
|
regulatory, legislative or tax changes that may affect the cost
of, or demand for, our products or services;
|
|
|
|
MetLife, Inc.s primary reliance, as a holding company, on
dividends from its subsidiaries to meet debt payment obligations
and the applicable regulatory restrictions on the ability of the
subsidiaries to pay such dividends;
|
|
|
|
deterioration in the experience of the closed block
established in connection with the reorganization of
Metropolitan Life Insurance Company;
|
|
|
|
economic, political, currency and other risks relating to our
international operations;
|
|
|
|
the effects of business disruption or economic contraction due
to terrorism or other hostilities;
|
|
|
|
our ability to identify and consummate on successful terms any
future acquisitions, and to successfully integrate acquired
businesses with minimal disruption;
|
|
|
|
other risks and uncertainties described from time to time in
MetLife, Inc.s or the trusts filings with the SEC;
|
|
|
|
the risk factors or uncertainties set forth herein or listed
from time to time in prospectus supplements or any document
incorporated by reference herein; and
|
|
|
|
other risks and uncertainties that have not been identified at
this time.
|
Neither MetLife, Inc. nor the trusts undertake any obligation to
publicly correct or update any forward-looking statement if any
of MetLife, Inc. or the trusts later become aware that it is not
likely to be achieved. You are advised, however, to consult any
further disclosures MetLife, Inc. or the trusts make on related
subjects in reports to the SEC.
WHERE YOU
CAN FIND MORE INFORMATION
MetLife, Inc. files reports, proxy statements and other
information with the SEC. These reports, proxy statements and
other information, including the registration statement of which
this prospectus is a part, can be read and copied at the
SECs public reference room at 100 F Street, N.E.,
Washington, D.C. 20549. Please call the SEC at
2
1-800-SEC-0330
for further information on the operation of the public reference
room. The SEC maintains an internet site at www.sec.gov that
contains reports, proxy and information statements and other
information regarding companies that file electronically with
the SEC, including MetLife, Inc. MetLife, Inc.s common
stock is listed and traded on the New York Stock Exchange under
the symbol MET. These reports, proxy statements and
other information can also be read at the offices of the New
York Stock Exchange, 11 Wall Street, New York, New York
10005.
The SEC allows incorporation by reference into this
prospectus of information that MetLife, Inc. files with the SEC.
This permits MetLife, Inc. to disclose important information to
you by referencing these filed documents. Any information
referenced this way is considered part of this prospectus, and
any information filed with the SEC subsequent to the date of
this prospectus will automatically be deemed to update and
supersede this information. Information furnished under
Item 2.02 and Item 7.01 of MetLife, Inc.s
Current Reports on
Form 8-K
is not incorporated by reference in this registration statement
and prospectus. MetLife, Inc. incorporates by reference the
following documents which have been filed with the SEC:
|
|
|
|
|
Registration Statement on
Form 8-A,
dated March 31, 2000, relating to registration of shares of
MetLife, Inc.s common stock and Registration Statement on
Form 8-A, dated March 31, 2000, relating to
registration of MetLife, Inc.s Series A Junior
Participating Preferred Stock purchase rights;
|
|
|
|
Annual Report on
Form 10-K
for the year ended December 31, 2006;
|
|
|
|
Quarterly Reports on
Form 10-Q
for the quarters ended March 31, 2007, June 30, 2007
and September 30, 2007; and
|
|
|
|
Current Reports on
Form 8-K
filed January 22, 2007, February 16, 2007,
March 5, 2007, May 15, 2007, May 25, 2007,
June 25, 2007, August 15, 2007, August 28, 2007,
September 26, 2007 and October 24, 2007.
|
MetLife, Inc. incorporates by reference the documents listed
above and any future filings made with the SEC in accordance
with Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934 until MetLife, Inc. and the trusts file a
post-effective amendment which indicates the termination of the
offering of the securities made by this prospectus. Any reports
filed by us with the SEC after the date of this prospectus and
before the date that the offering of the securities by means of
this prospectus is terminated will automatically update and,
where applicable, supersede any information contained in this
prospectus or incorporated by reference in this prospectus.
MetLife, Inc. will provide without charge upon written or oral
request, a copy of any or all of the documents which are
incorporated by reference into this prospectus, other than
exhibits to those documents, unless those exhibits are
specifically incorporated by reference into those documents.
Requests should be directed to Investor Relations, MetLife,
Inc., 1 MetLife Plaza, Long Island City, New York 11101 by
electronic mail (metir@metlife.com) or by telephone
(212-578-2211).
You may also obtain some of the documents incorporated by
reference into this document at MetLifes website,
www.metlife.com. You should be aware that all other information
contained on MetLifes website is not a part of this
document.
METLIFE,
INC.
We are a leading provider of insurance and other financial
services with operations throughout the United States and the
regions of Latin America, Europe and Asia Pacific. Through our
domestic and international subsidiaries and affiliates, we offer
life insurance, annuities, automobile and homeowners insurance,
retail banking and other financial services to individuals, as
well as group insurance, reinsurance, and retirement &
savings products and services to corporations and other
institutions.
We are one of the largest insurance and financial services
companies in the Unites States. Our franchises and brand names
uniquely position us to be the preeminent provider of protection
and savings and investment products in the Unites States. In
addition, our international operations are focused on markets
where the demand for insurance and savings and investment
products is expected to grow rapidly in the future.
As a holding company, the primary source of MetLife, Inc.s
liquidity is dividends it receives from its insurance
subsidiaries. MetLife, Inc.s insurance subsidiaries are
subject to regulatory restrictions on the payment of dividends
3
imposed by the regulators of their respective domiciles. The
dividend limitation for U.S. insurance subsidiaries is based on
the surplus to policyholders as of the immediately preceding
calendar year and statutory net gain from operations of the
immediately preceding calendar year. Statutory accounting
practices, as prescribed by insurance regulators of various
states in which we conduct business, differ in certain respects
from accounting principles used in financial statements prepared
in conformity with GAAP. The significant differences related to
the treatment of DAC, certain deferred income tax, required
investment reserves, reserve calculation assumptions, goodwill
and surplus notes.
MetLife, Inc. is incorporated under the laws of the State of
Delaware. MetLife, Inc.s principal executive offices are
located at 200 Park Avenue, New York, New York 10166-0188,
and its telephone number is
212-578-2211.
THE
TRUSTS
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX are statutory trusts formed on
October 31, 2007 under Delaware law pursuant to
declarations of trust between the trustees named therein and
MetLife, Inc. and the filing of certificates of trust with the
Secretary of State of the State of Delaware. MetLife, Inc., as
sponsor of the trusts, and the trustees named in the
declarations of trust will amend and restate the declarations of
trust in their entirety substantially in the forms which are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part, as of or prior
to the date the trusts issue any trust preferred securities. The
declarations of trust will be qualified as indentures under the
Trust Indenture Act of 1939, as amended (the Trust
Indenture Act).
The trusts exist for the exclusive purposes of:
|
|
|
|
|
issuing preferred securities offered by this prospectus and
common securities to MetLife, Inc.;
|
|
|
|
investing the gross proceeds of the preferred securities and
common securities in related series of debt securities, which
may be senior or subordinated, issued by MetLife, Inc.; and
|
|
|
|
engaging in only those other activities which are necessary,
appropriate, convenient or incidental to the purposes set forth
above.
|
The payment of periodic cash distributions on the trust
preferred securities and payments on liquidation and redemption
with respect to the trust preferred securities, in each case to
the extent the trusts have funds legally and immediately
available, will be guaranteed by MetLife, Inc. to the extent set
forth under Description of Guarantees.
MetLife, Inc. will own, directly or indirectly, all of the
common securities of the trusts. The common securities will
represent an aggregate liquidation amount equal to at least 3%
of each trusts total capitalization. The preferred
securities of each trust will represent the remaining 97% of
each trusts total capitalization. The common securities
will have terms substantially identical to, and will rank equal
in priority of payment with, the preferred securities. However,
if MetLife, Inc. defaults on the related series of debt
securities, then cash distributions and liquidation, redemption
and other amounts payable on the common securities will be
subordinate to the trust preferred securities in priority of
payment.
The trusts each have a term of approximately 55 years, but
may dissolve earlier as provided in their respective
declarations of trust. The trusts activities will be
conducted by the trustees appointed by MetLife, Inc., as the
direct or indirect holder of all of the common securities. The
holder of the common securities of each trust will be entitled
to appoint, remove or replace any of, or increase or reduce the
number of, the trustees of the trust. However, the number of
trustees shall be at least three, at least one of which shall be
an administrative trustee. The duties and obligations of the
trustees will be governed by the declaration of trust for each
trust. A majority of the trustees of each trust will be persons
who are employees or officers of or affiliated with MetLife,
Inc. One trustee of each trust will be a financial institution
which will be unaffiliated with MetLife, Inc. and which will act
as property trustee and as indenture trustee for purposes of the
Trust Indenture Act, pursuant to the terms set forth in a
prospectus supplement. In addition, unless the property trustee
maintains a principal place of business in the State of
Delaware,
4
and otherwise meets the requirements of applicable law, one
trustee of each trust will have its principal place of business
or reside in the State of Delaware.
The property trustee will hold title to the debt securities for
the benefit of the holders of the trust securities and the
property trustee will have the power to exercise all rights,
powers and privileges under the indenture as the holder of the
debt securities. In addition, the property trustee will maintain
exclusive control of a segregated non-interest bearing bank
account to hold all payments made in respect of the debt
securities for the benefit of the holders of the trust
securities. The property trustee will make payments of
distributions and payments on liquidation, redemption and
otherwise to the holders of the trust securities out of funds
from this property account.
The rights of the holders of the trust preferred securities,
including economic rights, rights to information and voting
rights, are provided in the declarations of trust of MetLife
Capital Trust V, MetLife Capital Trust VI, MetLife
Capital Trust VII, MetLife Capital Trust VIII and
MetLife Capital Trust IX, including any amendments thereto,
the trust preferred securities, the Delaware Statutory
Trust Act and the Trust Indenture Act.
MetLife, Inc. will pay all fees and expenses related to the
trusts and the offering of trust preferred securities. The
principal offices of each trust is: The Bank of New York
(Delaware), 100 White Clay Center, Route 273, Newark,
Delaware 19711, Attention: Corporate Trust Administration. The
telephone number of each trust is:
302-283-8905.
Please read the prospectus supplement relating to the trust
preferred securities for further information concerning the
trusts and the trust preferred securities.
USE OF
PROCEEDS
We may use the proceeds of securities sold or re-sold under this
registration statement for, among other things, general
corporate purposes. The prospectus supplement for each offering
of securities will specify the intended use of the proceeds of
that offering. Unless otherwise indicated in an accompanying
prospectus supplement, the trusts will use all of the proceeds
they receive from the sale of trust preferred securities to
purchase debt securities issued by MetLife, Inc.
RATIO OF
EARNINGS TO FIXED CHARGES
AND RATIO OF EARNINGS TO FIXED CHARGES AND PREFERRED STOCK
DIVIDENDS
The following table sets forth our historical ratio of earnings
to fixed
charges(1)
for the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
Year Ended December 31,
|
|
|
|
2007
|
|
|
2006
|
|
|
2006
|
|
|
2005
|
|
|
2004
|
|
|
2003
|
|
|
2002
|
|
|
Ratio of Earnings to Fixed Charges
|
|
|
1.80
|
|
|
|
1.72
|
|
|
|
1.67
|
|
|
|
1.92
|
|
|
|
2.03
|
|
|
|
1.73
|
|
|
|
1.47
|
|
Ratio of Earnings to Fixed Charges and Preferred Stock Dividends
|
|
|
1.78
|
|
|
|
1.70
|
|
|
|
1.65
|
|
|
|
1.90
|
|
|
|
2.03
|
|
|
|
1.73
|
|
|
|
1.47
|
|
|
|
(1) |
For purposes of this computation, earnings are defined as income
before provision for income tax and discontinued operations and
excluding undistributed income and losses from equity method
investments, minority interest and fixed charges, excluding
capitalized interest. Fixed charges are the sum of interest and
debt issue costs, interest credited to policyholder account
balances, and an estimated interest component of rent expense.
We did not have any preferred stock outstanding prior to the
initial issuances of our (i) Floating Rate Non-Cumulative
Preferred Stock, Series A, issued on June 13, 2005;
and (ii) 6.50% Non-Cumulative Preferred Stock,
Series B, issued on June 16, 2005. The preferred stock
dividends are included within the total fixed charges to
calculate the ratio of earnings to fixed charges and preferred
stock dividends.
|
DESCRIPTION
OF SECURITIES
This prospectus contains summary descriptions of the debt
securities, preferred stock, depositary shares, common stock,
warrants, purchase contracts and units that MetLife, Inc. may
sell from time to time, and the trust
5
preferred securities guaranteed by MetLife, Inc. that the trusts
may sell from time to time. These summary descriptions are not
meant to be complete descriptions of each security. However,
this prospectus and the accompanying prospectus supplement
contain the material terms of the securities being offered.
DESCRIPTION
OF DEBT SECURITIES
As used in this prospectus, debt securities means the
debentures, notes, bonds and other evidences of indebtedness
that MetLife, Inc. may issue from time to time. The debt
securities will either be senior debt securities or subordinated
debt securities. Unless the applicable prospectus supplement
states otherwise, senior debt securities will be issued under
the Senior Indenture dated as of November 9, 2001 between
MetLife, Inc, and Bank One Trust Company, N.A. (predecessor to
The Bank of New York Trust Company, N.A.) (the Senior
Indenture) and subordinated debt securities will be issued
under the Subordinated Indenture dated as of June 21, 2005
between MetLife, Inc. and J.P. Morgan Trust Company, National
Association (predecessor to The Bank of New York Trust Company,
N.A.) (the Subordinated Indenture). This prospectus
sometimes refers to the Senior Indenture and the Subordinated
Indenture collectively as the Indentures.
The Senior Indenture and the Subordinated Indenture are
incorporated by reference as exhibits to the registration
statement of which this prospectus forms a part. The statements
and descriptions in this prospectus or in any prospectus
supplement regarding provisions of the Indentures and debt
securities are summaries thereof, do not purport to be complete
and are subject to, and are qualified in their entirety by
reference to, all of the provisions of the Indentures and the
debt securities, including the definitions therein of certain
terms.
General
The debt securities will be direct unsecured obligations of
MetLife, Inc. The senior debt securities will rank equally with
all of MetLife, Inc.s other senior and unsubordinated
debt. The subordinated debt securities will be subordinate and
junior in right of payment to all of MetLife, Inc.s
present and future senior indebtedness.
Because MetLife, Inc. is principally a holding company, its
right to participate in any distribution of assets of any
subsidiary, including Metropolitan Life Insurance Company, upon
the subsidiarys liquidation or reorganization or
otherwise, is subject to the prior claims of creditors of the
subsidiary, except to the extent MetLife, Inc. may be recognized
as a creditor of that subsidiary. Accordingly, MetLife,
Inc.s obligations under the debt securities will be
effectively subordinated to all existing and future indebtedness
and liabilities of its subsidiaries, including liabilities under
contracts of insurance and annuities written by MetLife,
Inc.s insurance subsidiaries, and holders of debt
securities should look only to MetLife, Inc.s assets for
payment thereunder.
The Indentures do not limit the aggregate principal amount of
debt securities that MetLife, Inc. may issue and provide that
MetLife, Inc. may issue debt securities from time to time in one
or more series, in each case with the same or various
maturities, at par or at a discount. MetLife, Inc. may issue
additional debt securities of a particular series without the
consent of the holders of the debt securities of such series
outstanding at the time of the issuance. Any such additional
debt securities, together with all other outstanding debt
securities of that series, will constitute a single series of
debt securities under the applicable Indenture. The Indentures
also do not limit our ability to incur other debt.
Each prospectus supplement will describe the terms relating to
the specific series of debt securities being offered. These
terms will include some or all of the following:
|
|
|
|
|
the title of debt securities and whether they are subordinated
debt securities or senior debt securities;
|
|
|
|
any limit on the aggregate principal amount of the debt
securities;
|
|
|
|
the price or prices at which MetLife, Inc. will sell the debt
securities;
|
|
|
|
the maturity date or dates of the debt securities;
|
|
|
|
the rate or rates of interest, if any, which may be fixed or
variable, per annum at which the debt securities will bear
interest, or the method of determining such rate or rates, if
any;
|
6
|
|
|
|
|
the date or dates from which any interest will accrue, the dates
on which interest will be payable, or the method by which such
date or dates will be determined;
|
|
|
|
the right, if any, to extend the interest payment periods and
the duration of any such deferral period, including the maximum
consecutive period during which interest payment periods may be
extended;
|
|
|
|
whether the amount of payments of principal of (and premium, if
any) or interest on the debt securities may be determined with
reference to any index, formula or other method, such as one or
more currencies, commodities, equity indices or other indices,
and the manner of determining the amount of such payments;
|
|
|
|
the dates on which MetLife, Inc. will pay interest on the debt
securities and the regular record date for determining who is
entitled to the interest payable on any interest payment date;
|
|
|
|
the place or places where the principal of (and premium, if any)
and interest on the debt securities will be payable;
|
|
|
|
if MetLife, Inc. possesses the option to do so, the periods
within which and the prices at which MetLife, Inc. may redeem
the debt securities, in whole or in part, pursuant to optional
redemption provisions, and the other terms and conditions of any
such provisions;
|
|
|
|
MetLife, Inc.s obligation, if any, to redeem, repay or
purchase debt securities by making periodic payments to a
sinking fund or through an analogous provision or at the option
of holders of the debt securities, and the period or periods
within which and the price or prices at which MetLife, Inc. will
redeem, repay or purchase the debt securities, in whole or in
part, pursuant to such obligation, and the other terms and
conditions of such obligation;
|
|
|
|
the denominations in which the debt securities will be issued,
if other than denominations of $1,000 and integral multiples of
$1,000;
|
|
|
|
the portion, or methods of determining the portion, of the
principal amount of the debt securities which MetLife, Inc. must
pay upon the acceleration of the maturity of the debt securities
in connection with an Event of Default (as described below), if
other than the full principal amount;
|
|
|
|
the currency, currencies or currency unit in which MetLife, Inc.
will pay the principal of (and premium, if any) or interest, if
any, on the debt securities, if not United States dollars and
the manner of determining the equivalent thereof in United
States dollars;
|
|
|
|
provisions, if any, granting special rights to holders of the
debt securities upon the occurrence of specified events;
|
|
|
|
any deletions from, modifications of or additions to the Events
of Default or MetLife, Inc.s covenants with respect to the
applicable series of debt securities, and whether or not such
Events of Default or covenants are consistent with those
contained in the applicable Indenture;
|
|
|
|
the application, if any, of the terms of the Indenture relating
to defeasance and covenant defeasance (which terms are described
below) to the debt securities;
|
|
|
|
whether the subordination provisions summarized below or
different subordination provisions will apply to the debt
securities;
|
|
|
|
the terms, if any, upon which the holders may or are required to
convert or exchange such debt securities into or for MetLife,
Inc.s common stock or other securities or property or into
securities of a third party, including conversion price (which
may be adjusted), the method of calculating the conversion
price, or the conversion period;
|
|
|
|
whether any of the debt securities will be issued in global or
certificated form and, if so, the terms and conditions upon
which global debt securities may be exchanged for certificated
debt securities;
|
|
|
|
any change in the right of the trustee or the requisite holders
of debt securities to declare the principal amount thereof due
and payable because of an Event of Default;
|
7
|
|
|
|
|
the depositary for global or certificated debt securities;
|
|
|
|
if applicable, a discussion of the U.S. federal income tax
considerations applicable to specific debt securities;
|
|
|
|
any trustees, authenticating or paying agents, transfer agents
or registrars or other agents with respect to the debt
securities; and
|
|
|
|
any other terms of the debt securities not inconsistent with the
provisions of the Indentures, as amended or supplemented.
|
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will not be listed on any
securities exchange.
Unless otherwise specified in the applicable prospectus
supplement, the debt securities will be issued in fully
registered form without coupons.
Debt securities may be sold at a substantial discount below
their stated principal amount, bearing no interest or interest
at a rate which at the time of issuance is below market rates.
The applicable prospectus supplement will describe the federal
income tax consequences and special considerations applicable to
any such debt securities. The debt securities may also be issued
as indexed securities or securities denominated in foreign
currencies or currency units, as described in more detail in the
prospectus supplement relating to any of the particular debt
securities. The prospectus supplement relating to specific debt
securities will also describe any special considerations and
certain additional tax considerations applicable to such debt
securities.
Subordination
The prospectus supplement relating to any offering of
subordinated debt securities will describe the specific
subordination provisions. However, unless otherwise noted in the
prospectus supplement, subordinated debt securities will be
subordinate and junior in right of payment to all of MetLife,
Inc.s Senior Indebtedness (as described below).
Under the Subordinated Indenture, Senior
Indebtedness means all amounts due on obligations in
connection with any of the following, whether outstanding at the
date of execution of the Subordinated Indenture or thereafter
incurred or created:
|
|
|
|
|
the principal of (and premium, if any) and interest in respect
of indebtedness of MetLife, Inc. for borrowed money and
indebtedness evidenced by securities, debentures, bonds or other
similar instruments issued by MetLife, Inc.;
|
|
|
|
all capital lease obligations of MetLife, Inc.;
|
|
|
|
all obligations of MetLife, Inc. issued or assumed as the
deferred purchase price of property, all conditional sale
obligations of MetLife, Inc. and all obligations of MetLife,
Inc. under any title retention agreement (but excluding trade
accounts payable in the ordinary course of business);
|
|
|
|
all obligations of MetLife, Inc. for the reimbursement on any
letter of credit, bankers acceptance, security purchase
facility or similar credit transaction;
|
|
|
|
all obligations of MetLife, Inc. in respect of interest rate
swap, cap or other agreements, interest rate future or options
contracts, currency swap agreements, currency future or option
contracts and other similar agreements;
|
|
|
|
all obligations of the types referred to above of other persons
for the payment of which MetLife, Inc. is responsible or liable
as obligor, guarantor or otherwise; and
|
|
|
|
all obligations of the types referred to above of other persons
secured by any lien on any property or asset of MetLife, Inc.
whether or not such obligation is assumed by MetLife, Inc.
|
8
Senior Indebtedness does not include:
|
|
|
|
|
indebtedness or monetary obligations to trade creditors created
or assumed by MetLife, Inc. in the ordinary course of business
in connection with the obtaining of materials or services;
|
|
|
|
indebtedness that is, by its terms, subordinated to, or ranks
equal with, the subordinated debt securities; and
|
|
|
|
any indebtedness of MetLife, Inc. to its affiliates (including
all debt securities and guarantees in respect of those debt
securities issued to any trust, partnership or other entity
affiliated with MetLife, Inc. that is a financing vehicle of
MetLife, Inc. in connection with the issuance by such financing
entity of preferred securities or other securities guaranteed by
MetLife, Inc.) unless otherwise expressly provided in the terms
of any such indebtedness.
|
At both September 30, 2007 and December 31, 2006,
Senior Indebtedness aggregated approximately $7.0 billion.
The amount of Senior Indebtedness which MetLife, Inc. may issue
is subject to limitations imposed by its board of directors.
Senior Indebtedness shall continue to be Senior Indebtedness and
be entitled to the benefits of the subordination provisions
irrespective of any amendment, modification or waiver of any
term of such Senior Indebtedness.
Unless otherwise noted in the accompanying prospectus
supplement, if MetLife, Inc. defaults in the payment of any
principal of (or premium, if any) or interest on any Senior
Indebtedness when it becomes due and payable, whether at
maturity or at a date fixed for prepayment or by declaration or
otherwise, then, unless and until such default is cured or
waived or ceases to exist, MetLife, Inc. will make no direct or
indirect payment (in cash, property, securities, by set-off or
otherwise) in respect of the principal of or interest on the
subordinated debt securities or in respect of any redemption,
retirement, purchase or other requisition of any of the
subordinated debt securities.
In the event of the acceleration of the maturity of any
subordinated debt securities, the holders of all senior debt
securities outstanding at the time of such acceleration will
first be entitled to receive payment in full of all amounts due
on the senior debt securities before the holders of the
subordinated debt securities will be entitled to receive any
payment of principal (and premium, if any) or interest on the
subordinated debt securities.
If any of the following events occurs, MetLife, Inc. will pay in
full all Senior Indebtedness before it makes any payment or
distribution under the subordinated debt securities, whether in
cash, securities or other property, to any holder of
subordinated debt securities:
|
|
|
|
|
any dissolution or winding-up or liquidation or reorganization
of MetLife, Inc., whether voluntary or involuntary or in
bankruptcy, insolvency or receivership;
|
|
|
|
any general assignment by MetLife, Inc. for the benefit of
creditors; or
|
|
|
|
any other marshaling of MetLife, Inc.s assets or
liabilities.
|
In such event, any payment or distribution under the
subordinated debt securities, whether in cash, securities or
other property, which would otherwise (but for the subordination
provisions) be payable or deliverable in respect of the
subordinated debt securities, will be paid or delivered directly
to the holders of Senior Indebtedness in accordance with the
priorities then existing among such holders until all Senior
Indebtedness has been paid in full. If any payment or
distribution under the subordinated debt securities is received
by the trustee of any subordinated debt securities in
contravention of any of the terms of the Subordinated Indenture
and before all the Senior Indebtedness has been paid in full,
such payment or distribution or security will be received in
trust for the benefit of, and paid over or delivered and
transferred to, the holders of the Senior Indebtedness at the
time outstanding in accordance with the priorities then existing
among such holders for application to the payment of all Senior
Indebtedness remaining unpaid to the extent necessary to pay all
such Senior Indebtedness in full.
The Subordinated Indenture does not limit the issuance of
additional Senior Indebtedness.
If debt securities are issued to a trust in connection with the
issuance of trust preferred securities, such debt securities may
thereafter be distributed pro rata to the holders of such trust
securities in connection with the dissolution of such trust upon
the occurrence of certain events described in the applicable
prospectus supplement.
9
Restrictive
Covenants
Unless an accompanying prospectus supplement states otherwise,
the following restrictive covenants shall apply to each series
of senior debt securities:
Limitation on Liens. So long as any senior
debt securities are outstanding, neither MetLife, Inc. nor any
of its subsidiaries will create, assume, incur or guarantee any
debt which is secured by any mortgage, pledge, lien, security
interest or other encumbrance on any capital stock of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor.
|
However, this restriction will not apply if the debt securities
then outstanding are secured at least equally and ratably with
the otherwise prohibited secured debt so long as it is
outstanding.
Limitations on Dispositions of Stock of Certain
Subsidiaries. So long as any senior debt
securities are outstanding and subject to the provisions of the
Senior Indenture regarding mergers, consolidations and sales of
assets, neither MetLife, Inc. nor any of its subsidiaries will
sell or otherwise dispose of any shares of capital stock (other
than preferred stock having no voting rights of any kind) of:
|
|
|
|
|
Metropolitan Life Insurance Company;
|
|
|
|
any successor to substantially all of the business of
Metropolitan Life Insurance Company which is also a subsidiary
of MetLife, Inc.; or
|
|
|
|
any corporation (other than MetLife, Inc.) having direct or
indirect control of Metropolitan Life Insurance Company or any
such successor;
|
except for, in each case:
|
|
|
|
|
a sale or other disposition of any of such stock to a
wholly-owned subsidiary of MetLife, Inc. or of such subsidiary;
or
|
|
|
|
a sale or other disposition of all of such stock for at least
fair value (as determined by MetLife, Inc.s board of
directors acting in good faith); or a sale or other disposition
required to comply with an order of a court or regulatory
authority of competent jurisdiction, other than an order issued
at MetLife, Inc.s request or the request of any of
MetLife, Inc.s subsidiaries.
|
Consolidation,
Merger, Sale of Assets and Other Transactions
(i) MetLife, Inc. may not merge with or into or consolidate
with another corporation or sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to,
any other corporation other than a direct or indirect
wholly-owned subsidiary of MetLife, Inc., and (ii) no
corporation may merge with or into or consolidate with MetLife,
Inc. or, except for any direct or indirect wholly-owned
subsidiary of MetLife, Inc., sell, assign, transfer, lease or
convey all or substantially all of its properties and assets to
MetLife, Inc., unless:
|
|
|
|
|
MetLife, Inc. is the surviving corporation or the corporation
formed by or surviving such merger or consolidation or to which
such sale, assignment, transfer, lease or conveyance has been
made, if other than MetLife, Inc., has expressly assumed by
supplemental indenture all the obligations of MetLife, Inc.
under the debt securities, the Indentures, and any guarantees of
preferred securities or common securities issued by the trusts;
|
|
|
|
immediately after giving effect to such transaction, no default
or Event of Default has occurred and is continuing;
|
10
|
|
|
|
|
if at the time any preferred securities of the trusts are
outstanding, such transaction is not prohibited under the
applicable declaration of trust and the applicable preferred
securities guarantee of each trust; and
|
|
|
|
MetLife, Inc. delivers to the trustee an officers
certificate and an opinion of counsel, each stating that the
supplemental indenture complies with the applicable Indenture.
|
Events
of Default, Notice and Waiver
Unless an accompanying prospectus supplement states otherwise,
the following shall constitute Events of Default
under the Indentures with respect to each series of debt
securities:
|
|
|
|
|
MetLife, Inc.s failure to pay any interest on any debt
security of such series when due and payable, continued for
30 days;
|
|
|
|
MetLife, Inc.s failure to pay principal (or premium, if
any) on any debt security of such series when due, regardless of
whether such payment became due because of maturity, redemption,
acceleration or otherwise, or is required by any sinking fund
established with respect to such series;
|
|
|
|
MetLife, Inc.s failure to observe or perform any other of
its covenants or agreements with respect to such series for
90 days after MetLife, Inc. receives notice of such failure;
|
|
|
|
certain defaults with respect to MetLife, Inc.s debt which
result in a principal amount in excess of $100,000,000 becoming
or being declared due and payable prior to the date on which it
would otherwise have become due and payable (other than the debt
securities or non-recourse debt);
|
|
|
|
certain events of bankruptcy, insolvency or reorganization of
MetLife, Inc.; and
|
|
|
|
certain events of dissolution or winding-up of the trusts in the
event that debt securities are issued to the trusts or a trustee
of the trusts in connection with the issuance of securities by
the trusts.
|
If an Event of Default with respect to any debt securities of
any series outstanding under either of the Indentures shall
occur and be continuing, the trustee under such Indenture or the
holders of at least 25% in aggregate principal amount of the
debt securities of that series outstanding may declare, by
notice as provided in the applicable Indenture, the principal
amount (or such lesser amount as may be provided for in the debt
securities of that series) of all the debt securities of that
series outstanding to be due and payable immediately; provided
that, in the case of an Event of Default involving certain
events in bankruptcy, insolvency or reorganization, acceleration
is automatic; and, provided further, that after such
acceleration, but before a judgment or decree based on
acceleration, the holders of a majority in aggregate principal
amount of the outstanding debt securities of that series may,
under certain circumstances, rescind and annul such acceleration
if all Events of Default, other than the nonpayment of
accelerated principal, have been cured or waived. Upon the
acceleration of the maturity of original issue discount
securities, an amount less than the principal amount thereof
will become due and payable. Reference is made to the prospectus
supplement relating to any original issue discount securities
for the particular provisions relating to acceleration of
maturity thereof.
Any past default under either Indenture with respect to debt
securities of any series, and any Event of Default arising
therefrom, may be waived by the holders of a majority in
principal amount of all debt securities of such series
outstanding under such Indenture, except in the case of
(i) default in the payment of the principal of (or premium,
if any) or interest on any debt securities of such series, or
(ii) default in respect of a covenant or provision which
may not be amended or modified without the consent of the holder
of each outstanding debt security of such series affected.
The trustee is required, within 90 days after the
occurrence of a default (which is known to the trustee and is
continuing), with respect to the debt securities of any series
(without regard to any grace period or notice requirements), to
give to the holders of the debt securities of such series notice
of such default; provided, however, that, except in the case of
a default in the payment of the principal of (and premium, if
any) or interest, or in the payment of any sinking fund
installment, on any debt securities of such series, the trustee
shall be protected in withholding such notice if it in good
faith determines that the withholding of such notice is in the
interests of the holders of the debt securities of such series.
11
The trustee, subject to its duties during default to act with
the required standard of care, may require indemnification by
the holders of the debt securities of any series with respect to
which a default has occurred before proceeding to exercise any
right or power under the Indentures at the request of the
holders of the debt securities of such series. Subject to such
right of indemnification and to certain other limitations, the
holders of a majority in aggregate principal amount of the
outstanding debt securities of any series under either Indenture
may direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or
exercising any trust or power conferred on the trustee with
respect to the debt securities of such series.
No holder of a debt security of any series may institute any
action against MetLife, Inc. under either of the Indentures
(except actions for payment of overdue principal of (and
premium, if any) or interest on such debt security or for the
conversion or exchange of such debt security in accordance with
its terms) unless (i) the holder has given to the trustee
written notice of an Event of Default and of the continuance
thereof with respect to the debt securities of such series
specifying an Event of Default, as required under the applicable
Indenture, (ii) the holders of at least 25% in aggregate
principal amount of the debt securities of that series then
outstanding under such Indenture shall have requested the
trustee to institute such action and offered to the trustee
reasonable indemnity against the costs, expenses and liabilities
to be incurred in compliance with such request, and
(iii) the trustee shall not have instituted such action
within 60 days of such request.
MetLife, Inc. is required to furnish annually to the trustee
statements as to MetLife, Inc.s compliance with all
conditions and covenants under each Indenture.
Discharge,
Defeasance and Covenant Defeasance
If indicated in the applicable prospectus supplement, MetLife,
Inc. may discharge or defease its obligations under each
Indenture as set forth below.
MetLife, Inc. may discharge certain obligations to holders of
any series of debt securities issued under either the Senior
Indenture or the Subordinated Indenture which have not already
been delivered to the trustee for cancellation and which have
either become due and payable or are by their terms due and
payable within one year (or scheduled for redemption within one
year) by irrevocably depositing with the trustee cash or, in the
case of debt securities payable only in U.S. dollars,
U.S. government obligations (as defined in either
Indenture), as trust funds in an amount certified to be
sufficient to pay when due, whether at maturity, upon redemption
or otherwise, the principal of (and premium, if any) and
interest on such debt securities.
If indicated in the applicable prospectus supplement, MetLife,
Inc. may elect either (i) to defease and be discharged from
any and all obligations with respect to the debt securities of
or within any series (except as otherwise provided in the
relevant Indenture) (defeasance) or (ii) to be
released from its obligations with respect to certain covenants
applicable to the debt securities of or within any series
(covenant defeasance), upon the deposit with the
relevant Indenture trustee, in trust for such purpose, of money
and/or government obligations which, through the payment of
principal and interest in accordance with their terms, will
provide money in an amount sufficient, without reinvestment, to
pay the principal of (and premium, if any) or interest on such
debt securities to maturity or redemption, as the case may be,
and any mandatory sinking fund or analogous payments thereon. As
a condition to defeasance or covenant defeasance, MetLife, Inc.
must deliver to the trustee an opinion of counsel to the effect
that the holders of such debt securities will not recognize
income, gain or loss for federal income tax purposes as a result
of such defeasance or covenant defeasance and will be subject to
federal income tax on the same amounts and in the same manner
and at the same times as would have been the case if such
defeasance or covenant defeasance had not occurred. Such opinion
of counsel, in the case of defeasance under clause (i)
above, must refer to and be based upon a ruling of the Internal
Revenue Service or a change in applicable federal income tax law
occurring after the date of the relevant Indenture. In addition,
in the case of either defeasance or covenant defeasance,
MetLife, Inc. shall have delivered to the trustee (i) an
officers certificate to the effect that the relevant debt
securities exchange(s) have informed it that neither such debt
securities nor any other debt securities of the same series, if
then listed on any securities exchange, will be delisted as a
result of such deposit, and (ii) an officers
certificate and an opinion of counsel, each stating that all
conditions precedent with respect to such defeasance or covenant
defeasance have been complied with.
12
MetLife, Inc. may exercise its defeasance option with respect to
such debt securities notwithstanding its prior exercise of its
covenant defeasance option.
Modification
and Waiver
Under the Indentures, MetLife, Inc. and the applicable trustee
may supplement the Indentures for certain purposes which would
not materially adversely affect the interests or rights of the
holders of debt securities of a series without the consent of
those holders. MetLife, Inc. and the applicable trustee may also
modify the Indentures or any supplemental indenture in a manner
that affects the interests or rights of the holders of debt
securities with the consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each affected series issued under the Indenture.
However, the Indentures require the consent of each holder of
debt securities that would be affected by any modification which
would:
|
|
|
|
|
extend the fixed maturity of any debt securities of any series,
or reduce the principal amount thereof, or reduce the rate or
extend the time of payment of interest thereon, or reduce any
premium payable upon the redemption thereof;
|
|
|
|
reduce the amount of principal of an original issue discount
debt security or any other debt security payable upon
acceleration of the maturity thereof;
|
|
|
|
change the currency in which any debt security or any premium or
interest is payable;
|
|
|
|
impair the right to enforce any payment on or with respect to
any debt security;
|
|
|
|
adversely change the right to convert or exchange, including
decreasing the conversion rate or increasing the conversion
price of, any debt security (if applicable);
|
|
|
|
reduce the percentage in principal amount of outstanding debt
securities of any series, the consent of whose holders is
required for modification or amendment of the Indentures or for
waiver of compliance with certain provisions of the Indentures
or for waiver of certain defaults;
|
|
|
|
reduce the requirements contained in the Indentures for quorum
or voting; or
|
|
|
|
modify any of the above provisions.
|
If debt securities are held by a trust or a trustee of a trust,
a supplemental indenture that affects the interests or rights of
the holders of debt securities will not be effective until the
holders of not less than a majority in liquidation preference of
the preferred securities and common securities of the applicable
trust, collectively, have consented to the supplemental
indenture; provided, further, that if the consent of the holder
of each outstanding debt security is required, the supplemental
indenture will not be effective until each holder of the
preferred securities and the common securities of the applicable
trust has consented to the supplemental indenture.
The Indentures permit the holders of at least a majority in
aggregate principal amount of the outstanding debt securities of
any series issued under the Indenture which is affected by the
modification or amendment to waive MetLife, Inc.s
compliance with certain covenants contained in the Indentures.
Payment
and Paying Agents
Unless otherwise indicated in the applicable prospectus
supplement, payment of interest on a debt security on any
interest payment date will be made to the person in whose name a
debt security is registered at the close of business on the
record date for the interest.
Unless otherwise indicated in the applicable prospectus
supplement, principal, interest and premium on the debt
securities of a particular series will be payable at the office
of such paying agent or paying agents as MetLife, Inc. may
designate for such purpose from time to time. Notwithstanding
the foregoing, at MetLife, Inc.s option, payment of any
interest may be made by check mailed to the address of the
person entitled thereto as such address appears in the security
register.
Unless otherwise indicated in the applicable prospectus
supplement, a paying agent designated by MetLife, Inc. and
located in the Borough of Manhattan, The City of New York, will
act as paying agent for payments with
13
respect to debt securities of each series. All paying agents
initially designated by MetLife, Inc. for the debt securities of
a particular series will be named in the applicable prospectus
supplement. MetLife, Inc. may at any time designate additional
paying agents or rescind the designation of any paying agent or
approve a change in the office through which any paying agent
acts, except that MetLife, Inc. will be required to maintain a
paying agent in each place of payment for the debt securities of
a particular series.
All moneys paid by MetLife, Inc. to a paying agent for the
payment of the principal, interest or premium on any debt
security which remain unclaimed at the end of two years after
such principal, interest or premium has become due and payable
will be repaid to MetLife, Inc. upon request, and the holder of
such debt security thereafter may look only to MetLife, Inc. for
payment thereof.
Denominations,
Registrations and Transfer
Unless an accompanying prospectus supplement states otherwise,
debt securities will be represented by one or more global
certificates registered in the name of a nominee for The
Depository Trust Company (DTC). In such case, each
holders beneficial interest in the global securities will
be shown on the records of DTC and transfers of beneficial
interests will only be effected through DTCs records.
A holder of debt securities may only exchange a beneficial
interest in a global security for certificated securities
registered in the holders name if:
|
|
|
|
|
DTC notifies MetLife, Inc. that it is unwilling or unable to
continue serving as the depositary for the relevant global
securities or DTC ceases to maintain certain qualifications
under the Securities Exchange Act of 1934 and no successor
depositary has been appointed for 90 days; or
|
|
|
|
MetLife, Inc. determines, in its sole discretion and subject to
the procedures of DTC, that the global security shall be
exchangeable.
|
If debt securities are issued in certificated form, they will
only be issued in the minimum denomination specified in the
accompanying prospectus supplement and integral multiples of
such denomination. Transfers and exchanges of such debt
securities will only be permitted in such minimum denomination.
Transfers of debt securities in certificated form may be
registered at the trustees corporate office or at the
offices of any paying agent or trustee appointed by MetLife,
Inc. under the Indentures. Exchanges of debt securities for an
equal aggregate principal amount of debt securities in different
denominations may also be made at such locations.
Governing
Law
The Indentures and debt securities will be governed by, and
construed in accordance with, the internal laws of the State of
New York, without regard to its principles of conflicts of laws.
Relationship
with the Trustees
The trustee under the Indentures is The Bank of New York Trust
Company, N.A. (in the case of the Senior Indenture, as successor
to Bank One Trust Company, N.A., and in the case of the
Subordinated Indenture, as successor to J.P. Morgan Trust
Company, National Association). MetLife, Inc. and its
subsidiaries maintain ordinary banking and trust relationships
with a number of banks and trust companies, including the
trustee under the Indentures.
Conversion
or Exchange Rights
The prospectus supplement will describe the terms, if any, on
which a series of debt securities may be convertible into or
exchangeable for securities described in this prospectus. These
terms will include provisions as to whether conversion or
exchange is mandatory, at the option of the holder or at
MetLife, Inc.s option. These provisions may allow or
require the number of shares of MetLife, Inc.s common
stock or other securities to be received by the holders of such
series of debt securities to be adjusted.
14
DESCRIPTION
OF CAPITAL STOCK
MetLife, Inc.s authorized capital stock consists of:
|
|
|
|
|
200,000,000 shares of preferred stock, par value
$0.01 per share, of which 84,000,000 shares were
issued and outstanding as of September 30, 2007:
|
|
|
|
|
|
27,600,000 shares of Floating Rate Non-Cumulative Preferred
Stock, Series A (the Series A Preferred
Stock), of which 24,000,000 shares were issued and
outstanding as of September 30, 2007;
|
|
|
|
69,000,000 shares of 6.500% Non-Cumulative Preferred Stock,
Series B (the Series B Preferred Stock) of
which 60,000,000 shares were issued and outstanding as of
September 30, 2007; and
|
|
|
|
10,000,000 shares of Series A Junior Participating
Preferred Stock, par value $0.01 per share, of which no
shares were issued or outstanding as of the date of this
prospectus; and
|
|
|
|
|
|
3,000,000,000 shares of common stock, par value
$0.01 per share, of which 740,286,838 shares, as well
as the same number of rights to purchase shares of Series A
Junior Participating Preferred Stock pursuant to the stockholder
rights plan adopted by MetLife, Inc.s board of directors
on September 29, 1999, were outstanding as of
September 30, 2007. See Stockholder
Rights Plan for a description of the Series A Junior
Participating Preferred Stock. The remaining shares of
authorized and unissued common stock will be available for
future issuance without additional stockholder approval.
|
Common
Stock
Dividends. The holders of common stock, after
any preferences of holders of any preferred stock, are entitled
to receive dividends as determined by the board of directors.
The issuance of dividends will depend upon, among other factors
deemed relevant by MetLife, Inc.s board of directors,
MetLifes financial condition, results of operations, cash
requirements, future prospects and regulatory restrictions on
the payment of dividends by Metropolitan Life Insurance Company
and MetLife, Inc.s other subsidiaries. There is no
requirement or assurance that MetLife, Inc. will declare and pay
any dividends. In addition, (i) the certificates of
designation for the Series A Preferred Stock and the
Series B Preferred Stock, (ii) MetLife, Inc.s
6.40% Fixed-to-Floating Rate Junior Subordinated Debentures due
2066, and (iii) both series of junior subordinated debt
securities underlying MetLife, Inc.s common equity units,
all prohibit the declaration or payment of dividends or
distributions on common stock under certain circumstances. Under
the certificates of designation for the Series A Preferred
Stock and the Series B Preferred Stock, if dividends on
such securities are not paid, no dividends may be paid on the
common stock. Similarly, under the the 6.40% Fixed-to-Floating
Rate Junior Subordinated Debentures due 2066, under certain
circumstances, if interest is not paid in full on such
securities, whether because of an optional deferral or a trigger
event, subject to certain exceptions, than no dividends may be
paid on the common stock. The indenture governing the terms of
the junior subordinated debt securities underlying the common
equity units prohibits, during any period in which the payment
of interest on either series is deferred, or certain other
events have occurred, among other things, the declaration or
payment of any dividends or distributions on, the redemption,
purchase, acquisition of or making a liquidation payment with
respect to, any shares of capital stock.
Voting Rights. The holders of common stock are
entitled to one vote per share on all matters on which the
holders of common stock are entitled to vote and do not have any
cumulative voting rights.
Liquidation and Dissolution. In the event of
MetLife, Inc.s liquidation, dissolution or winding-up, the
holders of common stock are entitled to share equally and
ratably in MetLife, Inc.s assets, if any, remaining after
the payment of all of MetLife, Inc.s liabilities and the
liquidation preference of any outstanding class or series of
preferred stock.
Other Rights. The holders of common stock have
no preemptive, conversion, redemption or sinking fund rights.
The holders of shares of MetLife, Inc.s common stock are
not required to make additional capital contributions.
Transfer Agent and Registrar. The transfer
agent and registrar for MetLife, Inc.s common stock is
Mellon Investor Services LLC, successor to ChaseMellon
Shareholder Services, L.L.C.
15
Preferred
Stock
General. MetLife, Inc.s board of
directors has the authority to issue preferred stock in one or
more series and to fix the title and number of shares
constituting any such series and the designations, powers,
preferences, limitations and relative rights including offering
price, any dividend rights (including whether dividends will be
cumulative or non-cumulative), dividend rate, voting rights,
terms of any redemption, any redemption price or prices,
conversion or exchange rights and any liquidation preferences of
the shares constituting any series, without any further vote or
action by stockholders. The specific terms of the preferred
stock will be described in the prospectus supplement.
MetLife, Inc. has authorized 10,000,000 shares of
Series A Junior Participating Preferred Stock for issuance
in connection with its stockholder rights plan. See
Stockholder Rights Plan for a
description of the Series A Junior Participating Preferred
Stock.
Voting Rights. The Delaware General
Corporation Law provides that the holders of preferred stock
will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders
of such preferred stock. The prospectus supplement will describe
the voting rights, if any, of the preferred stock.
Conversion or Exchange. The prospectus
supplement will describe the terms, if any, on which the
preferred stock may be convertible into or exchangeable for
securities described in this prospectus. These terms will
include provisions as to whether conversion or exchange is
mandatory, at the option of the holder or at MetLife,
Inc.s option. These provisions may set forth the
conversion price, the method of determining the conversion price
and the conversion period and may allow or require the number of
shares of MetLife, Inc.s common stock or other securities
to be received by the holders of preferred stock to be adjusted.
Redemption. The prospectus supplement will
describe the obligation, if any, to redeem the preferred stock
in whole or in part at the times and at the redemption prices
set forth in the applicable prospectus supplement.
Unless otherwise indicated in the applicable prospectus
supplement, MetLife, Inc. may not purchase or redeem any of the
outstanding shares or any series of preferred stock unless full
cumulative dividends, if any, have been paid or declared and set
apart for payment upon all outstanding shares of any series of
preferred stock for all past dividend periods, and unless all of
MetLife, Inc.s matured obligations with respect to all
sinking funds, retirement funds or purchase funds for all series
of preferred stock then outstanding have been met.
Certain
Provisions in MetLife, Inc.s Certificate of Incorporation
and By-Laws and in Delaware and New York Law
A number of provisions of MetLife, Inc.s certificate of
incorporation and by-laws deal with matters of corporate
governance and rights of stockholders. The following discussion
is a general summary of selected provisions of MetLife,
Inc.s certificate of incorporation and by-laws and
regulatory provisions that might be deemed to have a potential
anti-takeover effect. These provisions may have the
effect of discouraging a future takeover attempt which is not
approved by MetLife, Inc.s board of directors but which
individual stockholders may deem to be in their best interests
or in which stockholders may receive a substantial premium for
their shares over then current market prices. As a result,
stockholders who might desire to participate in such a
transaction may not have an opportunity to do so. Such
provisions will also render the removal of the incumbent board
of directors or management more difficult. Some provisions of
the Delaware General Corporation Law and the New York Insurance
Law may also have an anti-takeover effect. The following
description of selected provisions of MetLife, Inc.s
certificate of incorporation and by-laws and selected provisions
of the Delaware General Corporation Law and the New York
Insurance Law is necessarily general and reference should be
made in each case to MetLife, Inc.s certificate of
incorporation and by-laws, which are incorporated by reference
as exhibits to the registration statement of which this
prospectus forms a part, and to the provisions of those laws.
Classified
Board of Directors and Removal of Directors
Pursuant to MetLife, Inc.s certificate of incorporation,
the directors are divided into three classes, as nearly equal in
number as possible, with each class having a term of three
years. The classes serve staggered terms, such that the term of
one class of directors expires each year. Any effort to obtain
control of MetLife, Inc.s board of
16
directors by causing the election of a majority of the board may
require more time than would be required without a staggered
election structure. MetLife, Inc.s certificate of
incorporation also provides that, subject to the rights of the
holders of any class of preferred stock, directors may be
removed only for cause at a meeting of stockholders by a vote of
a majority of the shares then entitled to vote. This provision
may have the effect of slowing or impeding a change in
membership of MetLife, Inc.s board of directors that would
effect a change of control.
Exercise
of Duties by Board of Directors
MetLife, Inc.s certificate of incorporation provides that
while the MetLife Policyholder Trust (as described below) is in
existence, each MetLife, Inc. director is required, in
exercising his or her duties as a director, to take the
interests of the trust beneficiaries into account as if they
were holders of the shares of common stock held in the trust,
except to the extent that any such director determines, based on
advice of counsel, that to do so would violate his or her duties
as a director under Delaware law.
Restriction
on Maximum Number of Directors and Filling of Vacancies on
MetLife, Inc.s Board of Directors
Pursuant to MetLife, Inc.s by-laws and subject to the
rights of the holders of any class of preferred stock, the
number of directors may be fixed and increased or decreased from
time to time by resolution of the board of directors, but the
board of directors will at no time consist of fewer than three
directors. Subject to the rights of the holders of any class of
preferred stock, stockholders can only remove a director for
cause by a vote of a majority of the shares entitled to vote, in
which case the vacancy caused by such removal may be filled at
such meeting by the stockholders entitled to vote for the
election of the director so removed. Any vacancy on the board of
directors, including a vacancy resulting from an increase in the
number of directors or resulting from a removal for cause where
the stockholders have not filled the vacancy, subject to the
rights of the holders of any class of preferred stock, may be
filled by a majority of the directors then in office, although
less than a quorum. If the vacancy is not so filled it will be
filled by the stockholders at the next annual meeting of
stockholders. The stockholders are not permitted to fill
vacancies between annual meetings, except where the vacancy
resulted from a removal for cause. These provisions give
incumbent directors significant authority that may have the
effect of limiting the ability of stockholders to effect a
change in management.
Advance
Notice Requirements for Nomination of Directors and Presentation
of New Business at Meetings of Stockholders; Action by Written
Consent
MetLife, Inc.s by-laws provide for advance notice
requirements for stockholder proposals and nominations for
director. In addition, pursuant to the provisions of both the
certificate of incorporation and the by-laws, action may not be
taken by written consent of stockholder. Rather, any action
taken by the stockholders must be effected at a duly called
meeting. Moreover, the stockholders do not have the power to
call a special meeting. Only the chief executive officer or the
secretary pursuant to a board resolution or, under some
circumstances, the president or a director who also is an
officer, may call a special meeting. These provisions make it
more difficult for a stockholder to place a proposal or
nomination on the meeting agenda and prohibit a stockholder from
taking action without a meeting, and therefore may reduce the
likelihood that a stockholder will seek to take independent
action to replace directors or with respect to other matters
that are not supported by management for stockholder vote.
Limitations
on Director Liability
MetLife, Inc.s certificate of incorporation contains a
provision that is designed to limit the directors
liability to the extent permitted by the Delaware General
Corporation Law and any amendments to that law. Specifically,
directors will not be held liable to MetLife, Inc. or its
stockholders for an act or omission in their capacity as a
director, except for liability as a result of:
|
|
|
|
|
a breach of the duty of loyalty to MetLife, Inc. or its
stockholders;
|
|
|
|
acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
|
17
|
|
|
|
|
payment of an improper dividend or improper repurchase of
MetLife, Inc.s stock under Section 174 of the
Delaware General Corporation Law; or
|
|
|
|
actions or omissions pursuant to which the director received an
improper personal benefit.
|
The principal effect of the limitation on liability provision is
that a stockholder is unable to prosecute an action for monetary
damages against a director of MetLife, Inc. unless the
stockholder can demonstrate one of the specified bases for
liability. This provision, however, does not eliminate or limit
director liability arising in connection with causes of action
brought under the federal securities laws. MetLife, Inc.s
certificate of incorporation also does not eliminate the
directors duty of care. The inclusion of the limitation on
liability provision in the certificate may, however, discourage
or deter stockholders or management from bringing a lawsuit
against directors for a breach of their fiduciary duties, even
though such an action, if successful, might otherwise have
benefited MetLife, Inc. and its stockholders. This provision
should not affect the availability of equitable remedies such as
injunction or rescission based upon a directors breach of
the duty of care.
MetLife, Inc.s by-laws also provide that MetLife, Inc.
indemnify its directors and officers to the fullest extent
permitted by Delaware law. MetLife, Inc. is required to
indemnify its directors and officers for all judgments, fines,
settlements, legal fees and other expenses reasonably incurred
in connection with pending or threatened legal proceedings
because of the directors or officers position with
MetLife, Inc. or another entity, including Metropolitan Life
Insurance Company, that the director or officer serves at
MetLife, Inc.s request, subject to certain conditions, and
to advance funds to MetLife, Inc.s directors and officers
to enable them to defend against such proceedings. To receive
indemnification, the director or officer must succeed in the
legal proceeding or act in good faith and in a manner reasonably
believed to be in or not opposed to the best interests of
MetLife, Inc. and with respect to any criminal action or
proceeding, in a manner he or she reasonably believed to be
lawful.
Supermajority
Voting Requirement for Amendment of Certain Provisions of the
Certificate of Incorporation and By-Laws
Some of the provisions of MetLife, Inc.s certificate of
incorporation, including those that authorize the board of
directors to create stockholder rights plans, that set forth the
duties, election and exculpation from liability of directors and
that prohibit stockholders from taking actions by written
consent, may not be amended, altered, changed or repealed unless
the amendment is approved by the vote of holders of 75% of the
then outstanding shares entitled to vote at an election of
directors. This requirement exceeds the majority vote of the
outstanding stock that would otherwise be required by the
Delaware General Corporation Law for the repeal or amendment of
such provisions of the certificate of incorporation. MetLife,
Inc.s by-laws may be amended, altered or repealed by the
board of directors or by the vote of holders of 75% of the then
outstanding shares entitled to vote in the election of
directors. These provisions make it more difficult for any
person to remove or amend any provisions that have an
anti-takeover effect.
Business
Combination Statute
In addition, as a Delaware corporation, MetLife, Inc. is subject
to Section 203 of the Delaware General Corporation Law,
unless it elects in its certificate of incorporation not to be
governed by the provisions of Section 203. MetLife, Inc.
has not made that election. Section 203 can affect the
ability of an interested stockholder of MetLife,
Inc. to engage in certain business combinations, including
mergers, consolidations or acquisitions of additional shares of
MetLife, Inc. for a period of three years following the time
that the stockholder becomes an interested
stockholder. An interested stockholder is
defined to include any person owning, directly or indirectly,
15% or more of the outstanding voting stock of a corporation.
The provisions of Section 203 are not applicable in some
circumstances, including those in which (1) the business
combination or transaction which results in the stockholder
becoming an interested stockholder is approved by
the corporations board of directors prior to the time the
stockholder becomes an interested stockholder or
(2) the interested stockholder, upon
consummation of such transaction, owns at least 85% of the
voting stock of the corporation outstanding prior to such
transaction.
18
Restrictions
on Acquisitions of Securities
The insurance laws and regulations of New York, the jurisdiction
in which MetLife, Inc.s principal insurance subsidiary,
Metropolitan Life Insurance Company, is organized, may delay or
impede a business combination involving MetLife, Inc. In
addition to the limitations described in the immediately
preceding paragraph, the New York Insurance Law prohibits any
person from acquiring control of Metropolitan Life Insurance
Company, either directly or indirectly through any acquisition
of control of MetLife, Inc., without the prior approval of
the New York Superintendent of Insurance. That law presumes that
control exists where any person, directly or indirectly, owns,
controls, holds the power to vote or holds proxies representing
10% or more of MetLife, Inc.s outstanding voting stock,
unless the New York Superintendent, upon application, determines
otherwise. Even persons who do not acquire beneficial ownership
of more than 10% of the outstanding shares of MetLife,
Inc.s common stock may be deemed to have acquired such
control, if the New York Superintendent determines that such
persons, directly or indirectly, exercise a controlling
influence over MetLife, Inc.s management or policies.
Therefore, any person seeking to acquire a controlling interest
in MetLife, Inc. would face regulatory obstacles which may
delay, deter or prevent an acquisition.
The insurance holding company law and other insurance laws of
many other states also regulate changes of control (generally
presumed upon acquisitions of 10% or more of voting securities)
of domestic insurers (including insurers owned by MetLife, Inc.)
and insurance holding companies such as MetLife, Inc.
Stockholder
Rights Plan
MetLife, Inc.s board of directors has adopted a
stockholder rights plan under which each outstanding share of
MetLife, Inc.s common stock issued between April 4,
2000 and the earlier of the distribution date (as described
below) and the expiration of the rights (as described below)
will be coupled with a stockholder right. Initially, the
stockholder rights will be attached to the certificates
representing outstanding shares of common stock, and no separate
rights certificates will be distributed. Each right will entitle
the holder to purchase one one-hundredth of a share of MetLife,
Inc.s Series A Junior Participating Preferred Stock.
Each one one-hundredth of a share of Series A Junior
Participating Preferred Stock will have economic and voting
terms equivalent to one share of MetLife, Inc.s common
stock. Until it is exercised, the right itself will not entitle
the holder thereof to any rights as a stockholder, including the
right to receive dividends or to vote at stockholder meetings.
The description and terms of the rights are set forth in a
rights agreement entered into between MetLife, Inc. and Mellon
Investor Services LLC, successor to ChaseMellon Shareholder
Services, L.L.C., as rights agent. Although the material
provisions of the rights agreement have been accurately
summarized, the statements below concerning the rights agreement
are not necessarily complete and in each instance reference is
made to the rights agreement itself, which is incorporated by
reference into this prospectus in its entirety. Each statement
is qualified in its entirety by such reference.
Stockholder rights are not exercisable until the distribution
date and will expire at the close of business on April 4,
2010, unless earlier redeemed or exchanged by MetLife, Inc. A
distribution date would occur upon the earlier of:
|
|
|
|
|
the tenth day after the first public announcement or
communication to MetLife, Inc. that a person or group of
affiliated or associated persons (referred to as an
acquiring person) has acquired beneficial ownership
of 10% or more of MetLife, Inc.s outstanding common stock
(the date of such announcement or communication is referred to
as the stock acquisition time); or
|
|
|
|
the tenth business day after the commencement or announcement of
the intention to commence a tender offer or exchange offer that
would result in a person or group becoming an acquiring person.
|
If any person becomes an acquiring person, each holder of a
stockholder right will be entitled to exercise the right and
receive, instead of Series A Junior Participating Preferred
Stock, common stock (or, in certain circumstances, cash, a
reduction in purchase price, property or other securities of
MetLife, Inc.) having a value equal to two times the purchase
price of the stockholder right. All stockholder rights that are
beneficially owned by an acquiring person or its transferee will
become null and void.
If at any time after a public announcement has been made or
MetLife, Inc. has received notice that a person has become an
acquiring person, (1) MetLife, Inc. is acquired in a merger
or other business combination, or (2) 50% or
19
more of MetLife, Inc.s and its subsidiaries assets,
cash flow or earning power is sold or transferred, each holder
of a stockholder right (except rights which previously have been
voided as set forth above) will have the right to receive, upon
exercise, common stock of the acquiring company having a value
equal to two times the purchase price of the right.
The purchase price payable, the number of one one-hundredths of
a share of Series A Junior Participating Preferred Stock or
other securities or property issuable upon exercise of rights
and the number of rights outstanding, are subject to adjustment
from time to time to prevent dilution. With certain exceptions,
no adjustment in the purchase price or the number of shares of
Series A Junior Participating Preferred Stock issuable upon
exercise of a stockholder right will be required until the
cumulative adjustment would require an increase or decrease of
at least one percent in the purchase price or number of shares
for which a right is exercisable.
At any time until the earlier of (1) the stock acquisition
time, or (2) the final expiration date of the rights
agreement, MetLife, Inc. may redeem all the stockholder rights
at a price of $0.01 per right. At any time after a person
has become an acquiring person and prior to the acquisition of
beneficial ownership by such person of 50% or more of the
outstanding shares of MetLife, Inc.s common stock,
MetLife, Inc. may exchange the stockholder rights, in whole or
in part, at an exchange ratio of one share of common stock, or
one one-hundredth of a share of Series A Junior
Participating Preferred Stock (or of a share of a class or
series of preferred stock having equivalent rights, preferences
and privileges), per right.
The stockholder rights plan is designed to protect stockholders
in the event of unsolicited offers to acquire MetLife, Inc. and
other coercive takeover tactics which, in the opinion of its
board of directors, could impair its ability to represent
stockholder interests. The provisions of the stockholder rights
plan may render an unsolicited takeover more difficult or less
likely to occur or may prevent such a takeover, even though such
takeover may offer MetLife, Inc.s stockholders the
opportunity to sell their stock at a price above the prevailing
market rate and may be favored by a majority of MetLife,
Inc.s stockholders.
MetLife
Policyholder Trust
Under a plan of reorganization adopted in September 1999,
Metropolitan Life Insurance Company converted from a mutual life
insurance company to a stock life insurance company subsidiary
of MetLife, Inc. MetLife established the MetLife Policyholder
Trust to hold the shares of common stock allocated to eligible
policyholders. A total of 494,466,664 shares of common
stock were distributed to the MetLife Policyholder Trust on the
effective date of the plan of reorganization. As of
October 31, 2007, the trust held 262,431,955 shares of
MetLife, Inc.s common stock. Because of the number of
shares held by the trust and the voting provisions of the trust,
the trust may affect the outcome of matters brought to a
stockholder vote.
The trustee will generally vote all of the shares of common
stock held in the trust in accordance with the recommendations
given by MetLife, Inc.s board of directors to its
stockholders or, if the board gives no such recommendation, as
directed by the board, except on votes regarding certain
fundamental corporate actions. As a result of the voting
provisions of the trust, MetLife, Inc.s board of directors
will effectively be able to control votes on all matters
submitted to a vote of stockholders, excluding those fundamental
corporate actions described below, so long as the trust holds a
substantial number of shares of MetLife, Inc.s common
stock.
If the vote relates to fundamental corporate actions specified
in the trust, the trustee will solicit instructions from the
beneficiaries and vote all shares held in the trust in
proportion to the instructions it receives, which would give
disproportionate weight to the instructions actually given by
trust beneficiaries. These actions include:
|
|
|
|
|
an election or removal of directors in which a stockholder has
properly nominated one or more candidates in opposition to a
nominee or nominees of MetLife, Inc.s board of directors
or a vote on a stockholders proposal to oppose a board
nominee for director, remove a director for cause or fill a
vacancy caused by the removal of a director by stockholders,
subject to certain conditions;
|
|
|
|
a merger or consolidation, a sale, lease or exchange of all or
substantially all of the assets, or a recapitalization or
dissolution of MetLife, Inc., in each case requiring a vote of
MetLife, Inc.s stockholders under applicable Delaware law;
|
20
|
|
|
|
|
any transaction that would result in an exchange or conversion
of shares of common stock held by the trust for cash, securities
or other property; and
|
|
|
|
any proposal requiring MetLife, Inc.s board of directors
to amend or redeem the rights under the stockholder rights plan,
other than a proposal with respect to which MetLife, Inc. has
received advice of nationally-recognized legal counsel to the
effect that the proposal is not a proper subject for stockholder
action under Delaware law.
|
DESCRIPTION
OF DEPOSITARY SHARES
The following outlines some of the general terms and provisions
of the depositary shares. Further terms of the depositary shares
and the applicable deposit agreement will be stated in the
applicable prospectus supplement. The following description and
any description of the depositary shares in a prospectus
supplement may not be complete and is subject to and qualified
in its entirety by reference to the terms and provisions of the
deposit agreement, a form of which has been or will be filed as
an exhibit to the registration statement of which this
prospectus forms a part.
The particular terms of the depositary shares offered by any
prospectus supplement and the extent to which the general
provisions described below may apply to such depositary shares
will be outlined in the applicable prospectus supplement.
General
MetLife, Inc. may choose to offer fractional interests in debt
securities or fractional shares of common stock or preferred
stock. MetLife, Inc. may issue fractional interests in debt
securities, common stock or preferred stock, as the case may be,
in the form of depositary shares. Each depositary share would
represent a fractional interest in a security of a particular
series of debt securities or a fraction of a share of common
stock or of a particular series of preferred stock, as the case
may be, and would be evidenced by a depositary receipt.
MetLife, Inc. will deposit the debt securities or shares of
common stock or preferred stock represented by depositary shares
under a deposit agreement between MetLife, Inc. and a depositary
which will be named in the applicable prospectus supplement.
Subject to the terms of the deposit agreement, as an owner of a
depositary share, you will be entitled, in proportion to the
applicable fraction of a debt security or share of common stock
or preferred stock represented by the depositary share, to all
the rights and preferences of the debt security, common stock or
preferred stock, as the case may be, represented by the
depositary share, including, as the case may be, interest,
dividend, voting, conversion, redemption, sinking fund,
repayment at maturity, subscription and liquidation rights.
Interest,
Dividends and Other Distributions
The depositary will distribute all payments of interest, cash
dividends or other cash distributions received on the debt
securities, common stock or preferred stock, as the case may be,
to you in proportion to the number of depositary shares that you
own. In the event of a distribution other than in cash, the
depositary will distribute property received by it to you in an
equitable manner, unless the depositary determines that it is
not feasible to make a distribution. In that case, the
depositary may sell the property and distribute the net proceeds
from the sale to you.
Redemption
of Depositary Shares
If a debt security, common stock or series of preferred stock
represented by depositary shares is redeemed, the depositary
will redeem your depositary shares from the proceeds received by
the depositary resulting from the redemption. The redemption
price per depositary share will be equal to the applicable
fraction of the redemption price per debt security or share of
common stock or preferred stock, as the case may be, payable in
relation to the redeemed series of debt securities, common stock
or preferred stock. Whenever MetLife, Inc. redeems debt
securities or shares of common stock or preferred stock held by
the depositary, the depositary will redeem, as of the same
redemption date, the number of depositary shares representing,
as the case may be, fractional interests in the debt securities
or shares of common stock or preferred stock redeemed. If fewer
than all the depositary shares are to
21
be redeemed, the depositary shares to be redeemed will be
selected by lot, proportionately or by any other equitable
method as the depositary may determine.
Exercise
of Rights under the Indentures or Voting the Common Stock or
Preferred
Upon receipt of notice of any meeting at which you are entitled
to vote, or of any request for instructions or directions from
you as holder of fractional interests in debt securities, common
stock or preferred stock, the depositary will mail to you the
information contained in that notice. Each record holder of the
depositary shares on the record date will be entitled to
instruct the depositary how to give instructions or directions
with respect to the debt securities represented by that
holders depositary shares or how to vote the amount of the
common stock or preferred stock represented by that
holders depositary shares. The record date for the
depositary shares will be the same date as the record date for
the debt securities, common stock or preferred stock, as the
case may be. The depositary will endeavor, to the extent
practicable, to give instructions or directions with respect to
the debt securities or to vote the amount of the common stock or
preferred stock, as the case may be, represented by the
depositary shares in accordance with those instructions.
MetLife, Inc. will agree to take all reasonable action which the
depositary may deem necessary to enable the depositary to do so.
The depositary will abstain from giving instructions or
directions with respect to your fractional interests in the debt
securities or voting shares of the common stock or preferred
stock, as the case may be, if it does not receive specific
instructions from you.
Amendment
and Termination of the Deposit Agreement
MetLife, Inc. and the depositary may amend the form of
depositary receipt evidencing the depositary shares and any
provision of the deposit agreement at any time. However, any
amendment which materially and adversely affects the rights of
the holders of the depositary shares will not be effective
unless the amendment has been approved by the holders of at
least a majority of the depositary shares then outstanding.
The deposit agreement will terminate if:
|
|
|
|
|
all outstanding depositary shares have been redeemed;
|
|
|
|
if applicable, the debt securities and the preferred stock
represented by depositary shares have been converted into or
exchanged for common stock or, in the case of debt securities,
repaid in full; or
|
|
|
|
there has been a final distribution in respect of the common
stock or preferred stock, including in connection with the
liquidation, dissolution or winding-up of MetLife, Inc., and the
distribution proceeds have been distributed to you.
|
Resignation
and Removal of Depositary
The depositary may resign at any time by delivering to MetLife,
Inc. notice of its election to do so. MetLife, Inc. also may, at
any time, remove the depositary. Any resignation or removal will
take effect upon the appointment of a successor depositary and
its acceptance of such appointment. MetLife, Inc. must appoint
the successor depositary within 60 days after delivery of
the notice of resignation or removal. The successor depositary
must be a bank or trust company having its principal office in
the United States and having total assets of not less than
$1,000,000,000.
Charges
of Depositary
MetLife, Inc. will pay all transfer and other taxes and
governmental charges arising solely from the existence of the
depositary arrangements. MetLife, Inc. will pay charges of the
depositary in connection with the initial deposit of the debt
securities or common stock or preferred stock, as the case may
be, and issuance of depositary receipts, all withdrawals of
depositary shares of debt securities or common stock or
preferred stock, as the case may be, by you and any repayment or
redemption of the debt securities or preferred stock, as the
case may be. You will pay other transfer and other taxes and
governmental charges, as well as the other charges that are
expressly provided in the deposit agreement to be for your
account.
22
Miscellaneous
The depositary will forward all reports and communications from
MetLife, Inc. which are delivered to the depositary and which
MetLife, Inc. is required or otherwise determines to furnish to
holders of debt securities, common stock or preferred stock, as
the case may be. Neither MetLife, Inc. nor the depositary will
be liable under the deposit agreement to you other than for its
gross negligence, willful misconduct or bad faith. Neither
MetLife, Inc. nor the depositary will be obligated to prosecute
or defend any legal proceedings relating to any depositary
shares, debt securities, common stock or preferred stock unless
satisfactory indemnity is furnished. MetLife, Inc. and the
depositary may rely upon written advice of counsel or
accountants, or upon information provided by persons presenting
debt securities or shares of common stock or preferred stock for
deposit, you or other persons believed to be competent and on
documents which MetLife, Inc. and the depositary believe to be
genuine.
DESCRIPTION
OF WARRANTS
MetLife, Inc. may issue warrants to purchase debt securities,
preferred stock, common stock or other securities described in
this prospectus, or any combination of these securities, and
these warrants may be issued independently or together with any
underlying securities and may be attached or separate from the
underlying securities. MetLife, Inc. will issue each series of
warrants under a separate warrant agreement to be entered into
between MetLife, Inc. and a warrant agent. The warrant agent
will act solely as MetLife, Inc.s agent in connection with
the warrants of such series and will not assume any obligation
or relationship of agency for or with holders or beneficial
owners of warrants.
The following outlines some of the general terms and provisions
of the warrants. Further terms of the warrants and the
applicable warrant agreement will be stated in the applicable
prospectus supplement. The following description and any
description of the warrants in a prospectus supplement may not
be complete and is subject to and qualified in its entirety by
reference to the terms and provisions of the warrant agreement,
a form of which has been or will be filed as an exhibit to the
registration statement of which this prospectus forms a part.
The applicable prospectus supplement will describe the terms of
any warrants that MetLife, Inc. may offer, including the
following:
|
|
|
|
|
the title of the warrants;
|
|
|
|
the total number of warrants;
|
|
|
|
the price or prices at which the warrants will be issued;
|
|
|
|
the currency or currencies investors may use to pay for the
warrants;
|
|
|
|
the designation and terms of the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the price at which and the currency, currencies, or currency
units in which investors may purchase the underlying securities
purchasable upon exercise of the warrants;
|
|
|
|
the date on which the right to exercise the warrants will
commence and the date on which the right will expire;
|
|
|
|
whether the warrants will be issued in registered form or bearer
form;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
if applicable, the minimum or maximum amount of warrants which
may be exercised at any one time;
|
|
|
|
if applicable, the designation and terms of the underlying
securities with which the warrants are issued and the number of
warrants issued with each underlying security;
|
|
|
|
if applicable, the date on and after which the warrants and the
related underlying securities will be separately transferable;
|
|
|
|
if applicable, a discussion of material United States federal
income tax considerations;
|
23
|
|
|
|
|
the identity of the warrant agent;
|
|
|
|
the procedures and conditions relating to the exercise of the
warrants; and
|
|
|
|
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants.
|
Warrant certificates may be exchanged for new warrant
certificates of different denominations, and warrants may be
exercised at the warrant agents corporate trust office or
any other office indicated in the applicable prospectus
supplement. Prior to the exercise of their warrants, holders of
warrants exercisable for debt securities will not have any of
the rights of holders of the debt securities purchasable upon
such exercise and will not be entitled to payments of principal
(or premium, if any) or interest, if any, on the debt securities
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for shares of
preferred stock or common stock will not have any rights of
holders of the preferred stock or common stock purchasable upon
such exercise and will not be entitled to dividend payments, if
any, or voting rights of the preferred stock or common stock
purchasable upon such exercise. Prior to the exercise of their
warrants, holders of warrants exercisable for other securities
described in this prospectus will not have any rights of holders
of such securities purchasable upon such exercise.
Exercise
of Warrants
A warrant will entitle the holder to purchase for cash an amount
of securities at an exercise price that will be stated in, or
that will be determinable as described in, the applicable
prospectus supplement. Warrants may be exercised at any time up
to the close of business on the expiration date set forth in the
applicable prospectus supplement. After the close of business on
the expiration date, unexercised warrants will become void.
Warrants may be exercised as set forth in the applicable
prospectus supplement. Upon receipt of payment and the warrant
certificate properly completed and duly executed at the
corporate trust office of the warrant agent or any other office
indicated in the prospectus supplement, MetLife, Inc. will, as
soon as practicable, forward the securities purchasable upon
such exercise. If less than all of the warrants represented by
such warrant certificate is exercised, a new warrant certificate
will be issued for the remaining warrants.
Enforceability
of Rights; Governing Law
The holders of warrants, without the consent of the warrant
agent, may, on their own behalf and for their own benefit,
enforce, and may institute and maintain any suit, action or
proceeding against MetLife, Inc. to enforce their rights to
exercise and receive the securities purchasable upon exercise of
their warrants. Unless otherwise stated in the prospectus
supplement, each issue of warrants and the applicable warrant
agreement will be governed by, and construed in accordance with,
the internal laws of the State of New York, without regard to
its principles of conflicts of laws.
DESCRIPTION
OF PURCHASE CONTRACTS
As may be specified in a prospectus supplement, MetLife, Inc.
may issue purchase contracts obligating holders to purchase from
MetLife, Inc., and MetLife, Inc. to sell to the holders, a
number of debt securities, shares of common stock or preferred
stock, or other securities described in this prospectus or the
applicable prospectus supplement at a future date or dates. The
purchase contracts may require MetLife, Inc. to make periodic
payments to the holders of the purchase contracts. These
payments may be unsecured or prefunded on some basis to be
specified in the applicable prospectus supplement.
The prospectus supplement relating to any purchase contracts
will specify the material terms of the purchase contracts and
any applicable pledge or depositary arrangements, including one
or more of the following:
|
|
|
|
|
The stated amount that a holder will be obligated to pay under
the purchase contract in order to purchase debt securities,
common stock, preferred stock, or other securities described in
this prospectus or the formula by which such amount shall be
determined.
|
24
|
|
|
|
|
The settlement date or dates on which the holder will be
obligated to purchase such securities. The prospectus supplement
will specify whether the occurrence of any events may cause the
settlement date to occur on an earlier date and the terms on
which an early settlement would occur.
|
|
|
|
The events, if any, that will cause MetLife, Inc.s
obligations and the obligations of the holder under the purchase
contract to terminate.
|
|
|
|
The settlement rate, which is a number that, when multiplied by
the stated amount of a purchase contract, determines the number
of securities that MetLife, Inc. or a trust will be obligated to
sell and a holder will be obligated to purchase under that
purchase contract upon payment of the stated amount of that
purchase contract. The settlement rate may be determined by the
application of a formula specified in the prospectus supplement.
If a formula is specified, it may be based on the market price
of such securities over a specified period or it may be based on
some other reference statistic.
|
|
|
|
Whether the purchase contracts will be issued separately or as
part of units consisting of a purchase contract and an
underlying security with an aggregate principal amount equal to
the stated amount. Any underlying securities will be pledged by
the holder to secure its obligations under a purchase contract.
|
|
|
|
The type of underlying security, if any, that is pledged by the
holder to secure its obligations under a purchase contract.
Underlying securities may be debt securities, common stock,
preferred stock, or other securities described in this
prospectus or the applicable prospectus supplement.
|
|
|
|
The terms of the pledge arrangement relating to any underlying
securities, including the terms on which distributions or
payments of interest and principal on any underlying securities
will be retained by a collateral agent, delivered to MetLife,
Inc. or be distributed to the holder.
|
|
|
|
The amount of the contract fee, if any, that may be payable by
MetLife, Inc. to the holder or by the holder to MetLife, Inc.,
the date or dates on which the contract fee will be payable and
the extent to which MetLife, Inc. or the holder, as applicable,
may defer payment of the contract fee on those payment dates.
The contract fee may be calculated as a percentage of the stated
amount of the purchase contract or otherwise.
|
The descriptions of the purchase contracts and any applicable
underlying security or pledge or depository arrangements in this
prospectus and in any prospectus supplement are summaries of the
material provisions of the applicable agreements and are subject
to and qualified in their entirety by reference to the terms and
provisions of the purchase contract agreement, pledge agreement
and deposit agreement, forms of which have been or will be filed
as exhibits to the registration statement of which this
prospectus forms a part.
DESCRIPTION
OF UNITS
As specified in the applicable prospectus supplement, MetLife,
Inc. may issue units comprised of one or more of the other
securities described in this prospectus in any combination. Each
unit may also include debt obligations of third parties, such as
U.S. Treasury securities. Each unit will be issued so that
the holder of the unit is also the holder of each security
included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security.
The prospectus supplement will describe:
|
|
|
|
|
the designation and terms of the units and of the securities
comprising the units, including whether and under what
circumstances the securities comprising the units may be held or
transferred separately;
|
|
|
|
a description of the terms of any unit agreement governing the
units;
|
|
|
|
a description of the provisions for the payment, settlement,
transfer or exchange of the units; and
|
|
|
|
whether the units will be issued in fully registered or global
form.
|
The descriptions of the units and any applicable underlying
security or pledge or depositary arrangements in this prospectus
and in any prospectus supplement are summaries of the material
provisions of the applicable agreements and are subject to, and
qualified in their entirety by reference to, the terms and
provisions of the applicable agreements, forms of which have
been or will be filed as exhibits to the registration statement
of which this prospectus forms a part.
25
DESCRIPTION
OF TRUST PREFERRED SECURITIES
The following outlines some of the general terms and provisions
of the trust preferred securities. Further terms of the trust
preferred securities and the amended and restated declarations
of trust will be stated in the applicable prospectus supplement.
The prospectus supplement will also indicate whether the general
terms described in this section apply to that particular series
of trust preferred securities. The following description and any
description of the trust preferred securities and amended and
restated declarations of trust in a prospectus supplement may
not be complete and are subject to and qualified in their
entirety by reference to the terms and provisions of the amended
and restated declarations of trust, forms of which have been or
will be filed as exhibits to the registration statement of which
this prospectus forms a part.
General
Each trust may issue only one series of trust preferred
securities having terms described in the prospectus supplement.
The declaration of trust of each trust will authorize the
administrative trustees, on behalf of the trust, to issue the
trust preferred securities of the trust. The trusts will use all
of the proceeds they receive from the sale of trust preferred
securities and common securities to purchase debt securities
issued by MetLife, Inc. The debt securities will be held in
trust by the trusts property trustee for the benefit of
the holders of the trust preferred securities and common
securities.
The trust preferred securities of each trust will have such
terms as are set forth in the trusts declaration of trust,
including as relates to distributions, redemption, voting,
liquidation rights and the other preferred, deferral and special
rights and restrictions. A prospectus supplement relating to the
trust preferred securities being offered will include specific
terms relating to the offering. These terms will include some or
all of the following:
|
|
|
|
|
the distinctive designation of the trust preferred securities;
|
|
|
|
the number of trust preferred securities issued by the trust;
|
|
|
|
the total and per-security liquidation amount of the trust
preferred securities;
|
|
|
|
the annual distribution rate, or method of determining such
rate, for trust preferred securities of the trust;
|
|
|
|
the date or dates on which distributions will be payable and any
corresponding record dates;
|
|
|
|
whether distributions on the trust preferred securities will be
cumulative;
|
|
|
|
if the trust preferred securities have cumulative distribution
rights, the date or dates, or method of determining the date or
dates, from which distributions on the trust preferred
securities will be cumulative;
|
|
|
|
the amount or amounts that will be paid out of the assets of the
trust to the holders of the trust preferred securities of the
trust upon voluntary or involuntary dissolution, winding-up or
termination of the trust;
|
|
|
|
the obligation, if any, of the trust to purchase or redeem the
trust preferred securities;
|
|
|
|
if the trust is to purchase or redeem the trust preferred
securities:
|
|
|
|
the price or prices at which the trust preferred securities will
be purchased or redeemed in whole or in part;
|
|
|
|
the period or periods within which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the terms and conditions upon which the trust preferred
securities will be purchased or redeemed, in whole or in part;
|
|
|
|
the voting rights, if any, of the trust preferred securities in
addition to those required by law, including:
|
|
|
|
|
|
the number of votes per trust preferred security; and
|
|
|
|
any requirement for the approval by the holders of trust
preferred securities as a condition to specified action or
amendments to the trusts declaration of trust;
|
26
|
|
|
|
|
the rights, if any, to defer distributions on the trust
preferred securities by extending the interest payment period on
the related debt securities;
|
|
|
|
if the trust preferred securities may be converted into or
exercised or exchanged for MetLifes common stock or
preferred stock or any other securities, the terms on which
conversion, exercise or exchange is mandatory, at the option of
the holder or at the option of each trust, the date on or the
period during which conversion, exercise or exchange may occur,
the initial conversion, exercise or exchange price or rate and
the circumstances or manner in which the amount of common stock
or preferred stock or other securities issuable upon conversion,
exercise or exchange may be adjusted;
|
|
|
|
the terms upon which the debt securities may be distributed to
holders of trust preferred securities;
|
|
|
|
whether the preferred securities are to be issued in book-entry
form and represented by one or more global certificates;
|
|
|
|
certain U.S. federal income tax considerations;
|
|
|
|
if applicable, any securities exchange upon which the trust
preferred securities shall be listed;
|
|
|
|
provisions relating to events of default and the rights of
holders of trust preferred securities in the event of default;
|
|
|
|
other agreements or other rights including upon the
consolidation or merger of the trust; and
|
|
|
|
any other relative rights, preferences, privileges, limitations
or restrictions of the trust preferred securities not
inconsistent with the trusts declaration of trust or
applicable law.
|
All trust preferred securities offered will be guaranteed by
MetLife, Inc. to the extent set forth under Description of
Guarantees. Any material United States federal income tax
considerations applicable to an offering of trust preferred
securities will be described in the applicable prospectus
supplement.
In connection with the issuance of preferred securities, each
trust will issue one series of common securities. The
declaration of each trust authorizes the administrative trustees
to issue on behalf of such trust one series of common securities
having such terms including distributions, redemption, voting,
liquidation rights or such restrictions as shall be set forth
therein. The terms of the common securities issued by the trust
will be substantially identical to the terms of the preferred
securities issued by such trust and the common securities will
rank equally, and payments will be made thereon pro rata, with
the preferred securities. However, upon an event of default
under the declaration of trust, the rights of the holders of the
common securities to payment in respect of distributions and
payments upon liquidation, redemption and otherwise will be
subordinated to the rights of the holders of the preferred
securities. Except in certain limited circumstances, the common
securities will also carry the right to vote, and appoint,
remove or replace any of the trustees of a trust. MetLife, Inc.
will own, directly or indirectly, all of the common securities
of each trust.
Enforcement
of Certain Rights by Holders of Trust Preferred
Securities
If an event of default occurs, and is continuing, under the
declaration of trust of any of the trusts, the holders of the
preferred securities of that trust would typically rely on the
property trustee to enforce its rights as a holder of the
related debt securities against MetLife, Inc. Additionally,
those who together hold a majority of the liquidation amount of
the trusts preferred securities will have the right to:
|
|
|
|
|
direct the time, method and place of conducting any proceeding
for any remedy available to the property trustee; or
|
|
|
|
direct the exercise of any trust or power that the property
trustee holds under the declaration of trust, including the
right to direct the property trustee to exercise the remedies
available to it as a holder of MetLife, Inc.s debt
securities.
|
If the property trustee fails to enforce its rights under the
applicable series of debt securities, to the fullest extent
permitted by law, a holder of trust preferred securities of such
trust may institute a legal proceeding directly against
27
MetLife, Inc. to enforce the property trustees rights
under the applicable series of debt securities without first
instituting any legal proceeding against the property trustee or
any other person or entity.
Notwithstanding the foregoing, if an event of default occurs and
the event is attributable to MetLife, Inc.s failure to pay
interest or principal on the debt securities when due, including
any payment on redemption, and this debt payment failure is
continuing, a preferred securities holder of the trust may
directly institute a proceeding for the enforcement of this
payment. Such a proceeding will be limited, however, to
enforcing the payment of this principal or interest only up to
the value of the aggregate liquidation amount of the
holders preferred securities as determined after the due
date specified in the applicable series of debt securities.
DESCRIPTION
OF GUARANTEES
The following outlines some of the general terms and provisions
of the guarantees. Further terms of the guarantees will be
stated in the applicable prospectus supplement. The prospectus
supplement will also indicate whether the general terms
described in this section apply to those guarantees. The
following description and any description of the guarantees in a
prospectus supplement may not be complete and is subject to and
qualified in its entirety by reference to the terms and
provisions of the guarantee agreements, forms of which have been
or will be filed as exhibits to the registration statement of
which this prospectus forms a part, and the Trust Indenture Act.
MetLife, Inc. will execute and deliver the guarantees for the
benefit of the holders of the trust preferred securities. Each
guarantee will be held by the guarantee trustee for the benefit
of holders of the trust preferred securities to which it relates.
Each guarantee will be qualified as an indenture under the Trust
Indenture Act. The Bank of New York Trust Company, N.A. will act
as indenture trustee under each guarantee for purposes of the
Trust Indenture Act.
General
Pursuant to each guarantee, MetLife, Inc. will irrevocably and
unconditionally agree, to the extent set forth in the guarantee,
to pay in full, to the holders of the related trust preferred
securities, the following guarantee payments, to the extent
these guarantee payments are not paid by, or on behalf of, the
related trust, regardless of any defense, right of set-off or
counterclaim that MetLife, Inc. may have or assert against any
person:
|
|
|
|
|
any accrued and unpaid distributions required to be paid on the
trust preferred securities of the trust, but if and only if and
to the extent that the trust has funds legally and immediately
available to make those payments;
|
|
|
|
any distributions of MetLifes common stock or preferred
stock or any of its other securities, in the event that the
trust preferred securities may be converted into or exercised
for common stock or preferred stock, to the extent the
conditions of such conversion or exercise have occurred or have
been satisfied and the trust does not distribute such shares or
other securities but has received such shares or other
securities;
|
|
|
|
the redemption price, including all accrued and unpaid
distributions to the date of redemption, with respect to any
trust preferred securities called for redemption by the trust,
but if and only to the extent the trust has funds legally and
immediately available to make that payment; and
|
|
|
|
upon a dissolution, winding-up or termination of the trust,
other than in connection with the distribution of debt
securities to the holders of trust preferred securities of the
trust, the lesser of:
|
|
|
|
|
|
the total of the liquidation amount and all accrued and unpaid
distributions on the trust preferred securities of the trust to
the date of payment, to the extent the trust has funds legally
and immediately available to make that payment; and
|
|
|
|
the amount of assets of the trust remaining available for
distribution to holders of trust preferred securities of the
trust in liquidation of the trust.
|
28
MetLife, Inc. may satisfy its obligation to make a guarantee
payment by directly paying the required amounts to the holders
of the related trust preferred securities or by causing the
related trust to pay such amounts to such holders.
Each guarantee will constitute a guarantee of payments with
respect to the related trust preferred securities from the time
of issuance of the trust preferred securities. The guarantees
will not apply to the payment of distributions and other
payments on the trust preferred securities when the related
trust does not have sufficient funds legally and immediately
available to make the distributions or other payments. If
MetLife, Inc. does not make interest payments on the debt
securities purchased by a trust, such trust will not pay
distributions on the preferred securities issued by such trust
and will not have funds available therefor. The guarantee, when
taken together with MetLife, Inc.s obligations under the
debt securities, the Indentures and the declarations of trust,
will provide a full and unconditional guarantee by MetLife, Inc.
of payments due on the trust preferred securities.
MetLife, Inc. will also agree separately, through guarantees of
the common securities, to irrevocably and unconditionally
guarantee the obligations of the trusts with respect to the
common securities to the same extent as the guarantees of the
preferred securities. However, upon an event of default under
the Indentures, holders of preferred securities shall have
priority over holders of common securities with respect to
distributions and payments on liquidation, redemption or
otherwise.
Subordination
MetLife, Inc.s obligation under each guarantee to make the
guarantee payments will be an unsecured obligation of MetLife,
Inc. and, if subordinated debt securities are issued to the
applicable trust and unless otherwise noted in the prospectus
supplement, will rank:
|
|
|
|
|
subordinate and junior in right of payment to all of MetLife,
Inc.s other liabilities, including the subordinated debt
securities, except those obligations or liabilities ranking
equal or subordinate to the guarantees by their terms;
|
|
|
|
equally with any other securities, liabilities or obligations
that may have equal ranking by their terms; and
|
|
|
|
senior to all of MetLife, Inc.s common stock.
|
If subordinated debt securities are issued to the applicable
trust, the terms of the trust preferred securities will provide
that each holder of trust preferred securities, by accepting the
trust preferred securities, agrees to the subordination
provisions and other terms of the guarantee related to
subordination.
Each guarantee will constitute a guarantee of payment and not of
collection. This means that the holder of trust preferred
securities may institute a legal proceeding directly against
MetLife, Inc. to enforce its rights under the guarantee without
first instituting a legal proceeding against any other person or
entity.
Each guarantee will be unsecured and, because MetLife, Inc. is
principally a holding company, will be effectively subordinated
to all existing and future liabilities of MetLife, Inc.s
subsidiaries, including liabilities under contracts of insurance
and annuities written by MetLife, Inc.s insurance
subsidiaries. The guarantee does not limit the incurrence or
issuance of other secured or unsecured debt by MetLife, Inc.
Amendments
and Assignment
For any changes that materially and adversely affect the rights
of holders of the related trust preferred securities, each
guarantee may be amended only if there is prior approval of the
holders of more than 50% in liquidation amount of the
outstanding trust preferred securities issued by the applicable
trust. All guarantees and agreements contained in each guarantee
will bind the successors, assigns, receivers, trustees and
representatives of MetLife, Inc. and will inure to the benefit
of the holders of the related trust preferred securities of the
applicable trust then outstanding.
29
Termination
Each guarantee will terminate and will have no further force and
effect as to the related trust preferred securities upon:
|
|
|
|
|
distribution of debt securities to the holders of all trust
preferred securities of the applicable trust; or
|
|
|
|
full payment of the amounts payable upon liquidation of the
applicable trust.
|
Each guarantee will continue to be effective or will be
reinstated, as the case may be, if at any time any holder of the
related trust preferred securities must restore payment of any
sums paid with respect to the trust preferred securities or
under the guarantee.
Events
of Default
Each guarantee provides that an event of default under a
guarantee occurs upon MetLife, Inc.s failure to perform
any of its obligations under the applicable guarantee.
The holders of a majority or more in liquidation amount of the
trust preferred securities to which any guarantee relates may
direct the time, method and place of conducting any proceeding
for any remedy available to the guarantee trustee with respect
to the guarantee or may direct the exercise of any trust or
power conferred upon the guarantee trustee in respect of the
guarantee.
If the guarantee trustee fails to enforce the guarantee, any
holder of the related trust preferred securities may institute a
legal proceeding directly against MetLife, Inc. to enforce the
holders rights under such guarantee without first
instituting a legal proceeding against the trust, the guarantee
trustee or any other person or entity.
Furthermore, if MetLife, Inc. fails to make a guarantee payment,
a holder of trust preferred securities may directly institute a
proceeding against MetLife, Inc. for enforcement of the trust
preferred securities guarantee for such payment.
The holders of a majority or more in liquidation amount of trust
preferred securities of any series may, by vote, on behalf of
the holders of all the trust preferred securities of the series,
waive any past event of default and its consequences.
Information
Concerning the Guarantee Trustee
Prior to an event of default with respect to any guarantee and
after the curing or waiving of all events of default with
respect to the guarantee, the guarantee trustee may perform only
the duties that are specifically set forth in the guarantee.
Once a guarantee event of default has occurred and is
continuing, the guarantee trustee is to exercise, with respect
to the holder of the trust preferred securities of the series,
the same degree of care as a prudent individual would exercise
in the conduct of his or her own affairs. Unless the guarantee
trustee is offered reasonable indemnity against the costs,
expenses and liabilities which may be incurred by the guarantee
trustee by a holder of the related trust preferred securities,
the guarantee trustee is not required to exercise any of its
powers under any guarantee at the request of the holder.
Additionally, the guarantee trustee is not required to expend or
risk its own funds or otherwise incur any financial liability in
the performance of its duties if the guarantee trustee
reasonably believes that it is not assured repayment or adequate
indemnity.
The guarantee trustee is The Bank of New York Trust Company,
N.A., which is one of a number of banks and trust companies with
which MetLife, Inc. and its subsidiaries maintain ordinary
banking and trust relationships.
Governing
Law
Each guarantee will be governed by, and construed in accordance
with, the internal laws of the State of New York, without regard
to its principles of conflicts of laws.
30
PLAN OF
DISTRIBUTION
MetLife, Inc. may sell the securities being offered hereby in
one or more of the following ways from time to time:
|
|
|
|
|
to underwriters or dealers for resale to the public or to
institutional investors;
|
|
|
|
directly to institutional investors; or
|
|
|
|
through agents to the public or to institutional investors.
|
The prospectus supplement with respect to each series of
securities will state the terms of the offering of the
securities, including:
|
|
|
|
|
the name or names of any underwriters or agents;
|
|
|
|
the purchase price of the securities and the proceeds to be
received by MetLife, Inc. or the applicable trust from the sale;
|
|
|
|
any underwriting discounts or agency fees and other items
constituting underwriters or agents compensation;
|
|
|
|
any initial public offering price;
|
|
|
|
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
|
|
any securities exchange on which the securities may be listed.
|
If MetLife, Inc. or the trusts use underwriters in the sale, the
securities will be acquired by the underwriters for their own
account and may be resold from time to time in one or more
transactions, including:
|
|
|
|
|
negotiated transactions;
|
|
|
|
at a fixed public offering price or prices, which may be changed;
|
|
|
|
at market prices prevailing at the time of sale;
|
|
|
|
at prices related to prevailing market prices; or
|
|
|
|
at negotiated prices.
|
The securities may also be offered and sold, if so indicated in
the prospectus supplement, in connection with a remarketing upon
their purchase, in accordance with a redemption or repayment
pursuant to their terms, or otherwise, by one or more
remarketing firms, acting as principals for their own accounts
or as agents for MetLife, Inc. or the trusts. The prospectus
supplement will identify any remarketing firm and will describe
the terms of its agreement, if any, with MetLife, Inc. or the
trusts and its compensation.
Unless otherwise stated in a prospectus supplement, the
obligations of the underwriters to purchase any securities will
be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of
securities, if any are purchased.
If MetLife, Inc. sells the securities directly or through agents
designated by it, MetLife, Inc. will identify any agent involved
in the offering and sale of the securities and will list any
commissions payable by MetLife, Inc. to the agent in the
accompanying prospectus supplement. Unless indicated otherwise
in the prospectus supplement, any such agent will be acting on a
best efforts basis to solicit purchases for the period of its
appointment.
MetLife, Inc. may authorize agents, underwriters or dealers to
solicit offers by certain institutional investors to purchase
securities and provide for payment and delivery on a future date
specified in an accompanying prospectus supplement. MetLife,
Inc. will describe any such arrangement in the prospectus
supplement. Any such institutional investor may be subject to
limitations on the minimum amount of securities that it may
purchase or on the portion of the aggregate principal amount of
such securities that it may sell under such arrangements.
Institutional investors from which such authorized offers may be
solicited include:
|
|
|
|
|
commercial and savings banks;
|
|
|
|
insurance companies;
|
31
|
|
|
|
|
pension funds;
|
|
|
|
investment companies;
|
|
|
|
educational and charitable institutions; and
|
|
|
|
such other institutions as MetLife, Inc. may approve.
|
Underwriters, dealers, agents and remarketing firms may be
entitled under agreements entered into with MetLife, Inc. and/or
the applicable trust, or both, to indemnification by MetLife,
Inc. against certain civil liabilities, including liabilities
under the Securities Act, or to contribution with respect to
payments which the underwriters, dealers, agents and remarketing
firms may be required to make. Underwriters, dealers, agents and
remarketing agents may be customers of, engage in transactions
with, or perform services for MetLife, Inc., any trust, and/or
MetLife, Inc.s affiliates in the ordinary course of
business.
Each series of securities will be a new issue of securities and
will have no established trading market other than the common
stock which is listed on the New York Stock Exchange. Any common
stock sold will be listed on the New York Stock Exchange, upon
official notice of issuance. The securities, other than the
common stock, may or may not be listed on a national securities
exchange. Any underwriters to whom securities are sold by
MetLife, Inc. or any trust for public offering and sale may make
a market in the securities, but such underwriters will not be
obligated to do so and may discontinue any market making at any
time without notice.
Any offering of trust preferred securities will be made in
compliance with Rule 2810 of the Conduct Rules of the
National Association of Securities Dealers, Inc.
LEGAL
OPINIONS
Unless otherwise indicated in the applicable prospectus
supplement, the validity of the securities offered hereby will
be passed upon for MetLife, Inc. by Richard S. Collins,
Senior Chief Counsel General Corporate, of
Metropolitan Life Insurance Company and for any underwriters or
agents by counsel named in the applicable prospectus supplement.
Mr. Collins is paid a salary by MetLife, is a participant
in various employee benefit plans offered by MetLife to
employees generally and has options to purchase shares of
MetLife, Inc. common stock. Certain matters of Delaware law
relating to the validity of the trust preferred securities of
MetLife Capital Trust V, MetLife Capital Trust VI,
MetLife Capital Trust VII, MetLife Capital Trust VIII
and MetLife Capital Trust IX will be passed upon for the
trust by Richards, Layton & Finger, P.A., Wilmington,
Delaware, special Delaware counsel for the trusts.
EXPERTS
The consolidated financial statements, consolidated financial
statement schedules, and managements report on the
effectiveness of internal control over financial reporting,
incorporated in this Prospectus by reference from MetLifes
Annual Report on
Form 10-K
for the year ended December 31, 2006, have been audited by
Deloitte & Touche LLP, an independent registered
public accounting firm, as stated in their reports which are
incorporated herein by reference, (which (1) express an
unqualified opinion on the consolidated financial statements and
consolidated financial statement schedules and include an
explanatory paragraph referring to MetLifes change of its
method of accounting for defined benefit pension and other
postretirement plans, and for certain non-traditional long
duration contracts and separate accounts as required by
accounting guidance which MetLife adopted on December 31,
2006 and January 1, 2004, respectively, (2) express an
unqualified opinion on managements assessment regarding
the effectiveness of internal control over financial reporting,
and (3) express an unqualified opinion on the effectiveness
of internal control over financial reporting), and have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
(This page
intentionally left blank)